

(19)



(11)

**EP 2 808 390 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**03.12.2014 Bulletin 2014/49**

(51) Int Cl.:

**C12N 15/11** <sup>(2006.01)</sup>  
**C12Q 1/68** <sup>(2006.01)</sup>

**C12N 15/113** <sup>(2010.01)</sup>

(21) Application number: **14177498.4**

(22) Date of filing: **14.11.2005**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI  
SK TR**

(30) Priority: **12.11.2004 US 627171 P**

**03.02.2005 US 649634 P**

**23.05.2005 US 683736 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

**05858321.2 / 1 838 852**

(71) Applicant: **Asuragen, Inc.**

**Austin TX 78744 (US)**

(72) Inventors:

- **Brown, David**  
**Austin, TX 78704 (US)**
- **Ford, Lance**  
**Austin, TX 78739 (US)**

- **Cheng, Angie**  
**Austin, TX 78748 (US)**
- **Jarvis, Rich**  
**Austin, TX 78739 (US)**
- **Byrom, Mike**  
**Austin, TX 78744 (US)**
- **Ovcharenko, Dmitriy**  
**Austin, TX 78745 (US)**
- **Devroe, Eric**  
**Pflugerville, TX 78660 (US)**
- **Kelnar, Kevin**  
**Kyle, TX 78640 (US)**

(74) Representative: **Sonn & Partner Patentanwälte  
Riemergasse 14  
1010 Wien (AT)**

Remarks:

This application was filed on 17-07-2014 as a divisional application to the application mentioned under INID code 62.

(54) **Methods and compositions involving miRNA and miRNA inhibitor molecules**

(57) The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular

functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

**EP 2 808 390 A1**

**Description****BACKGROUND OF THE INVENTION**

5 **[0001]** This application claims the benefit of priority to U.S. Provisional Patent Application serial no. 60/683,736, filed on May 23, 2005, U.S. Provisional Patent Application serial no. 60/627,171, filed on November 12, 2004, and U.S. Provisional Patent Application serial no. 60/649,634, filed on February 3, 2005, all of which are hereby incorporated by reference.

**1. Field of the Invention**

10 **[0002]** The present invention relates generally to the field of molecular biology. More particularly, it concerns methods and compositions involving nucleic acid molecules that simulate microRNA (miRNAs) and that inhibit miRNAs. Methods and compositions involving synthetic miRNAs and miRNA inhibitor molecules are described. In addition, methods and compositions for identifying miRNAs that contribute to cellular processes are also described. In addition, the identification of miRNAs that contribute to cellular processes provides targets for therapeutic intervention as well as diagnostic and/or prognostic analysis.

**2. Description of the Related Art**

20 **[0003]** In 2001, several groups used a novel cloning method to isolate and identify a large group of "microRNAs" (miRNAs) from *C. elegans*, *Drosophila*, and humans (Lagos-Quintana *et al.*, 2001; Lau *et al.*, 2001; Lee and Ambros, 2001). Several hundreds of miRNAs have been identified in plants and animals-including humans-which do not appear to have endogenous siRNAs. Thus, while similar to siRNAs, miRNAs are nonetheless distinct.

25 **[0004]** miRNAs thus far observed have been approximately 21-22 nucleotides in length and they arise from longer precursors, which are transcribed from non-protein-encoding genes. See review of Carrington *et al.* (2003). The precursors form structures that fold back on each other in self-complementary regions; they are then processed by the nuclease Dicer in animals or DCL1 in plants. miRNA molecules interrupt translation through precise or imprecise base-pairing with their targets.

30 **[0005]** miRNAs seem to be involved in gene regulation. Some miRNAs, including *lin-4* and *let-7*, inhibit protein synthesis by binding to partially complementary 3' untranslated regions (3' UTRs) of target mRNAs. Others, including the *Scarecrow* miRNA found in plants, function like siRNA and bind to perfectly complementary mRNA sequences to destroy the target transcript (Grishok *et al.*, 2001).

35 **[0006]** Research on microRNAs is increasing as scientists are beginning to appreciate the broad role that these molecules play in the regulation of eukaryotic gene expression. The two best understood miRNAs, *lin-4* and *let-7*, regulate developmental timing in *C. elegans* by regulating the translation of a family of key mRNAs (reviewed in Pasquinelli, 2002). Several hundred miRNAs have been identified in *C. elegans*, *Drosophila*, mouse, and humans. As would be expected for molecules that regulate gene expression, miRNA levels have been shown to vary between tissues and developmental states. In addition, one study shows a strong correlation between reduced expression of two miRNAs and chronic lymphocytic leukemia, providing a possible link between miRNAs and cancer (Calin, 2002). Although the field is still young, there is speculation that miRNAs could be as important as transcription factors in regulating gene expression in higher eukaryotes.

40 **[0007]** There are a few examples of miRNAs that play critical roles in cell differentiation, early development, and cellular processes like apoptosis and fat metabolism. *lin-4* and *let-7* both regulate passage from one larval state to another during *C. elegans* development (Ambros, 2003). *mir-14* and *bantam* are *drosophila* miRNAs that regulate cell death, apparently by regulating the expression of genes involved in apoptosis (Brennecke *et al.*, 2003, Xu *et al.*, 2003). MiR14 has also been implicated in fat metabolism (Xu *et al.*, 2003). *Lsy-6* and *miR-273* are *C. elegans* miRNAs that regulate asymmetry in chemosensory neurons (Chang *et al.*, 2004). Another animal miRNA that regulates cell differentiation is miR-181, which guides hematopoietic cell differentiation (Chen *et al.*, 2004). These molecules represent the full range of animal miRNAs with known functions. Enhanced understanding of the functions of miRNAs will undoubtedly reveal regulatory networks that contribute to normal development, differentiation, inter- and intra-cellular communication, cell cycle, angiogenesis, apoptosis, and many other cellular processes. Given their important roles in many biological functions, it is likely that miRNAs will offer important points for therapeutic intervention or diagnostic analysis.

45 **[0008]** Characterizing the functions of biomolecules like miRNAs often involves introducing the molecules into cells or removing the molecules from cells and measuring the result. If introducing a miRNA into cells results in apoptosis, then the miRNA undoubtedly participates in an apoptotic pathway. Methods for introducing and removing miRNAs from cells have been described. Two recent publications describe antisense molecules that can be used to inhibit the activity of specific miRNAs (Meister *et al.*, 2004; Hutvagner *et al.*, 2004). Another publication describes the use of plasmids that

are transcribed by endogenous RNA polymerases and yield specific miRNAs when transfected into cells (Zeng *et al.*, 2002). These two reagent sets have been used to evaluate single miRNAs.

5 [0009] A limitation of the plasmid-based miRNA expression system is that the transfection efficiencies for plasmids tend to be very low, with only approximately 50% of cells expressing RNA from the plasmid in cells that are easy to transfect. Transfection efficiencies for plasmids in primary cells are much lower, with fewer than 10% of cells typically expressing the desired RNA. Therefore, there is a need for alternative compositions and methods for introducing miRNA molecules into cells so that they can be characterized and studied.

## 10 SUMMARY OF THE INVENTION

[0010] The present invention is based on the inventors' studies regarding the introduction into cells of one or more nucleic acids that function like miRNA or inhibit the activities of one or more miRNAs in cells to characterize their roles in various biological processes. The invention concerns nucleic acids that perform the activities of endogenous miRNAs when introduced into cells. These nucleic acids are synthetic miRNA in some embodiments. The invention further concerns a library of synthetic miRNAs specific to a variety of known miRNAs that can be used to introduce sequentially or in combination one or more miRNAs into cells *in vitro* or *in vivo* for the purpose of identifying miRNAs that participate in cellular processes. The invention further involves a library of sequence-specific miRNA inhibitors that can be used to inhibit sequentially or in combination the activities of one or more miRNAs in cells. The two libraries of miRNA-specific reagents are used to introduce or eliminate specific miRNAs or combinations of miRNAs to define the roles of miRNAs in cells.

20 [0011] The term "miRNA" is used according to its ordinary and plain meaning and refers to a microRNA molecule found in eukaryotes that is involved in RNA-based gene regulation. See, *e.g.*, Carrington *et al.*, 2003, which is hereby incorporated by reference. The term will be used to refer to the single-stranded RNA molecule processed from a precursor. Individual miRNAs have been identified and sequenced in different organisms, and they have been given names. Names of miRNAs and their sequences are provided herein. Additionally, other miRNAs are known to those of skill in the art and can be readily implemented in embodiments of the invention. The methods and compositions should not be limited to miRNAs identified in the application, as they are provided as examples, not necessarily as limitations of the invention.

25 [0012] The present invention concerns, in some embodiments of the invention, short nucleic acid molecules that function as miRNAs or as inhibitors of miRNA in a cell. The term "short" refers to a length of a single polynucleotide that is 150 nucleotides or fewer. The nucleic acid molecules are synthetic. The term "synthetic" means the nucleic acid molecule is isolated and not identical in sequence (the entire sequence) and/or chemical structure to a naturally-occurring nucleic acid molecule, such as an endogenous precursor miRNA molecule. While in some embodiments, nucleic acids of the invention do not have an *entire* sequence that is identical to a sequence of a naturally-occurring nucleic acid, such molecules may encompass all or part of a naturally-occurring sequence. It is contemplated, however, that a synthetic nucleic acid administered to a cell may subsequently be modified or altered in the cell such that its structure or sequence is the same as non-synthetic or naturally occurring nucleic acid, such as a mature miRNA sequence. For example, a synthetic nucleic acid may have a sequence that differs from the sequence of a precursor miRNA, but that sequence may be altered once in a cell to be the same as an endogenous, processed miRNA. The term "isolated" means that the nucleic acid molecules of the invention are initially separated from different (in terms of sequence or structure) and unwanted nucleic acid molecules such that a population of isolated nucleic acids is at least about 90% homogenous, and may be at least about 95, 96, 97, 98, 99, or 100% homogenous with respect to other polynucleotide molecules. In many embodiments of the invention, a nucleic acid is isolated by virtue of it having been synthesized *in vitro* separate from endogenous nucleic acids in a cell. It will be understood, however, that isolated nucleic acids may be subsequently mixed or pooled together.

35 [0013] Of course, it is understood that a "synthetic nucleic acid" of the invention means that the nucleic acid does not have a chemical structure or sequence of a naturally occurring nucleic acid. Consequently, it will be understood that the term "synthetic miRNA" refers to a "synthetic nucleic acid" that functions in a cell or under physiological conditions as a naturally occurring miRNA.

40 [0014] While many of the embodiments of the invention involve synthetic miRNAs or synthetic nucleic acids, in some embodiments of the invention, the nucleic acid molecule(s) need not be "synthetic." In certain embodiments, a non-synthetic miRNA employed in methods and compositions of the invention may have the entire sequence and structure of a naturally occurring miRNA precursor or the mature miRNA. For example, non-synthetic miRNAs used in methods and compositions of the invention may not have one or more modified nucleotides or nucleotide analogs. In these embodiments, the non-synthetic miRNA may or may not be recombinantly produced. In particular embodiments, the nucleic acid in methods and/or compositions of the invention is specifically a synthetic miRNA and not a non-synthetic miRNA (that is, not an miRNA that qualifies as "synthetic"); though in other embodiments, the invention specifically involves a non-synthetic miRNA and not a synthetic miRNA. Any embodiments discussed with respect to the use of synthetic miRNAs can be applied with respect to non-synthetic miRNAs, and vice versa.

**[0015]** It will be understood that the term "naturally occurring" refers to something found in an organism without any intervention by a person; it could refer to a naturally-occurring wildtype or mutant molecule. In some embodiments a synthetic miRNA molecule does not have the sequence of a naturally occurring miRNA molecule. In other embodiments, a synthetic miRNA molecule may have the sequence of a naturally occurring miRNA molecule, but the chemical structure of the molecule, particularly in the part unrelated specifically to the precise sequence (non-sequence chemical structure) differs from chemical structure of the naturally occurring miRNA molecule with that sequence. In some cases, the synthetic miRNA has both a sequence and non-sequence chemical structure that are not found in a naturally-occurring miRNA. Moreover, the sequence of the synthetic molecules will identify which miRNA is effectively being provided or inhibited; the endogenous miRNA will be referred to as the "corresponding miRNA." Corresponding miRNA sequences that can be used in the context of the invention include, but are not limited to, those sequences in SEQ ID NOs: 1-593 and those miRNAs listed in the appendix.. In addition synthetic nucleic acids of the invention may include SEQ ID NOs:594-703 as well as any other miRNA sequence, miRNA precursor sequence, or any sequence complementary thereof. In some embodiments, the sequence is or is derived from a probe sequence identified in the appendix to target the particular miRNA (or set of miRNAs) that can be used with that probe sequence.

**[0016]** Synthetic miRNA of the invention are RNA or RNA analogs in some embodiments of the invention. MiRNA inhibitors may be DNA or RNA, or analogs thereof. miRNA and miRNA inhibitors of the invention are collectively referred to as "synthetic nucleic acids."

**[0017]** In some embodiments, there is a synthetic miRNA having a length of between 17 and 130 residues. The present invention concerns synthetic miRNA molecules that are, are at least, or are at most 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, or 130 residues in length, or any range derivable therein.

**[0018]** In certain embodiments, synthetic miRNA have a) an "miRNA region" whose sequence from 5' to 3' is identical to a mature miRNA sequence, and b) a "complementary region" whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence. In certain embodiments, these synthetic miRNA are also isolated, as defined above. The term "miRNA region" refers to a region on the synthetic miRNA that is at least 90% identical to the entire sequence of a mature, naturally occurring miRNA sequence. In certain embodiments, the miRNA region is or is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% identical to the sequence of a naturally-occurring miRNA.

**[0019]** The term "complementary region" refers to a region of a synthetic miRNA that is or is at least 60% complementary to the mature, naturally occurring miRNA sequence that the miRNA region is identical to. The complementary region is or is at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary, or any range derivable therein. With single polynucleotide sequences, there is a hairpin loop structure as a result of chemical bonding between the miRNA region and the complementary region. In other embodiments, the complementary region is on a different nucleic acid molecule than the miRNA region, in which case the complementary region is on the complementary strand and the miRNA region is on the active strand.

**[0020]** In other embodiments of the invention, there are synthetic nucleic acids that are miRNA inhibitors. An miRNA inhibitor is between about 17 to 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA. In certain embodiments, an miRNA inhibitor molecule is 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, or any range derivable therein. Moreover, an miRNA inhibitor has a sequence (from 5' to 3') that is or is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary, or any range derivable therein, to the 5' to 3' sequence of a mature miRNA, particularly a mature, naturally occurring miRNA. Probe sequences for miRNAs are disclosed in the appendix. While they have more sequence than an miRNA inhibitor, one of skill in the art could use that portion of the probe sequence that is complementary to the sequence of a mature miRNA as the sequence for an miRNA inhibitor. Table 1 indicates what the mature sequence of an miRNA is. Moreover, that portion of the probe sequence can be altered so that it is still 90% complementary to the sequence of a mature miRNA.

**[0021]** In some embodiments, of the invention, a synthetic miRNA contains one or more design elements. These design elements include, but are not limited to: i) a replacement group for the phosphate or hydroxyl of the nucleotide at the 5' terminus of the complementary region; ii) one or more sugar modifications in the first or last 1 to 6 residues of the complementary region; or, iii) noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the miRNA region.

**[0022]** In certain embodiments, a synthetic miRNA has a nucleotide at its 5' end of the complementary region in which the phosphate and/or hydroxyl group has been replaced with another chemical group (referred to as the "replacement design"). In some cases, the phosphate group is replaced, while in others, the hydroxyl group has been replaced. In

particular embodiments, the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2'-O-Me (2'-oxygen-methyl), DMTO (4,4'-dimethoxytrityl with oxygen), fluorescein, a thiol, or acridine, though other replacement groups are well known to those of skill in the art and can be used as well. This design element can also be used with an miRNA inhibitor.

**[0023]** Additional embodiments concern a synthetic miRNA having one or more sugar modifications in the first or last 1 to 6 residues of the complementary region (referred to as the "sugar replacement design"). In certain cases, there is one or more sugar modifications in the first 1, 2, 3, 4, 5, 6 or more residues of the complementary region, or any range derivable therein. In additional cases, there is one or more sugar modifications in the last 1, 2, 3, 4, 5, 6 or more residues of the complementary region, or any range derivable therein, have a sugar modification. It will be understood that the terms "first" and "last" are with respect to the order of residues from the 5' end to the 3' end of the region. In particular embodiments, the sugar modification is a 2'-O-Me modification. In further embodiments, there is one or more sugar modifications in the first or last 2 to 4 residues of the complementary region or the first or last 4 to 6 residues of the complementary region. This design element can also be used with an miRNA inhibitor. Thus, an miRNA inhibitor can have this design element and/or a replacement group on the nucleotide at the 5' terminus, as discussed above.

**[0024]** In other embodiments of the invention, there is a synthetic miRNA in which one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region are not complementary to the corresponding nucleotides of the miRNA region ("noncomplementarity") (referred to as the "noncomplementarity design"). The noncomplementarity may be in the last 1, 2, 3, 4, and/or 5 residues of the complementary miRNA. In certain embodiments, there is noncomplementarity with at least 2 nucleotides in the complementary region.

**[0025]** It is contemplated that synthetic miRNA of the invention have one or more of the replacement, sugar modification, or noncomplementarity designs. In certain cases, synthetic RNA molecules have two of them, while in others these molecules have all three designs in place.

**[0026]** The miRNA region and the complementary region may be on the same or separate polynucleotides. In cases in which they are contained on or in the same polynucleotide, the miRNA molecule will be considered a single polynucleotide. In embodiments in which the different regions are on separate polynucleotides, the synthetic miRNA will be considered to be comprised of two polynucleotides.

**[0027]** When the RNA molecule is a single polynucleotide, there is a linker region between the miRNA region and the complementary region. In some embodiments, the single polynucleotide is capable of forming a hairpin loop structure as a result of bonding between the miRNA region and the complementary region. The linker constitutes the hairpin loop. It is contemplated that in some embodiments, the linker region is, is at least, or is at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 residues in length, or any range derivable therein. In certain embodiments, the linker is between 3 and 30 residues (inclusive) in length.

**[0028]** In addition to having an miRNA region and a complementary region, there may be flanking sequences as well at either the 5' or 3' end of the region. In some embodiments, there is or is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides or more, or any range derivable therein, flanking one or both sides of these regions.

**[0029]** The present invention also concerns a collection of synthetic nucleic acid molecules, referred to as a library. A collection may contain, contain at least or contain at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517,

518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550 or more different types (by structure and/or sequence) of nucleic acids. Libraries may contain synthetic miRNAs and/or miRNA inhibitors.

**[0030]** Embodiments involving libraries and methods of using nucleic acids of the invention may be applied to miRNA and miRNA inhibitors. Thus, any embodiment discussed with respect to nucleic acids of the invention may generally be applicable to miRNA and miRNA inhibitor molecules, and vice versa. Moreover, embodiments discussed with respect to miRNA may be applied to miRNA inhibitors and vice versa.

**[0031]** The present invention also concerns methods of characterizing an miRNA activity or function in a cell. In some embodiments, a method comprises: a) introducing into one or more cells a synthetic miRNA molecule; and b) comparing one or more characteristics of cell(s) having the RNA molecule with cells in which the synthetic miRNA molecule has not been introduced. In certain embodiments, the cells with the synthetic miRNA may be compared to cells in which a different molecule was introduced (such as a negative control that does not include an miRNA region or has an miRNA region for a different miRNA). It is contemplated that the compared cells need not be evaluated at the same time. In fact, the comparison cells need not have been cultured at the same time; one may refer to a report or previous observation.

**[0032]** Other methods include reducing or eliminating activity of one or more miRNAs from a cell comprising: a) introducing into a cell an miRNA inhibitor. In certain embodiment, methods also include comparing one or more characteristics of a cell having the miRNA inhibitor with a cell not having the miRNA inhibitor.

**[0033]** The synthetic nucleic acids discussed above and herein can be used in methods of the invention. Thus, in certain embodiments, the methods involve synthetic nucleic acids with the different designs in them.

**[0034]** Characteristics of cells that may be evaluated are not limited. They include the following characteristics and characteristics associated with the following: cell proliferation, mitotic index, cell cycle, apoptosis, motility, adhesion, signal transduction, protein localization, gene expression, RNA localization, cell division, DNA replication, post-translational modification, differentiation, de-differentiation, transcriptional activation, protein activation, angiogenesis, metabolism (energy production and/or consumption), protein degradation, chromatin condensation, microtubule production, DNA replication, recombination, and DNA repair functions. It is contemplated that these characteristics may be relevant globally to the cell (for example, overall protein production reduced) or to individual species in the cell (for example, induction of a specific protein(s)).

**[0035]** It is contemplated that this method may be applied with respect to a variety of different synthetic and/or non-synthetic miRNAs in separate or the same cells. In some cases, the following numbers of different synthetic miRNA molecules may be introduced into different cells: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300 or more, or any range derivable therein (or at least or at most these numbers). The invention is not limited by cell type. It is contemplated that any cell expressing miRNA or any cell having a characteristic altered by an miRNA is amenable to the methods and compositions of the invention. Use of two or more miRNAs may be combined in a single pharmaceutical composition as a cocktail or may be used in any therapeutic, diagnostic or prognostic method of the invention. It is contemplated that methods of the invention may involve, involve at least, or involve at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300 or more, or any range derivable therein, nucleic acid molecules corresponding to different miRNAs. Such

nucleic acid molecules include synthetic miRNAs molecules, nonsynthetic miRNA molecules, and miRNA inhibitors.

**[0036]** In some embodiments, it may be useful to know whether a cell expresses a particular miRNA endogenously or whether such expression is affected under particular conditions or when it is in a particular disease state. Thus, in some embodiments of the invention, methods include assaying the cell for the presence of the miRNA that is effectively being introduced by the synthetic miRNA molecule or inhibited by an miRNA inhibitor. Consequently, in some embodiments, methods include a step of generating an miRNA profile for a sample. The term "miRNA profile" refers to a set of data regarding the expression pattern for a plurality of miRNAs in the sample; it is contemplated that the miRNA profile can be obtained using an miRNA array. In some embodiments of the invention, an miRNA profile is generated by steps that include: a) labeling miRNA in the sample; b) hybridizing the miRNA to an miRNA array; and, c) determining miRNA hybridization to the array, wherein an miRNA profile is generated. See U.S. Provisional Patent Application 60/575,743 and the U.S. Provisional Patent Application 60/649,584, and U.S. Patent Application Serial No. 11/141,707, all of which are hereby incorporated by reference.

**[0037]** Additionally, a cell that is introduced with a synthetic miRNA or an miRNA inhibitor may be subsequently evaluated or assayed for the amount of endogenous or exogenous miRNA or miRNA inhibitor. Any cell type is contemplated for use with the invention. The cell may be from or in a mammal, such as a monkey, horse, cow, pig, sheep, dog, cat, rabbit, mouse, rat, or human.

**[0038]** In other methods of the invention, a step of synthesizing or obtaining the synthetic RNA molecule is included.

**[0039]** In additional embodiments, the synthetic nucleic acid is introduced into the cell by calcium phosphate transfection, lipid transfection, electroporation, microinjection, or injection. In addition, a cell may be in a subject, which may be a patient or an animal model. In this case, synthetic nucleic acids can be administered to the subject or patient using modes of administration that are well known to those of skill in the art, particularly for therapeutic applications. It is particularly contemplated that a patient is human or any other mammal or animal having miRNA.

**[0040]** The present invention also concerns inducing certain cellular characteristics by providing to a cell a particular nucleic acid, such as a specific synthetic miRNA molecule or a synthetic miRNA inhibitor molecule. However, in methods of the invention, the miRNA molecule or miRNA inhibitor need not be synthetic. They may have a sequence that is identical to a naturally occurring miRNA or they may not have any design modifications. In certain embodiments, the miRNA molecule and/or an miRNA inhibitor are synthetic, as discussed above.

**[0041]** The particular nucleic acid molecule provided to the cell is understood to correspond to a particular miRNA in the cell, and thus, the miRNA in the cell is referred to as the "corresponding miRNA." In situations in which a named miRNA molecule is introduced into a cell, the corresponding miRNA will be understood to be the induced miRNA. It is contemplated, however, that the miRNA molecule provided introduced into a cell is not a mature miRNA but is capable of becoming a mature miRNA under the appropriate physiological conditions. In cases in which a particular corresponding miRNA is being inhibited by a miRNA inhibitor, the particular miRNA will be referred to as the targeted miRNA. It is contemplated that multiple corresponding miRNAs may be involved. In particular embodiments, more than one miRNA molecule is introduced into a cell. Moreover, in other embodiments, more than one miRNA inhibitor is introduced into a cell. Furthermore, a combination of miRNA molecule(s) and miRNA inhibitor(s) may be introduced into a cell.

**[0042]** Methods include identifying a cell or patient in need of inducing those cellular characteristics. Also, it will be understood that an amount of a synthetic nucleic acid that is provided to a cell or organism is an "effective amount," which refers to an amount needed to achieve a desired goal, such as inducing a particular cellular characteristic(s).

**[0043]** In certain embodiments of the methods include providing or introducing to a cell a nucleic acid molecule corresponding to a mature miRNA in the cell in an amount effective to achieve a desired physiological result. Such methods are disclosed herein. Moreover, methods of the invention involve diagnosing a patient based on an miRNA expression profile. In certain embodiments, the elevation or reduction in the level of expression of a particular miRNA in a cell is correlated with a disease state compared to the expression level of that miRNA in a normal cell. This correlation allows for diagnostic methods to be carried out when that the expression level of an miRNA is measured in a biological sample being assessed and then compared to the expression level of a normal cell.

**[0044]** In these different methods, the corresponding miRNA involved in the method may be one or more of at least the following: Let 7a, let 7a-1, let 7b, let 7b-1, let-7c, let-7d, let 7g, miR-1, miR-1-d, miR-1-2, miR-9, miR-10a, miR-10b, miR-15a, miR-16, miR-17, miR-17-3p, miR-18, miR-19a, miR-20, miR-21, miR-22, miR-23, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-27a, miR-28, miR-29a, miR-29b, miR-30a-3p, miR-30a, miR-30e-5p, miR-31, miR-32, miR-34a, miR-92, miR-93, miR-95, miR-96, miR-98, miR-99a, miR-100, miR-101, miR-105, miR-106, miR-107, miR-108, miR-122, miR-124, miR-125, miR-125b, miR-126, miR-127, miR-128, miR-129, miR-130, miR-130a, miR-133, miR-133a, miR-133a-2, miR-133b, miR-134, miR-135, miR-137, miR-138, miR-139, miR-140, miR-141, miR-142, miR-143, miR-145, miR-147, miR-148, miR-149, miR-150, miR-152, miR-153, miR-154, miR-155, miR-181, miR-182, miR-183, miR-184, miR-186, miR-187, miR-188, miR-190, miR-191, miR-192, miR-193, miR-194, miR-195, miR-196, miR-197, miR-198, miR-199, miR-199a-1, miR-200b, miR-201, miR-203, miR-204, miR-206, miR-207, miR-208, miR-210, miR-211, miR-212, miR-213, miR-214, miR-215, miR-216, miR-217, miR-218, miR-222, miR-223, miR-224, miR-291-3p, miR-292, miR-292-3p, miR-293, miR-294, miR-295, miR-296, miR-297, miR-298, miR-299, miR-320, miR-321, miR-322,

miR-324, miR-325, miR-326, miR-328, miR-329, miR-330, miR-331, miR-333, miR-335, miR-337, miR-338, miR-340, miR-341, miR-342, miR-344, miR-345, miR-346, miR-350, miR-367, miR-368, miR-369, miR-370, miR-371, miR-373, miR-380-3p, miR-409, miR-410, or miR-412.

**[0045]** Moreover, methods can involve providing synthetic or nonsynthetic miRNA molecules. It is contemplated that in these embodiments, methods may or may not be limited to providing only one or more synthetic miRNA molecules or only on or more nonsynthetic miRNA molecules. Thus, in certain embodiments, methods may involve providing both synthetic and nonsynthetic miRNA molecules. In this situation, a cell or cells are most likely provided a synthetic miRNA molecule corresponding to a particular miRNA and a nonsynthetic miRNA molecule corresponding to a different miRNA. Furthermore, any method articulated a list of miRNAs using Markush group language may be articulated without the Markush group language and a disjunctive article (*i.e.*, or) instead, and vice versa.

**[0046]** In some embodiments, there is a method for reducing or inhibiting cell proliferation in a cell comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves introducing into the cell an effective amount of i) an miRNA inhibitor molecule having a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of: mir-31, mir-92, mir-99a, mir-100, mir-125a, mir-129, mir-130a, mir-150, mir-187, miR-190, miR-191, miR-193, miR 204, mir-210, mir-211, mir-212, mir-213, mir-215, mir-216, mir-217, miR 218, mir-224, mir-292, mir-294, mir-320, mir-324, mir-325, mir-326, mir-330, mir-331, mir-338, mir-341, mir-369, and mir-370; or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence selected from the group consisting of: miR-15a, miR-16, miR 21, miR 24, miR-96, miR-101, miR-105, miR-124, miR-126, miR-142, miR-147, miR-192, miR-194, miR-206, miR-215, or miR-346.

**[0047]** In addition or alternatively, any of the following may be included in the group from which the miRNA inhibitor molecule (i) may be chosen: Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, miR-7, mir-9, miR-10a, miR-10b, miR-18, miR-19a, miR-17-3p, miR-20, miR-23b, mir-25, miR-26a, miR-26a, mir-30e-5p, mir-31, mir-32, mir-92, mir-93, miR-100, miR-125a, miR-125b, mir-127, miR-128, miR-129, mir-130a, mir-135, mir-138, mir-139, miR-140, mir-141, mir-143, mir-145, mir-146, miR-150, mir-154, mir-155, mir-181a, miR-182, mir-186, miR-187, miR-188, mir-190, mir-191, mir-193, mir-196, mir-197, mir-198, mir-199, mir-201, mir-204, mir-216, mir-218, miR-223, mir-293, miR-291-3p, miR-294, miR-295, miR-322, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, miR-373, mir-410, and mir-412. In addition or alternatively, any of the following may be included in the group from which the miRNA molecule that corresponds to an miRNA sequence (ii) may be chosen: let7a-1, Let-7a, Let-7b, let7b-1, let7c, let7d, Let-7g, mir-9, mir-10a, mir-10b, mir-15a, mir-16, mir-21, mir-23a, mir-23b, mir-24, mir-25, mir-92, mir-95, mir-133a, mir-133a-2, mir-133b, mir-142, mir-152, mir-153, mir-155, mir-181a, mir-182, mir-183, mir-184, mir-186, mir-187, mir-191, mir-193, mir-194, mir-196, mir-199a-1, mir-200b, mir-204, mir-206, mir-211, mir-222, mir-223, mir-298, mir-328, mir-342, mir-371, and mir-412.

**[0048]** In other words, methods involve providing a synthetic miRNA inhibitor having a sequence that is at least 90% complementary to the 5' to 3' sequence of a corresponding miRNA that is mir-31, mir-92, mir-99a, mir-100, mir-125a, mir-129, mir-130a, mir-150, mir-187, miR-190, miR-191, miR-193, miR 204, mir-210, mir-211, mir-212, mir-213, mir-215, mir-216, mir-217, miR 218, mir-224, mir-292, mir-294, mir-320, mir-324, mir-325, mir-326, mir-330, mir-331, mir-338, mir-341, mir-369, mir-370, Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, miR-7, mir-9, miR-10a, miR-10b, miR-18, miR-19a, miR-17-3p, miR-20, miR-23b, mir-25, miR-26a, miR-26a, mir-30e-5p, mir-31, mir-32, mir-92, mir-93, miR-100, miR-125a, miR-125b, mir-127, miR-128, miR-129, mir-130a, mir-135, mir-138, mir-139, miR-140, mir-141, mir-143, mir-145, mir-146, miR-150, mir-154, mir-155, mir-181a, miR-182, mir-186, miR-187, miR-188, mir-190, mir-191, mir-193, mir-196, mir-197, mir-198, mir-199, mir-201, mir-204, mir-216, mir-218, miR-223, mir-293, miR-291-3p, miR-294, miR-295, miR-322, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, miR-373, mir-410, or mir-412. Alternatively or additionally, methods involve providing a synthetic or nonsynthetic miRNA molecule that corresponds to miR-15a, miR-16, miR 21, miR 24, miR-96, miR-101, miR-105, miR-124, miR-126, miR-142, miR-147, miR-192, miR-194, miR-206, miR-215, miR-346, let7a-1, Let-7a, Let-7b, let7b-1, let7c, let7d, Let-7g, mir-9, mir-10a, mir-10b, mir-15a, mir-16, mir-21, mir-23a, mir-23b, mir-24, mir-25, mir-92, mir-95, mir-133a, mir-133a-2, mir-133b, mir-142, mir-152, mir-153, mir-155, mir-181a, mir-182, mir-183, mir-184, mir-186, mir-187, mir-191, mir-193, mir-194, mir-196, mir-199a-1, mir-200b, mir-204, mir-206, mir-211, mir-222, mir-223, mir-298, mir-328, mir-342, mir-371, or mir-412. Methods for reducing or inhibiting cell proliferation can be used as a treatment for diseases and conditions that include, but are not limited to, hyperproliferative diseases, such as cancer.

**[0049]** The present invention also concerns methods for inducing or increasing cell proliferation in a cell comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves introducing into or providing the cell an effective amount of i) an miRNA inhibitor corresponding to let7a-1, Let-7a, Let-7b, let7b-1, let7c, let7d, Let-7g, mir-9, mir-10a, mir-10b, mir-15a, mir-16, mir-21, mir-23a, mir-23b, mir-24, mir-25, mir-92, mir-95, mir-133a, mir-133a-2, mir-133b, mir-142, mir-152, mir-153, mir-155, mir-181a, mir-182, mir-183, mir-184, mir-186, mir-187, mir-191, mir-193, mir-194, mir-196, mir-199a-1, mir-200b, mir-204, mir-206, mir-211, mir-222, mir-223, mir-298, mir-328, mir-342, mir-371, and mir-412; or ii) a miRNA molecule corresponding to Let-7a, Let-7b, Let-7c, Let-

7d, Let-7g, miR-7, mir-9, miR-10a, miR-10b, miR-15a, miR-18, miR-19a, miR-17-3p, miR-20, miR-23b, mir-25, miR-26a, miR-26a, mir-30e-5p, mir-31, mir-32, mir-92, mir-93, miR-100, miR-125a, miR-125b, miR-126, mir-127, miR-128, miR-129, mir-130a, mir-135, mir-138, mir-139, miR-140, mir-141, mir-143, mir-145, mir-146, miR-150, mir-154, mir-155, mir-181a, miR-182, mir-186, miR-187, miR-188, mir-190, mir-191, mir-193, mir-194, mir-196, mir-197, mir-198, mir-199, mir-201, mir-204, mir-216, mir-218, miR-223, mir-293, miR-291-3p, miR-294, miR-295, miR-322, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, miR-373, mir-410, and mir-412. Alternatively or additionally, the group of miRNA inhibitors includes miR-15a, miR-16, miR 21, miR 24, miR-96, miR-101, miR-105, miR-124, miR-126, miR-142, miR-147, miR-192, miR-194, miR-206, miR-215, or miR-346 and the group of miRNAs molecules corresponding to miRNAs includes mir-31, mir-92, mir-99a, mir-100, mir-125a, mir-129, mir-130a, mir-150, mir-187, miR-190, miR-191, miR-193, miR 204, mir-210, mir-211, mir-212, mir-213, mir-215, mir-216, mir-217, miR 218, mir-224, mir-292, mir-294, mir-320, mir-324, mir-325, mir-326, mir-330, mir-331, mir-338, mir-341, mir-369, and mir-370.

**[0050]** Such methods can be used for the treatment of wounds, burns, ischemia, or any other condition, disease, or symptom in which cell proliferation is desirable.

**[0051]** It will be understood in methods of the invention that a cell or other biological matter such as an organism (including patients) can be provided an miRNA or miRNA molecule corresponding to a particular miRNA by administering to the cell or organism a nucleic acid molecule that functions as the corresponding miRNA once inside the cell. The form of the molecule provided to the cell may not be the form that acts as an miRNA once inside the cell. Thus, it is contemplated that in some embodiments, biological matter is provided a synthetic miRNA or a nonsynthetic miRNA, such as one that becomes processed into a mature and active miRNA once it has access to the cell's miRNA processing machinery. In certain embodiments, it is specifically contemplated that the miRNA molecule provided to the biological matter is not a mature miRNA molecule but a nucleic acid molecule that can be processed into the mature miRNA once it is accessible to miRNA processing machinery. The term "nonsynthetic" in the context of miRNA means that the miRNA is not "synthetic," as defined herein. Furthermore, it is contemplated that in embodiments of the invention that concern the use of synthetic miRNAs, the use of corresponding nonsynthetic miRNAs is also considered an aspect of the invention, and vice versa.

**[0052]** In other embodiments, the methods involve reducing cell viability comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves introducing into one or more cells an effective amount of i) an miRNA inhibitor corresponding to miR-107, miR-133, miR-137, miR-152, miR-155, miR-181a, miR-191, miR-203, or miR-215; or ii) an miRNA molecule corresponding to let-7a, let-7b, mir-1, mir-7, miR-10b, miR-17-3p, miR-19a, mir-23, mir-24, mir-27a, miR-29a, miR-30a-3p, mir-31, mir-32, miR-34a, miR-101, miR-107, miR-108, miR-122, mir-124, miR-133a, miR-134, miR-135, miR-139, mir-140, miR-141, miR-145, mir-150, mir-192, mir-193, mir-195, mir-206, mir-208, mir-210, mir-210, mir-292-3p, mir-293, mir-297, mir-299, mir-329, mir-337, mir-337, mir-345, mir-346, and mir-409. Alternatively or additionally, the group of miRNA inhibitors (group i) includes let-7a, let-7b, let-7c, let-7d, let-7g, miR-10a, miR-10b, miR-15a, miR-17-3p, miR-18, miR-19a, miR-20, mir-23a, mir-23b, mir-24, miR-25, miR-26a, mir-32, miR-107, miR-125a, miR-126, mir-128, miR-129, miR-133, miR-137, mir-139, miR-143, miR-152, miR-155, miR-181a, miR-182, miR-191, miR-203, miR-215, and mir-331.

**[0053]** Other aspects of the invention include a method for increasing cell viability comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves introducing into one or more cells an effective amount of i) an miRNA inhibitor corresponding to miR-7, miR-19a, miR-23, miR-24, miR-27a, miR-31, miR-32, miR-134, miR-140, miR-150, miR-192, or miR-193; or ii) an miRNA molecule corresponding to let-7a, let-7b, let-7c, let-7d, let-7g, miR-10a, miR-10b, miR-15a, miR-17-3p, miR-18, miR-19a, miR-20, mir-23a, mir-23b, mir-24, miR-25, miR-26a, mir-32, miR-107, miR-125a, miR-126, mir-128, miR-129, miR-133, miR-137, mir-139, miR-143, miR-152, miR-155, miR-181a, miR-182, miR-191, miR-203, miR-215, and mir-331. Alternatively or additionally, the group of miRNA inhibitors (group i) includes let-7a, let-7b, mir-1, mir-7, miR-10b, miR-17-3p, miR-19a, mir-23, mir-24, mir-27a, miR-29a, miR-30a-3p, mir-31, mir-32, miR-34a, miR-101, miR-107, miR-108, miR-122, mir-124, miR-133a, miR-134, miR-135, miR-139, mir-140, miR-141, miR-145, mir-150, mir-192, mir-193, mir-195, mir-206, mir-208, mir-210, mir-210, mir-292-3p, mir-293, mir-297, mir-299, mir-329, mir-337, mir-337, mir-345, mir-346, or mir-409, and the group of miRNAs molecules corresponding to miRNAs (group ii) includes .The present invention also concerns a method for inducing apoptosis in a cell comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves introducing into the cell an effective amount of i) an miRNA inhibitor corresponding to miR-31 or miR-214; or ii) an miRNA molecule corresponding to let-7b, let-7g, mir-1, mir-1d, mir-7, mir-10a, miR-10b, miR-17-3p, miR-19a, miR-28, miR-28, miR-28, miR-29a, miR-32, miR-34a, miR-122, mir-148, mir-149, mir-154, mir-184, mir-186, mir-188, mir-192, mir-195, mir-196, mir-199a, mir-204, mir-208, mir-210, mir-211, mir-212, mir-214, mir-215, mir-216, mir-217, mir-218, mir-293, mir-296, mir-299, mir-321, mir-328, or mir-344. Alternatively or additionally, the group of miRNA inhibitors (group i) includes Let-7b, mir-21, mir-23b, mir-25, miR-26a, mir-28, mir-29a, mir-31, miR-32, mir-30a-3p, mir-34a, mir-96, miR-98, mir-100, mir-101, mir-105, mir-108, miR-125b, miR-126, mir-126, mir-128, mir-137,

miR-143, miR-155, mir-207, mir-214, mir-216, mir-223, mir-292-3p, mir-328, mir-335, mir-340, mir-341, mir-367, mir-368, mir-380-3p, andmir-410 .

**[0054]** Methods for inducing apoptosis have a number of therapeutic applications including, but not limited to, the treatment of cancer.

**[0055]** Other embodiments of the invention involve a method for inhibiting apoptosis in a cell comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves introducing into the cell an effective amount of i) an miRNA inhibitor corresponding to miR-7, miR-1-2, miR-148, miR-195, miR-196, miR-199a, miR-204, miR-210, miR-211, miR-212, miR-215, miR-216, miR-218, miR-296, or miR-321; or ii) an miRNA molecule corresponding to Let-7b, mir-21, mir-23b, mir-25, miR-26a, mir-28, mir-29a, mir-31, miR-32, mir-30a-3p, mir-34a, mir-96, miR-98, mir-100, mir-101, mir-105, mir-108, miR-125b, miR-126, mir-126, mir-128, mir-137, miR-143, miR-155, mir-207, mir-214, mir-216, mir-223, mir-292-3p, mir-328, mir-335, mir-340, mir-341, mir-367, mir-368, mir-380-3p, or mir-410. Alternatively or additionally, the group of miRNA inhibitors (group i) includes let-7b, let-7g, mir-1, mir-1d, mir-7, mir-10a, miR-10b, miR-17-3p, miR-19a, miR-28, miR-28, miR-28, miR-29a, miR-32, miR-34a, miR-122, mir-148, mir-149, mir-154, mir-184, mir-186, mir-188, mir-192, mir-195, mir-196, mir-199a, mir-204, mir-208, mir-210, mir-211, mir-212, mir-214, mir-215, mir-216, mir-217, mir-218, mir-293, mir-296, mir-299, mir-321, mir-328, or mir-344.

**[0056]** The present invention also concerns using miRNA compositions to treat diseases or conditions or to prepare therapeutics for the treatment of diseases or conditions. In some embodiments, the invention involves one or more human miRNA selected from the group consisting of let-7, miR-10a, miR-15a, miR-16, miR-17, miR-21, miR-22, miR-23, miR-24, miR-26a, miR-29b, miR-30a, miR-96, miR-101, miR-105, miR-106, miR-124, miR-125a, miR-126, miR-130, miR130a, miR-133, miR-142, miR-143, miR-144, miR-145, miR-147, miR-181a, miR-182, miR-183, miR-188, miR-189, miR-192, miR-194, miR-195, miR-199a, miR-200b, miR-201, miR-205, miR-219, 206, miR-215, miR-219, miR-223, miR-224, miR-321, miR-328, miR-331, miR-342. and miR-219,346. It is contemplated that 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 more miRNA (or any range derivable therein) may be used for these embodiments. In certain embodiments, methods involve one or more miRNA inhibitors and/or an miRNA molecules corresponding to any of these miRNAs, particularly for the treatment or prevention of cancer. Cancer includes, but is not limited to, malignant cancers, tumors, metastatic cancers, unresectable cancers, chemo- and/or radiation-resistant cancers, and terminal cancers.

**[0057]** In some embodiments of the invention, methods involve one or more miRNA inhibitors and/or an miRNA molecules corresponding to miR-17, miR-21, miR-126, miR-143, miR-145, miR-188, miR-200b, miR-219, or miR-331. In certain embodiments, methods involve one or more of 1) an inhibitor of miR-17, miR-21, miR-182, miR-183, miR-200b, miR-205, miR-223, and/or miR-224; and/or 2) an miRNA corresponding to let-7, miR-10a, miR-16, miR-22, miR-23, miR-24, miR-26a, miR-29b, miR-30a, miR-106, miR-125a, miR-126, miR-130, miR-133, miR-143, miR-144, miR-145, miR-181a, miR-188, miR-219, miR-192, miR-194, miR-195, miR-199a, mmu-miR-201, miR-215, miR-321, miR-328, miR-331, and/or miR-342. Such methods can be used, in some embodiments to treat cancer, including specific cancers. Additionally, an miRNA corresponding to one or more of miR-15a, miR-16, miR-96, miR-101, miR-105, miR-124, miR-126, miR-142, miR-147, miR-192, miR-194, miR-206, miR-215, or miR-346 maybe used to treat cancer or inhibit cell proliferation. It is contemplated that these miRNAs may be used regardless of the source of the cell in which proliferation is undesirable.

**[0058]** It will be understood that shorthand notations are employed such that a generic description of an miRNA refers to any of its gene family members (distinguished by a number), unless otherwise indicated. It is understood by those of skill in the art that a "gene family" refers to a group of genes having the same miRNA coding sequence. Typically, members of a gene family are identified by a number following the initial designation. For example, miR-16-1 and miR-16-2 are members of the miR-16 gene family and "mir-7" refers to miR-7-1, miR-7-2 and miR-7-3. Moreover, unless otherwise indicated, a shorthand notation refers to related miRNAs (distinguished by a letter). Thus, "let-7," for example, refers to let-7a-1, let7-a-2, let-7b, let-7c, let-7d, let-7e, let-7f-1, and let-7f-2." Exceptions to this shorthand notations will be otherwise identified.

**[0059]** The present invention concerns treating breast cancer or decreasing cell proliferation of breast cancer cells by introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or non-synthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing an effective amount of at least 1) one or more miRNA inhibitors corresponding to miR-21, miR-15a, miR-16, miR-24, and/or miR-25, and/or 2) one or more miRNAs corresponding to miR-99, miR-100, miR-205, miR-197, miR-126, miR-143, miR-145 and/or miR-321. Alternatively or additionally, the miRNAs molecules corresponding to miRNAs (group ii) can include mir-27a, mir-92, mir-96, mir-98, mir-99a, mir-101, mir-105, mir-124, mir-126, mir-129, mir-132, mir-142, mir-147, mir-192, mir-201, mir-206, mir-208, mir-210, mir-211, mir-214, mir-215, mir-219, mir-220, mir-221, mir-223, mir-297, mir-329, mir-331, mir-345, mir-346, mir-409, or mir-411.

**[0060]** It will be understand that the term "providing" an agent is used to include "administering" the agent to a patient.

**[0061]** The present invention also relates to treating colon cancer by introducing into or providing to a colon cancer

cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing 1) one or more miRNA inhibitors corresponding to miR-21, miR-106, miR-200b, miR-223, miR-224, miR-31, and/or miR-17; and/or 2) one or more miRNAs corresponding to miR-145, miR-143, miR-133, miR-342, miR-125a, miR-195, miR-30a, miR-10a, miR-130, miR-192, miR-194, miR-215, miR-144, miR-23, miR-26a, miR-126, miR-199a, miR-188, miR-331, and/or miR-21.

**[0062]** Moreover, methods for treating thyroid cancer involve introducing into or providing to a thyroid cancer cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to the patient 1) one or more miRNA inhibitors corresponding to miR-21 miR-125, miR-24, miR-200b, miR-29b, miR-221, miR-222, miR-224, miR-10a, and/or miR-183; and/or 2) one or more miRNAs corresponding to miR-145, miR-22, miR-331, miR-126, miR-30a, miR-199a, miR-223, and/or miR-321.

**[0063]** The treatment of lung cancer is also contemplated as part of the invention. Methods involve introducing into or providing to a lung cancer cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to the patient 1) one or more miRNA inhibitors corresponding to miR-223, miR-106, miR-21, miR-200b, miR-321, miR-182, miR-183, miR-17, and/or miR-205; and/or 2) one or more miRNAs corresponding to miR-130a, miR-145, miR-126, miR-331, miR-342, miR-143, Let-7, miR-30a, miR-16, miR-26a, miR-125a, miR-29b, miR-24, miR-328, miR-195, miR-22, miR-181a, miR-331, and/or miR-321. Alternatively or additionally, the group of miRNA inhibitors (group 1) includes miR-30e-5p, mir-25, mir-32, mir-92, mir-130a, mir-135, mir-145, mir-216, mir-293, mir-294, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, or mir-412, and the group of miRNAs molecules corresponding to miRNAs (group 2) includes ambi-mir7100, Let-7b, Let-7d, Let-7g, mir-7, mir-15a, mir-16, mir-22, mir-28, mir-29a, mir-34a, mir-96, mir-101, mir-105, mir-108, mir-122, mir-124, mir-125a, mir-125b, mir-126, mir-128, mir-129, mir-132, mir-133A, mir-136, mir-137, mir-141, mir-142, mir-147, mir-149, mir-151, mir-152, mir-182, mir-183, mir-186, mir-188, mir-192, mir-193, mir-195, mir-223, mir-292-3p, mir-337, mir-337, mir-344, mir-345, mir-346, mir-377, or mir-526b\*.

**[0064]** The present invention concerns treating cervical cancer or decreasing cell proliferation of cervical cancer cells by providing an effective amount of at least 1) one or more miRNA inhibitors corresponding to Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, mir-9, mir-145, mir-155, mir-181a, mir-186, mir-190, mir-191, or mir-199, and/or 2) one or more miRNAs corresponding to mir-1, mir-34a, mir-101, mir-124, mir-192, mir-193, mir-195, mir-201, mir-206, mir-208, mir-210, mir-215, mir-292-3p, mir-293, mir-297, mir-299, mir-337, mir-339, mir-340, mir-344, mir-345, mir-367, or mir-409.

**[0065]** The present invention concerns treating prostate cancer or decreasing cell proliferation of prostate cancer cells by introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing an effective amount of at least 1) one or more miRNA inhibitors corresponding to Let-7a, Let-7b, mir-93, mir-127, mir-154, mir-181a, mir-194, mir-198, mir-199, mir-201, or mir-369, and/or 2) one or more miRNAs corresponding to mir-15a, mir-16, mir-27a, mir-28, mir-30a-3p, mir-34a, mir-101, mir-103, mir-105, mir-107, mir-124, mir-126, mir-128, mir-129, mir-132, mir-135, mir-137, mir-141, mir-142, mir-147, or mir-297.

**[0066]** The present invention concerns treating skin cancer or decreasing cell proliferation of skin cancer cells by introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing an effective amount of at least 1) one or more miRNA inhibitors corresponding to miR-26a, miR-125a, miR-128, mir-138, mir-139, mir-141, mir-143, miR-145, mir-146, miR-150, miR-187, mir-188, mir-190, mir-196, mir-197, mir-198, mir-199, miR-201, mir-204, mir-216, miR-223, miR-291-3p, miR-294, miR-295, miR-322, miR-373, mir-410, or mir-412, and/or 2) one or more miRNAs corresponding to let 7a, mir-1, mir-7, mir-15a, mir-16, mir-20, mir-26a, mir-28, mir-34a, mir-96, mir-101, mir-105, miR-105, mir-124, mir-126, mir-128, mir-132, mir-133A, mir-136, mir-137, mir-141, mir-142, mir-144, miR-147, mir-154, mir-181a, mir-192, mir-193, miR-195, mir-201, mir-206, mir-206, mir-215, mir-221, mir-223, mir-291, miR-297, mir-302, miR-324-3p, mir-329, mir-330, miR-337, mir-346, mir-346, mir-373, mu-mir-376b, mir-380-3p, or mir-411. The present invention concerns treating leukemia or decreasing cell proliferation of cancerous T cells by introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing an effective amount of at least 1) one or more miRNA inhibitors corresponding to miR-15a, miR-23b, miR-25, miR-26a, miR-100, miR-125b, miR-126, miR-129, miR-140, miR-143, or miR-155, and/or 2) one or more miRNAs corresponding to let-7a, let-7b, miR-10b, miR-17-3p, miR-29a, miR-30a-3p, miR-34a, miR-101, miR-122, or miR-133a. Alternatively or additionally, the group of miRNA inhibitors (group 1) includes let-7a, let-7b, let-7c, let-7d, let-7g, miR-7, miR-10a, miR-10b, miR-15a, miR-17-3p, miR-18, miR-19a, miR-20, miR-125a, miR-126, or miR-182, and the group of miRNAs molecules corresponding to miRNAs (group 2) includes miR-107, miR-134, miR-135, miR-139, miR-141, or miR-145. Moreover, such methods can extend to T-cells generally.

**[0067]** In addition to any miRNAs disclosed herein in the context of decreasing cell proliferation, embodiments of the invention include methods for decreasing cell proliferation comprising introducing into or providing to the cell an effective

amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing or introducing an effective amount of at least 1) one or more miRNA inhibitors corresponding to Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, miR-7, mir-9, miR-10a, miR-10b, miR-15a, miR-18, miR-19a, miR-17-3p, miR-20, miR-23b, mir-25, miR-25, miR-26a, miR-26a, mir-30e-5p, mir-32, mir-92, mir-93, miR-100, miR-125a, miR-125b, miR-126, mir-127, miR-128, miR-129, mir-130a, mir-135, mir-138, mir-139, miR-140, mir-141, mir-143, mir-145, mir-146, miR-150, mir-154, mir-155, mir-181a, miR-182, mir-186, miR-187, miR-188, mir-190, mir-191, mir-194, mir-196, mir-197, mir-198, mir-199, mir-201, mir-204, mir-216, miR-223, mir-293, miR-291-3p, miR-294, miR-295, miR-322, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, miR-373, mir-410, or mir-412, and/or 2) one or more miRNAs corresponding to ambi-mir7100, let 7a, let-7b, let-7d, let-7g, mir-1, mir-7, miR-10b, mir-15a, mir-16, miR-17-3p, mir-20, mir-22, mir-26a, mir-27a, mir-28, mir-28, miR-29a, mir-30a-3p, mir-34a, mir-92, mir-96, mir-98, mir-99a, mir-101, mir-103, mir-105, mir-107, mir-108, mir-122, mir-124, mir-125a, mir-125b, mir-126, mir-128, mir-129, mir-132, miR-133a, miR-134, mir-135, mir-136, mir-137, miR-139, mir-141, mir-142, mir-144, miR-145, mir-147, mir-149, mir-151, mir-152, mir-154, mir-181a, mir-182, mir-183, mir-186, mir-188, mir-192, mir-193, mir-195, mir-195, mir-201, mir-206, mir-208, mir-210, mir-211, mir-214, mir-215, mir-219, mir-220, mir-221, mir-223, mir-291, mir-292-3p, mir-293, mir-297, mir-299, mir-302, miR-324-3p, mir-329, mir-330, mir-331, mir-337, mir-339, mir-340, mir-344, mir-345, mir-346, mir-367, mir-373, miR-376b, mir-377, mir-380-3p, mir-409, mir-411, or mir-526b\*. It is particularly contemplated that such methods may be employed in the context of treating cancer or another disease or condition in which cell proliferation plays a role, such as hyperproliferative diseases and conditions.

**[0068]** The present invention also concerns embodiments methods for increasing cell proliferation comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing or introducing an effective amount of at least 1) one or more miRNA inhibitors corresponding to ambi-mir7100, let 7a, let-7b, let-7d, let-7g, mir-1, mir-7, miR-10b, mir-15a, mir-16, miR-17-3p, mir-20, mir-22, mir-26a, mir-27a, mir-28, mir-28, miR-29a, mir-30a-3p, mir-34a, mir-92, mir-96, mir-98, mir-99a, mir-101, mir-103, mir-105, mir-107, mir-108, mir-122, mir-124, mir-125a, mir-125b, mir-126, mir-128, mir-129, mir-132, miR-133a, miR-134, mir-135, mir-136, mir-137, miR-139, mir-141, mir-142, mir-144, miR-145, mir-147, mir-149, mir-151, mir-152, mir-154, mir-181a, mir-182, mir-183, mir-186, mir-188, mir-192, mir-193, mir-195, mir-195, mir-201, mir-206, mir-208, mir-210, mir-211, mir-214, mir-215, mir-219, mir-220, mir-221, mir-223, mir-291, mir-292-3p, mir-293, mir-297, mir-299, mir-302, miR-324-3p, mir-329, mir-330, mir-331, mir-337, mir-339, mir-340, mir-344, mir-345, mir-346, mir-367, mir-373, miR-376b, mir-377, mir-380-3p, mir-409, mir-411, or mir-526b\*, and/or 2) one or more miRNAs corresponding to Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, miR-7, mir-9, miR-10a, miR-10b, miR-15a, miR-18, miR-19a, miR-17-3p, miR-20, miR-23b, mir-25, miR-25, miR-26a, miR-26a, mir-30e-5p, mir-32, mir-92, mir-93, miR-100, miR-125a, miR-125b, miR-126, mir-127, miR-128, miR-129, mir-130a, mir-135, mir-138, mir-139, miR-140, mir-141, mir-143, mir-145, mir-146, miR-150, mir-154, mir-155, mir-181a, miR-182, mir-186, miR-187, miR-188, mir-190, mir-191, mir-194, mir-196, mir-197, mir-198, mir-199, mir-201, mir-204, mir-216, miR-223, mir-293, miR-291-3p, miR-294, miR-295, miR-322, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, miR-373, mir-410, or mir-412. While not limited to such an embodiment, one use for such a method is to increase or induce proliferation of normal cells or other desirable cells in the context of pretreatment or therapy.

**[0069]** Other aspects of the invention include the treatment of systemic lupus erythematosus (SLE). In certain embodiments, methods concern introducing into or providing to a patient an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to a patient with SLE or suspect of having SLE 1) one or more miRNA inhibitors corresponding to miR-21, miR-223, and/or mir-342 expression; and/or 2) one or more miRNAs corresponding to miR-95, miR-105, miR-137, miR-186, miR-188, miR-199, miR-211, miR-215, mu-miR-290, miR-301, and/or miR-331.

**[0070]** Treatment or prevention of prion diseases is included in methods of the invention. In some cases, method include introducing into or providing to a patient with a prion disease an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to a patient 1) one or more miRNA inhibitors corresponding miR-7, miR-9, miR-16, miR-24, miR-26A, miR-27A, and/or miR-130A; and/or 2) one or more miRNAs corresponding to miR-95 and/or miR-135A. The patient may be one diagnosed with a prion disease, one at risk for a prion disease, or one suspected of having a prion disease. It is specifically contemplated that in some embodiments of the invention, a nucleic acid molecule corresponding to an miRNA is double stranded, wherein both strands have the sequence of the mature miRNA it corresponds to. Such a molecule may be designated with an "as" suffix in embodiments of the invention. For example, a nucleic acid molecule called miR-9-as was used in some experiments described herein. It is contemplated that in some embodiments, a nucleic acid molecule is an miRNA-as molecule.

**[0071]** The present invention also concerns patients diagnosed as having ischemia, those at risk for ischemia, those suspected of having ischemia, or patients with symptoms of ischemia. Methods involve introducing into or providing to a patient an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to a patient 1) one or more

miRNA inhibitors corresponding to miR-28, miR-30A, miR-31, miR-138, miR-139, miR-140, miR-291 and/or mmu-miR-298; and/or 2) one or more miRNAs corresponding to Let-7f-2 and/or miR-16.

**[0072]** In certain experiments, a synthetic miRNA in which both the sense and antisense strand are derived from a single precursor miRNA is used in methods and compositions of the invention. These are frequently designated with a "P" suffix in which "5P" indicates that the mature miRNA derives from the 5' end of the precursor and a corresponding "3P" indicates that it derives from the 3' end of the precursor, as described on the world wide web at sanger.ac.uk/cgi-bin/rfam/mirna. Moreover, in some embodiments, an miRNA that does not correspond to a known human miRNA was evaluated. It is contemplated that these non-human miRNAs may be used in embodiments of the invention or that there may exist a human miRNA that is homologous to the non-human miRNA.

**[0073]** The present invention in some embodiments concerns methods for reducing cell viability comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is let-7a, let-7b, miR-1, miR-10b, miR-17, miR-19a, miR-20, miR-28, miR-29a, miR-30a, miR-32, miR-34a, miR-96, miR-101, miR-122, miR-124, miR-132, miR-133a, miR-134, miR-139, miR-140, miR-144, miR-145, miR-147, miR-155, miR-182, miR-183, miR-184, miR-186, miR-190, miR-193, miR-197, miR-206, miR-208, miR-210, miR-216, miR-217, miR-224, mu-miR-292, mu-miR-293, mu-miR-298, miR-299, miR-301, mu-miR-329, miR-337, mu-miR-344, miR-345, miR-346, miR-369, mu-miR-380, or mu-miR-409; or 2) at least one miRNA inhibitor corresponding to let-7a, let-7b, let-7c, miR-9, miR-10a, miR-10b, miR-15a, miR-17, miR-18, miR-20, miR-23b, miR-25, miR-26a, miR-98, miR-100, miR-125a, miR-125b, miR-126, miR-129, miR-140, miR-141, miR-143, miR-155, or miR-181-a. The term "reducing cell viability" means reducing the number of live cells.

**[0074]** Methods concerning cell viability and cell proliferation may generally be used for therapeutics, diagnostics, creating cell lines with interesting research properties, and inducing differentiation. miRNAs that selectively reduce the proliferation of cancer cells may be employed as therapeutics since they can be delivered to cancer and non-cancer cells alike but will only affect the growth of the cancerous cells. In addition, methods may be used to halt or prevent metastasis or reduce the number of metastases.

**[0075]** It is contemplated in some embodiments that the cell in which the effect is desired (referred to as a "targeted cell"), such as a reduction in cell viability, may be a cell that is diseased or involved in maintaining, promoting, or causing a disease or condition. In certain embodiments, the cell is a cancer cell, while in other embodiments, it is contemplated to be a healthy (non-diseased) cell. In certain embodiments, a targeted cell is in an organism.

**[0076]** Moreover, it is particularly contemplated that a nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell is a synthetic miRNA in some embodiments of the invention.

**[0077]** In other embodiments, the present invention involves methods for increasing cell viability comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is let-7a, let-7b, let-7c, miR-9, miR-10a, miR-10b, miR-15a, miR-17, miR-18, miR-20, miR-23b, miR-25, miR-26a, miR-98, miR-100, miR-125a, miR-125b, miR-126, miR-129, miR-140, miR-141, miR-143, miR-155, or miR-181-a; or 2) at least one miRNA inhibitor corresponding to let-7a, let-7b, miR-1, miR-10b, miR-17, miR-19a, miR-20, miR-28, miR-29a, miR-30a, miR-32, miR-34a, miR-96, miR-101, miR-122, miR-124, miR-132, miR-133a, miR-134, miR-139, miR-140, miR-144, miR-145, miR-147, miR-155, miR-182, miR-183, miR-184, miR-186, miR-190, miR-193, miR-197, miR-206, miR-208, miR-210, miR-216, miR-217, miR-224, mu-miR-292, mu-miR-293, mu-miR-298, miR-299, miR-301, mu-miR-329, miR-337, mu-miR-344, miR-345, miR-346, miR-369, mu-miR-380, or mu-miR-409. The term "increasing cell viability" means that cell death is inhibited. In particular embodiments, a cancer cell, such as a leukemia cell, is provided with an effective amount of a nucleic acid capable of being processed into a mature let-7a, let-7b, or miR-10b molecule.

**[0078]** Methods of the invention also relate to inhibiting cellular proliferation comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is let-7a, let-7b, let-7c, let-7d, let-7g, miR-1, miR-7, miR-15a, miR-16, miR-19a, miR-22, miR-28, miR-29a, miR-34a, miR-92, miR-96, miR-98, miR-101, miR-122, miR-124, miR-126, miR-129, miR-133b, miR-137, miR-147, miR-192, miR-193, miR-195, miR-205, miR-206, miR-208, miR-210, mu-miR-292, mu-miR-297, miR-299, miR-337, mu-miR-344, miR-345, or miR-346; or 2) at least one miRNA inhibitor corresponding to miR-25, miR-27a, miR-31, miR-32, miR-92, miR-139, miR-145, miR-198, miR-212, mu-miR-290, mu-miR-294, miR-323, miR-324, miR-325, miR-331, miR-335, mu-miR-351, miR-369, miR-370, or miR-373.

**[0079]** In some embodiments there are methods of increasing cellular proliferation comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA

molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is miR-25, miR-27a, miR-31, miR-32, miR-92, miR-139, miR-145, miR-198, miR-212, mu-miR-290, mu-miR-294, miR-323, miR-324, miR-325, miR-331, miR-335, mu-miR-351, miR-369, miR-370, or miR-373; or 2) at least one miRNA inhibitor corresponding to let-7a, let-7b, let-7c, let-7d, let-7g, miR-1, miR-7, miR-15a, miR-16, miR-19a, miR-22, miR-28, miR-29a, miR-34a, miR-92, miR-96, miR-98, miR-101, miR-122, miR-124, miR-126, miR-129, miR-133b, miR-137, miR-147, miR-192, miR-193, miR-195, miR-205, miR-206, miR-208, miR-210, mu-miR-292, mu-miR-297, miR-299, miR-337, mu-miR-344, miR-345, or miR-346.

**[0080]** The present invention also covers methods of inhibiting ERK activation introducing into or providing to a cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves comprising providing to or introducing into cells an effective amount of one or more miRNA inhibitor corresponding to let-7a, mir-294, mir-295, miR-19a, miR-25, miR-96, miR-125a, miR-134, miR-148, miR-152, miR-206, miR-207, miR-210, miR-212, miR-216, miR-217, miR-218, miR-223, mu-miR-294, mu-miR-295, miR-301, miR-328, mu-miR-329, miR-339, miR-370, or miR-372.

**[0081]** In certain embodiments, it also covers methods of activating ERK by introducing into or providing to a cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing or introducing into cells an effective amount of one or more nucleic acids capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is miR-19a, miR-25, miR-96, miR-125a, miR-134, miR-148, miR-152, miR-206, miR-207, miR-210, miR-212, miR-216, miR-217, miR-218, miR-223, mu-miR-294, mu-miR-295, miR-301, miR-328, mu-miR-329, miR-339, miR-370, or miR-372. Alternatively or in addition to the mature miRNA is let-7, miR-19a, miR-25, miR-96, miR-125a, miR-134, miR-148, miR-152, miR-206, miR-207, miR-210, miR-212, miR-216, miR-217, miR-218, miR-223, mu-miR-294, mu-miR-295, miR-301, miR-328, mu-miR-329, miR-339, miR-370, or miR-372.

**[0082]** In other embodiments of the invention, there are methods of increasing the percentage of apoptotic cells in a population comprising introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) one or more nucleic acid molecules capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is let-7d, miR-22, miR-23a, miR-23b, miR-24, miR-27a, miR-31, miR-128, miR-181a, miR-196, miR-198, miR-199, miR-214, miR-217, mu-miR-290, mu-miR-293, miR-324, miR-338, or mu-miR-412; or 2) an miRNA inhibitor corresponding to miR-34a, miR-96, miR-101, miR-105, miR-126, miR-137, or mu-miR-292. It is specifically contemplated that the population of cells may be diseased or related to a disease or condition.

**[0083]** In further embodiments of the invention, there are methods of decreasing the percentage of apoptotic cells in a population comprising introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is miR-34a, miR-96, miR-101, miR-105, miR-126, miR-137, or mu-miR-292; or 2) at least one miRNA inhibitor corresponding to let-7d, miR-22, miR-23a, miR-23b, miR-24, miR-27a, miR-31, miR-128, miR-181a, miR-196, miR-198, miR-199, miR-214, miR-217, mu-miR-290, mu-miR-293, miR-324, miR-338, or mu-miR-412. It is specifically contemplated that the population of cells may be involved in diseases or conditions involving atrophy or the decrease in the number of healthy cells as a result of apoptosis. One or more of the miRNAs that induce apoptosis may be introduced into abnormal cells like cancer cells to induce cell death, providing a therapeutic response. This could be especially beneficial if the apoptosis-inducing synthetic miRNAs were injected directly into tumor tissues or otherwise delivered with high efficiency to primary or metastatic cancer cells. These same miRNAs may be co-delivered with other therapeutic agents like chemotherapies to supplement their activities and evoke a therapeutic response. Alternatively, the miRNAs that reduce apoptosis may be introduced into normal cells at the same time that a chemotherapeutic reagent that induces apoptosis is introduced, providing some level of protection to the normal cells while the cancer cells are induced to undergo cell death. The miRNAs may also be used as targets for diagnostic assays or to differentiate cells or to create cell lines with interesting research properties.

**[0084]** Methods of the invention include methods for inhibiting or preventing hTert activity in a cell comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into the cell an effective amount of at least one i) miRNA inhibitor corresponding to miR-15a, miR-16, miR-21, miR-24, miR-26a, miR-92, miR-105, miR-125a, miR-125b, miR-128, mir-147, miR-195, miR-207, miR-224, miR-295, mir-301, miR-337, mir-368, or mir-371 or ii) a nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is miR-26a, miR-147, mir-195, and mir-368. It is specifically contemplated that it is desirable to inhibit hTert activity in cancer cells or in a patient at risk for or suspected of having cancer. Methods

of the invention include methods for inducing hTert activity in a cell comprising providing to or introducing into the cell an effective amount of at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is miR-15a, miR-16, miR-21, mir-24, miR-26a, miR-92, miR-105, miR-125a, miR-125b, miR-128, mir-147, miR-195, miR-207, miR-224, miR-295, mir-301, miR-337, mir-368, or mir-371. Alternatively or additionally, hTert activity may be induced in a cell comprising providing to or introducing into the cell an miRNA inhibitor corresponding to miR-26a, miR-147, mir-195, or mir-368.

**[0085]** In other embodiments of the invention there are methods for identifying an miRNA that inhibits an hTert activating gene product comprising: a) introducing into a cell a candidate miRNA into a cell; and, b) assaying the level of hTert expression or hTert activity in the cell, wherein a reduction in hTert expression or activity compared to a cell lacking the miRNA identifies the miRNA as a potential inhibitor of an hTert activating gene product. In particular embodiments, the sequence of the candidate miRNA was previously evaluated for an ability to inhibit an hTert activating gene product. Computer programs and algorithms may be employed to assess whether a particular miRNA sequence can target a particular cellular gene. In certain embodiments, thTert activating gene product is selected from the group consisting of ACOX1, AKT1, APAF1, COX-5B, COX6, COX7B, CPOX, DUOX2, GPX1, GPX2, GPX4, LPO, MAPK1, MAPK4, MTCO1, NOX3, NOX5, PAOX, PPOX, PRKCA, PRKCD, and TNFRSF6. These methods may be used for combating telomerase activity and cancer progression. The invention also includes methods for inhibiting stimulation of Stat3 in a cell comprising introducing into or providing to the cell an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or non-synthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to the cell an effective amount of an miRNA selected from the group consisting of mir-93, mir-100, mir-134, mir-99a, mir-103, mir-128, mir-129, mir-181b, mir-193, mir-197, mir-212, mir-218, mir-219, mir-302, mir-323, mir-324-3p, mir-325, mir-330, mir-331, mir-340, mmu-mir-350, mir-425, mir-491, mir-518f, mir-520a\*. Such methods can be used for treating diseases and conditions characterized by inflammation. These include, but are not limited to, tissue destruction, organ failure or inflammatory diseases such as Rheumatoid arthritis, Psoriasis, Asthma, Inflammatory bowel disease (Crohn's disease and related conditions), Multiple Sclerosis, obstructive pulmonary disease (COPD), Allergic rhinitis (hay fever), and Cardiovascular disease. Additionally, such methods may be used for therapeutics, diagnostics, prognostics, creating cell lines with interesting research properties, and inducing differentiation.

**[0086]** The present invention also concerns methods of influencing the cell cycle of a cell or population of cells. It is contemplated that methods can involve relatively increasing the number of cells in a particular phase of the cell cycle, such as S, G1, G2/M, or when the number of chromosomes is greater than 2N. Alternatively, it can involve inducing DNA synthesis in a cell. One or more of the miRNAs involved in the cell cycle can be used to modulate a cell, particularly a cancer cell, to achieve a therapeutic benefit for a patient with such cells. Such methods may be used, for example, to enhance the efficacy of a therapeutic agent or they may be employed in the context of research, for instance, to synchronize cells so as to generate a more homogeneous population of cells. Moreover, these miRNAs may regulate genes that are involved in controlling cell cycle progression. Mis-expression of one or more of these miRNAs may profoundly affect the cells in which they reside, leading potentially toward cancer or other diseases associated with altered cell cycle regulation. In addition to using these miRNAs as diagnostic analytes, they might also provide targets for treating disease. For instance, a cancer cell that has bypassed a critical cell cycle signal by having a cell cycle-specific miRNA might be returned to normalcy by introducing the miRNA.

**[0087]** Methods of promoting cells to be in S phase can be achieved by introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is let-7a, mir-15a, mir-16, mir-20, mir-26a, mir-191, mir-197, mir-205, mir-220, mir-224, mir-290, mir-291, mir-294, mir-295, mir-302, mir-345, mir-372, or mir-411; or 2) at least one miRNA inhibitor corresponding to mir-108, mir-122, mir-128, mir-129, mir-137, mir-142, mir-146, mir-147, mir-186, mir-187, mir-195, mir-297, mir-324-3p, mir-337, or mir-376b.

**[0088]** The invention also includes methods of inhibiting cells to be in S phase by introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is mir-108, mir-122, mir-128, mir-129, mir-137, mir-142, mir-146, mir-147, mir-186, mir-187, mir-195, mir-297, mir-324-3p, mir-337, or mir-376b; or 2) at least one miRNA inhibitor corresponding to let-7a, mir-15a, mir-16, mir-20, mir-26a, mir-191, mir-197, mir-205, mir-220, mir-224, mir-290, mir-291, mir-294, mir-295, mir-302, mir-345, mir-372, or mir-411.

**[0089]** Methods of promoting cells to be in G1 phase can be achieved by introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the

cell, wherein the mature miRNA is mir-108, mir-122, mir-124, mir-125a, mir-126, mir-128, mir-129, mir-137, mir-142, mir-146, mir-147, mir-195, mir-201, mir-297, mir-320, mir-325, mir-324-3p, mir-337, mir-371, mir-376b, or mir-409; or 2) at least one miRNA inhibitor corresponding to Let-7a, mir-1, mir-7d, mir-20, mir-21, mir-26a, mir-192, mir-193, mir-206, mir-220, mir-290, mir-294, mir-329, mir-371, mir-373, or mir-409.

5 **[0090]** Other methods concern inhibiting cells in G1 phase by introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is Let-7a, mir-1, mir-7d, mir-20, mir-21, mir-26a, mir-192, mir-193, mir-206, mir-220, mir-290, mir-294, mir-329, mir-371, mir-373, mir-409; or 2) at least one miRNA inhibitor corresponding to mir-108, mir-122, mir-124, mir-125a, mir-126, mir-128, mir-129, mir-137, mir-142, mir-146, mir-147, mir-195, mir-201, mir-297, mir-320, mir-325, mir-324-3p, mir-337, mir-371, mir-376b, or mir-409.

10 **[0091]** Also, there are methods of promoting cells to be in G2/M phase by introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is mir-1, mir-7a, mir-7d, mir-7g, mir-20, mir-21, mir-26a, mir-145, mir-187, mir-192, mir-193, mir-206, mir-215, mir-220, mir-223, mir-294, mir-329, mir-371, mir-373, or mir-409; or 2) at least one miRNA inhibitor corresponding to mir-15a, mir-18, mir-122, mir-124, mir-126, mir-128, mir-129, mir-137, mir-146, mir-147, mir-195, mir-219, mir-337, or mir-371.

15 **[0092]** In other embodiments there are methods relating to inhibiting cells to be in G2/M phase by introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of 1) at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is mir-15a, mir-18, mir-122, mir-124, mir-126, mir-128, mir-129, mir-137, mir-146, mir-147, mir-195, mir-219, mir-337, or mir-371; or 2) at least one miRNA inhibitor corresponding to mir-1, mir-7a, mir-7d, mir-7g, mir-20, mir-21, mir-26a, mir-145, mir-187, mir-192, mir-193, mir-206, mir-215, mir-220, mir-223, mir-294, mir-329, mir-371, mir-373, or mir-409.

20 **[0093]** The present invention also includes methods of increasing the number of cells with 2x or more DNA in the cell comprising introducing into or providing to the cells an effective amount of i) an miRNA inhibitor molecule or ii) a synthetic or nonsynthetic miRNA molecule that corresponds to an miRNA sequence. In certain embodiments the methods involves providing to or introducing into cells an effective amount of at least one nucleic acid molecule capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is miR-1, miR-20, miR-21, miR-337, miR-345, or miR-373. The present invention is also concerned with reducing the number of cells with 2x (also referred to as 2N, where N is the number of sets of chromosomes) comprising providing to or introducing into cells an effective amount of an miRNA inhibitor corresponding to miR-1, miR-20, miR-21, miR-337, miR-345, or miR-373.

25 **[0094]** In certain embodiments, methods also include targeting an miRNA to modulate in a cell or organism. The term "targeting an miRNA to modulate" means a nucleic acid of the invention will be employed so as to modulate the selected miRNA. In some embodiments the modulation is achieved with a synthetic or non-synthetic miRNA that corresponds to the targeted miRNA, which effectively provides the targeted miRNA to the cell or organism (positive modulation). In other embodiments, the modulation is achieved with an miRNA inhibitor, which effectively inhibits the targeted miRNA in the cell or organism (negative modulation).

30 **[0095]** In some embodiments, the miRNA targeted to be modulated is an miRNA that affects a disease, condition, or pathway. In certain embodiments, the miRNA is targeted because a treatment can be provided by negative modulation of the targeted miRNA. In other embodiments, the miRNA is targeted because a treatment can be provided by positive modulation of the targeted miRNA.

35 **[0096]** In further embodiments of the invention, there is a step of obtaining a nucleic molecule of the invention that achieves negative modulation of the targeted miRNA. Alternatively, in some cases there is a step of obtaining a nucleic molecule of the invention that achieves positive modulation of the targeted miRNA. Thus, it is contemplated that methods involve selecting and/or obtaining a synthetic miRNA, non-synthetic miRNA or an miRNA inhibitor (collectively "miRNA modulators") that corresponds to a targeted miRNA, such as one that is involved with, affects or is characteristic of a particular disease, condition, pathway, or factor in the pathway.

40 **[0097]** In certain methods of the invention, there is a further step of administering the selected miRNA modulator to a cell, tissue, organ, or organism (collectively "biological matter") in need of treatment related to modulation of the targeted miRNA or in need of the physiological or biological results discussed herein (such as with respect to a particular cellular pathway or result like decrease in cell viability). Consequently, in some methods of the invention there is a step of identifying a patient in need of treatment that can be provided by the miRNA modulator(s). It is contemplated that an effective amount of an miRNA modulator can be administered in some embodiments. In particular embodiments, there

is a therapeutic benefit conferred on the biological matter, where a "therapeutic benefit" refers to an improvement in the one or more conditions or symptoms associated with a disease or condition or an improvement in the prognosis, duration, or status with respect to the disease. It is contemplated that a therapeutic benefit includes, but is not limited to, a decrease in pain, a decrease in morbidity, a decrease in a symptom. For example, with respect to cancer, it is contemplated that

a therapeutic benefit can be inhibition of tumor growth, prevention of metastasis, reduction in number of metastases, inhibition of cancer cell proliferation, inhibition of cancer cell proliferation, induction of cell death in cancer cells, inhibition of angiogenesis near cancer cells, induction of apoptosis of cancer cells, reduction in pain, reduction in risk of recurrence, induction of chemo- or radiosensitivity in cancer cells, prolongation of life, and/or delay of death directly or indirectly related to cancer.

**[0098]** It is specifically contemplated that miRNA profiles for patients, particularly those suspected of having a particular disease or condition, can be generated by evaluating any of the miRNAs discussed in this application. The miRNA profile that is generated from the patient will be one that provides information regarding the particular disease or condition. In many embodiments, the miRNA profile is generated using the miRNA array discussed.

**[0099]** Furthermore, it is contemplated that the miRNA compositions may be provided as part of a therapy to a patient, in conjunction with traditional therapies or preventative agents. Moreover, it is contemplated that any method discussed in the context of therapy may be applied as preventatively, particularly in a patient identified to be potentially in need of the therapy or at risk of the condition or disease for which a therapy is needed.

**[0100]** In other embodiments, the invention concerns a method for inducing transformation in a cell comprising administering to the cell an effective amount of at least one miRNA selected from the group consisting of mir-192, mir-198, and mir-199. Alternatively, methods for preventing cell transformation may be achieved by administering to the cell an effective amount of at least one miRNA inhibitor of mir-192, mir-198, or mir-199.

**[0101]** In addition, methods of the invention concern employing one or more nucleic acids corresponding to an miRNA and a therapeutic drug. The nucleic acid can enhance the effect or efficacy of the drug, reduce any side effects or toxicity, modify its bioavailability, and/or decrease the dosage or frequency needed. In certain embodiments, the therapeutic drug is a cancer therapeutic. Consequently, in some embodiments, there is a method of treating cancer in a patient comprising administering to the patient the cancer therapeutic and an effective amount of at least one miRNA molecule that improves the efficacy of the cancer therapeutic or protects non-cancer cells. Furthermore, in some cases the miRNA molecule enhances the efficacy of the cancer therapeutic and is selected from the group consisting of ambi- miR-7100, mir-28, mir-101, mir-124, mir-125a, mir-126, mir-132, mir-136, mir-147, mir-155, mir-182, mir-186, mir-202, mir-206, mir-216, mir-221, mir-224, mir-291, mir-292-3p, mir-297, mir-302, mir-337, mir-372, mir-373, and mir-376b.

**[0102]** Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments. Combination chemotherapies include but are not limited to, for example, bevacizumab, cisplatin (CDDP), carboplatin, EGFR inhibitors (gefitinib and cetuximab), procarbazine, mechlorethamine, cyclophosphamide, camptothecin, COX-2 inhibitors (e.g., celecoxib) ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin (adriamycin), bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, taxotere, gemcitabine, navelbine, farnesyl-protein transferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.

**[0103]** Alternatively or additionally, the miRNA molecule in methods of the invention protects non-cancer cells from the cancer therapeutic and is selected from the group consisting of mir-16, mir-24, mir-30a-3p, mir-125b, mir-152, mir-194, mir-197, mir-214, and mir-331.

**[0104]** Generally, inhibitors of miRNAs can be given to achieve the opposite effect as compared to when nucleic acid molecules corresponding to the mature miRNA are given. Similarly, nucleic acid molecules corresponding to the mature miRNA can be given to achieve the opposite effect as compared to when inhibitors of the miRNA are given. For example, miRNA molecules that increase cell proliferation can be provided to cells to increase proliferation or inhibitors of such molecules can be provided to cells to decrease cell proliferation. The present invention contemplates these embodiments in the context of the different physiological effects observed with the different miRNA molecules and miRNA inhibitors disclosed herein. These include, but are not limited to, the following physiological effects: increase and decreasing cell proliferation, increasing or decreasing apoptosis, increasing transformation, increasing or decreasing cell viability, activating ERK, activating/inducing or inhibiting hTert, inhibit stimulation of Stat3, reduce or increase viable cell number, and increase or decrease number of cells at a particular phase of the cell cycle. Methods of the invention are generally contemplated to include providing or introducing one or more different nucleic acid molecules corresponding to one or more different miRNA molecules. It is contemplated that the following, at least the following, or at most the following number of different nucleic acid molecules may be provided or introduced: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or any range derivable therein. This also applies to the number of different miRNA molecules that can be provided or introduced into a cell.

**[0105]** The present invention also concerns kit containing compositions of the invention or compositions to implement

methods of the invention. In some embodiments, kits can be used to evaluate one or more miRNA molecules. In certain embodiments, a kit contains, contains at least or contains at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more synthetic miRNA molecules or miRNA inhibitors, or any range and combination derivable therein. In

some embodiments, there are kits for evaluating miRNA activity in a cell.

**[0106]** Kits may comprise components, which may be individually packaged or placed in a container, such as a tube, bottle, vial, syringe, or other suitable container means.

**[0107]** Individual components may also be provided in a kit in concentrated amounts; in some embodiments, a component is provided individually in the same concentration as it would be in a solution with other components. Concentrations of components may be provided as 1x, 2x, 5x, 10x, or 20x or more.

**[0108]** Kits for using synthetic miRNAs, nonsynthetic, and/or miRNA inhibitors of the invention for therapeutic, prognostic, or diagnostic applications are included as part of the invention. Specifically contemplated are any such molecules corresponding to any miRNA reported to influence biological activity, such as those discussed herein.

**[0109]** Negative and/or Positive Control synthetic miRNAs and/or miRNA inhibitors are included in some kit embodiments. The Control molecules can be used to verify transfection efficiency and/or control for transfection-induced changes in cells..

**[0110]** It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein and that different embodiments may be combined. It is specifically contemplated that any methods and compositions discussed herein with respect to miRNA molecules or miRNA may be implemented with respect to synthetic miRNAs to the extent the synthetic miRNA is exposed to the proper conditions to allow it to become a mature miRNA under physiological circumstances. The claims originally filed are contemplated to cover claims that are multiply dependent on any filed claim or combination of filed claims.

**[0111]** Any embodiment of the invention involving specific miRNAs by name is contemplated also to cover embodiments involving miRNAs whose sequences are at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical to the mature sequence of the specified miRNA.

**[0112]** Throughout this application, the term "about" is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

**[0113]** The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."

**[0114]** It is specifically contemplated that any embodiments described in the Examples section are included as an embodiment of the invention.

**[0115]** Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

**[0116]** The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

**FIG. 1 Overview of miRNA Expression and Activation.** MiRNAs are transcribed as part of longer RNA molecules that can be as long as a thousand nucleotides (Lee, 2002). The RNAs are processed in the nucleus into hairpin RNAs of 70-100 nucleotides by the dsRNA-specific ribonuclease Drosha (Lee 2003) (FIG. 1). The hairpin RNAs are transported to the cytoplasm and digested by a second, double-strand specific ribonuclease called Dicer. The resulting 19-23mer miRNA is bound by a complex that is similar to or identical to the RNA-Induced Silencing Complex (RISC) that participates in RNA interference (Hutvagner, 2002). The complex-bound, single-stranded miRNA binds mRNAs with sequences that are significantly, though not completely, complementary to the miRNA. By a mechanism that is not fully understood, but that does not involve mRNA degradation, the bound mRNA is not translated, resulting in reduced expression of the corresponding gene.

**FIG. 2. Methods for Introducing miRNAs into Cells.** There are three basic methods for introducing miRNAs into cells. In the first, a DNA bearing a promoter upstream of a sequence encoding a miRNAs is introduced into cells where it is transcribed to produce an RNA molecule that includes the mature miRNA. Processing and uptake by the protein complex for miRNA-induced gene regulation results in the activation of the miRNA. This method suffers from inefficient introduction of the DNA construct into cells. In the second method, an siRNA-like dsRNA molecule, one of whose strands is identical to an active miRNA is introduced into cells where it is taken up by the protein complex

for miRNA activation. This method provides efficient deliver, but often uptake of the unintended complementary RNA molecule. The third method, described herein, involves modifying the complementary strand so as to favor uptake and activation of the active strand of the synthetic miRNA construct.

**FIG 3. Preferential Uptake of Active Strands in synthetic miRNAs of the invention.** Reporter vectors with luciferase under the control of target sites for miR-33 or let-7 or the complementary strands of the afore-mentioned siRNAs. Co-transfection of synthetic miRNAs and reporter vectors followed by luciferase assay 24 hours post-transfection revealed miRNAs that are activated following transfection.

**FIG 4. Synthetic miRNA Activity for various miRNAs.** Synthetic miRNAs with siRNA and Pre-miR (5'amine) design were prepared and transfected into HeLa cells at 3 and 10 nM final concentration. The synthetic miRNAs were co-transfected with reporter vectors bearing target sites for the mature miRNAs. The expression of the luciferase reporter in co-transfected cells was measured twenty-four hours post-transfected and expressed in the figure as the reporter expression relative to cells co-transfected with negative control synthetic miRNAs.

**FIG 5. Synthetic miRNA Activity across Cell Types and Against Natural Targets.** Synthetic miRNAs were tested for proper strand activation and cell-type specificity to ensure that the design is robust. Four different cell types were co-transfected with synthetic miRNA and associated active and complementary strand strand activation. Panel A shows that different cell types respond similarly to synthetic miRNAs. Four different synthetic miRNAs were then transfected into various cell types and the expression levels of natural targets of the miRNAs were measured (Panel B).

**FIG 6. Schematic for screening with libraries of synthetic miRNAs or miRNA inhibitors.** Synthetic miRNAs and/or miRNA inhibitors are distributed to wells of a microtiter plate. Transfection reagent and then cells are added to each well. At some time post-transfection, samples are evaluated for a phenotype. MiRNAs that induce a change that is significant relative to a negative control are selected for further study.

**FIG 7. Screen for miRNAs that affect cell proliferation.** In 96-well plates, 8,000 HeLa cells were reverse transfected with miRNA inhibitors (5 pmoles) in triplicates using Ambion siPORT Neo-FX. 72 hours post-transfection, cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% TritonX 100 and stained with propidium iodide to look at total cell number. The plates were scanned using the TTP labtech Acumen Explorer. Morphology changes in cells inhibited for mir 31. HeLa cells were transfected with Anti-mir31 and cells were fixed and stained with anti-beta actin antibody and DAPI to visualize cell morphology changes in response to inhibition to mir-31 micro-RNA function.

**FIG 8. Screen for miRNAs that affect cell proliferation in A549 cells.** Screen for miRNA involved in cell viability in A549 cells. In 96-well plates, 8,000 A549 cells were reverse transfected with miRNA inhibitors (5 pmoles) in triplicates using Ambion siPORT Neo-FX. 72 hours post-transfection cells were trypsinized and counted using the Guava cell counting instrument. Cell number was graphed and normalized to a gap inhibitor. In this figure, "mird" refers to mir-1-2.

**FIG 9. Screen for miRNAs that affect apoptosis in HeLa cells.** Effects of miRNA inhibitors on caspase activity in HeLa. In 96-well plates, 8,000 HeLa cells were reverse transfected with miRNA inhibitors (5 pmoles) in triplicates using Ambion siPORT Neo-FX. 72 hours post-transfection cells were analyzed using caspase activity assay and normalized based on esterase activity assay. In this figure, "mir1d" refers to mir-1-2.

**FIG 10. miRNA Expression in Lung and Colon Cancer Patients.** The miRNA expression profiles of tumor vs normal adjacent tissues were compared for lung and colon cancer patients. The miRNAs are provided in rows; the patients are presented in columns. Green in the heat map shows miRNAs that are down-regulated in the tumor sample relative to the normal adjacent tissue sample, and red shows miRNAs that are up-regulated in the tumor sample relative to the normal adjacent tissue sample.

**FIG 11. Validation of miRNA Array Expression Results in Lung Cancer Patients.** Total RNA samples from two lung cancer patients were analyzed for expression of miR-16, miR-21, miR-143, miR-145, and let-7 using Northern analysis. The graphs show the relative abundance of each miRNA (ratio of tumor:NAT) from the array analysis and Northern phosphoimager analysis.

**FIG 12. Some miRNAs are differentially expressed in multiple cancer types.** miRNA array analysis comparing tumor and normal adjacent tissues from patients with various types of cancer was used to identify miRNAs that are differentially expressed in cancer. The percentage of patients exhibiting up- or down-regulation of a given miRNA was calculated for each cancer type. The eight that were most often differentially expressed across sample types are presented.

**FIG 13.** Shown are miRNAs having greater than 1.5-fold expression changes between both infected vs. uninfected and sensitive vs. insensitive. On the right is a cluster of the results from 2 arrays of each model.

**FIG 14. Differentially expressed miRNAs in 3 preconditioned mice relative to non-treated mice.**

**FIG 15A-C. Synthetic miRNAs that decrease cell proliferation.** **A.** BT549 and MCF12A (breast), HeLa (cervical) and 22 Rv1 (prostate) cells were evaluated for cell proliferation. **B.** TE354T and TE353SK (skin), BJ (skin), and A549 (lung) cells were examined for cell proliferation. **C.** CRL5826 and HTB-57 (lung), Jurkats (T cell), and primary

T cells were evaluated for cell proliferation.

**FIG. 16. Synthetic miRNAs that increase cell proliferation.** HeLa (cervical), 22 Rv1 (prostate), TE354T and TE353SK (skin), BJ (skin), A549 (lung), Jurkats (T cell), primary T cells, CRL5826 and HTB-57 (lung) cells were evaluated for cell proliferation.

**FIG. 17. miRNA inhibitors that reduce cell proliferation.** 22 Rv1 (prostate), TE354T (skin), MCF12a (breast), and A549 (lung) cells were evaluated for cell proliferation.

**FIG. 18. miRNA inhibitors that increase cell proliferation.** 22 Rv1 (prostate), TE354T (skin), MCF12a (breast), and A549 (lung) cells were evaluated for cell proliferation.

**FIG. 19. miRNAs that affect cell viability.** Jurkats (T cell), primary T cells, HeLa (cervical) and A549 (lung) cells were evaluated for increases and decreases in cell viability.

**FIG. 20. miRNAs that affect apoptosis.** 22 Rv1 (prostate), TE354T (skin), Jurkats (T cell), and HeLa (cervical) cells were evaluated for increases and decreases in apoptosis.

**FIG. 21. miRNAs that affect cell viability in the presence of a therapeutic.** A549 (lung) cells were evaluated for increases and decreases in cell viability in the presence and absence of TRAIL or etoposide. HTB-57 and CRL5826 (lung) and HeLa (cervical) cells were evaluated for a reduction in cell viability in the absence and presence of etoposide.

**FIG. 22. miRNAs that affect cell cycle.** BJ (skin) and HeLa (cervical) cells were evaluated for increases or decreases in the number of cells at certain phases of the cell cycle (G1, S, G2/M, DNA replication).

**FIG. 23. Phenotypes of miRNAs with similar sequences.** Comparison of related sequences and their effects on cell proliferation.

**FIG. 24. Genes associated with hTert regulation and miRNA sequences predicted to modulate their expression.**

## DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

**[0117]** The present invention is directed to compositions and methods relating to preparation and characterization of miRNAs, as well as use of miRNAs for therapeutic, prognostic, and diagnostic applications. To overcome the problem with previous inefficient plasmid-based systems for introducing miRNA into cells, the inventors developed small, partially double-stranded RNAs that can be delivered with high efficiency to both immortalized and primary cells. The small RNAs have the same functional activities as endogenously expressed miRNAs. Because the small RNAs can be delivered to cells with much higher efficiency than can plasmids, they induce a much stronger phenotype that is easier to detect and quantify, making it possible to identify many of the functions of miRNAs in cells.

**[0118]** The inventors have also created a library of the small, double-stranded RNA molecules that can be used to introduce miRNAs into cells, as well as a library of antisense molecules that inhibit the activities of known miRNAs that are present in cells. These libraries have been used to sequentially up- or down-regulate one or more miRNAs in cells to identify those miRNAs that are critical for cellular processes like cell cycle, apoptosis, differentiation, viability, angiogenesis, metabolism, and other processes with therapeutic potential. miRNAs that regulate the expression of important genes like p53, MYC, and RAS are also being identified and characterized to further pinpoint miRNAs that might provide important intervention points for treating disease. For example, let-7 has been shown to be involved with RAS. See Johnson *et al.*, 2005, which is hereby incorporated by reference. These processes of serially modulating miRNA activities and assaying for cellular phenotypes are collectively referred to as miRNA functional screening.

### **I. miRNA Molecules**

**[0119]** MicroRNA molecules ("miRNAs") are generally 21 to 22 nucleotides in length, though lengths of 17 and up to 25 nucleotides have been reported. The miRNAs are each processed from a longer precursor RNA molecule ("precursor miRNA"). Precursor miRNAs are transcribed from non-protein-encoding genes. The precursor miRNAs have two regions of complementarity that enables them to form a stem-loop- or fold-back-like structure, which is cleaved by an enzyme called Dicer in animals. Dicer is ribonuclease III-like nuclease. The processed miRNA is typically a portion of the stem.

**[0120]** The processed miRNA (also referred to as "mature miRNA") become part of a large complex to down-regulate a particular target gene. Examples of animal miRNAs include those that imperfectly basepair with the target, which halts translation (Olsen *et al.*, 1999; Seggerson *et al.*, 2002). SiRNA molecules also are processed by Dicer, but from a long, double-stranded RNA molecule. SiRNAs are not naturally found in animal cells, but they can function in such cells in a RNA-induced silencing complex (RISC) to direct the sequence-specific cleavage of an mRNA target (Denli *et al.*, 2003).

**[0121]** The study of endogenous miRNA molecules is described in U.S. Patent Application 60/575,743, which is hereby incorporated by reference in its entirety.

Synthetic miRNAs

**[0122]** miRNAs are apparently active in the cell when the mature, single-stranded RNA is bound by a protein complex that regulates the translation of mRNAs that hybridize to the miRNA. Introducing exogenous RNA molecules that affect cells in the same way as endogenously expressed miRNAs requires that a single-stranded RNA molecule of the same sequence as the endogenous mature miRNA be taken up by the protein complex that facilitates translational control. A variety of RNA molecule designs have been evaluated. Three general designs that maximize uptake of the desired single-stranded miRNA by the miRNA pathway have been identified. An RNA molecule with an miRNA sequence having at least one of the three designs is referred to as a synthetic miRNA.

**[0123]** Synthetic miRNAs of the invention comprise, in some embodiments, two RNA molecules wherein one RNA is identical to a naturally occurring, mature miRNA. The RNA molecule that is identical to a mature miRNA is referred to as the active strand. The second RNA molecule, referred to as the complementary strand, is at least partially complementary to the active strand. The active and complementary strands are hybridized to create a double-stranded RNA, called the synthetic miRNA, that is similar to the naturally occurring miRNA precursor that is bound by the protein complex immediately prior to miRNA activation in the cell. Maximizing activity of the synthetic miRNA requires maximizing uptake of the active strand and minimizing uptake of the complementary strand by the miRNA protein complex that regulates gene expression at the level of translation. The molecular designs that provide optimal miRNA activity involve modifications to the complementary strand.

**[0124]** Two designs incorporate chemical modifications in the complementary strand. The first modification involves creating a complementary RNA with a chemical group other than a phosphate or hydroxyl at its 5' terminus. The presence of the 5' modification apparently eliminates uptake of the complementary strand and subsequently favors uptake of the active strand by the miRNA protein complex. The 5' modification can be any of a variety of molecules including NH<sub>2</sub>, NHCOCH<sub>3</sub>, biotin, and others.

**[0125]** The second chemical modification strategy that significantly reduces uptake of the complementary strand by the miRNA pathway is incorporating nucleotides with sugar modifications in the first 2-6 nucleotides of the complementary strand. It should be noted that the sugar modifications consistent with the second design strategy can be coupled with 5' terminal modifications consistent with the first design strategy to further enhance synthetic miRNA activities.

**[0126]** The third synthetic miRNA design involves incorporating nucleotides in the 3' end of the complementary strand that are not complementary to the active strand. Hybrids of the resulting active and complementary RNAs are very stable at the 3' end of the active strand but relatively unstable at the 5' end of the active strand. Studies with siRNAs indicate that 5' hybrid stability is a key indicator of RNA uptake by the protein complex that supports RNA interference, which is at least related to the miRNA pathway in cells. The inventors have found that the judicious use of mismatches in the complementary RNA strand significantly enhances the activity of the synthetic miRNA.

MiRNA Libraries

**[0127]** A key application for the synthetic miRNAs is the identification of cellular functions for individual or groups of miRNAs. The inventors have created a library of synthetic miRNAs that can be used to sequentially introduce each of the known miRNAs into cultured cells (FIG. 6). Cell populations with each of the different synthetic miRNAs can then be assayed to identify miRNAs whose presence induces a cellular phenotype.

**[0128]** The inventors have created a library of antisense molecules that inhibit miRNA activity. The miRNA inhibitors are used to serially inhibit the activities of miRNAs in cells to identify miRNAs whose absence induces a cellular phenotype.

**[0129]** The number of different synthetic miRNAs or miRNA inhibitors in the libraries is variable. It is contemplated that there may be, be at least, or be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 31, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 6000, 7000, 8000, 9000, 10000 or more, or any range derivable therein, different miRNA-specific molecules in the library. In specific embodiments, libraries have between 5 and 1000 different miRNA-specific molecules, between 20 and 500 different miRNA-specific molecules, between 50 and 250 different miRNA-specific molecules, or between 100 and 225 different miRNA-specific molecules. "Different" miRNA-specific molecules refers to nucleic acids that are specific to miRNAs with different sequences.

**[0130]** Synthetic miRNAs are contemplated to be made primarily of RNA, though in some embodiments, they may be

RNA, nucleotide analogs, DNA, or any combination of DNA, RNA, nucleotide analogs, and PNAs.

**[0131]** As suggested above, it is contemplated that libraries of the invention may be specific for one or more miRNAs. In embodiments of the invention, a library has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 31, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 6000, 7000, 8000, 9000, 10000 or more, or any range derivable therein, different miRNAs or miRNA inhibitors. Accordingly, it is understood that the library contains one or more nucleic acids for these different miRNAs. In specific embodiments, the library is specific to human miRNAs, though libraries for multiple organisms are contemplated.

**[0132]** RNA molecules of the invention have miRNA regions or complementary regions. In specific embodiments, a synthetic miRNA or miRNA inhibitor has a sequence or complementary sequence that derives from any of SEQ ID NOs: 1-805, inclusive. It is particularly contemplated that synthetic nucleic acid molecules of the invention may be derived from any of the mature miRNA sequences in SEQ ID NOs: 1-805 or their complement.

**[0133]** As discussed above, miRNAs are processed from a precursor molecule. In certain embodiments, the specific length of a mature miRNA is unknown. It is contemplated that versions of the synthetic miRNA and miRNA inhibitor libraries will include sequence that extends at least 1 to 5 nucleotides of coding sequence upstream and/or downstream of the predicted miRNA sequence. In some embodiments, molecules have up to 1, 2, 3, 4, 5, 6, 7, or more contiguous nucleotides, or any range derivable therein, that flank the sequence encoding the predominant processed miRNA on one or both sides (5' and/or 3' end).

**[0134]** The present invention concerns methods for creating functional profile for all of the known miRNAs. The term "functional profile" refers to a set of data regarding the cellular phenotypes that result from introducing and inhibiting miRNAs in cells using synthetic miRNA and miRNA inhibitor libraries. Functional profiles for individual miRNAs will enable identification of miRNAs with therapeutic or diagnostic potential. For instance, a functional profile for a miRNA might reveal that its absence leads to uncontrolled cell proliferation and an inability to induce apoptosis following DNA damage. Furthermore, the expression of p53 correlates with whether the miRNA is being up-regulated with a synthetic miRNA or down-regulated with a miRNA inhibitor. Based on its ties to cell proliferation, apoptosis, and p53 expression, this miRNA might be a target for cancer therapeutics.

**[0135]** In certain embodiments, methods concern identifying miRNAs indicative of a disease or condition by detecting a correlation between the activity of particular miRNAs and cellular phenotypes that coincide with a disease or condition.

**[0136]** Libraries of the invention can contain miRNA sequences from any organism having miRNAs, specifically including but not limited to, mammals such as humans, mice, and rats. Specifically contemplated are libraries having, having at least, or having at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522,

523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000 or more different synthetic miRNAs and/or miRNA inhibitors (that is, miRNA-specific molecules having different sequences derived from different miRNA genes). Specifically contemplated are such libraries described in the previous sentence with respect to any of SEQ ID NOs:1-805, particularly those corresponding to miRNA sequence s(mature sequence) or the complement thereof.

**A. Nucleic Acids**

15 **[0137]** The present invention concerns nucleic acid molecules that can introduce or inhibit miRNAs in cultured cells. The nucleic acids may have been produced in cells or in vitro by purified enzymes though they are preferentially produced by chemical synthesis. They may be crude or purified. The term "miRNA," unless otherwise indicated, refers to the processed RNA, after it has been cleaved from its precursor. Table 1 indicates which SEQ ID NO corresponds to the particular precursor sequence of an miRNA and what sequences within the SEQ ID NO correspond to the mature sequence. The name of the miRNA is often abbreviated and referred to without the prefix and will be understood as such, depending on the context. Unless otherwise indicated, miRNAs referred to in the application are human sequences identified as mir-X or let-X, where X is a number and/or letter.

**Table 1**

Human miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
hsa-mir-1-2	SEQ ID NO:1	53-73
hsa-mir-1-1	SEQ ID NO:2	46-66
hsa-let-7a-1	SEQ ID NO:3	6-27
hsa-let-7a-2	SEQ ID NO:4	5-26
hsa-let-7a-3	SEQ ID NO:5	4-25
hsa-let-7b	SEQ ID NO:6	6-27
hsa-let-7c	SEQ ID NO:7	11-32
hsa-let-7d	SEQ ID NO:8	8-28
hsa-let-7e	SEQ ID NO:9	8-28
hsa-let-7f-1	SEQ ID NO:10	7-28
hsa-let-7f-2	SEQ ID NO:11	8-29
hsa-mir-7-1	SEQ ID NO:12	24-44
hsa-mir-7-2	SEQ ID NO:13	32-52
hsa-mir-7-3	SEQ ID NO:14	31-51
hsa-let-7g	SEQ ID NO:15	5-25
hsa-let-7i	SEQ ID NO:16	6-24
hsa-mir-9-1	SEQ ID NO:17	16-38 and/or 56-76
hsa-mir-9-2	SEQ ID NO:18	16-38 and/or 54-74
hsa-mir-9-3	SEQ ID NO:19	16-38 and/or 56-76
hsa-mir-10a	SEQ ID NO:20	22-44

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Human miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
hsa-mir-10b	SEQ ID NO:21	27-48
hsa-mir-15a	SEQ ID NO:22	14-35
hsa-mir-15b	SEQ ID NO:23	20-41
hsa-mir-16-1	SEQ ID NO:24	14-35
hsa-mir-16-2	SEQ ID NO:25	10-31
hsa-mir-17	SEQ ID NO:26	14-37 and/or 51-70
hsa-mir-18	SEQ ID NO:27	6-27
hsa-mir-19a	SEQ ID NO:28	49-71
hsa-mir-19b-1	SEQ ID NO:29	54-76
hsa-mir-19b-2	SEQ ID NO:30	62-84
hsa-mir-20	SEQ ID NO:31	8-29
hsa-mir-21	SEQ ID NO:32	8-29
hsa-mir-22	SEQ ID NO:33	53-74
hsa-mir-23a	SEQ ID NO:34	45-65
hsa-mir-23b	SEQ ID NO:35	58-80
hsa-mir-24-1	SEQ ID NO:36	6-28 and/or 44-65
hsa-mir-24-2	SEQ ID NO:37	50-71
hsa-mir-25	SEQ ID NO:38	52-73
hsa-mir-26a-1	SEQ ID NO:39	10-31
hsa-mir-26b	SEQ ID NO:40	12-32
hsa-mir-26a-2	SEQ ID NO:41	14-35
hsa-mir-27a	SEQ ID NO:42	51-72
hsa-mir-27b	SEQ ID NO:43	61-80
hsa-mir-28	SEQ ID NO:44	14-35
hsa-mir-29a	SEQ ID NO:45	41-62
hsa-mir-29b-1	SEQ ID NO:46	51-70
hsa-mir-29b-2	SEQ ID NO:47	52-71
hsa-mir-29c	SEQ ID NO:48	54-75
hsa-mir-30a	SEQ ID NO:49	47-68
hsa-mir-30c-2	SEQ ID NO:50	7-29
hsa-mir-30d	SEQ ID NO:51	6-27
hsa-mir-30b	SEQ ID NO:52	17-37
hsa-mir-30c-1	SEQ ID NO:53	17-39
hsa-mir-30e	SEQ ID NO:54	2-21
hsa-mir-31	SEQ ID NO:55	9-29
hsa-mir-32	SEQ ID NO:56	6-26

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Human miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
hsa-mir-33	SEQ ID NO:57	6-24
hsa-mir-34a	SEQ ID NO:58	22-43
hsa-mir-34b	SEQ ID NO:59	14-35
hsa-mir-34c	SEQ ID NO:60	13-34
hsa-mir-92-1	SEQ ID NO:61	48-69
hsa-mir-92-2	SEQ ID NO:62	48-69
hsa-mir-93	SEQ ID NO:63	12-33
hsa-mir-95	SEQ ID NO:64	49-70
hsa-mir-96	SEQ ID NO:65	9-30
hsa-mir-98	SEQ ID NO:66	2-23
hsa-mir-99a	SEQ ID NO:67	13-34
hsa-mir-99b	SEQ ID NO:68	7-28
hsa-mir-100	SEQ ID NO:69	13-34
hsa-mir-101-1	SEQ ID NO:70	47-68
hsa-mir-101-2	SEQ ID NO:71	49-70
hsa-mir-103-2	SEQ ID NO:72	48-70
hsa-mir-103-1	SEQ ID NO:73	48-70
hsa-mir-105-1	SEQ ID NO:74	13-32
hsa-mir-105-2	SEQ ID NO:75	13-32
hsa-mir-106a	SEQ ID NO:76	13-36
hsa-mir-106b	SEQ ID NO:77	12-32
hsa-mir-107	SEQ ID NO:78	50-72
hsa-mir-122a	SEQ ID NO:79	15-37
hsa-mir-124a-1	SEQ ID NO:80	52-73
hsa-mir-124a-2	SEQ ID NO:81	61-82
hsa-mir-124a-3	SEQ ID NO:82	52-73
hsa-mir-125b-1	SEQ ID NO:83	15-36
hsa-mir-125a	SEQ ID NO:84	15-37
hsa-mir-125b-2	SEQ ID NO:85	17-38
hsa-mir-126	SEQ ID NO:86	15-35 and/or 52-72
hsa-mir-127	SEQ ID NO:87	57-78
hsa-mir-128a	SEQ ID NO:88	50-71
hsa-mir-128b	SEQ ID NO:89	52-73
hsa-mir-129-2	SEQ ID NO:90	15-35
hsa-mir-130a	SEQ ID NO:91	55-74
hsa-mir-130b	SEQ ID NO:92	51-72

**EP 2 808 390 A1**

(continued)

5  
  
10  
  
15  
  
20  
  
25  
  
30  
  
35  
  
40  
  
45  
  
50  
  
55

<b>Human miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
hsa-mir-132	SEQ ID NO:93	59-80
hsa-mir-133a-1	SEQ ID NO:94	54-75
hsa-mir-133a-2	SEQ ID NO:95	60-81
hsa-mir-133b	SEQ ID NO:96	67-87
hsa-mir-134	SEQ ID NO:97	8-28
hsa-mir-135a-1	SEQ ID NO:98	17-39
hsa-mir-135a-2	SEQ ID NO:99	23-45
hsa-mir-135b	SEQ ID NO:100	16-37
hsa-mir-136	SEQ ID NO:101	15-37
hsa-mir-137	SEQ ID NO:102	60-81
hsa-mir-138-2	SEQ ID NO:103	10-26
hsa-mir-138-1	SEQ ID NO:104	23-39
hsa-mir-139	SEQ ID NO:105	7-24
hsa-mir-140	SEQ ID NO:106	24-44
hsa-mir-141	SEQ ID NO:107	60-80
hsa-mir-142	SEQ ID NO:108	16-35 and/or 52-74
hsa-mir-143	SEQ ID NO:109	61-82
hsa-mir-144	SEQ ID NO:110	52-73
hsa-mir-145	SEQ ID NO:111	16-39
hsa-mir-146	SEQ ID NO:112	21-42
hsa-mir-147	SEQ ID NO:113	47-66
hsa-mir-148a	SEQ ID NO:114	44-65
hsa-mir-148b	SEQ ID NO:115	63-84
hsa-mir-149	SEQ ID NO:116	15-36
hsa-mir-150	SEQ ID NO:117	16-37
hsa-mir-151	SEQ ID NO:118	46-67
hsa-mir-152	SEQ ID NO:119	54-74
hsa-mir-153-1	SEQ ID NO:120	54-73
hsa-mir-153-2	SEQ ID NO:121	53-72
hsa-mir-154	SEQ ID NO:122	15-36
hsa-mir-155	SEQ ID NO:123	4-25
hsa-mir-181a	SEQ ID NO:124	39-61
hsa-mir-181b-1	SEQ ID NO:125	36-59
hsa-mir-181c	SEQ ID NO:126	27-48
hsa-mir-181b-2	SEQ ID NO:127	16-39
hsa-mir-182	SEQ ID NO:128	23-44 and/or 67-87

EP 2 808 390 A1

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Human miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
hsa-mir-183	SEQ ID NO:129	27-49
hsa-mir-184	SEQ ID NO:130	53-74
hsa-mir-185	SEQ ID NO:131	15-32
hsa-mir-186	SEQ ID NO:132	15-37
hsa-mir-187	SEQ ID NO:133	71-91
hsa-mir-188	SEQ ID NO:134	15-36
hsa-mir-190	SEQ ID NO:135	15-36
hsa-mir-191	SEQ ID NO:136	16-37
hsa-mir-192	SEQ ID NO:137	24-44
hsa-mir-193	SEQ ID NO:138	55-75
hsa-mir-194-1	SEQ ID NO:139	15-36
hsa-mir-194-2	SEQ ID NO:140	15-36
hsa-mir-195	SEQ ID NO:141	15-35
hsa-mir-196-1	SEQ ID NO:142	7-27
hsa-mir-196-2	SEQ ID NO:143	25-45
hsa-mir-197	SEQ ID NO:144	48-69
hsa-mir-198	SEQ ID NO:145	6-24
hsa-mir-199a-1	SEQ ID NO:146	6-28 and/or 46-67
hsa-mir-199a-2	SEQ ID NO:147	31-53 and/or 69-90
hsa-mir-199b	SEQ ID NO:148	26-48
hsa-mir-200b	SEQ ID NO:149	54-77
hsa-mir-200c	SEQ ID NO:150	45-66
hsa-mir-200a	SEQ ID NO:151	54-75
hsa-mir-203	SEQ ID NO:152	65-86
hsa-mir-204	SEQ ID NO:153	33-54
hsa-mir-205	SEQ ID NO:154	34-55
hsa-mir-206	SEQ ID NO:155	53-74
hsa-mir-208	SEQ ID NO:156	44-65
hsa-mir-210	SEQ ID NO:157	66-86
hsa-mir-211	SEQ ID NO:158	26-47
hsa-mir-212	SEQ ID NO:159	71-91
hsa-mir-213	SEQ ID NO:160	24-46 and/or 64-85
hsa-mir-214	SEQ ID NO:161	71-91
hsa-mir-215	SEQ ID NO:162	27-47
hsa-mir-216	SEQ ID NO:163	19-39
hsa-mir-217	SEQ ID NO:164	35-58

**EP 2 808 390 A1**

(continued)

5  
  
10  
  
15  
  
20  
  
25  
  
30  
  
35  
  
40  
  
45  
  
50  
  
55

<b>Human miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
hsa-mir-218-1	SEQ ID NO:165	25-45
hsa-mir-218-2	SEQ ID NO:166	25-45
hsa-mir-219-1	SEQ ID NO:167	21-41
hsa-mir-219-2	SEQ ID NO:168	19-39
hsa-mir-220	SEQ ID NO:169	23-43
hsa-mir-221	SEQ ID NO:170	65-87
hsa-mir-222	SEQ ID NO:171	69-92
hsa-mir-223	SEQ ID NO:172	68-88
hsa-mir-224	SEQ ID NO:173	8-30
hsa-mir-296	SEQ ID NO:174	14-34
hsa-mir-299	SEQ ID NO:175	7-28
hsa-mir-301	SEQ ID NO:176	51-73
hsa-mir-302	SEQ ID NO:177	44-66
hsa-mir-320	SEQ ID NO:178	48-70
hsa-mir-321	SEQ ID NO:179	10-30
hsa-mir-323	SEQ ID NO:180	50-71
hsa-mir-324	SEQ ID NO:181	16-38 and/or 51-72
hsa-mir-326	SEQ ID NO:182	60-79
hsa-mir-328	SEQ ID NO:183	48-69
hsa-mir-330	SEQ ID NO:184	57-79
hsa-mir-331	SEQ ID NO:185	61-81
hsa-mir-335	SEQ ID NO:186	16-38
hsa-mir-337	SEQ ID NO:187	56-78
hsa-mir-338	SEQ ID NO:188	42-64
hsa-mir-339	SEQ ID NO:189	15-35
hsa-mir-340	SEQ ID NO:190	58-80
hsa-mir-342	SEQ ID NO:191	61-84
hsa-mir-345	SEQ ID NO:573	17-37
hsa-mir-346	SEQ ID NO:574	4-26
hsa-mir-367	SEQ ID NO:575	44-65
hsa-mir-368	SEQ ID NO:576	44-65
hsa-mir-369	SEQ ID NO:577	44-64
hsa-mir-370	SEQ ID NO:578	48-68
hsa-mir-371	SEQ ID NO:579	44-64
hsa-mir-372	SEQ ID NO:580	42-64
hsa-mir-373	SEQ ID NO:581	44-66

EP 2 808 390 A1

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Human miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
hsa-mir-374	SEQ ID NO:582	12-33
hsa-mir-375	SEQ ID NO:677	40-61
hsa-mir-376a	SEQ ID NO:678	44-64
hsa-mir-377	SEQ ID NO:679	45-66
hsa-mir-378	SEQ ID NO:680	5-26 and 44-65
hsa-mir-379	SEQ ID NO:681	6-24
hsa-mir-380	SEQ ID NO:682	5-26 and 40-61
hsa-mir-381	SEQ ID NO:683	49-70
hsa-mir-382	SEQ ID NO:684	11-32
hsa-mir-383	SEQ ID NO:685	7-28
hsa-mir-384	SEQ ID NO:686	57-76
hsa-mir-422a	SEQ ID NO:687	11-32
hsa-mir-423	SEQ ID NO:688	53-74
hsa-mir-424	SEQ ID NO:689	11-32
hsa-mir-425	SEQ ID NO:690	55-75
hsa-mir-448	SEQ ID NO:691	71-92
hsa-mir-429	SEQ ID NO:692	51-72
hsa-mir-449	SEQ ID NO:693	16-37
hsa-mir-450-1	SEQ ID NO:694	17-38
hsa-mir-450-2	SEQ ID NO:704	22-43
hsa-mir-451	SEQ ID NO:705	17-39
hsa-mir-452	SEQ ID NO:706	17-38
hsa-mir-453	SEQ ID NO:707	43-64
hsa-mir-455	SEQ ID NO:708	16-37
hsa-mir-483	SEQ ID NO:709	48-70
hsa-mir-484	SEQ ID NO:710	2-23
hsa-mir-485	SEQ ID NO:711	9-30
hsa-mir-486	SEQ ID NO:712	4-25
hsa-mir-487	SEQ ID NO:713	49-70
hsa-mir-488	SEQ ID NO:714	14-34
hsa-mir-489	SEQ ID NO:715	51-73
hsa-mir-490	SEQ ID NO:716	76-97
hsa-mir-491	SEQ ID NO:717	16-38
hsa-mir-492	SEQ ID NO:718	30-52
hsa-mir-493	SEQ ID NO:719	16-37
hsa-mir-494	SEQ ID NO:720	48-71

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Human miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
hsa-mir-495	SEQ ID NO:721	50-72
hsa-mir-496	SEQ ID NO:722	61-77
hsa-mir-497	SEQ ID NO:723	24-44
hsa-mir-498	SEQ ID NO:724	34-56
hsa-mir-499	SEQ ID NO:725	33-55
hsa-mir-500	SEQ ID NO:726	52-73
hsa-mir-501	SEQ ID NO:727	14-35
hsa-mir-502	SEQ ID NO:728	1-21
hsa-mir-503	SEQ ID NO:729	6-28
hsa-mir-504	SEQ ID NO:730	13-33
hsa-mir-505	SEQ ID NO:731	52-73
hsa-mir-506	SEQ ID NO:732	71-91
hsa-mir-507	SEQ ID NO:733	56-76
hsa-mir-508	SEQ ID NO:734	61-83
hsa-mir-509	SEQ ID NO:735	55-77
hsa-mir-510	SEQ ID NO:736	10-32
hsa-mir-511-1	SEQ ID NO:737	16-36
hsa-mir-511-2	SEQ ID NO:738	16-36
hsa-mir-512-1	SEQ ID NO:739	14-36
hsa-mir-512-2	SEQ ID NO:740	20-42
hsa-mir-513-1	SEQ ID NO:741	37-58
hsa-mir-513-2	SEQ ID NO:742	36-57
hsa-mir-514-1	SEQ ID NO:743	39-58
hsa-mir-514-2	SEQ ID NO:744	39-58
hsa-mir-514-3	SEQ ID NO:745	39-58
hsa-mir-515-1	SEQ ID NO:746	14-37
hsa-mir-515-2	SEQ ID NO:747	14-37
hsa-mir-516-1	SEQ ID NO:748	61-78
hsa-mir-516-2	SEQ ID NO:749	61-78
hsa-mir-516-3	SEQ ID NO:750	15-37
hsa-mir-516-4	SEQ ID NO:751	15-37
hsa-mir-517a	SEQ ID NO:752	15-36
hsa-mir-517b	SEQ ID NO:753	6-27
hsa-mir-517c	SEQ ID NO:754	20-41
hsa-mir-518a-1	SEQ ID NO:755	14-34
hsa-mir-518a-2	SEQ ID NO:756	15-34

EP 2 808 390 A1

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Human miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
hsa-mir-518b	SEQ ID NO:757	51-72
hsa-mir-518c	SEQ ID NO:758	24-46
hsa-mir-518d	SEQ ID NO:759	16-36
hsa-mir-518e	SEQ ID NO:760	54-75
hsa-mir-518f	SEQ ID NO:761	16-38
hsa-mir-519a-1	SEQ ID NO:762	15-38
hsa-mir-519a-2	SEQ ID NO:763	54-78
hsa-mir-519b	SEQ ID NO:764	13-36
hsa-mir-519c	SEQ ID NO:765	16-39
hsa-mir-519d	SEQ ID NO:766	54-76
hsa-mir-519e	SEQ ID NO:767	14-35
hsa-mir-520a	SEQ ID NO:768	15-35
hsa-mir-520b	SEQ ID NO:769	41-61
hsa-mir-520c	SEQ ID NO:770	16-36
hsa-mir-520d	SEQ ID NO:771	15-37
hsa-mir-520e	SEQ ID NO:772	54-74
hsa-mir-520f	SEQ ID NO:773	55-76
hsa-mir-520g	SEQ ID NO:774	55-78
hsa-mir-520h	SEQ ID NO:775	55-76
hsa-mir-521-1	SEQ ID NO:776	54-75
hsa-mir-521-2	SEQ ID NO:777	54-75
hsa-mir-522	SEQ ID NO:778	16-39
hsa-mir-523	SEQ ID NO:779	16-39
hsa-mir-524	SEQ ID NO:780	16-37
hsa-mir-525	SEQ ID NO:781	15-35
hsa-mir-526a-1	SEQ ID NO:782	15-35
hsa-mir-526a-2	SEQ ID NO:783	7-27
hsa-mir-526b	SEQ ID NO:784	14-37
hsa-mir-527	SEQ ID NO:785	14-34
ambi-mir-7100	SEQ ID NO:803	
mir-526b*	SEQ ID NO:804	
mir-520a*	SEQ ID NO:805	

EP 2 808 390 A1

Table 2

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Mouse miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
mmu-mir-1-1	SEQ ID NO:192	49-69
mmu-mir-1-2	SEQ ID NO:193	47-67
mmu-let-7g	SEQ ID NO:194	7-27
mmu-let-7i	SEQ ID NO:195	6-24
mmu-let-7d	SEQ ID NO:196	16-36 + 70-91
mmu-let-7a-1	SEQ ID NO:197	13-34
mmu-let-7a-2	SEQ ID NO:198	17-38
mmu-let-7b	SEQ ID NO:199	7-28
mmu-let-7c-1	SEQ ID NO:200	16-37
mmu-let-7c-2	SEQ ID NO:201	14-35
mmu-let-7e	SEQ ID NO:202	15-35
mmu-let-7f-1	SEQ ID NO:203	8-29
mmu-let-7f-2	SEQ ID NO:204	8-29
mmu-mir-7-1	SEQ ID NO:205	24-44
mmu-mir-7-2	SEQ ID NO:206	19-39
mmu-mir-7b	SEQ ID NO:207	30-50
mmu-mir-9-2	SEQ ID NO:208	8-30 and/or 46-66
mmu-mir-9-1	SEQ ID NO:209	16-38 and/or 56-76
mmu-mir-9-3	SEQ ID NO:210	16-38 and/or 56-76
mmu-mir-10b	SEQ ID NO:211	7-28
mmu-mir-10a-1	SEQ ID NO:212	22-44
mmu-mir-10a-2	SEQ ID NO:213	22-44
mmu-mir-15b	SEQ ID NO:214	4-25
mmu-mir-15a	SEQ ID NO:215	15-36
mmu-mir-16-1	SEQ ID NO:216	16-37
mmu-mir-16-2	SEQ ID NO:217	17-38
mmu-mir-17	SEQ ID NO:218	14-37 and/or 51-70
mmu-mir-18	SEQ ID NO:219	17-38
mmu-mir-19b-2	SEQ ID NO:220	54-76
mmu-mir-19a	SEQ ID NO:221	49-71
mmu-mir-19b-1	SEQ ID NO:222	54-76
mmu-mir-20	SEQ ID NO:223	27-49
mmu-mir-21	SEQ ID NO:224	18-39
mmu-mir-22	SEQ ID NO:225	57-78
mmu-mir-23b	SEQ ID NO:226	46-68
mmu-mir-23a	SEQ ID NO:227	46-66

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Mouse miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
mmu-mir-24-1	SEQ ID NO:228	6-28 and/or 44-65
mmu-mir-24-2	SEQ ID NO:229	61-82
mmu-mir-25	SEQ ID NO:230	52-73
mmu-mir-26a-1	SEQ ID NO:231	16-37
mmu-mir-26b	SEQ ID NO:232	15-36
mmu-mir-26a-2	SEQ ID NO:233	14-35
mmu-mir-27b	SEQ ID NO:234	49-68
mmu-mir-27a	SEQ ID NO:235	56-76
mmu-mir-28	SEQ ID NO:236	14-35
mmu-mir-29b-1	SEQ ID NO:237	47-68
mmu-mir-29a	SEQ ID NO:238	53-74
mmu-mir-29c	SEQ ID NO:239	54-75
mmu-mir-29b-2	SEQ ID NO:240	52-73
mmu-mir-30a	SEQ ID NO:241	47-68
mmu-mir-30b	SEQ ID NO:242	2-22
mmu-mir-30e	SEQ ID NO:243	2-21
mmu-mir-30c-1	SEQ ID NO:244	17-39
mmu-mir-30c-2	SEQ ID NO:245	14-36
mmu-mir-30d	SEQ ID NO:246	12-33
mmu-mir-31	SEQ ID NO:247	28-49
mmu-mir-32	SEQ ID NO:248	6-26
mmu-mir-3	SEQ ID NO:249	6-24
mmu-mir-34c	SEQ ID NO:250	13-35
mmu-mir-34b	SEQ ID NO:251	13-35
mmu-mir-34a	SEQ ID NO:252	20-42
mmu-mir-92-2	SEQ ID NO:253	55-75
mmu-mir-92-1	SEQ ID NO:254	50-70
mmu-mir-93	SEQ ID NO:255	15-37
mmu-mir-96	SEQ ID NO:256	24-46
mmu-mir-98	SEQ ID NO:257	2-23
mmu-mir-99a	SEQ ID NO:258	6-25
mmu-mir-99b	SEQ ID NO:259	7-28
mmu-mir-100	SEQ ID NO:260	13-34
mmu-mir-101	SEQ ID NO:261	38-57
mmu-mir-101b	SEQ ID NO:262	61-82
mmu-mir-103-1	SEQ ID NO:263	52-74

EP 2 808 390 A1

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Mouse miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
mmu-mir-103-2	SEQ ID NO:264	52-74
mmu-mir-106a	SEQ ID NO:265	5-26
mmu-mir-106b	SEQ ID NO:266	12-32
mmu-mir-107	SEQ ID NO:267	52-74
mmu-mir-122a	SEQ ID NO:268	6-28
mmu-mir-124a-3	SEQ ID NO:269	43-64
mmu-mir-124a-1	SEQ ID NO:270	52-73
mmu-mir-124a-2	SEQ ID NO:271	61-82
mmu-mir-125a	SEQ ID NO:272	6-28
mmu-mir-125b-2	SEQ ID NO:273	7-28
mmu-mir-125b-1	SEQ ID NO:274	15-36
mmu-mir-126	SEQ ID NO:275	9-29 and/or 46-66
mmu-mir-127	SEQ ID NO:276	43-64
mmu-mir-128a	SEQ ID NO:277	44-65
mmu-mir-128b	SEQ ID NO:278	48-69
mmu-mir-129-1	SEQ ID NO:279	6-27
mmu-mir-129-2	SEQ ID NO:280	15-36
mmu-mir-130a	SEQ ID NO:281	42-61
mmu-mir-130b	SEQ ID NO:282	51-72
mmu-mir-132	SEQ ID NO:283	42-63
mmu-mir-133a-1	SEQ ID NO:284	44-65
mmu-mir-133a-2	SEQ ID NO:285	60-81
mmu-mir-133b	SEQ ID NO:286	67-87
mmu-mir-134	SEQ ID NO:287	7-27
mmu-mir-135a-1	SEQ ID NO:288	17-39
mmu-mir-135b	SEQ ID NO:289	16-37
mmu-mir-135a-2	SEQ ID NO:290	23-45
mmu-mir-136	SEQ ID NO:291	5-27
mmu-mir-137	SEQ ID NO:292	46-67
mmu-mir-138-2	SEQ ID NO:293	2-18
mmu-mir-138-1	SEQ ID NO:294	23-39
mmu-mir-139	SEQ ID NO:295	7-24
mmu-mir-140	SEQ ID NO:296	7-27
mmu-mir-141	SEQ ID NO:297	49-69
mmu-mir-142	SEQ ID NO:298	4-23 and/or 40-61
mmu-mir-143	SEQ ID NO:299	40-61

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Mouse miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
mmu-mir-144	SEQ ID NO:300	43-64
mmu-mir-145	SEQ ID NO:301	7-30
mmu-mir-146	SEQ ID NO:302	6-27
mmu-mir-148a	SEQ ID NO:303	61-82
mmu-mir-149	SEQ ID NO:304	4-25
mmu-mir-150	SEQ ID NO:305	6-27
mmu-mir-151	SEQ ID NO:306	43-63
mmu-mir-152	SEQ ID NO:307	47-67
mmu-mir-153	SEQ ID NO:308	44-63
mmu-mir-154	SEQ ID NO:309	6-27
mmu-mir-155	SEQ ID NO:310	4-25
mmu-mir-181a	SEQ ID NO:311	7-29
mmu-mir-181b-1	SEQ ID NO:312	12-35
mmu-mir-181c	SEQ ID NO:313	17-38
mmu-mir-181b-2	SEQ ID NO:314	16-39
mmu-mir-182	SEQ ID NO:315	7-28
mmu-mir-183	SEQ ID NO:316	6-28
mmu-mir-184	SEQ ID NO:317	45-66
mmu-mir-185	SEQ ID NO:318	7-24
mmu-mir-186	SEQ ID NO:319	7-29
mmu-mir-187	SEQ ID NO:320	40-61
mmu-mir-188	SEQ ID NO:321	6-27
mmu-mir-190	SEQ ID NO:322	6-27
mmu-mir-191	SEQ ID NO:323	7-28
mmu-mir-192	SEQ ID NO:324	14-31
mmu-mir-193	SEQ ID NO:325	41-61
mmu-mir-194-1	SEQ ID NO:326	7-28
mmu-mir-194-2	SEQ ID NO:327	16-37
mmu-mir-195	SEQ ID NO:328	1-21
mmu-mir-196-1	SEQ ID NO:329	24-44
mmu-mir-196-2	SEQ ID NO:330	16-36
mmu-mir-199a-1	SEQ ID NO:331	6-28 and/or 45-66
mmu-mir-199a-2	SEQ ID NO:332	31-53 and/or 69-90
mmu-mir-199b	SEQ ID NO:333	26-48
mmu-mir-200b	SEQ ID NO:334	45-67
mmu-mir-200a	SEQ ID NO:335	54-75

EP 2 808 390 A1

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Mouse miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
mmu-mir-200c	SEQ ID NO:336	46-67
mmu-mir-201	SEQ ID NO:337	6-26
mmu-mir-202	SEQ ID NO:338	45-66
mmu-mir-203	SEQ ID NO:339	49-69
mmu-mir-204	SEQ ID NO:340	6-28
mmu-mir-205	SEQ ID NO:341	7-28
mmu-mir-206	SEQ ID NO:342	46-67
mmu-mir-207	SEQ ID NO:343	52-74
mmu-mir-208	SEQ ID NO:344	50-71
mmu-mir-210	SEQ ID NO:345	66-86
mmu-mir-211	SEQ ID NO:346	26-47
mmu-mir-212	SEQ ID NO:347	56-76
mmu-mir-213	SEQ ID NO:348	14-36 and/or 54-75
mmu-mir-214	SEQ ID NO:349	71-91
mmu-mir-215	SEQ ID NO:350	30-50
mmu-mir-216	SEQ ID NO:351	7-27
mmu-mir-217	SEQ ID NO:352	34-57
mmu-mir-218-2	SEQ ID NO:353	25-45
mmu-mir-219-1	SEQ ID NO:354	21-41
mmu-mir-219-2	SEQ ID NO:355	19-39
mmu-mir-221	SEQ ID NO:356	60-81
mmu-mir-222	SEQ ID NO:357	49-71
mmu-mir-223	SEQ ID NO:358	68-88
mmu-mir-224	SEQ ID NO:359	8-30
mu-miR-290	SEQ ID NO:360	15-37
mmu-mir-291	SEQ ID NO:361	14-35 and/or 50-72
mmu-mir-292	SEQ ID NO:362	12-33 and/or 51-73
mmu-mir-293	SEQ ID NO:363	48-69
mmu-mir-294	SEQ ID NO:364	51-72
mmu-mir-295	SEQ ID NO:365	43-65
mmu-mir-296	SEQ ID NO:366	13-33
mmu-mir-297-1	SEQ ID NO:367	15-35
mmu-mir-297-2	SEQ ID NO:368	36-56
mmu-mir-298	SEQ ID NO:369	11-32
mmu-mir-299	SEQ ID NO:370	7-28
mmu-mir-300	SEQ ID NO:371	51-72

EP 2 808 390 A1

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Mouse miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
mmu-mir-301	SEQ ID NO:372	51-73
mmu-mir-302	SEQ ID NO:373	44-66
mmu-mir-320	SEQ ID NO:374	48-70
mmu-mir-321	SEQ ID NO:375	10-30
mmu-mir-323	SEQ ID NO:376	50-71
mmu-mir-324	SEQ ID NO:377	18-40 and/or 53-74
mmu-mir-325	SEQ ID NO:378	16-38
mmu-mir-326	SEQ ID NO:379	60-80
mmu-mir-328	SEQ ID NO:380	61-82
mmu-mir-329	SEQ ID NO:381	61-82
mmu-mir-330	SEQ ID NO:382	61-83
mmu-mir-331	SEQ ID NO:383	61-81
mmu-mir-337	SEQ ID NO:384	61-83
mmu-mir-338	SEQ ID NO:385	61-83
mmu-mir-339	SEQ ID NO:386	16-36
mmu-mir-340	SEQ ID NO:387	61-83
mmu-mir-341	SEQ ID NO:388	61-81
mmu-mir-342	SEQ ID NO:389	61-84
mmu-mir-344	SEQ ID NO:390	61-83
mmu-mir-345	SEQ ID NO:391	16-36
mmu-mir-346	SEQ ID NO:392	16-38
mmu-mir-350	SEQ ID NO:393	61-84
mmu-mir-351	SEQ ID NO:583	16-39
mmu-mir-370	SEQ ID NO:584	48-70
mmu-mir-376a	SEQ ID NO:585	44-64
mmu-mir-376b	SEQ ID NO:586	51-72
mmu-mir-380	SEQ ID NO:587	40-61
mmu-mir-409	SEQ ID NO:588	47-69
mmu-mir-410	SEQ ID NO:589	50-71
mmu-mir-411	SEQ ID NO:590	56-78
mmu-mir-412	SEQ ID NO:591	50-72
mmu-mir-425	SEQ ID NO:695	54-74
mmu-mir-429	SEQ ID NO:696	51-72
mmu-mir-448	SEQ ID NO:697	72-93
mmu-mir-449	SEQ ID NO:698	16-37
mmu-mir-450	SEQ ID NO:699	17-38

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Mouse miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
mmu-mir-451	SEQ ID NO:786	17-38
mmu-mir-452	SEQ ID NO:787	17-38
mmu-mir-463	SEQ ID NO:788	4-24
mmu-mir-464	SEQ ID NO:789	47-69
mmu-mir-465	SEQ ID NO:790	5-27
mmu-mir-466	SEQ ID NO:791	51-73
mmu-mir-467	SEQ ID NO:792	50-71
mmu-mir-468	SEQ ID NO:793	53-75
mmu-mir-469	SEQ ID NO:794	6-31
mmu-mir-470	SEQ ID NO:795	9-29
mmu-mir-471	SEQ ID NO:796	7-29
mmu-mir-483	SEQ ID NO:797	45-67
mmu-mir-484	SEQ ID NO:798	2-23
mmu-mir-485	SEQ ID NO:799	9-30
mmu-mir-486	SEQ ID NO:800	4-25

**Table 3**

<b>Rat miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
rno-let-7d	SEQ ID NO:394	14-34 and/or 68-89
rno-mir-7-1	SEQ ID NO:395	19-39 and/or 61-82
rno-let-7a-1	SEQ ID NO:396	13-34
rno-let-7a-2	SEQ ID NO:397	17-38
rno-let-7b	SEQ ID NO:398	7-28
rno-let-7c-1	SEQ ID NO:399	16-37
rno-let-7c-2	SEQ ID NO:400	14-35
rno-let-7e	SEQ ID NO:401	15-35
rno-let-7f-1	SEQ ID NO:402	8-29
rno-let-7f-2	SEQ ID NO:403	8-29
rno-let-7i	SEQ ID NO:404	6-24
rno-mir-7-2	SEQ ID NO:405	19-39
rno-mir-7b	SEQ ID NO:406	29-49
rno-mir-9-1	SEQ ID NO:407	16-38
rno-mir-9-3	SEQ ID NO:408	16-38
rno-mir-9-2	SEQ ID NO:409	16-38

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Rat miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
rno-mir-10a	SEQ ID NO:410	22-44
rno-mir-10b	SEQ ID NO:411	26-47
rno-mir-15b	SEQ ID NO:412	20-41
rno-mir-16	SEQ ID NO:413	17-38
rno-mir-17	SEQ ID NO:414	14-37
rno-mir-18	SEQ ID NO:415	17-38
rno-mir-19b-1	SEQ ID NO:416	54-76
rno-mir-19b-2	SEQ ID NO:417	62-84
rno-mir-19a	SEQ ID NO:418	49-71
rno-mir-20	SEQ ID NO:419	16-38 and/or 52-72
rno-mir-21	SEQ ID NO:420	18-39
rno-mir-22	SEQ ID NO:421	57-78
rno-mir-23a	SEQ ID NO:422	46-66
rno-mir-23b	SEQ ID NO:423	58-80
rno-mir-24-1	SEQ ID NO:424	44-65
rno-mir-24-2	SEQ ID NO:425	61-82
rno-mir-25	SEQ ID NO:426	52-73
rno-mir-26a	SEQ ID NO:427	16-37
rno-mir-26b	SEQ ID NO:428	15-36
rno-mir-27b	SEQ ID NO:429	61-80
rno-mir-27a	SEQ ID NO:430	56-76
rno-mir-28	SEQ ID NO:431	14-35
rno-mir-29b-2	SEQ ID NO:432	52-73
rno-mir-29a	SEQ ID NO:433	53-74
rno-mir-29b-1	SEQ ID NO:434	51-72
rno-mir-29c	SEQ ID NO:435	54-75
rno-mir-30c-1	SEQ ID NO:436	17-39
rno-mir-30e	SEQ ID NO:437	2-21
rno-mir-30b	SEQ ID NO:438	16-36
rno-mir-30d	SEQ ID NO:439	12-33
rno-mir-30a	SEQ ID NO:440	47-68
rno-mir-30c-2	SEQ ID NO:441	14-36
rno-mir-31	SEQ ID NO:442	28-49
rno-mir-32	SEQ ID NO:443	6-26
rno-mir-33	SEQ ID NO:444	6-24
rno-mir-34b	SEQ ID NO:445	13-35

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Rat miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
rno-mir-34c	SEQ ID NO:446	13-35
rno-mir-34a	SEQ ID NO:447	20-42
rno-mir-92-1	SEQ ID NO:448	48-68
rno-mir-92-2	SEQ ID NO:449	55-75
rno-mir-93	SEQ ID NO:450	15-37
rno-mir-96	SEQ ID NO:451	24-46
rno-mir-98	SEQ ID NO:452	2-23
rno-mir-99a	SEQ ID NO:453	13-34
rno-mir-99b	SEQ ID NO:454	7-28
rno-mir-100	SEQ ID NO:455	13-34
rno-mir-101b	SEQ ID NO:456	61-82
rno-mir-101	SEQ ID NO:457	47-68
rno-mir-103-2	SEQ ID NO:458	52-74
rno-mir-103-1	SEQ ID NO:459	52-74
rno-mir-106b	SEQ ID NO:460	12-32
rno-mir-107	SEQ ID NO:461	52-74
rno-mir-122a	SEQ ID NO:462	15-37
rno-mir-124a-3	SEQ ID NO:463	52-73
rno-mir-124a-1	SEQ ID NO:464	52-73
rno-mir-124a-2	SEQ ID NO:465	61-82
rno-mir-125a	SEQ ID NO:466	15-37
rno-mir-125b-1	SEQ ID NO:467	15-36
rno-mir-125b-2	SEQ ID NO:468	17-38
rno-mir-126	SEQ ID NO:469	9-29 and/or 46-66
rno-mir-127	SEQ ID NO:470	57-78
rno-mir-128a	SEQ ID NO:471	50-71
rno-mir-128b	SEQ ID NO:472	52-73
rno-mir-129-2	SEQ ID NO:473	19-40 and/or 61-82
rno-mir-129-1	SEQ ID NO:474	6-27
rno-mir-130a	SEQ ID NO:475	55-74
rno-mir-130b	SEQ ID NO:476	51-72
rno-mir-132	SEQ ID NO:477	59-80
rno-mir-133a	SEQ ID NO:478	53-74
rno-mir-134	SEQ ID NO:479	8-28
rno-mir-135b	SEQ ID NO:480	16-37
rno-mir-135a	SEQ ID NO:481	23-45

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Rat miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
rno-mir-136	SEQ ID NO:482	15-37
rno-mir-137	SEQ ID NO:483	60-81
rno-mir-138-2	SEQ ID NO:484	9-25
rno-mir-138-1	SEQ ID NO:485	23-39
rno-mir-139	SEQ ID NO:486	7-24
rno-mir-140	SEQ ID NO:487	23-43 and/or 61-84
rno-mir-141	SEQ ID NO:488	59-79
rno-mir-142	SEQ ID NO:489	16-35 and/or 52-74
rno-mir-143	SEQ ID NO:490	60-81
rno-mir-144	SEQ ID NO:491	50-71
rno-mir-145	SEQ ID NO:492	16-39
rno-mir-146	SEQ ID NO:493	17-38
rno-mir-148b	SEQ ID NO:494	61-82
rno-mir-150	SEQ ID NO:495	16-37
rno-mir-151	SEQ ID NO:496	16-37 and/or 50-71
rno-mir-152	SEQ ID NO:497	53-73
rno-mir-153	SEQ ID NO:498	53-72
rno-mir-154	SEQ ID NO:499	15-36
rno-mir-181c	SEQ ID NO:500	24-45
rno-mir-181a	SEQ ID NO:501	39-61
rno-mir-181b-1	SEQ ID NO:502	36-59
rno-mir-181b-2	SEQ ID NO:503	15-38
rno-mir-183	SEQ ID NO:504	27-49
rno-mir-184	SEQ ID NO:505	47-68
rno-mir-185	SEQ ID NO:506	14-31
rno-mir-186	SEQ ID NO:507	15-37
rno-mir-187	SEQ ID NO:508	66-86
rno-mir-190	SEQ ID NO:509	15-36
rno-mir-191	SEQ ID NO:510	15-36
rno-mir-192	SEQ ID NO:511	24-44
rno-mir-193	SEQ ID NO:512	54-74
rno-mir-194-1	SEQ ID NO:513	15-36
rno-mir-194-2	SEQ ID NO:514	15-36
rno-mir-195	SEQ ID NO:515	15-35
rno-mir-196	SEQ ID NO:516	25-45
rno-mir-199a	SEQ ID NO:517	31-53

**EP 2 808 390 A1**

(continued)

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<b>Rat miRNA Sequences</b>		
<b>miRNA name</b>	<b>Precursor</b>	<b>Processed Sequence Relative to Precursor</b>
rno-mir-200c	SEQ ID NO:518	46-67
rno-mir-200a	SEQ ID NO:519	54-75
rno-mir-200b	SEQ ID NO:520	54-77
rno-mir-203	SEQ ID NO:521	52-73
rno-mir-204	SEQ ID NO:522	33-54
rno-mir-205	SEQ ID NO:523	33-54
rno-mir-206	SEQ ID NO:524	51-72
rno-mir-208	SEQ ID NO:525	50-71
rno-mir-210	SEQ ID NO:526	66-86
rno-mir-211	SEQ ID NO:527	26-47
rno-mir-212	SEQ ID NO:528	72-92
rno-mir-213	SEQ ID NO:529	55-76
rno-mir-214	SEQ ID NO:530	71-91
rno-mir-216	SEQ ID NO:531	19-39
rno-mir-217	SEQ ID NO:532	32-55
rno-mir-218-2	SEQ ID NO:533	25-45
rno-mir-218-1	SEQ ID NO:534	25-45
rno-mir-219-1	SEQ ID NO:535	21-41
rno-mir-219-2	SEQ ID NO:536	19-39
rno-mir-221	SEQ ID NO:537	65-87
rno-mir-222	SEQ ID NO:538	62-85
rno-mir-223	SEQ ID NO:539	68-88
rno-mir-290	SEQ ID NO:540	14-36
rno-mir-291	SEQ ID NO:541	14-35 and/or 50-72
rno-mir-292	SEQ ID NO:542	12-33 and/or 51-73
rno-mir-296	SEQ ID NO:543	13-33
rno-mir-297	SEQ ID NO:544	26-48
rno-mir-298	SEQ ID NO:545	11-32
rno-mir-299	SEQ ID NO:546	7-28
mo-mir-300	SEQ ID NO:547	51-72
mo-mir-301	SEQ ID NO:548	61-85
rno-mir-320	SEQ ID NO:549	48-70
rno-mir-321	SEQ ID NO:550	10-30
rno-mir-322	SEQ ID NO:551	61-80
rno-mir-323	SEQ ID NO:552	50-71
rno-mir-324	SEQ ID NO:553	16-38 and/or 51-72

(continued)

Rat miRNA Sequences		
miRNA name	Precursor	Processed Sequence Relative to Precursor
rno-mir-325	SEQ ID NO:554	16-38
rno-mir-326	SEQ ID NO:555	60-80
rno-mir-328	SEQ ID NO:556	48-69
rno-mir-329	SEQ ID NO:557	61-82
rno-mir-330	SEQ ID NO:558	60-82
rno-mir-331	SEQ ID NO:559	61-81
rno-mir-333	SEQ ID NO:560	16-35
rno-mir-336	SEQ ID NO:561	16-36
rno-mir-337	SEQ ID NO:562	60-82
rno-mir-338	SEQ ID NO:563	41-63
rno-mir-339	SEQ ID NO:564	16-36
rno-mir-341	SEQ ID NO:565	61-81
rno-mir-342	SEQ ID NO:566	61-84
rno-mir-344	SEQ ID NO:567	61-83
rno-mir-345	SEQ ID NO:568	16-36
rno-mir-346	SEQ ID NO:569	16-38
rno-mir-349	SEQ ID NO:570	61-82
rno-mir-350	SEQ ID NO:571	61-84
rno-mir-351	SEQ ID NO:572	16-39
rno-mir-352	SEQ ID NO:592	61-81
rno-mir-421	SEQ ID NO:593	10-30
rno-mir-429	SEQ ID NO:700	53-74
rno-mir-448	SEQ ID NO:701	72-93
rno-mir-449	SEQ ID NO:702	16-37
rno-mir-450	SEQ ID NO:703	17-38
rno-mir-451	SEQ ID NO:801	17-38
rno-mir-483	SEQ ID NO:802	45-67

**[0138]** It is understood that an miRNA is derived from genomic sequences or a gene. In this respect, the term "gene" is used for simplicity to refer to the genomic sequence encoding the precursor miRNA for a given miRNA. However, embodiments of the invention may involve genomic sequences of a miRNA that are involved in its expression, such as a promoter or other regulatory sequences.

**[0139]** The term "recombinant" may be used and this generally refers to a molecule that has been manipulated *in vitro* or that is the replicated or expressed product of such a molecule.

**[0140]** The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (one or more strands) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g., an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (e.g., an A, a G, an uracil "U" or a C). The term "nucleic acid" encompass the terms "oligonucleotide" and "polynucleotide," each as a subgenus of the term "nucleic acid."

**[0141]** The term "miRNA" generally refers to a single-stranded molecule, but in specific embodiments, molecules

implemented in the invention will also encompass a region or an additional strand that is partially (between 10 and 50% complementary across length of strand), substantially (greater than 50% but less than 100% complementary across length of strand) or fully complementary to another region of the same single-stranded molecule or to another nucleic acid. Thus, nucleic acids may encompass a molecule that comprises one or more complementary or self-complementary strand(s) or "complement(s)" of a particular sequence comprising a molecule. For example, precursor miRNA may have a self-complementary region, which is up to 100% complementary.

**[0142]** As used herein, "hybridization", "hybridizes" or "capable of hybridizing" is understood to mean the forming of a double or triple stranded molecule or a molecule with partial double or triple stranded nature. The term "anneal" as used herein is synonymous with "hybridize." The term "hybridization", "hybridize(s)" or "capable of hybridizing" encompasses the terms "stringent condition(s)" or "high stringency" and the terms "low stringency" or "low stringency condition(s)."

**[0143]** Synthetic nucleic acids of the invention will comprise, in some embodiments the miRNA sequence of any miRNA described in SEQ ID NOs:1-805, and/or any sequence with the complement thereof. It is contemplated that nucleic acids sequences of the invention can have, have at least, or have at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150 contiguous nucleotides from SEQ ID NOs:1-805 (or any ranger derivable therein), or be a complement thereof. In other embodiments, nucleic acids are, are at least, or are at most 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% identical or complementary to the miRNA sequence of SEQ ID NOs: 1-805 or to the entire sequence of any of SEQ ID NOs: 1-805, or any combination or range derivable therein.

**[0144]** Moreover, sequences are provided in the appendix. The appendix provides a list of 1) miRNAs that were screened, any one of which can be screened for using any array or method of the present invention; 2) the names of the probe used to screen for that miRNA; and, 3) the sequence of the named probe. It is clear that a particular probe can be used for identifying the level of expression of one or more target miRNAs, or set of target miRNAs (sets of targeted miRNAs may include completely unrelated RNAs, inadditions to sets that are either related or in the same gene family). It is contemplated that any of these sequences in the appendix can be used in embodiments of the invention.

## 1. Nucleobases

**[0145]** As used herein a "nucleobase" refers to a heterocyclic base, such as for example a naturally occurring nucleobase (*i.e.*, an A, T, G, C or U) found in at least one naturally occurring nucleic acid (*i.e.*, DNA and RNA), and naturally or non-naturally occurring derivative(s) and analogs of such a nucleobase. A nucleobase generally can form one or more hydrogen bonds ("anneal" or "hybridize") with at least one naturally occurring nucleobase in manner that may substitute for naturally occurring nucleobase pairing (*e.g.*, the hydrogen bonding between A and T, G and C, and A and U).

**[0146]** "Purine" and/or "pyrimidine" nucleobase(s) encompass naturally occurring purine and/or pyrimidine nucleobases and also derivative(s) and analog(s) thereof, including but not limited to, those a purine or pyrimidine substituted by one or more of an alkyl, caboxyalkyl, amino, hydroxyl, halogen (*i.e.*, fluoro, chloro, bromo, or iodo), thiol or alkylthiol moiety. Preferred alkyl (*e.g.*, alkyl, caboxyalkyl, etc.) moieties comprise of from about 1, about 2, about 3, about 4, about 5, to about 6 carbon atoms. Other non-limiting examples of a purine or pyrimidine include a deazapurine, a 2,6-diaminopurine, a 5-fluorouracil, a xanthine, a hypoxanthine, a 8-bromoguanine, a 8-chloroguanine, a bromothymine, a 8-aminoguanine, a 8-hydroxyguanine, a 8-methylguanine, a 8-thioguanine, an azaguanine, a 2-aminopurine, a 5-ethylcytosine, a 5-methylcytosine, a 5-bromouracil, a 5-ethyluracil, a 5-iodouracil, a 5-chlorouracil, a 5-propyluracil, a thiouracil, a 2-methyladenine, a methylthioadenine, a N,N-dimethyladenine, an azaadenines, a 8-bromoadenine, a 8-hydroxyadenine, a 6-hydroxyaminopurine, a 6-thiopurine, a 4-(6-aminohexyl/cytosine), and the like. Other examples are well known to those of skill in the art.

**[0147]** A nucleobase may be comprised in a nucleoside or nucleotide, using any chemical or natural synthesis method described herein or known to one of ordinary skill in the art. Such nucleobase may be labeled or it may be part of a molecule that is labeled and contains the nucleobase.

## 2. Nucleosides

**[0148]** As used herein, a "nucleoside" refers to an individual chemical unit comprising a nucleobase covalently attached to a nucleobase linker moiety. A non-limiting example of a "nucleobase linker moiety" is a sugar comprising 5-carbon atoms (*i.e.*, a "5-carbon sugar"), including but not limited to a deoxyribose, a ribose, an arabinose, or a derivative or an analog of a 5-carbon sugar. Non-limiting examples of a derivative or an analog of a 5-carbon sugar include a 2'-fluoro-

2'-deoxyribose or a carbocyclic sugar where a carbon is substituted for an oxygen atom in the sugar ring.

[0149] Different types of covalent attachment(s) of a nucleobase to a nucleobase linker moiety are known in the art. By way of non-limiting example, a nucleoside comprising a purine (*i.e.*, A or G) or a 7-deazapurine nucleobase typically covalently attaches the 9 position of a purine or a 7-deazapurine to the 1'-position of a 5-carbon sugar. In another non-limiting example, a nucleoside comprising a pyrimidine nucleobase (*i.e.*, C, T or U) typically covalently attaches a 1 position of a pyrimidine to a 1'-position of a 5-carbon sugar (Kornberg and Baker, 1992).

### 3. Nucleotides

[0150] As used herein, a "nucleotide" refers to a nucleoside further comprising a "backbone moiety". A backbone moiety generally covalently attaches a nucleotide to another molecule comprising a nucleotide, or to another nucleotide to form a nucleic acid. The "backbone moiety" in naturally occurring nucleotides typically comprises a phosphorus moiety, which is covalently attached to a 5-carbon sugar. The attachment of the backbone moiety typically occurs at either the 3'- or 5'-position of the 5-carbon sugar. However, other types of attachments are known in the art, particularly when a nucleotide comprises derivatives or analogs of a naturally occurring 5-carbon sugar or phosphorus moiety.

### 4. Nucleic Acid Analogs

[0151] A nucleic acid may comprise, or be composed entirely of, a derivative or analog of a nucleobase, a nucleobase linker moiety and/or backbone moiety that may be present in a naturally occurring nucleic acid. RNA with nucleic acid analogs may also be labeled according to methods of the invention. As used herein a "derivative" refers to a chemically modified or altered form of a naturally occurring molecule, while the terms "mimic" or "analog" refer to a molecule that may or may not structurally resemble a naturally occurring molecule or moiety, but possesses similar functions. As used herein, a "moiety" generally refers to a smaller chemical or molecular component of a larger chemical or molecular structure. Nucleobase, nucleoside and nucleotide analogs or derivatives are well known in the art, and have been described (see for example, Scheit, 1980, incorporated herein by reference).

[0152] Additional non-limiting examples of nucleosides, nucleotides or nucleic acids comprising 5-carbon sugar and/or backbone moiety derivatives or analogs, include those in: U.S. Patent No. 5,681,947, which describes oligonucleotides comprising purine derivatives that form triple helices with and/or prevent expression of dsDNA; U.S. Patents 5,652,099 and 5,763,167, which describe nucleic acids incorporating fluorescent analogs of nucleosides found in DNA or RNA, particularly for use as fluorescent nucleic acid probes; U.S. Patent 5,614,617, which describes oligonucleotide analogs with substitutions on pyrimidine rings that possess enhanced nuclease stability; U.S. Patents 5,670,663, 5,872,232 and 5,859,221, which describe oligonucleotide analogs with modified 5-carbon sugars (*i.e.*, modified 2'-deoxyfuranosyl moieties) used in nucleic acid detection; U.S. Patent 5,446,137, which describes oligonucleotides comprising at least one 5-carbon sugar moiety substituted at the 4' position with a substituent other than hydrogen that can be used in hybridization assays; U.S. Patent 5,886,165, which describes oligonucleotides with both deoxyribonucleotides with 3'-5' internucleotide linkages and ribonucleotides with 2'-5' internucleotide linkages; U.S. Patent 5,714,606, which describes a modified internucleotide linkage wherein a 3'-position oxygen of the internucleotide linkage is replaced by a carbon to enhance the nuclease resistance of nucleic acids; U.S. Patent 5,672,697, which describes oligonucleotides containing one or more 5' methylene phosphonate internucleotide linkages that enhance nuclease resistance; U.S. Patents 5,466,786 and 5,792,847, which describe the linkage of a substituent moiety which may comprise a drug or label to the 2' carbon of an oligonucleotide to provide enhanced nuclease stability and ability to deliver drugs or detection moieties; U.S. Patent 5,223,618, which describes oligonucleotide analogs with a 2 or 3 carbon backbone linkage attaching the 4' position and 3' position of adjacent 5-carbon sugar moiety to enhanced cellular uptake, resistance to nucleases and hybridization to target RNA; U.S. Patent 5,470,967, which describes oligonucleotides comprising at least one sulfamate or sulfamide internucleotide linkage that are useful as nucleic acid hybridization probe; U.S. Patents 5,378,825, 5,777,092, 5,623,070, 5,610,289 and 5,602,240, which describe oligonucleotides with three or four atom linker moiety replacing phosphodiester backbone moiety used for improved nuclease resistance, cellular uptake and regulating RNA expression; U.S. Patent 5,858,988, which describes hydrophobic carrier agent attached to the 2'-O position of oligonucleotides to enhanced their membrane permeability and stability; U.S. Patent 5,214,136, which describes oligonucleotides conjugated to anthraquinone at the 5' terminus that possess enhanced hybridization to DNA or RNA; enhanced stability to nucleases; U.S. Patent 5,700,922, which describes PNA-DNA-PNA chimeras wherein the DNA comprises 2'-deoxy-erythro-pentofuranosyl nucleotides for enhanced nuclease resistance, binding affinity, and ability to activate RNase H; and U.S. Patent 5,708,154, which describes RNA linked to a DNA to form a DNA-RNA hybrid; U.S. Patent 5,728,525, which describes the labeling of nucleoside analogs with a universal fluorescent label.

[0153] Additional teachings for nucleoside analogs and nucleic acid analogs are U.S. Patent 5,728,525, which describes nucleoside analogs that are end-labeled; U.S. Patent 5,637,683, 6,251,666 (L-nucleotide substitutions), and 5,480,980 (7-deaza-2'-deoxyguanosine nucleotides and nucleic acid analogs thereof).

[0154] The use of other analogs is specifically contemplated for use in the context of the present invention. Such analogs may be used in synthetic nucleic acid molecules of the invention, both throughout the molecule or at selected nucleotides. They include, but are not limited to, 1) ribose modifications (such as 2'F, 2' NH<sub>2</sub>, 2'N<sub>3</sub>, 4'thio, or 2' O-CH<sub>3</sub>) and 2) phosphate modifications (such as those found in phosphorothioates, methyl phosphonates, and phosphoroborates). Such analogs have been created to confer stability on RNAs by reducing or eliminating their capacity to be cleaved by ribonucleases. When these nucleotide analogs are present in RNAs, they can have profoundly positive effects on the stability of the RNAs in animals. It is contemplated that the use of nucleotide analogs can be used alone or in conjunction with any of the design modifications of a synthetic miRNA for any nucleic acid of the invention.

## 5. Modified Nucleotides

[0155] Both synthetic miRNAs and miRNA inhibitors of the invention specifically contemplate the use of nucleotides that are modified to enhance their activities. Such nucleotides include those that are at the 5' or 3' terminus of the RNA as well as those that are internal within the molecule. Modified nucleotides used in the complementary strands of synthetic miRNAs either block the 5'OH or phosphate of the RNA or introduce internal sugar modifications that enhance uptake of the active strand of the synthetic miRNA. Modifications for the miRNA inhibitors include internal sugar modifications that enhance hybridization as well as stabilize the molecules in cells and terminal modifications that further stabilize the nucleic acids in cells. Further contemplated are modifications that can be detected by microscopy or other methods to identify cells that contain the synthetic miRNAs or miRNA inhibitors.

## B. Preparation of Nucleic Acids

[0156] A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production or biological production. Though synthetic miRNAs according to the invention could be produced using recombinant methods, it is preferred to produce synthetic miRNAs by chemical synthesis or enzymatic production. Likewise, miRNA inhibitors are preferentially produced by chemical synthesis or enzymatic production. Non-synthetic miRNAs can be produced by a number of methods, including methods involving recombinant DNA technology.

[0157] Nucleic acid synthesis is performed according to standard methods. See, for example, Itakura and Riggs (1980). Additionally, U.S. Patent 4,704,362, U.S. Patent 5,221,619, and U.S. Patent 5,583,013 each describe various methods of preparing synthetic nucleic acids. Non-limiting examples of a synthetic nucleic acid (e.g., a synthetic oligonucleotide), include a nucleic acid made by *in vitro* chemically synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, 1986 and U.S. Patent Serial No. 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

[0158] A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCR™ (see for example, U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide described in U.S. Patent No. 5,645,897, incorporated herein by reference.

[0159] Oligonucleotide synthesis is well known to those of skill in the art. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

[0160] Basically, chemical synthesis can be achieved by the diester method, the triester method polynucleotides phosphorylase method and by solid-phase chemistry. These methods are discussed in further detail below.

[0161] **Diester method.** The diester method was the first to be developed to a usable state, primarily by Khorana and co-workers. (Khorana, 1979). The basic step is the joining of two suitably protected deoxynucleotides to form a dideoxynucleotide containing a phosphodiester bond. The diester method is well established and has been used to synthesize DNA molecules (Khorana, 1979).

[0162] **Triester method.** The main difference between the diester and triester methods is the presence in the latter of an extra protecting group on the phosphate atoms of the reactants and products (Itakura *et al.*, 1975). The phosphate protecting group is usually a chlorophenyl group, which renders the nucleotides and polynucleotide intermediates soluble in organic solvents. Therefore purification's are done in chloroform solutions. Other improvements in the method include (i) the block coupling of trimers and larger oligomers, (ii) the extensive use of high-performance liquid chromatography for the purification of both intermediate and final products, and (iii) solid-phase synthesis.

[0163] **Polynucleotide phosphorylase method.** This is an enzymatic method of DNA synthesis that can be used to

synthesize many useful oligonucleotides (Gillam *et al.*, 1978; Gillam *et al.*, 1979). Under controlled conditions, polynucleotide phosphorylase adds predominantly a single nucleotide to a short oligonucleotide. Chromatographic purification allows the desired single adduct to be obtained. At least a trimer is required to start the procedure, and this primer must be obtained by some other method. The polynucleotide phosphorylase method works and has the advantage that the procedures involved are familiar to most biochemists.

**[0164] Solid-phase methods.** Drawing on the technology developed for the solid-phase synthesis of polypeptides, it has been possible to attach the initial nucleotide to solid support material and proceed with the stepwise addition of nucleotides. All mixing and washing steps are simplified, and the procedure becomes amenable to automation. These syntheses are now routinely carried out using automatic nucleic acid synthesizers.

**[0165]** Phosphoramidite chemistry (Beaucage and Lyer, 1992) has become by far the most widely used coupling chemistry for the synthesis of oligonucleotides. As is well known to those skilled in the art, phosphoramidite synthesis of oligonucleotides involves activation of nucleoside phosphoramidite monomer precursors by reaction with an activating agent to form activated intermediates, followed by sequential addition of the activated intermediates to the growing oligonucleotide chain (generally anchored at one end to a suitable solid support) to form the oligonucleotide product.

**[0166] Recombinant methods.** Recombinant methods for producing nucleic acids in a cell are well known to those of skill in the art. These include the use of vectors, plasmids, cosmids, and other vehicles for delivery a nucleic acid to a cell, which may be the target cell or simply a host cell (to produce large quantities of the desired RNA molecule). Alternatively, such vehicles can be used in the context of a cell free system so long as the reagents for generating the RNA molecule are present. Such methods include those described in Sambrook, 2003, Sambrook, 2001 and Sambrook, 1989, which are hereby incorporated by reference.

**[0167]** In certain embodiments, the present invention concerns nucleic acid molecules that are not synthetic. In some embodiments, the nucleic acid molecule has a chemical structure of a naturally occurring nucleic acid and a sequence of a naturally occurring nucleic acid, such as the exact and entire sequence of a single stranded primary miRNA (see Lee 2002), a single-stranded precursor miRNA, or a single-stranded mature miRNA. In addition to the use of recombinant technology, such non-synthetic nucleic acids may be generated chemically, such as by employing technology used for creating oligonucleotides.

### C. Design of Synthetic miRNAs

**[0168]** Synthetic miRNAs typically comprise two strands, an active strand that is identical in sequence to the mature miRNA that is being studied and a complementary strand that is at least partially complementary to the active strand. The active strand is the biologically relevant molecule and should be preferentially taken up by the complex in cells that modulates translation either through mRNA degradation or translational control. Preferential uptake of the active strand has two profound results: (1) the observed activity of the synthetic miRNA increases dramatically and (2) non-intended effects induced by uptake and activation of the complementary strand are essentially eliminated. According to the invention, several synthetic miRNA designs can be used to ensure the preferential uptake of the active strand.

**[0169] 5' Blocking Agent.** The introduction of a stable moiety other than phosphate or hydroxyl at the 5' end of the complementary strand impairs its activity in the miRNA pathway. This ensures that only the active strand of the synthetic miRNA will be used to regulate translation in the cell. 5' modifications include, but are not limited to, NH<sub>2</sub>, biotin, an amine group, a lower alkylamine group, an acetyl group, DMTO, fluoroscein, a thiol, or acridine or any other group with this type of functionality.

**[0170] Other sense strand modifications.** The introduction of nucleotide modifications like 2'-OMe, NH<sub>2</sub>, biotin, an amine group, a lower alkylamine group, an acetyl group, DMTO, fluoroscein, a thiol, or acridine or any other group with this type of functionality in the complementary strand of the synthetic miRNA can eliminate the activity of the complementary strand and enhance uptake of the active strand of the miRNA.

**[0171] Base mismatches in the sense strand.** As with siRNAs (Schwarz 2003), the relative stability of the 5' and 3' ends of the active strand of the synthetic miRNA apparently determines the uptake and activation of the active by the miRNA pathway. Destabilizing the 5' end of the active strand of the synthetic miRNA by the strategic placement of base mismatches in the 3' end of the complementary strand of the synthetic miRNA enhances the activity of the active strand and essentially eliminates the activity of the complementary strand.

### D. Host Cells and Target Cells

**[0172]** The cells used to understand miRNA function may be derived from or contained in any organism (*e.g.*, plant, animal, protozoan, virus, bacterium, or fungus). The plant may be a monocot, dicot or gymnosperm; the animal may be a vertebrate or invertebrate. Preferred microbes are those used in agriculture or by industry, and those that are pathogenic for plants or animals. Fungi include organisms in both the mold and yeast morphologies. Examples of vertebrates include fish and mammals, including cattle, goat, pig, sheep, hamster, mouse, rat and human; invertebrate animals include

nematodes, insects, arachnids, and other arthropods. Preferably, the cell is a vertebrate cell. More preferably, the cell is a mammalian cell.

**[0173]** The cells used to understand miRNA function may be from the germ line or somatic, totipotent or pluripotent, dividing or non-dividing, parenchyma or epithelium, immortalized or transformed, or the like. The cell can be a gamete or an embryo; if an embryo, it can be a single cell embryo or a constituent cell or cells from a multicellular embryo. The term "embryo" thus encompasses fetal tissue. The cell used for miRNA functional analysis may be an undifferentiated cell, such as a stem cell, or a differentiated cell, such as from a cell of an organ or tissue, including fetal tissue, or any other cell present in an organism. Cell types that are differentiated include adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelium, neurons, glia, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells, of the endocrine or exocrine glands. Alternatively, cells may be qualified as germ cells, nurse cells, epithelial cells, endothelial cells, hormone secreting cells, contractile cells, skeletal muscle cells, cardiac muscle cells, blood cells, or cells from the bone, bone marrow, brain, breast, cervix, colon, gastrointestinal tract, heart, kidney, large intestine, liver, lung, lymph nodes, ovary, pancreas, prostate, small intestine, spine or spinal cord, spleen, stomach, testes, thymus, or uterus.

**[0174]** As used herein, the terms "cell," "cell line," and "cell culture" may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations formed by cell division. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations. A host cell may be "transfected" or "transformed," which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny. As used herein, the terms "engineered" and "recombinant" cells or host cells are intended to refer to a cell into which an exogenous nucleic acid sequence, such as, for example, a small, interfering RNA or a template construct encoding a reporter gene has been introduced. Therefore, recombinant cells are distinguishable from naturally occurring cells that do not contain a recombinantly introduced nucleic acid.

**[0175]** A tissue may comprise a host cell or cells to be transformed or contacted with a nucleic acid delivery composition and/or an additional agent. The tissue may be part or separated from an organism. In certain embodiments, a tissue and its constituent cells may comprise, but is not limited to, blood (e.g., hematopoietic cells (such as human hematopoietic progenitor cells, human hematopoietic stem cells, CD34<sup>+</sup> cells CD4<sup>+</sup> cells), lymphocytes and other blood lineage cells), bone marrow, brain, stem cells, blood vessel, liver, lung, bone, breast, cartilage, cervix, colon, cornea, embryonic, endometrium, endothelial, epithelial, esophagus, fascia, fibroblast, follicular, ganglion cells, glial cells, goblet cells, kidney, lymph node, muscle, neuron, ovaries, pancreas, peripheral blood, prostate, skin, skin, small intestine, spleen, stomach, testes.

**[0176]** In certain embodiments, the host cell or tissue may be comprised in at least one organism. In certain embodiments, the organism may be, human, primate or murine. In other embodiments the organism may be any eukaryote or even a prokaryote (e.g., a eubacteria, an archaea), as would be understood by one of ordinary skill in the art (see, for example, webpage <http://phylogeny.arizona.edu/tree/phylogeny.html>). One of skill in the art would further understand the conditions under which to incubate all of the above described host cells to maintain them and to permit their division to form progeny.

## E. Labels and Tags

**[0177]** Synthetic miRNAs and miRNA inhibitors may be labeled with a radioactive, enzymatic, colorimetric, or other label or tag for detection or isolation purposes. Nucleic acids may be labeled with fluorescence in some embodiments of the invention. The fluorescent labels contemplated for use as conjugates include, but are not limited to, Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5, 6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, SYPRO, TAMRA, TET, Tetramethylrhodamine, and/or Texas Red.

**[0178]** It is contemplated that synthetic miRNAs and miRNA inhibitors may be labeled with two different labels. Furthermore, fluorescence resonance energy transfer (FRET) may be employed in methods of the invention (e.g., Klostermeier *et al.*, 2002; Emptage, 2001; Didenko, 2001, each incorporated by reference).

**[0179]** A number of techniques for visualizing or detecting labeled nucleic acids are readily available. The reference by Stanley T. Croke, 2000 has a discussion of such techniques (Chapter 6) which is incorporated by reference. Such techniques include, microscopy, arrays, Fluorometry, Light cyclers or other real time PCR<sup>™</sup> machines, FACS analysis, scintillation counters, Phosphoimagers, Geiger counters, MRI, CAT, antibody-based detection methods (Westerns, immunofluorescence, immunohistochemistry), histochemical techniques, HPLC (Griffey *et al.*, 1997, spectroscopy, capillary gel electrophoresis (Cummins *et al.*, 1996), spectroscopy; mass spectroscopy; radiological techniques; and mass balance techniques. Alternatively, nucleic acids may be labeled or tagged to allow for their efficient isolation. In other embodiments of the invention, nucleic acids are biotinylated.

## F. Delivery Methods

**[0180]** The present invention involves in some embodiments delivering a nucleic acid into a cell. This may be done as part of a screening method, or it may be related to a therapeutic or diagnostic application.

**[0181]** RNA molecules may be encoded by a nucleic acid molecule comprised in a vector. The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous," which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques, which are described in Sambrook *et al.*, 1989 and Ausubel *et al.*, 1996, both incorporated herein by reference. In addition to encoding a modified polypeptide such as modified gelonin, a vector may encode non-modified polypeptide sequences such as a tag or targetting molecule. A targetting molecule is one that directs the desired nucleic acid to a particular organ, tissue, cell, or other location in a subject's body.

**[0182]** The term "expression vector" refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described

**[0183]** There are a number of ways in which expression vectors may be introduced into cells. In certain embodiments of the invention, the expression vector comprises a virus or engineered vector derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells (Ridgeway, 1988; Nicolas and Rubenstein, 1988; Baichwal and Sugden, 1986; Temin, 1986). The first viruses used as gene vectors were DNA viruses including the papovaviruses (simian virus 40, bovine papilloma virus, and polyoma) (Ridgeway, 1988; Baichwal and Sugden, 1986) and adenoviruses (Ridgeway, 1988; Baichwal and Sugden, 1986). These have a relatively low capacity for foreign DNA sequences and have a restricted host spectrum. Furthermore, their oncogenic potential and cytopathic effects in permissive cells raise safety concerns. They can accommodate only up to 8 kb of foreign genetic material but can be readily introduced in a variety of cell lines and laboratory animals (Nicolas and Rubenstein, 1988; Temin, 1986).

**[0184]** The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells; they can also be used as vectors. Other viral vectors may be employed as expression constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988) adeno-associated virus (AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpesviruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar *et al.*, 1988; Horwich *et al.*, 1990).

**[0185]** Other suitable methods for nucleic acid delivery to effect expression of compositions of the present invention are believed to include virtually any method by which a nucleic acid (e.g., DNA, including viral and nonviral vectors) can be introduced into an organelle, a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by injection (U.S. Patent Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (Harlan and Weintraub, 1985; U.S. Patent No. 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE-dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer *et al.*, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patent Nos. 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein by reference); by agitation with silicon carbide fibers (Kaeppler *et al.*, 1990; U.S. Patent Nos. 5,302,523 and 5,464,765, each incorporated herein by reference); by *Agrobacterium*-mediated transformation (U.S. Patent Nos. 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG-mediated transformation of protoplasts (Omirulleh *et al.*, 1993; U.S. Patent Nos. 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition-mediated DNA uptake (Potrykus *et al.*, 1985). Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

## II. Screening with Synthetic miRNA and miRNA Inhibitor Libraries

5 [0186] As used in the patent application, screening is a process wherein multiple miRNA-specific reagents are delivered separately into individual cell populations or animals. At one or more designated times after delivery, the cell populations or animals are assayed for one or more phenotypes. Those cells or animals that have a significantly different phenotype than cells or animals in the negative control group are classified as positives. The miRNA that was being manipulated in the sample is defined as a hit. Hits represent targets for additional research and potential therapeutic development.

10 [0187] In some embodiments, there is a multi-step process for screening. In certain embodiments, there are four general steps:

(1) *Develop quantitative assay to monitor cellular process being studied.*

15 [0188] Assays that measure the intensity of a cellular phenotype range from microscopic assays that monitor cell size, cell cycle status, or antibody staining to enzymatic assays that assess the turnover of a specific substrate in a cell lysate to direct measurements of biomolecules or small molecules in lysates, on cells, or in medium.

20 [0189] Critical to the success of a screen is creating an assay that truly measures the cellular phenotype and maximizing the signal-to-noise ratio of the assay. Maximizing signal-to-noise involves testing variables like assay time, assay components, cell type, and length of time between transfection and assay. The greater the difference in the assay results between a positive phenotype and a negative control phenotype, the greater the spread will be in the screening results and the better the opportunity will be to identify interesting genes.

(2) *Optimize transfection conditions for the desired cells.*

25 [0190] The first step in this process is identifying a transfection reagent and plating conditions that maximize the uptake of synthetic miRNAs or miRNA inhibitors while maintaining high cell viability. We find it useful to test 2-5 different transfection reagents when using cell lines or 5-10 electroporation conditions when using primary or suspension cells. Transfection can be optimized for the reagent or electroporation condition that worked best among the conditions tested. Screening miRNA-specific libraries requires conditions for high-throughput transfection. The inventors have developed and used a rapid process that facilitates the transfection of up to 1,000 wells in less than an hour without the need for robotics (see delivery below).

(3) *Screen*

35 [0191] Once the assay and transfection process have been developed, a library of synthetic miRNAs or miRNA inhibitors can be introduced sequentially into cells in a 24- or 96-well plate. Triplicate transfections for each reagent provide enough data for reasonable statistical analysis.

(4) *Validate hits*

40 [0192] Validating a hit involves showing that the observed phenotype is due to the miRNA being targeted. Hits are typically confirmed by delivering a dilution series of the miRNA inhibitor or synthetic miRNA that registered as a hit into the cell that was originally assayed. It has been the experience of the inventors that true hits show a dose response.

### A. Synthetic miRNA and miRNA Inhibitor Library Preparation

45 [0193] The present invention concerns the preparation and use of synthetic miRNA and miRNA inhibitor libraries to induce changes in the activity of specific miRNAs in cells. Preparation of synthetic miRNAs and miRNA inhibitors typically involves the chemical synthesis of the active and complementary strands of the synthetic miRNA and the single-stranded miRNA inhibitor using any of the methods described in this application. If the active and complementary strands of the synthetic miRNAs are two distinct molecules, then the two strands must be hybridized prior to delivery. Hybridization can be achieved by mixing the two nucleic acids together in roughly equimolar amounts and incubating for a time and at a temperature that is appropriate for hybridization. The addition of salt (e.g., NaCl or NaOAC) enhances hybridization as does the inclusion of a heat denaturation step prior to the incubation used for hybridization.

### B. Delivery of Synthetic miRNAs and miRNA Inhibitors

55 [0194] Libraries of the invention can be used to sequentially up- or down-regulate one or more miRNAs in samples. This requires methods for introducing the synthetic miRNAs and miRNA inhibitors into cell types with associated cell

assays. Lipid-based transfection is typically employed to introduce the nucleic acids into immortalized cells and electroporation for primary cells.

**[0195]** Suitable methods for nucleic acid delivery according to the present invention are believed to include virtually any method by which a nucleic acid (e.g., DNA, RNA, including viral and nonviral vectors) can be introduced into an organelle, a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of nucleic acids such as by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and 5,580,859, each incorporated herein by reference), including microinjection (Harland and Weintraub, 1985; U.S. Patent 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); by using DEAE-dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer *et al.*, 1987); by liposome mediated transfection (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Nicolau *et al.*, 1987; Wong *et al.*, 1980; Kaneda *et al.*, 1989; Kato *et al.*, 1991); by microprojectile bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S. Patents 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and 5,538,880, and each incorporated herein by reference); by agitation with silicon carbide fibers (Kaepler *et al.*, 1990; U.S. Patents 5,302,523 and 5,464,765, each incorporated herein by reference); by *Agrobacterium*-mediated transformation (U.S. Patents 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG-mediated transformation of protoplasts (Omirulleh *et al.*, 1993; U.S. Patents 4,684,611 and 4,952,500, each incorporated herein by reference); by desiccation/inhibition-mediated DNA uptake (Potrykus *et al.*, 1985). Through the application of techniques such as these, organelle(s), cell(s), tissue(s) or organism(s) may be stably or transiently transformed.

**[0196]** A variety of compounds have been attached to the ends of oligonucleotides to facilitate their transport across cell membranes. Short signal peptides found in the HIV TAT, HSV VP22, *Drosophila antennapedia*, and other proteins have been found to enable the rapid transfer of biomolecules across membranes (reviewed by Schwarze 2000). These signal peptides, referred to as Protein Transduction Domains (PTDs), have been attached to oligonucleotides to facilitate their delivery into cultured cells. Cholesterols have been conjugated to oligonucleotides to improve their uptake into cells in animals (MacKellar 1992). The terminal cholesterol groups apparently interact with receptors or lipids on the surfaces of cells and facilitate the internalization of the modified oligonucleotides. Likewise, poly-1-lysine has been conjugated to oligonucleotides to decrease the net negative charge and improve uptake into cells (Leonetti 1990).

**[0197]** A variety of compounds have been developed that complex with nucleic acids, deliver them to surfaces of cells, and facilitate their uptake in and release from endosomes. Among these are: (1) a variety of lipids such as DOTAP (or other cationic lipid), DDAB, DHDEAB, and DOPE and (2) non-lipid-based polymers like polyethylenimine, polyamidoamine, and dendrimers of these and other polymers. In certain of these embodiments a combination of lipids is employed such as DOTAP and cholesterol or a cholesterol derivative (U.S. Patent 6,770,291, which is hereby incorporated by reference). Several of these reagents have been shown to facilitate nucleic acid uptake in animals.

**[0198]** The cellular components involved in the miRNA pathway are becoming known. Proteins that stabilize and/or transport miRNAs within cells might enhance the stability and activity of miRNAs because they should protect and guide the bound miRNAs once they are in cells. Mixtures of miRNA-transporter proteins and miRNAs could enhance the efficacy of miRNA-based therapeutics.

**[0199]** RNAs are hydrophilic molecules by virtue of their anionic phosphate and sugar backbone. Although the nucleobases are hydrophobic, hydrophilicity dominates owing to the extensive hydrogen bonding resulting from the phosphate and sugar residues. The hydrophilic character and anionic backbone reduces cellular permeation. Conjugation of lipophilic groups like cholesterol (Manoharan, 2002) and lauric and lithocholic acid derivatives with C32 functionality (Lorenz *et al.*, 2004), have been shown to improve cellular uptake. Moreover binding of steroid conjugated oligonucleotides to different lipoproteins in the bloodstream, such as LDL, protect their integrity and govern their biodistribution (Rump *et al.*, 2000). Cholesterol attached to anti-sense molecules (Bijsterbosch *et al.*, 2001) and aptamers (Rusconi *et al.*, 2004) has also been shown to stabilize oligonucleotides by allowing binding to lipoproteins. Cholesterol has been demonstrated to enhance uptake and serum stability of siRNAs *in vitro* (Lorenz *et al.*, 2004) and *in vivo* (Soutschek *et al.*, 2004). Additionally, a number of small molecules like SB-435495 (Blackie *et al.*, (2002), Isradipine (Oravcova *et al.*, 1994), amlodipine (Oravcova *et al.*, 1994) and 2,2',4,4',5,5'-hexachlorobiphenyl (Borlakoglu *et al.*, 1990) could enhance cellular uptake, and improve nuclease resistance by promoting lipoprotein association.

**[0200]** The present methods and kits may be employed for high volume screening. A library of synthetic miRNAs and/or miRNA inhibitors can be created using methods of the invention. This library may then be used in high throughput assays, including microarrays. Specifically contemplated by the present inventors are chip-based nucleic acid technologies such as those described by Ziauddin and Sabatini (2001). Briefly, nucleic acids can be immobilized on solid supports. Cells can then be overlaid on the solid support and take up the nucleic acids at the defined locations. The impact on the cells can then be measured to identify cocktails that are having a desirable effect.

## C. Labeling and Labeling Techniques

**[0201]** In some embodiments, the present invention concerns miRNA that are labeled, such as for screening assays to evaluate the therapeutic or diagnostic relevance of a particular miRNA species. It is contemplated that miRNA may first be isolated (either from a cell in which the miRNA is endogenous to the cell or from a cell in which miRNA is exogenous to the cell) and/or purified prior to labeling. This may achieve a reaction that more efficiently labels the miRNA, as opposed to other RNA in a sample in which the miRNA is not isolated or purified prior to labeling. In many embodiments of the invention, the label is non-radioactive. Generally, nucleic acids may be labeled by adding labeled nucleotides (one-step process) or adding nucleotides and labeling the added nucleotides (two-step process).

**[0202]** Moreover, miRNA may be labeled as is described in U.S. Patent Application Ser. No.60/649,584, which is hereby incorporated by reference. Such nucleotides include those that can be labeled with a dye, including a fluorescent dye, or with a molecule such as biotin. Labeled nucleotides are readily available; they can be acquired commercially or they can be synthesized by reactions known to those of skill in the art.

### 1. Nucleotides for Labeling

**[0203]** Nucleotides for labelling are not naturally occurring nucleotides, but instead, refer to prepared nucleotides that have a reactive moiety on them. Specific reactive functionalities of interest include: amino, sulfhydryl, sulfoxyl, amino-sulfhydryl, azido, epoxide, isothiocyanate, isocyanate, anhydride, monochlorotriazine, dichlorotriazine, mono- or dihalogen substituted pyridine, mono- or disubstituted diazine, maleimide, epoxide, aziridine, sulfonyl halide, acid halide, alkyl halide, aryl halide, alkylsulfonate, N-hydroxysuccinimide ester, imido ester, hydrazine, azidonitrophenyl, azide, 3-(2-pyridyl dithio)-propionamide, glyoxal, aldehyde, iodoacetyl, cyanomethyl ester, p-nitrophenyl ester, o-nitrophenyl ester, hydroxypyridine ester, carbonyl imidazole, and the other such chemical groups. In some embodiments, the reactive functionality may be bonded directly to a nucleotide, or it may be bonded to the nucleotide through a linking group. The functional moiety and any linker cannot substantially impair the ability of the nucleotide to be added to the miRNA or to be labeled. Representative linking groups include carbon containing linking groups, typically ranging from about 2 to 18, usually from about 2 to 8 carbon atoms, where the carbon containing linking groups may or may not include one or more heteroatoms, e.g. S, O, N etc., and may or may not include one or more sites of unsaturation. Of particular interest in many embodiments are alkyl linking groups, typically lower alkyl linking groups of 1 to 16, usually 1 to 4 carbon atoms, where the linking groups may include one or more sites of unsaturation. The functionalized nucleotides (or primers) used in the above methods of functionalized target generation may be fabricated using known protocols or purchased from commercial vendors, e.g., Sigma, Roche, Ambion, and NEN. Functional groups may be prepared according to ways known to those of skill in the art, including the representative information found in U.S. Pat. Nos. 4,404,289; 4,405,711; 4,337,063 and 5,268,486, and Br. Pat. No. 1,529,202, which are all incorporated by reference.

**[0204]** Amine-modified nucleotides are used in several embodiments of the invention. The amine-modified nucleotide is a nucleotide that has a reactive amine group for attachment of the label. It is contemplated that any ribonucleotide (G, A, U, or C) or deoxyribonucleotide (G,A,T, or C) can be modified for labeling. Examples include, but are not limited to, the following modified ribo- and deoxyribo-nucleotides: 5-(3-aminoallyl)-UTP; 8-[(4-amino)butyl]-amino-ATP and 8-[(6-amino)butyl]-amino-ATP; N<sup>6</sup>-(4-amino)butyl-ATP, N<sup>6</sup>-(6-amino)butyl-ATP, N<sup>4</sup>-[2,2-oxy-bis-(ethylamine)]-CTP; N<sup>6</sup>-(6-Amino)hexyl-ATP; 8-[(6-Amino)hexyl]-amino-ATP; 5-propargylamino-CTP, 5-propargylamino-UTP; 5-(3-aminoallyl)-dUTP; 8-[(4-amino)butyl]-amino-dATP and 8-[(6-amino)butyl]-amino-dATP; N<sup>6</sup>-(4-amino)butyl-dATP, N<sup>6</sup>-(6-amino)butyl-dATP, N<sup>4</sup>-[2,2-oxy-bis-(ethylamine)]-dCTP; N<sup>6</sup>-(6-Amino)hexyl-dATP; 8-[(6-Amino)hexyl]-amino-dATP; 5-propargylamino-dCTP, and 5-propargylamino-dUTP. Such nucleotides can be prepared according to methods known to those of skill in the art. Moreover, a person of ordinary skill in the art could prepare other nucleotide entities with the same amine-modification, such as a 5-(3-aminoallyl)-CTP, GTP, ATP, dCTP, dGTP, dTTP, or dUTP in place of a 5-(3-aminoallyl)-UTP.

### 2. Labeling Techniques

**[0205]** In some embodiments, nucleic acids are labeled by catalytically adding to the nucleic acid an already labeled nucleotide or nucleotides. One or more labeled nucleotides can be added to miRNA molecules. See U.S Patent 6,723,509, which is hereby incorporated by reference.

**[0206]** In other embodiments, an unlabeled nucleotide or nucleotides is catalytically added to an miRNA, and the unlabeled nucleotide is modified with a chemical moiety that enables it to be subsequently labeled. In embodiments of the invention, the chemical moiety is a reactive amine such that the nucleotide is an amine-modified nucleotide.

**[0207]** Examples of amine-modified nucleotides are well known to those of skill in the art, many being commercially available such as from Ambion, Sigma, Jena Bioscience, and TriLink.

**[0208]** In contrast to labeling of cDNA during its synthesis, the issue for labeling miRNA is how to label the already

existing molecule. The present invention concerns the use of an enzyme capable of using a di- or tri-phosphate ribonucleotide or deoxyribonucleotide as a substrate for its addition to an miRNA, a small RNA molecule. Moreover, in specific embodiments, it involves using a modified di- or tri-phosphate ribonucleotide, which is added to the 3' end of an miRNA. The source of the enzyme is not limiting. Examples of sources for the enzymes include yeast, gram-negative bacteria

such as *E. coli*, *Lactococcus lactis*, and sheep pox virus.

**[0209]** Enzymes capable of adding such nucleotides include, but are not limited to, poly(A) polymerase, terminal transferase, and polynucleotide phosphorylase. In specific embodiments of the invention, ligase is contemplated as NOT being the enzyme used to add the label, and instead, a non-ligase enzyme is employed.

**[0210]** Poly(A) polymerase has been cloned from a number of organisms from plants to humans. It has been shown to catalyze the addition of homopolymer tracts to RNA (Martin et al., RNA, 4(2):226-30, 1998).

**[0211]** Terminal transferase catalyzes the addition of nucleotides to the 3' terminus of a nucleic acid.

**[0212]** Polynucleotide phosphorylase can polymerize nucleotide diphosphates without the need for a primer.

### 3. Labels

**[0213]** Labels on miRNA or miRNA probes may be colorimetric (includes visible and UV spectrum, including fluorescent), luminescent, enzymatic, or positron emitting (including radioactive). The label may be detected directly or indirectly. Radioactive labels include <sup>125</sup>I, <sup>32</sup>P, <sup>33</sup>P, and <sup>35</sup>S. Examples of enzymatic labels include alkaline phosphatase, luciferase, horseradish peroxidase, and β-galactosidase. Labels can also be proteins with luminescent properties, e.g., green fluorescent protein and phycoerythrin.

**[0214]** The colorimetric and fluorescent labels contemplated for use as conjugates include, but are not limited to, Alexa Fluor dyes, BODIPY dyes, such as BODIPY FL; Cascade Blue; Cascade Yellow; coumarin and its derivatives, such as 7-amino-4-methylcoumarin, aminocoumarin and hydroxycoumarin; cyanine dyes, such as Cy3 and Cy5; eosins and erythrosins; fluorescein and its derivatives, such as fluorescein isothiocyanate; macrocyclic chelates of lanthanide ions, such as Quantum Dye™; Marina Blue; Oregon Green; rhodamine dyes, such as rhodamine red, tetramethylrhodamine and rhodamine 6G; Texas Red; , fluorescent energy transfer dyes, such as thiazole orange-ethidium heterodimer; and, TOTAB.

**[0215]** Specific examples of dyes include, but are not limited to, those identified above and the following: Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500. Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, and, Alexa Fluor 750; amine-reactive BODIPY dyes, such as BODIPY 493/503, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/655, BODIPY FL, BODIPY R6G, BODIPY TMR, and, BODIPY-TR; Cy3, Cy5, 6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, SYPRO, TAMRA, 2',4',5',7'-Tetrabromosulfonefluorescein, and TET.

**[0216]** Specific examples of fluorescently labeled ribonucleotides are available from Molecular Probes, and these include, Alexa Fluor 488-5-UTP, Fluorescein-12-UTP, BODIPY FL-14-UTP, BODIPY TMR-14-UTP, Tetramethylrhodamine-6-UTP, Alexa Fluor 546-14-UTP, Texas Red-5-UTP, and BODIPY TR-14-UTP. Other fluorescent ribonucleotides are available from Amersham Biosciences, such as Cy3-UTP and Cy5-UTP.

**[0217]** Examples of fluorescently labeled deoxyribonucleotides include Dinitrophenyl (DNP)-11-dUTP, Cascade Blue-7-dUTP, Alexa Fluor 488-5-dUTP, Fluorescein-12-dUTP, Oregon Green 488-5-dUTP, BODIPY FL-14-dUTP, Rhodamine Green-5-dUTP, Alexa Fluor 532-5-dUTP, BODIPY TMR-14-dUTP, Tetramethylrhodamine-6-dUTP, Alexa Fluor 546-14-dUTP, Alexa Fluor 568-5-dUTP, Texas Red-12-dUTP, Texas Red-5-dUTP, BODIPY TR-14-dUTP, Alexa Fluor 594-5-dUTP, BODIPY 630/650-14-dUTP, BODIPY 650/665-14-dUTP; Alexa Fluor 488-7-OBEA-dCTP, Alexa Fluor 546-16-OBEA-dCTP, Alexa Fluor 594-7-OBEA-dCTP, Alexa Fluor 647-12-OBEA-dCTP.

**[0218]** It is contemplated that nucleic acids may be labeled with two different labels. Furthermore, fluorescence resonance energy transfer (FRET) may be employed in methods of the invention (e.g., Klostermeier *et al.*, 2002; Emptage, 2001; Didenko, 2001, each incorporated by reference).

**[0219]** Alternatively, the label may not be detectable per se, but indirectly detectable or allowing for the isolation or separation of the targeted nucleic acid. For example, the label could be biotin, digoxigenin, polyvalent cations, chelator groups and the other ligands, include ligands for an antibody.

### 4. Visualization Techniques

**[0220]** A number of techniques for visualizing or detecting labeled nucleic acids are readily available. The reference by Stanley T. Croke, 2000 has a discussion of such techniques (Chapter 6), which is incorporated by reference. Such techniques include, microscopy, arrays, Fluorometry, Light cyclers or other real time PCR machines, FACS analysis, scintillation counters, Phosphoimagers, Geiger counters, MRI, CAT, antibody-based detection methods (Westerns, im-

munofluorescence, immunohistochemistry), histochemical techniques, HPLC (Griffey *et al.*, 1997, spectroscopy, capillary gel electrophoresis (Cummins *et al.*, 1996), spectroscopy; mass spectroscopy; radiological techniques; and mass balance techniques.

5 [0221] When two or more differentially colored labels are employed, fluorescent resonance energy transfer (FRET) techniques may be employed to characterize the dsRNA. Furthermore, a person of ordinary skill in the art is well aware of ways of visualizing, identifying, and characterizing labeled nucleic acids, and accordingly, such protocols may be used as part of the invention. Examples of tools that may be used also include fluorescent microscopy, a BioAnalyzer, a plate reader, Storm (Molecular Dynamics), Array Scanner, FACS (fluorescent activated cell sorter), or any instrument that has the ability to excite and detect a fluorescent molecule.

### 10 C. Array Preparation

[0222] The present invention can be employed with miRNA arrays, which are ordered macroarrays or microarrays of nucleic acid molecules (probes) that are fully or nearly complementary or identical to a plurality of miRNA molecules or precursor miRNA molecules and that are positioned on a support material in a spatially separated organization. Macroarrays are typically sheets of nitrocellulose or nylon upon which probes have been spotted. Microarrays position the nucleic acid probes more densely such that up to 10,000 nucleic acid molecules can be fit into a region typically 1 to 4 square centimeters. Microarrays can be fabricated by spotting nucleic acid molecules, e.g., genes, oligonucleotides, etc., onto substrates or fabricating oligonucleotide sequences in situ on a substrate. Spotted or fabricated nucleic acid molecules can be applied in a high density matrix pattern of up to about 30 non-identical nucleic acid molecules per square centimeter or higher, e.g. up to about 100 or even 1000 per square centimeter. Microarrays typically use coated glass as the solid support, in contrast to the nitrocellulose-based material of filter arrays. By having an ordered array of miRNA-complementing nucleic acid samples, the position of each sample can be tracked and linked to the original sample. A variety of different array devices in which a plurality of distinct nucleic acid probes are stably associated with the surface of a solid support are known to those of skill in the art. Useful substrates for arrays include nylon, glass and silicon. Such arrays may vary in a number of different ways, including average probe length, sequence or types of probes, nature of bond between the probe and the array surface, e.g. covalent or non-covalent, and the like.

[0223] Representative methods and apparatus for preparing a microarray have been described, for example, in U.S. Patent Nos. 5,143,854; 5,202,231; 5,242,974; 5,288,644; 5,324,633; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,432,049; 5,436,327; 5,445,934; 5,468,613; 5,470,710; 5,472,672; 5,492,806; 5,525,464; 5,503,980; 5,510,270; 5,525,464; 5,527,681; 5,529,756; 5,532,128; 5,545,531; 5,547,839; 5,554,501; 5,556,752; 5,561,071; 5,571,639; 5,580,726; 5,580,732; 5,593,839; 5,599,695; 5,599,672; 5,610,287; 5,624,711; 5,631,134; 5,639,603; 5,654,413; 5,658,734; 5,661,028; 5,665,547; 5,667,972; 5,695,940; 5,700,637; 5,744,305; 5,800,992; 5,807,522; 5,830,645; 5,837,196; 5,871,928; 5,847,219; 5,876,932; 5,919,626; 6,004,755; 6,087,102; 6,368,799; 6,383,749; 6,617,112; 6,638,717; 6,720,138, as well as WO 93/17126; WO 95/11995; WO 95/21265; WO 95/21944; WO 95/35505; WO 96/31622; WO 97/10365; WO 97/27317; WO 99/35505; WO 09923256; WO 09936760; WO0138580; WO 0168255; WO 03020898; WO 03040410; WO 03053586; WO 03087297; WO 03091426; WO03100012; WO 04020085; WO 04027093; EP 373 203; EP 785 280; EP 799 897 and UK 8 803 000; the disclosures of which are all herein incorporated by reference.

[0224] It is contemplated that the arrays can be high density arrays, such that they contain 100 or more different probes. It is contemplated that they may contain 1000, 16,000, 65,000, 250,000 or 1,000,000 or more different probes. The probes can be directed to targets in one or more different organisms. The oligonucleotide probes range from 5 to 50, 5 to 45, 10 to 40, or 15 to 40 nucleotides in length in some embodiments. In certain embodiments, the oligonucleotide probes are 20 to 25 nucleotides in length.

[0225] The location and sequence of each different probe sequence in the array are generally known. Moreover, the large number of different probes can occupy a relatively small area providing a high density array having a probe density of generally greater than about 60, 100, 600, 1000, 5,000, 10,000, 40,000, 100,000, or 400,000 different oligonucleotide probes per cm<sup>2</sup>. The surface area of the array can be about or less than about 1, 1.6, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm<sup>2</sup>.

[0226] Moreover, a person of ordinary skill in the art could readily analyze data generated using an array. Such protocols are disclosed above, and include information found in WO 9743450; WO 03023058; WO 03022421; WO 03029485; WO 03067217; WO 03066906; WO 03076928; WO 03093810; WO 03100448A1, all of which are specifically incorporated by reference.

### 55 D. Sample Preparation

[0227] It is contemplated that the miRNA of a wide variety of samples can be analyzed using assays described herein. While endogenous miRNA is contemplated for use with some embodiments, recombinant miRNA-including nucleic acids that are complementary or identical to endogenous miRNA or precursor miRNA-can also be handled and analyzed as

described herein. Samples may be biological samples, in which case, they can be from blood, tissue, organs, semen, saliva, tears, other bodily fluid, hair follicles, skin, or any sample containing or constituting biological cells. Alternatively, the sample may not be a biological sample, but be a chemical mixture, such as a cell-free reaction mixture (which may contain one or more biological enzymes).

## E. Hybridization

**[0228]** After the array is prepared and the miRNA in the sample is labeled, the population of target nucleic acids is contacted with the array under hybridization conditions, where such conditions can be adjusted, as desired, to provide for an optimum level of specificity in view of the particular assay being performed. Suitable hybridization conditions are well known to those of skill in the art and reviewed in Sambrook *et al.*, 1989 and WO 95/21944. Of particular interest in many embodiments is the use of stringent conditions during hybridization. Stringent conditions are known to those of skill in the art.

**[0229]** It is specifically contemplated that a single array may be contacted with multiple samples. The samples may be labeled with different labels to distinguish the samples. For example, a single array can be contacted with a tumor tissue sample labeled with Cy3, and normal tissue sample labeled with Cy5. Differences between the samples for particular miRNAs corresponding to probes on the array can be readily ascertained and quantified.

**[0230]** The small surface area of the array permits uniform hybridization conditions, such as temperature regulation and salt content. Moreover, because of the small area occupied by the high density arrays, hybridization may be carried out in extremely small fluid volumes (e.g., about 250  $\mu$ l or less, including volumes of about or less than about 5, 10, 25, 50, 60, 70, 80, 90, 100  $\mu$ l, or any range derivable therein). In small volumes, hybridization may proceed very rapidly.

## F. Differential Expression Analyses

**[0231]** Arrays can be used to detect differences between two samples. This can also be used for diagnostic purposes. Specifically contemplated applications include identifying and/or quantifying differences between miRNA from a sample that is normal and from a sample that is not normal or between two differently treated samples. Also, miRNA may be compared between a sample believed to be susceptible to a particular disease or condition and one believed to be not susceptible or resistant to that disease or condition. A sample that is not normal is one exhibiting phenotypic trait(s) of a disease or condition or one believed to be not normal with respect to that disease or condition. It may be compared to a cell that is normal with respect to that disease or condition. Phenotypic traits include symptoms of, or susceptibility to, a disease or condition of which a component is or may or may not be genetic.

## G. Cell Assays To Identify miRNAs with Ties to Disease

**[0232]** Specifically contemplated applications include identifying miRNAs that contribute to cellular processes that are themselves parts of a disease or might otherwise be associated with a particular disease state. Also, miRNA functions may be compared between a sample believed to be susceptible to a particular disease or condition and one believed to be not susceptible or resistant to that disease or condition. It is specifically contemplated that RNA molecules of the present invention can be used to treat any of the diseases or conditions discussed in the previous section or modulate any of the cellular pathways discussed in the previous section.

**[0233]** Specifically contemplated applications include identifying miRNAs that contribute to cellular processes that are themselves parts of a disease or might otherwise be associated with a particular disease state. Also, miRNA functions may be compared between a sample believed to be susceptible to a particular disease or condition and one believed to be not susceptible or resistant to that disease or condition.

**[0234]** AIDS, autoimmune diseases (rheumatoid arthritis, multiple sclerosis, diabetes-insulin-dependent and non-independent, systemic lupus erythematosus and Graves disease); cancer (e.g., malignant, benign, metastatic, precancer); cardiovascular diseases (heart disease or coronary artery disease, stroke-ischemic and hemorrhagic, and rheumatic heart disease); diseases of the nervous system; and infection by pathogenic microorganisms (Athlete's Foot, Chickenpox, Common cold, Diarrheal diseases, Flu, Genital herpes, Malaria, Meningitis, Pneumonia, Sinusitis, Skin diseases, Strep throat, Tuberculosis, Urinary tract infections, Vaginal infections, Viral hepatitis); inflammation (allergy, asthma); prion diseases (e.g., CJD, kuru, GSS, FFI).

**[0235]** Moreover, miRNA can be evaluated with respect to the following diseases, conditions, and disorders: Abdominal Adhesions; Anal Abscess; Brain Abscess; Peritonsillar Abscess; Absence Seizures; Achalasia; Acne; Acoustic Neuroma; Acquired Immunodeficiency Syndrome (AIDS); Acrochordon; Actinic Keratosis; Adenocarcinoma of the Lung; ADHD; Adult-Onset Diabetes; Aero-Otitis; Age Spots; Age-Related Hearing Loss; Age-Related Macular Degeneration; Age-Related Vision Change (Presbyopia); Agoraphobia; Alcohol Withdrawal; Alcoholism; Allergen Immunotherapy; Allergic Rhinitis; Allergies; Alopecia (Areata, Hereditary-Patterned, and Traumatic); Altitude Sickness; Alzheimer's Disease;

Amaurotic Familial Infantile Idiocy; Amblyopia; Amenorrhea; Amyloidosis; Amyotrophic Lateral Sclerosis (ALS); Anaphylaxis; Androgenetic Alopecia; Anemia (Aplastic, Hemolytic, Pernicious, and Sickle Cell); Angina; Angiomas, Spider; Angioplasty; Ankylosing Spondylitis; Anorexia Nervosa; Anovulatory Bleeding; Antibiotic-Associated Diarrhea; Antiphospholipid Antibody Syndrome; Antisocial Personality Disorder; Anus Fissure, Fistula, Hemorrhoids, Anus Itch, Stricture;

5 Anxiety Disorders (Generalized, Obsessive-Compulsive Disorder, Panic Disorder, Phobia, and Post-Traumatic Stress Disorder); Aortic Aneurysm; Aortic Arch Syndrome; Appendicitis; Arrhythmias, Cardiac; Arteritis, Takayasu's; Arthritic Diseases (Ankylosing Spondylitis, Gout, Infectious, Juvenile, Osteoarthritis, Pseudogout, Psoriatic Arthritis, and Rheumatoid); Asbestosis; Ascending Cholangitis; Asteatotic Eczema; Asthma; Astigmatism; Asymptomatic Bacteriuria; Ataxia, Friedreich's; Atherosclerosis; Athlete's Foot; Atopic Dermatitis; Atrial Fibrillation; Atrophic Vaginitis; Attention-Deficit

10 Hyperactivity Disorder; Autism; Autoimmune Diseases (Celiac Disease, Crohn's Disease, Diabetes Mellitus, Type 1 (Insulin-Dependent; Juvenile-Onset), Diabetes Mellitus, Type 2 (Non-Insulin-Dependent; Adult-Onset), Graves' Disease, Hyperthyroidism, Immune Thrombocytopenic Purpura, Lupus, Myasthenia Gravis, Polyarteritis Nodosa, Rheumatoid Arthritis, Scleroderma, Takayasu's Arteritis, and Ulcerative Colitis); B12 Deficiency; Bacillary Dysentery; Bacterial Gastroenteritis; Bacterial Vaginosis; Balanitis; Baldness, Hereditary- Patterned; Barber's Itch; Barotitis; Barotrauma; Bartholin's Gland Cyst; Basal-Cell Carcinoma; Bed-Wetting; Bedsores; Behcet's Syndrome; Bell's Palsy; Bends; Benign Prostatic Hyperplasia; Bile-Duct Diseases; Biliary Colic; Biopsy; Bipolar Disorder; Bladder conditions (Infection; Interstitial Cystitis; Prolapse; Urethritis; Urinary Incontinence; Urinary Tract Infection); Blepharitis; Blepharoptosis; Blighted Ovum; Friction Blisters; Blood Pressure, High; Boils; Bone diseases and conditions (Osteoporosis; Paget's Disease); Bone

15 Yaws; Borderline Personality Disorder; Bornholm Disease; Botulism; Bowel Obstruction; Bradycardia; Bronchitis; Bulimia Nervosa; Bunion; Bursitis; C. Difficile Colitis; Calcaneal Apophysitis; Calcium Pyrophosphate Deposition Disease; Campylobacteriosis; Cancer; Candidiasis; Carbon-Monoxide Poisoning; Carbuncles; Cardiac Arrhythmias (Atrial Fibrillation, Bradycardia); Cardiomyopathy; Carpal Tunnel Syndrome; Cataracts; Cellulitis; Central Serous Retinopathy; Cerebral Palsy; Cerebromacular Degeneration; Cerumen Impaction; Cervicitis, Nabothian Cysts, Cervical Polyps, Cervical Warts; Chalazion; Chickenpox; Chlamydia; Chloasma; Cholangitis; Cholecystitis; Cholesteatoma; Chondromalacia; Chorea; Choroidal Melanoma; Chronic Bronchitis; Chronic Fatigue Syndrome; Chronic Hepatitis; Chronic Leukemia; Chronic Obstructive Pulmonary Disease; Chronic Otitis Media; Cirrhosis; Cluster Headache; Cogan's Syndrome; Cold, Common; Colic, Biliary; Pseudomembranous Colitis, Ulcerative Colitis, Collapsed Lung; Collarbone Fracture; Coma; Complex Regional Pain Syndrome; Congestive Heart Failure; Conjunctivitis; Constipation; Contact Dermatitis; Conversion Disorder; COPD; Cornea Abrasion, Cornea Keratitis; Corns; Coronary Artery Disease; Creutzfeldt-Jakob Disease; Crossed

20 Eyes; Croup; Cryptorchidism; Cystic Fibrosis; Interstitial Cystitis; Cystocele; Cysts; Cytomegalovirus infection; Dacryocystitis; Dandruff; Decompression Sickness; Decubitus Ulcers; Delirium Tremens; Delusional Disorder; Dementia; Depressive Disorders (Bipolar Disorder, Dysthymia, Major Depression, Manic Depression, Postpartum Depression); Dermatitis; Dermatofibroma; Dermatomyositis; Detached Retina; Developmental Dysplasia of the Hip; Deviated Septum; Devil's Grip; Diabetes (Gestational Diabetes; Type 1 Diabetes (Insulin-Dependent; Juvenile); Type 2 Diabetes (Non-Insulin-Dependent; Adult-Onset); Hypoglycemia, Ketoacidosis, Nephropathy, Neuropathies, Retinopathy) Antibiotic-Associated Diarrhea; Diplopia; Herniated Disk; Dislocated Lens; Hip Dislocation (Developmental); Diverticulitis; Diverticulosis; Dizziness; Doerderland's Vaginitis; Double Vision; Down Syndrome; Drooping Eyelid; Dry Skin; Sun-Damaged Skin; Dry-Eye Syndrome; Duck-Foot; Dysautonomia, Familial; Dysfunctional Uterine Bleeding; Dyslexia; Dyspareunia; Dysthymia; Dysuria; Eating Disorders (Anorexia Nervosa, Bulimia Nervosa); Eclampsia; Eczema; Edema; Emphysema;

25 Encephalitis; Encopresis; End-Stage Renal Disease; Endocarditis; Endometriosis; Endophthalmitis; Endoscopy; Enlarged Prostate; Enuresis; Epidemic Benign Dry Pleurisy; Epididymitis; Epiglottitis; Epilepsy; Epistaxis; Erectile Dysfunction; Erythema Infectiosum; Esophagitis; Esophagus Achalasia; Esophagitis; Essential Hypertension; Essential Tremor; Ewing's Sarcoma; Familial Dysautonomia; Farsightedness; Febrile Seizures; Fecal Incontinence; Fever; Fever-Induced Seizures; Fibroids; Fibromyalgia; Fifth Disease; Filiform Warts; Flat Warts; Flatulence; Flu; Focal Seizures; Food Allergy; Food Poisoning; Forefoot Neuroma; Fragile X Syndrome; Friction Blisters; Friedreich's Ataxia; Frostbite; Fungal Infections (Athlete's Foot, Brain Abscess, Infectious Arthritis, Jock Itch, Onychomycosis, Ringworm, Swimmer's Ear, Tinea Cruris, Tinea Unguium, Tinea Versicolor); Furuncle; Gallstones; Gardnerella Vaginitis; Gastritis; Gastrocnemius Strain; Gastroenteritis; Gastroesophageal Reflux Disease; Gastrointestinal Amebiasis; Generalized Anxiety Disorder; Generalized Barotrauma; Genital Herpes; Genital Warts; GERD; Germ Cell Tumors, Extragonadal; Giant Cell Arteritis; Giardiasis;

30 Glaucoma; Glomerulonephritis; Gluten-Sensitive Enteropathy; GM2 Gangliosidosis; Gonorrhoea; Gout; Grand Mal Seizures; Graves' Disease; Graves' Ophthalmopathy; Guillain-Barré Syndrome; Hammertoe; Hay Fever; Headache; Hearing Loss; Heart Attack;; Heat Stroke; Heel Spur; Heloma; Spider Hemangiomas; Hematoma; Hematuria; Hemochromatosis; Hemolytic Anemia; Hemophilia; Hemorrhagic Stroke; Subarachnoid Hemorrhagic Stroke; Hemorrhoids; Hepatitis A; Hepatitis B; Hepatitis C; Hereditary-Patterned Baldness; Hernia; Herniated Disk; High Blood Pressure; High Cholesterol; Hirsutism; Histiocytosis X; HIV/AIDS; Hordeolum; Human Papilloma Virus (HPV); Huntington's Disease; Hydatidiform Mole; Hydrocephalus; Hyperactivity; Hypercholesterolemia; Hyperkeratosis; Hyperopia; Hypertension; Ocular Hypertension; Secondary Hypertension; Hypertensive Retinopathy; Hyperthermia; Hyperthyroidism; Hypochondriasis; Hypoglycemia; Hypoparathyroidism; Hypothyroidism; IBS; ICD; Ichthyosis; Immune Thrombocytopenic Purpura; Impetigo;

Impotence; Incontinence; Infantile Ganglioside Lipidosis; Infectious Arthritis; Infectious Mononucleosis; Infertility; Inflammatory Bowel Disease; Inguinal Hernia; Insomnia; Intercerebral Hemorrhage; Interdigital Neuroma; Intermetatarsal Neuroma; Intermittent Claudication; Interstitial Cystitis; Intestinal Obstruction; Iron Deficiency; Irritable Bowel Syndrome; Juvenile Arthritis; Kaposi's Sarcoma; Kawasaki Syndrome; Keloids; Keratitis; Actinic Keratosis; Labyrinthitis; Lactose Intolerance; Lacunar Stroke; Langerhans' Cell Histiocytosis; Laryngitis; Laryngotracheitis; Lateral Epicondylitis; Latex Allergy; Lazy Eye; Lead Poisoning; Intermittent Claudication; Restless Legs Syndrome; Shin Splints; Leg Strain; Cataract; Dislocated Lens; Leukemia; Lice; Lichen Simplex Chronicus; Cirrhosis; Hepatitis; Liver Spots; Lockjaw; Lou Gehrig's Disease; Lupus Erythematosus, Systemic; Lyme Disease; Lymphedema; Lymphoma; Macular Degeneration; Malabsorption Syndromes; Malaria; Male Pattern Baldness; Malignant Hyperthermia; Manic Depression; Marfan's Syndrome; Mastoiditis; Measles; Meckel's Diverticulum; Melasma; Meniere's Disease; Meningitis; Menopause; Mental Retardation; Phenylketonuria; Migraine; Miscarriage; Mitral-Valve Prolapse; Mittelschmerz; Molar Pregnancy; Molluscum Contagiosum; Mononucleosis; Morton's Neuroma; Mosaic Warts; Motor Tics; Mucocutaneous Lymph Node Syndrome; Multiple Sclerosis; Mumps; Muscular Dystrophy; Musculoskeletal Disorders (Fibromyalgia, Giant Cell Arteritis, Gout, Infectious Arthritis, Muscular Dystrophy, Myositis, Osteoarthritis, Osteoporosis, Paget's Disease Of Bone, Polymyalgia Rheumatica, Pseudogout, Reflex Sympathetic Dystrophy, Rheumatoid Arthritis, Scleroderma, Systemic Lupus Erythematosus, Tendinitis); Myasthenia Gravis; Myocardial Infarction; Myocarditis; Myopia; Myositis; Nail Felon; Onycholysis; Onychomycosis; Paronychia; Subungual Hematoma; Narcolepsy; Nasal Polyps; Nausea; Nearsightedness; Needle Biopsy; Nephrectomy; Nephroblastoma; Nephrolithiasis; Nephropathy, Diabetic; Neuritis, Retrobulbar; Neuroblastoma; Neuromuscular Disorders; Neuropathies; Guillain-Barre Syndrome; Retrobulbar; Nevi; Nevus Flammeus; Nevus Simplex; Nocturnal Enuresis; Non-Tropical Sprue; Obesity; Obsessive-Compulsive Disorder; Occupational Hearing Loss; Ocular Hypertension; Ocular Rosacea; Onycholysis; Onychomycosis; Glaucoma; Retrobulbar Neuritis; Optic Nerve Swelling; Orbit Fracture; Orchitis; Osgood-Schlatter Disease; Osteoarthritis; Osteoporosis; Osteosarcoma; Otitis Externa; Otitis Media; Chronic Otitis Media; Otosclerosis; Ototoxicity; Pelvic Inflammatory Disease; Polycystic Ovary Syndrome; Painful-Bladder Syndrome; Pancreatitis; Panic Disorder; Papilledema; Paraphimosis; Parkinson's Disease; Paronychia; Partial Seizures; PCL Injuries; Pedunculated Warts; Pelvic Relaxation; Paraphimosis; Peyronie's Disease; Peptic Ulcer; Perforated Eardrum; Pericarditis; Perimenopause; Peripheral Vascular Disease; Peritonsillar Abscess; Persistent Vegetative State; Personality Disorders; Petit Mal Seizures; Peyronie's Disease; Pharyngitis; Pharynx Cancer; Phenylketonuria; Phimosis; Phobia; Photosensitivity; Pigmentation Disorders (Chloasma, Melasma, Vitiligo); Piles; Pinkeye; Pityriasis Rosea; PKU; Plague; Plantar Fasciitis; Plantar Warts; Plantaris Strain; Pleurisy; Pleurodynia; PMS; Pneumoconiosis; Pneumonectomy; Pneumonia; Pneumothorax; Lead Poisoning; Polio; Poliomyelitis; Polyarteritis Nodosa; Polychondritis; Polymyalgia Rheumatica; Polymyositis; Colonic Polyps; Nasal Polyps; Vocal Cord Polyps; Port-Wine Stain; Post-Polio Syndrome; Postinfectious Thrombocytopenia; Postpartum Depression; Preeclampsia; Pregnancy-Induced Hypertension; Premenstrual Syndrome; Pressure Sores; Primary Sclerosing Cholangitis; Prolapse; Enlarged Prostate; Acute Prostatitis; Chronic Prostatitis; Pruritus Ani; Pseudogout; Psoriasis; Psoriatic Arthritis; Ptosis; Pulseless Disease; Pyelonephritis; Quadriceps Strain; Quinsy; Rash; Raynaud's Phenomenon; Rectal Itch; Rectocele; Reflex Sympathetic Dystrophy; Renal Failure; Respiratory Disorders Respiratory Syncytial Virus; Retina Detachment; Retinitis Pigmentosa; Retinopathy; Retrobulbar Neuritis; Reye's Syndrome; Rhabdomyosarcoma; Rheumatoid Arthritis; Allergic Rhinitis; Viral Rhinitis (Common Cold); Riley-Day Syndrome; Ringworm; Rocky Mountain Spotted Fever; Rosacea; Rubeola; Mumps; Salivary Gland Disorders; Salmon Patch; Sarcoidosis; Scabies; Scarlet Fever; Scars; Schizophrenia; Schizotypal Personality Disorder; Sciatica; Scleritis; Scleroderma; Scoliosis; Sebaceous Cysts; Seborrhea; Seborrheic Keratoses; Secondary Hypertension; Seizures; Sexual Dysfunction; Sexually Transmitted Diseases; Shigellosis; Shingles; Sialadenitis; Sialadenosis; Sialolithiasis; Sickle-Cell Anemia; Siderosis; Silicosis; Sinus Cancer; Sjögren's Syndrome; Sleep Disorders; Smallpox; Social Anxiety Disorder; Solar Lentigo; Somatoform Disorders (Hypochondriasis, Somatization Disorder); Somnambulism; Spastic Colon; Spider Veins; Spina Bifida; Spinal Cord Trauma; Spontaneous Abortion; Stasis Dermatitis; Strabismus; Strep Throat; Streptococcal Toxic Shock Syndrome; Stroke; Subarachnoid Hemorrhage; Transient Ischemic Attack; Stuttering; Subungual Hematoma; Sun Allergy; Sun-Damaged Skin; Sylvest's Disease; Systemic Lupus Erythematosus; Systemic Sclerosis; Tachycardia; Takayasu's Arteritis; Tay-Sachs Disease; Tear-Duct Infection; Telogen Effluvium; Temporal Arteritis; Tendinitis; Tennis Elbow; Tension Headache; Testicular Torsion; Undescended Testicles; Tetanus; Thrombocytopenia; Thrombophlebitis; Thrombotic Stroke; Tinea; Tinnitus; Tonsillitis; Torsional Deformities; Toxemia Of Pregnancy; Toxic Shock Syndrome, Streptococcal; Toxoplasmosis; Trichomoniasis; Trigeminal Neuralgia (Tic Douloureux); Tuberculosis; Tylosis; Ulcer; Urethritis; Urinary Tract disorders and conditions; Urolithiasis; Urticaria; Uterine disorders; Uterine Prolapse; Uveitis; Vaginitis; Bacterial (Gardnerella) Vaginosis; Varicella; Varices, Esophageal; Varicose Veins;; Vascular Disorders (Hypertension, Intermittent Claudication, Peripheral Vascular Disease, Polyarteritis Nodosa, Raynaud's Phenomenon, Takayasu's Arteritis, Thrombophlebitis, Vasculitis, Wegener's Granulomatosis); Vein Inflammation; Varicose Veins; Vertigo; Vestibular Schwannoma; Viral Rhinitis; Vitamin B12 Deficiency; Vitiligo; Vocal Tics; Vocal-Cord Disorders; Common Warts; Genital Warts; Plantar Warts; Water On The Brain; Wax Blockage Of Ear Canal; Esophageal Webs; Werlhof's Disease; Wrinkles; Yersinia Pestis Infection. It is contemplated that such diseases can be diagnosed or treated using a nucleic acids of the invention that correspond to miRNAs.

**[0236]** Cancers that may be evaluated, diagnosed, and/or treated by methods and compositions of the invention include cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; bronchiole-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometrioid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; androblastoma, malignant; sertoli cell carcinoma; leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extra-mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malig melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's lymphoma; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia. Moreover, miRNA can be evaluated in precancers, such as metaplasia, dysplasia, and hyperplasia.

**[0237]** It is specifically contemplated that the invention can be used to evaluate or diagnose differences between stages of disease, such as between pre-cancer and cancer, or between a primary tumor and a metastasized tumor.

**[0238]** The efficacy of different therapeutic drugs is altered by miRNAs according to the present invention. Such therapeutic drugs include, but are not limited to, chemotherapeutic drugs. A "chemotherapeutic agent" is used to connote a compound or composition that is administered in the treatment of cancer. These agents or drugs are categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle. Alternatively, an agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis. Most chemotherapeutic agents fall into the following categories: alkylating agents, antimetabolites, antitumor antibiotics, mitotic inhibitors, and nitrosoureas.

**[0239]** Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, tro-

fosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegal1; dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores, aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabycin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, encitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitostanol, mepitostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; PSK polysaccharide complex); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., paclitaxel and docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

**[0240]** Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene; aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate, exemestane, formestanie, fadrozole, vorozole, letrozole, and anastrozole; and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras; ribozymes such as a VEGF expression inhibitor and a HER2 expression inhibitor; vaccines such as gene therapy vaccines and pharmaceutically acceptable salts, acids or derivatives of any of the above. A list of U.S. FDA approved oncology drugs with their approved indications can be found on the World Wide Web at [accessdata.fda.gov/scripts/cder/onctools/druglist.cfm](http://accessdata.fda.gov/scripts/cder/onctools/druglist.cfm). Moreover, it is contemplated that samples that have differences in the activity of certain pathways may also be compared. Such cellular pathways include but are not limited to the following: any adhesion or motility pathway including but not limited to those involving cyclic AMP, protein kinase A, G-protein couple receptors, adenylyl cyclase, L-selectin, E-selectin, PECAM, VCAM-1,  $\alpha$ -actinin, paxillin, cadherins, AKT, integrin- $\alpha$ , integrin- $\beta$ , RAF-1, ERK, PI-3 kinase, vinculin, matrix metalloproteinases, Rho GTPases, p85, trefoil factors, profilin, FAK, MAP kinase, Ras, caveolin, calpain-1, calpain-2, epidermal growth factor receptor, ICAM-1, ICAM-2, cofilin, actin, gelsolin, RhoA, RAC1, myosin light chain kinase, platelet-derived growth factor receptor or ezrin; any apoptosis pathway including but not limited to those involving AKT, Fas ligand, NF $\kappa$ B, caspase-9, PI3 kinase, caspase-3, caspase-7, ICAD, CAD, EndoG, Granzyme B, Bad, Bax, Bid, Bak, APAF-1, cytochrome C, p53, ATM, Bcl-2, PARP, Chk1, Chk2, p21, c-Jun, p73, Rad51, Mdm2, Rad50, c-Abl, BRCA-1, perforin, caspase-4, caspase-8, caspase-6, caspase-1, caspase-2, caspase-10, Rho, Jun kinase, Jun kinase kinase, Rip2, lamin-A, lamin-B1, lamin-B2, Fas receptor, H<sub>2</sub>O<sub>2</sub>, Granzyme A, NADPH oxidase, HMG2, CD4, CD28, CD3, TRADD, IKK, FADD, GADD45, DR3 death receptor, DR4/5 death receptor, FLIPs, APO-3, GRB2, SHC, ERK, MEK, RAF-1, cyclic AMP, protein kinase A, E2F, retinoblastoma protein, Smac/Diablo, ACH receptor, 14-3-3, FAK, SODD, TNF receptor, RIP, cyclin-D1, PCNA, Bcl-XL, PIP2, PIP3, PTEN, ATM, Cdc2, protein kinase C, calcineurin, IKK $\alpha$ , IKK $\beta$ , IKK $\gamma$ , SOS-1, c-FOS, Traf-1, Traf-2, I $\kappa$ B $\beta$  or the proteasome; any cell activation pathway including but not limited to those involving protein kinase A, nitric oxide, caveolin-1, actin, calcium, protein kinase C, Cdc2, cyclin B, Cdc25, GRB2, SRC protein kinase, ADP-ribosylation factors (ARFs), phospholipase D, AKAP95, p68, Aurora B, CDK1, Eg7, histone H3, PKAc, CD80, PI3 kinase, WASP, Arp2, Arp3, p16, p34, p20, PP2A, angiotensin, angiotensin-converting enzyme, protease-activated receptor-1, protease-activated receptor-4, Ras, RAF-1, PLC $\beta$ , PLC $\gamma$ , COX-1, G-protein-coupled receptors, phospholipase A2, IP3, SUMO1, SUMO 2/3, ubiquitin, Ran, Ran-GAP, Ran-GEF, p53, glucocorticoids, glucocorticoid receptor, components of the SWI/SNF complex, RanBP1, RanBP2, importins, ex-

portins, RCC1, CD40, CD40 ligand, p38, IKK $\alpha$ , IKK $\beta$ , NF $\kappa$ B, TRAF2, TRAF3, TRAF5, TRAF6, IL-4, IL-4 receptor, CDK5, AP-1 transcription factor, CD45, CD4, T cell receptors, MAP kinase, nerve growth factor, nerve growth factor receptor, c-Jun, c-Fos, Jun kinase, GRB2, SOS-1, ERK-1, ERK, JAK2, STAT4, IL-12, IL-12 receptor, nitric oxide synthase, TYK2, IFN $\gamma$ , elastase, IL-8, epithelins, IL-2, IL-2 receptor, CD28, SMAD3, SMAD4, TGF $\beta$  or TGF $\beta$  receptor; any cell cycle regulation, signaling or differentiation pathway including but not limited to those involving TNFs, SRC protein kinase, Cdc2, cyclin B, Grb2, Sos-1, SHC, p68, Aurora kinases, protein kinase A, protein kinase C, Eg7, p53, cyclins, cyclin-dependent kinases, neural growth factor, epidermal growth factor, retinoblastoma protein, ATF-2, ATM, ATR, AKT, CHK1, CHK2, 14-3-3, WEE1, CDC25 CDC6, Origin Recognition Complex proteins, p15, p16, p27, p21, ABL, c-ABL, SMADs, ubiquitin, SUMO, heat shock proteins, Wnt, GSK-3, angiotensin, p73 any PPAR, TGF $\alpha$ , TGF $\beta$ , p300, MDM2, GADD45, Notch, cdc34, BRCA-1, BRCA-2, SKP1, the proteasome, CUL1, E2F, p107, steroid hormones, steroid hormone receptors, I $\kappa$ B $\alpha$ , I $\kappa$ B $\beta$ , Sin3A, heat shock proteins, Ras, Rho, ERKs, IKKs, PI3 kinase, Bcl-2, Bax, PCNA, MAP kinases, dynein, RhoA, PKAc, cyclin AMP, FAK, PIP2, PIP3, integrins, thrombopoietin, Fas, Fas ligand, PLK3, MEKs, JAKs, STATs, acetylcholine, paxillin calcineurin, p38, importins, exportins, Ran, Rad50, Rad51, DNA polymerase, RNA polymerase, Ran-GAP, Ran-GEF, NuMA, Tpx2, RCC1, Sonic Hedgehog, Crm1, Patched (Ptc-1), MPF, CaM kinases, tubulin, actin, kinetochore-associated proteins, centromere-binding proteins, telomerase, TERT, PP2A, c-MYC, insulin, T cell receptors, B cell receptors, CBP, IKB, NF $\kappa$ B, RAC1, RAF1, EPO, diacylglycerol, c-Jun, c-Fos, Jun kinase, hypoxia-inducible factors, GATA4,  $\beta$ -catenin,  $\alpha$ -catenin, calcium, arrestin, survivin, caspases, procaspases, CREB, CREM, cadherins, PECAMs, corticosteroids, colony-stimulating factors, calpains, adenylyl cyclase, growth factors, nitric oxide, transmembrane receptors, retinoids, G-proteins, ion channels, transcriptional activators, transcriptional coactivators, transcriptional repressors, interleukins, vitamins, interferons, transcriptional corepressors, the nuclear pore, nitrogen, toxins, proteolysis, or phosphorylation; or any metabolic pathway including but not limited to those involving the biosynthesis of amino acids, oxidation of fatty acids, biosynthesis of neurotransmitters and other cell signaling molecules, biosynthesis of polyamines, biosynthesis of lipids and sphingolipids, catabolism of amino acids and nutrients, nucleotide synthesis, eicosanoids, electron transport reactions, ER-associated degradation, glycolysis, fibrinolysis, formation of ketone bodies, formation of phagosomes, cholesterol metabolism, regulation of food intake, energy homeostasis, prothrombin activation, synthesis of lactose and other sugars, multi-drug resistance, biosynthesis of phosphatidylcholine, the proteasome, amyloid precursor protein, Rab GTPases, starch synthesis, glycosylation, synthesis of phosphoglycerides, vitamins, the citric acid cycle, IGF-1 receptor, the urea cycle, vesicular transport, or salvage pathways. It is further contemplated that nucleic acids molecules of the invention can be employed in diagnostic and therapeutic methods with respect to any of the above pathways or factors. Thus, in some embodiments of the invention, a synthetic miRNA, nonsynthetic nucleic acid, or miRNA inhibitor inhibits, eliminate, activates, induces, increases, or otherwise modulates one or more of the above pathways or factors is contemplated as part of methods of the invention. The nucleic acid can be used to diagnosis a disease or condition based on the relation of that miRNA to any of the pathways described above.

**[0241]** Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments. Synthetic miRNAs or miRNA inhibitors that affect phenotypic traits may provide intervention points for therapeutic development.

#### H. Other Assays

**[0242]** In addition to the use of arrays and microarrays, it is contemplated that a number of difference assays could be employed to analyze miRNAs, their activities, and their effects. Such assays include, but are not limited to, RT-PCR, *in situ* hybridization, hybridization protection assay (HPA)(GenProbe), branched DNA (bDNA) assay (Chiron), rolling circle amplification (RCA), single molecule hybridization detection (US Genomics), Invader assay (ThirdWave Technologies), and Bridge Litigation Assay (Genaco). It is contemplated that such methods may be used in the context of arrays, as well as in the context of diagnostic assays.

#### III. Therapeutic and Diagnostic Applications

**[0243]** Synthetic miRNAs or miRNA inhibitors that affect phenotypic traits provide intervention points for therapeutic applications as well as diagnostic applications (by screening for the presence or absence of a particular miRNA). It is specifically contemplated that RNA molecules of the present invention can be used to treat any of the diseases or conditions discussed in the previous section. Moreover, any of the methods described above can also be employed with respect to therapeutic and diagnostic aspects of the invention. For example, methods with respect to detecting miRNAs or screening for them can also be employed in a diagnostic context.

**[0244]** In therapeutic applications, an effective amount of the synthetic miRNAs or miRNA inhibitors of the present invention is administered to a cell, which may or may not be in an animal. In some embodiments, a therapeutically effective amount of the synthetic miRNAs or miRNA inhibitors of the present invention is administered to an individual for the treatment of disease or condition. The term "effective amount" as used herein is defined as the amount of the

molecules of the present invention that are necessary to result in the desired physiological change in the cell or tissue to which it is administered. The term "therapeutically effective amount" as used herein is defined as the amount of the molecules of the present invention that achieves a desired effect with respect to a disease or condition. A skilled artisan readily recognizes that in many cases the molecules may not provide a cure but may provide a partial benefit, such as alleviation or improvement of at least one symptom. In some embodiments, a physiological change having some benefit is also considered therapeutically beneficial. Thus, in some embodiments, an amount of molecules that provides a physiological change is considered an "effective amount" or a "therapeutically effective amount."

[0245] In some embodiments the molecule has a sequence that corresponds to the miRNA sequence from that particular animal, as opposed to from another animal. Thus, in some embodiments, a human sequence is utilized in the RNA molecules of the present invention.

#### A. Modes of Administration and Formulations

[0246] The nucleic acid molecules of the invention may be administered to a subject alone or in the form of a pharmaceutical composition for the treatment of a condition or disease. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0247] For topical administration the proteins of the invention may be formulated as solutions, gels, ointments, creams, suspensions, *etc.* as are well-known in the art. Systemic formulations include those designed for administration by injection, *e.g.* subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, inhalation, oral or pulmonary administration. For injection, the nucleic acids of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the nucleic acid molecules may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For oral administration, the nucleic acids can be readily formulated by combining the molecules with pharmaceutically acceptable carriers well known in the art. Such carriers enable the nucleic acids of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. For oral solid formulations such as, for example, powders, capsules and tablets, suitable excipients include fillers such as sugars, *e.g.* lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques. For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, glycols, oils, alcohols, *etc.* Additionally, flavoring agents, preservatives, coloring agents and the like may be added. For buccal administration, the molecules may take the form of tablets, lozenges, *etc.* formulated in conventional manner. For administration by inhalation, the molecules for use according to the present invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the nucleic acids and a suitable powder base such as lactose or starch. The RNA molecules may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

[0248] In addition to the formulations described previously, the molecules may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the molecules may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0249] Alternatively, other pharmaceutical delivery systems may be employed. Liposomes and emulsions are well-known examples of delivery vehicles that may be used to deliver nucleic acids of the invention.

[0250] A nucleic acid of the invention may be administered in combination with a carrier or lipid to increase cellular uptake. For example, the oligonucleotide may be administered in combination with a cationic lipid. Examples of cationic lipids include, but are not limited to, lipofectin, DOTMA, DOPE, and DOTAP. The publication of WO0071096, which is specifically incorporated by reference, describes different formulations, such as a DOTAP:cholesterol or cholesterol

derivative formulation that can effectively be used for gene therapy. Other disclosures also discuss different lipid or liposomal formulations including nanoparticles and methods of administration; these include, but are not limited to, U.S. Patent Publication 20030203865, 20020150626, 20030032615, and 20040048787, which are specifically incorporated by reference to the extent they disclose formulations and other related aspects of administration and delivery of nucleic acids. Methods used for forming particles are also disclosed in U.S. Pat. Nos. 5,844,107, 5,877,302, 6,008,336, 6,077,835, 5,972,901, 6,200,801, and 5,972,900, which are incorporated by reference for those aspects.

**[0251]** The nucleic acids may also be administered in combination with a cationic amine such as poly (L-lysine). Nucleic acids may also be conjugated to a chemical moiety, such as transferrin and cholesteryls. In addition, oligonucleotides may be targeted to certain organelles by linking specific chemical groups to the oligonucleotide. For example, linking the oligonucleotide to a suitable array of mannose residues will target the oligonucleotide to the liver.

**[0252]** Additionally, the molecules may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the molecules for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the chimeric molecules, additional strategies for molecule stabilization may be employed.

**[0253]** Nucleic acids may be included in any of the above-described formulations as the free acids or bases or as pharmaceutically acceptable salts. Pharmaceutically acceptable salts are those salts that substantially retain the biologic activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

**[0254]** Pharmaceutical compositions of the present invention comprise an effective amount of one or more synthetic miRNA molecules or miRNA inhibitors dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains at least one chimeric polypeptide or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.

**[0255]** As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.

**[0256]** The chimeric molecules may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it need to be sterile for such routes of administration as injection. The present invention can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctival, intravesicularily, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, inhalation (e.g. aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, *via* a catheter, *via* a lavage, in cremes, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference).

**[0257]** The actual dosage amount of a composition of the present invention administered to an animal patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.

**[0258]** In certain embodiments, pharmaceutical compositions may comprise, for example, at least about 0.1 % of an active compound. In other embodiments, the an active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milli-

gram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, *etc.*, can be administered, based on the numbers described above.

5 **[0259]** In any case, the composition may comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (*e.g.*, methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.

10 **[0260]** The molecules may be formulated into a composition in a free base, neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts, *e.g.*, those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine.

15 **[0261]** In embodiments where the composition is in a liquid form, a carrier can be a solvent or dispersion medium comprising but not limited to, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, liquid polyethylene glycol, *etc.*), lipids (*e.g.*, triglycerides, vegetable oils, liposomes) and combinations thereof. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example liquid polyol or lipids; by the use of surfactants such as, for example hydroxypropylcellulose; or combinations thereof such methods. In many cases, it will be preferable to include isotonic agents, such as, for example, sugars, sodium chloride or combinations thereof.

20 **[0262]** In other embodiments, one may use eye drops, nasal solutions or sprays, aerosols or inhalants in the present invention. Such compositions are generally designed to be compatible with the target tissue type. In a non-limiting example, nasal solutions are usually aqueous solutions designed to be administered to the nasal passages in drops or sprays. Nasal solutions are prepared so that they are similar in many respects to nasal secretions, so that normal ciliary action is maintained. Thus, in preferred embodiments the aqueous nasal solutions usually are isotonic or slightly buffered to maintain a pH of about 5.5 to about 6.5. In addition, antimicrobial preservatives, similar to those used in ophthalmic preparations, drugs, or appropriate drug stabilizers, if required, may be included in the formulation. For example, various commercial nasal preparations are known and include drugs such as antibiotics or antihistamines.

25 **[0263]** In certain embodiments, the molecules are prepared for administration by such routes as oral ingestion. In these embodiments, the solid composition may comprise, for example, solutions, suspensions, emulsions, tablets, pills, capsules (*e.g.*, hard or soft shelled gelatin capsules), sustained release formulations, buccal compositions, troches, elixirs, suspensions, syrups, wafers, or combinations thereof. Oral compositions may be incorporated directly with the food of the diet. Preferred carriers for oral administration comprise inert diluents, assimilable edible carriers or combinations thereof. In other aspects of the invention, the oral composition may be prepared as a syrup or elixir. A syrup or elixir, and may comprise, for example, at least one active agent, a sweetening agent, a preservative, a flavoring agent, a dye, a preservative, or combinations thereof.

30 **[0264]** In certain preferred embodiments an oral composition may comprise one or more binders, excipients, disintegration agents, lubricants, flavoring agents, and combinations thereof. In certain embodiments, a composition may comprise one or more of the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, *etc.*; or combinations thereof the foregoing. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, carriers such as a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both.

35 **[0265]** The composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein.

40 **[0266]** In particular embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.

45 **[0267]** Any embodiment discussed above with respect to delivery or transport to cells can also be employed with respect to implementing delivery of medicinal compounds discussed in this section.

**B. Effective Dosages**

[0268] The molecules of the invention will generally be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the molecules of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. A therapeutically effective amount is an amount effective to ameliorate or prevent the symptoms, or prolong the survival of, the patient being treated. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0269] For systemic administration, a therapeutically effective dose can be estimated initially from *in vitro* assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC<sub>50</sub> as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.

[0270] Initial dosages can also be estimated from *in vivo* data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.

[0271] Dosage amount and interval may be adjusted individually to provide plasma levels of the molecules which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 5 mg/kg/day, preferably from about 0.5 to 1 mg/kg/day. Therapeutically effective serum levels may be achieved by administering multiple doses each day.

[0272] In cases of local administration or selective uptake, the effective local concentration of the proteins may not be related to plasma concentration. One having skill in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

[0273] The amount of molecules administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

[0274] The therapy may be repeated intermittently while symptoms detectable or even when they are not detectable. The therapy may be provided alone or in combination with other drugs or treatment (including surgery).

**C. Toxicity**

[0275] Preferably, a therapeutically effective dose of the molecules described herein will provide therapeutic benefit without causing substantial toxicity.

[0276] Toxicity of the molecules described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD<sub>50</sub> (the dose lethal to 50% of the population) or the LD<sub>100</sub> (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. Proteins which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in human. The dosage of the proteins described herein lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl et al., 1975, In: The Pharmacological Basis of Therapeutics, Ch.1, p.1).

**D. Pendant Groups**

[0277] A "pendant group" may be attached or conjugated to the nucleic acid. Pendant groups may increase cellular uptake of the nucleic acid. Pendant groups can be linked to any portion of the nucleic acid but are commonly linked to the end(s) of the oligonucleotide chain. Examples of pendant groups include, but are not limited to: acridine derivatives (i.e. 2-methoxy-6-chloro-9-aminoacridine); cross-linkers such as psoralen derivatives, azidophenacyl, proflavin, and azidoproflavin; artificial endonucleases; metal complexes such as EDTA-Fe(II), o-phenanthroline-Cu(I), and porphyrin-Fe(II); alkylating moieties; nucleases such as amino-1-hexanolstaphylococcal nuclease and alkaline phosphatase; terminal transferases; abzymes; cholesteryl moieties; lipophilic carriers; peptide conjugates; long chain alcohols; phosphate esters; amino; mercapto groups; radioactive markers; nonradioactive markers such as dyes; and polylysine or other polyamines. In one example, the nucleic acid is conjugated to a carbohydrate, sulfated carbohydrate, or glycan.

**IV. Kits**

[0278] Any of the compositions described herein may be comprised in a kit. In a non-limiting example, individual synthetic miRNAs are included in a kit. The kit may further include one or more negative control synthetic miRNAs that can be used to control for the effects of synthetic miRNA delivery. The kit may further include water and hybridization buffer to facilitate hybridization of the two strands of the synthetic miRNAs. The kit may also include one or more transfection reagent(s) to facilitate delivery of the synthetic miRNA to cells.

**[0279]** In another non-limiting example, multiple synthetic miRNAs and/or multiple miRNA inhibitors are included in a kit. The kit may further include one or more negative control synthetic miRNAs and/or miRNA inhibitors that can be used to control for the effects of synthetic miRNA and/or miRNA inhibitor delivery. The kit may also include one or more transfection reagents to facilitate delivery into cells.

**[0280]** The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there is more than one component in the kit (labeling reagent and label may be packaged together), the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.

**[0281]** When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred.

**[0282]** However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

**[0283]** The container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means, into which the nucleic acid formulations are placed, preferably, suitably allocated. The kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.

**[0284]** The kits of the present invention will also typically include a means for containing the vials in close confinement for commercial sale, such as, *e.g.*, injection and/or blow-molded plastic containers into which the desired vials are retained.

**[0285]** Such kits may also include components that preserve or maintain the miRNA or that protect against its degradation. Such components may be RNase-free or protect against RNases. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or solution.

**[0286]** A kit will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.

**[0287]** Kits of the invention may also include one or more of the following: synthetic miRNA, nonsynthetic miRNA, library of synthetic miRNAs, library of miRNA inhibitors, library of nonsynthetic miRNA, combination library of synthetic miRNA, miRNA inhibitors, and/or nonsynthetic miRNAs, negative control synthetic miRNA, negative control miRNA inhibitor, negative control nonsynthetic miRNA, nuclease-free water; RNase-free containers, such as 1.5 ml tubes; hybridization buffer; and transfection reagent(s).

**[0288]** It is contemplated that such reagents are embodiments of kits of the invention. Such kits, however, are not limited to the particular items identified above and may include any reagent used for the manipulation or characterization of miRNA.

Preferably the present invention is defined as in the following definitions:

**[0289]**

1. A synthetic RNA molecule of between 17 and 125 residues in length comprising
  - a) an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and
  - b) a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence.
2. The RNA molecule of definition 1, further comprising one or more of the following:
  - i) a replacement group for phosphate or hydroxyl of the nucleotide at the 5' terminus of the RNA molecule;
  - ii) one or more sugar modifications in the first or last 1 to 6 residues of the complementary region; or,
  - iii) noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the miRNA region.
3. The RNA molecule of definition 2, comprising a replacement group for phosphate or hydroxyl of the nucleotide at the 5' terminus of the RNA molecule.

## EP 2 808 390 A1

4. The RNA molecule of definition 3, wherein the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2'-oxygen-methyl (2'-O-Me), 4,4'-dimethoxytrityl with oxygen (DMTO), fluorescein, a thiol, or acridine.
5. The RNA molecule of definition 3, wherein the phosphate of the nucleotide at the 5' terminus of the RNA molecule has been replaced.
6. The RNA molecule of definition 3, wherein the hydroxyl of the nucleotide at the 5' terminus of the RNA molecule has been replaced.
7. The RNA molecule of definition 2, comprising one or more sugar modifications in the first or last 1 to 6 residues of the complementary region.
8. The RNA molecule of definition 7, wherein the sugar modification is a 2'-O-Me modification.
9. The RNA molecule of definition 7, comprising one or more sugar modifications in the first 1 to 6 residues of the complementary region.
10. The RNA molecule of definition 7, comprising one or more sugar modifications in the last 1 to 6 residues of the complementary region.
11. The RNA molecule of definition 7, comprising one or more sugar modifications in the first or last 2 to 4 residues of the complementary region.
12. The RNA molecule of definition 2, comprising noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the miRNA region.
13. The RNA molecules of definition 12, wherein there is noncomplementarity with at least 2 nucleotides in the complementary region.
14. The RNA molecule of definition 2, comprising at least two of i), ii), or iii).
15. The RNA molecule of definition 14, comprising i), ii), and iii).
16. The RNA molecule of definition 1, wherein the RNA molecule is a single polynucleotide.
17. The RNA molecule of definition 16, further comprising a linker region between the miRNA region and the complementary region.
18. The RNA molecule of definition 17, wherein the linker region is between 3 and 30 residues in length.
19. The RNA molecule of definition 1, wherein the RNA molecule is double stranded.
20. A library of 10 or more different RNA molecules of definition 1.
21. A library of 10 or more different miRNA inhibitor molecules, wherein each miRNA inhibitor molecule is between about 17 to 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA.
22. The library of definition 21, wherein the miRNA inhibitor molecules have a replacement group for the phosphate or hydroxyl of the nucleotide at the 5' terminus of the molecule.
23. The library of definition 22, wherein the replacement group is an amine group, a lower alkylamine group, an acetyl group, or 2'-O-Me.
24. The library of definition 22, wherein the phosphate of the nucleotide at the 5' terminus of the miRNA inhibitor molecule has been replaced.

25. The library of definition 22, wherein the hydroxyl of the nucleotide at the 5' terminus of the miRNA inhibitor molecule has been replaced.

26. The library of definition 21, wherein the miRNA inhibitor comprises DNA.

27. A method of characterizing an miRNA activity or function in a cell comprising:

a) introducing into one or more cells the RNA molecule of definition 1;

b) comparing one or more characteristics of cell(s) having the RNA molecule with cells not having the RNA molecule.

28. The method of definition 27, wherein at least five RNA molecules are introduced into different cells.

29. The method of definition 27, further comprising assaying the cell for the presence of the RNA molecule.

30. The method of definition 27, further comprising synthesizing the RNA molecule.

31. The method of definition 30, wherein the RNA molecule further comprises one or more of the following:

i) a replacement group for phosphate or hydroxyl of the nucleotide at the 5' terminus of the RNA molecule;

ii) one or more sugar modifications in the first or last 1 to 6 residues of the complementary region; or,

iii) noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the miRNA region.

32. The method of definition 31, wherein the RNA molecule comprises a replacement group for phosphate or hydroxyl of the nucleotide at the 5' terminus of the RNA molecule.

33. The method of definition 32, wherein the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2'O-Me, DMTO, fluorescein, a thiol, or acridine.

34. The method of definition 32, wherein the phosphate of the nucleotide at the 5' terminus of the RNA molecule has been replaced.

35. The method of definition 32, wherein the hydroxyl of the nucleotide at the 5' terminus of the RNA molecule has been replaced.

36. The method of definition 31, wherein the RNA molecule comprises one or more sugar modifications in the first or last 1 to 6 residues of the complementary region.

37. The method of definition 36, wherein the sugar modification is a 2'O-Me modification.

38. The method of definition 36, wherein the RNA molecule comprises one or more sugar modifications in the first 1 to 6 residues of the complementary region.

39. The method of definition 36, wherein the RNA molecule comprises one or more sugar modifications in the last 1 to 6 residues of the complementary region.

40. The method of definition 36, wherein the RNA molecule comprises one or more sugar modifications in the first or last 2 to 4 residues of the complementary region.

41. The method of definition 31, wherein the RNA molecule comprises noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3' end of the complementary region and the corresponding nucleotides of the miRNA region.

42. The method of definition 41, wherein there is noncomplementarity with at least 2 nucleotides in the complementary

region.

43. The method of definition 31, wherein the RNA molecule comprises at least two of i), ii), or iii).

5 44. The method of definition 43, wherein the RNA molecule comprises i), ii), and iii).

45. The method of definition 27, wherein the RNA molecule is a single polynucleotide.

10 46. The method of definition 45, wherein the RNA molecule further comprises a linker region between the miRNA region and the complementary region.

47. The method of definition 46, wherein the linker region is between 3 and 30 residues in length.

15 48. The method of definition 27, wherein the RNA molecule is composed of two polynucleotides.

49. The method of definition 27, wherein the RNA molecule is introduced into the cell by calcium phosphate transfection, lipid transfection, electroporation, microinjection, or injection.

20 50. A method of reducing or eliminating activity of one or more miRNAs from a cell comprising:

a) introducing into a cell an miRNA inhibitor that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA.

25 51. The method of definition 50, further comprising:

b) comparing one or more characteristics of a cell having the miRNA inhibitor with a cell not having the miRNA inhibitor.

30 52. The method of definition 50, further comprising assaying the cell for expression of the mature miRNA.

53. The method of definition 50, further comprising synthesizing the miRNA inhibitor.

54. The method of definition 51, wherein the miRNA inhibitor further comprises one or more of the following:

35 i) a replacement group for phosphate or hydroxyl of the nucleotide at the 5' terminus of the miRNA inhibitor; or

ii) one or more sugar modifications.

40 55. The method of definition 54, wherein the miRNA inhibitor comprises a replacement group for phosphate or hydroxyl of the nucleotide at the 5' terminus of the miRNA inhibitor.

56. The method of definition 55, wherein the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2'O-Me, DMTO, fluorescein, a thiol, or acridine.

45 57. The method of definition 55, wherein the phosphate of the nucleotide at the 5' terminus of the miRNA inhibitor has been replaced.

58. The method of definition 55, wherein the hydroxyl of the nucleotide at the 5' terminus of the miRNA inhibitor has been replaced.

50 59. The method of definition 54, wherein the miRNA inhibitor comprises one or more sugar modifications in the first or last 1 to 6 residues.

60. The method of definition 59, wherein the sugar modification is a 2'O-Me modification.

55 61. The method of definition 59, wherein the miRNA inhibitor comprises one or more sugar modifications in the first 1 to 6 residues of the complementary region.

62. The method of definition 59, wherein the miRNA inhibitor comprises one or more sugar modifications in the last 1 to 6 residues of the complementary region.

63. The method of definition 59, wherein the miRNA inhibitor comprises one or more sugar modifications in the first or last 2 to 4 residues of the complementary region.

64. The method of definition 54, wherein the miRNA inhibitor comprises both i) and ii).

65. The method of definition 50, wherein the miRNA inhibitor is a single polynucleotide.

66. The method of definition 50, wherein the miRNA inhibitor is introduced into the cell by calcium phosphate transfection, lipid transfection, electroporation, microinjection, or injection.

67. A method for reducing or inhibiting cell proliferation in a cell comprising introducing into the cell an effective amount of at least one

i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of: mir-31, mir-92, mir-99a, mir-100, mir-125a, mir-129, mir-130a, mir-150, mir-187, miR-190, miR-191, miR-193, miR 204, mir-210, mir-211, mir-212, mir-213, mir-215, mir-216, mir-217, miR 218, mir-224, mir-292, mir-294, mir-320, mir-324, mir-325, mir-326, mir-330, mir-331, mir-338, mir-341, mir-369, and mir-370; or

ii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the mature miRNA sequence, wherein the mature miRNA sequence is selected from the group consisting of: miR-15a, miR-16, miR 21, miR 24, miR-96, miR-101, miR-105, miR-124, miR-126, miR-142, miR-147, miR-192, miR-194, miR-206, miR-215, or miR-346.

68. The method of definition 67, further comprising identifying a cell or a patient having the cell as in need of reducing or inhibiting cell proliferation.

69. A method for inducing or increasing cell proliferation in a cell comprising introducing into the cell an effective amount of at least one

i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of let7a-1, Let-7a, Let-7b, let7b-1, let7c, let7d, Let-7g, mir-9, mir-10a, mir-10b, mir-15a, mir-16, mir-21, mir-23a, mir-23b, mir-24, mir-25, mir-92, mir-95, mir-133a, mir-133a-2, mir-133b, mir-142, mir-152, mir-153, mir-155, mir-181a, mir-182, mir-183, mir-184, mir-186, mir-187, mir-191, mir-193, mir-194, mir-196, mir-199a-1 mir-200b, mir-204, mir-206, mir-211, mir-222, mir-223, mir-298, mir-328, mir-342, mir-371, and mir-412; or

ii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of: Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, miR-7, mir-9, miR-10a, miR-10b, miR-15a, miR-18, miR-19a, miR-17-3p, miR-20, miR-23b, mir-25, miR-26a, miR-26a, mir-30e-5p, mir-31, mir-32, mir-92, mir-93, miR-100, miR-125a, miR-125b, miR-126, mir-127, miR-128, miR-129, mir-130a, mir-135, mir-138, mir-139, miR-140, mir-141, mir-143, mir-145, mir-146, miR-150, mir-154, mir-155, mir-181a, miR-182, mir-186, miR-187, miR-188, mir-190, mir-191, mir-193, mir-194, mir-196, mir-197, mir-198, mir-199, mir-201, mir-204, mir-216, mir-218, miR-223, mir-293, miR-291-3p, miR-294, miR-295, miR-322, mir-333, mir-335, mir-338, mir-341, mir-350, mir-369, miR-373, mir-410, and mir-412.

70. The method of definition 69, further comprising identifying a cell or a patient having the cell as in need of inducing or increasing cell proliferation.

71. A method for reducing cell viability comprising introducing into one or more cells an effective amount of at least one

i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence

that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of: miR-107, miR-133, miR-137, miR-152, miR-155, miR-181a, miR-191, miR-203, and miR-215; or

5 ii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of: let-7a, let-7b, mir-1, mir-7, miR-10b, miR-17-3p, miR-19a, mir-23, mir-24, mir-27a, miR-29a, miR-30a-3p, mir-31, mir-32, miR-34a, miR-101, miR-107, miR-108, miR-122, mir-124, miR-133a, miR-134, miR-135, miR-139, mir-140, miR-141, miR-145, mir-150, mir-192, mir-193, mir-195, mir-206, mir-208, mir-210, mir-210, mir-292-3p, mir-293, mir-297, mir-299, mir-329, mir-337, mir-337, mir-345, mir-346, and mir-409.

72. The method of definition 71, further comprising identifying a cell or a patient having the cell as in need of reducing cell viability.

15 73. A method for increasing cell viability comprising introducing into one or more cells an effective amount of at least one

20 i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of miR-7, miR-19a, miR-23, miR-24, miR-27a, miR-31, miR-32, miR-134, miR-140, miR-150, miR-192, and miR-193; or

25 ii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of: let-7a, let-7b, let-7c, let-7d, let-7g, miR-10a, miR-10b, miR-15a, miR-17-3p, miR-18, miR-19a, miR-20, mir-23a, mir-23b, mir-24, miR-25, miR-26a, mir-32, miR-107, miR-125a, miR-126, mir-128, miR-129, miR-133, miR-137, mir-139, miR-143, miR-152, miR-155, miR-181a, miR-182, miR-191, miR-203, miR-215, and mir-331.

30 74. The method of definition 73, further comprising identifying a cell or a patient having the cell as in need of increasing cell viability.

35 75. A method for inducing apoptosis in a cell comprising introducing into the cell an effective amount of at least one

i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of: miR-31 and miR-214; or

40 ii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of: let-7b, let-7g, mir-1, mir-1d, mir-7, mir-10a, miR-10b, miR-17-3p, miR-19a, miR-28, miR-28, miR-28, miR-29a, miR-32, miR-34a, miR-122, mir-148, mir-149, mir-154, mir-184, mir-186, mir-188, mir-192, mir-195, mir-196, mir-199a, mir-204, mir-208, mir-210, mir-211, mir-212, mir-214, mir-215, mir-216, mir-217, mir-218, mir-293, mir-296, mir-299, mir-321, mir-328, and mir-344.

50 76. The method of definition 75, further comprising identifying a cell or a patient having the cell as in need of inducing apoptosis.

77. A method for inhibiting apoptosis in a cell comprising introducing into the cell an effective amount of at least one

55 i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA selected from the group consisting of: miR-7, miR-1d, miR-148, miR-195, miR-196, miR-199a, miR-204, miR-210, miR-211, miR-212, miR-215, miR-216, miR-218, miR-296, and miR-321; or

ii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose

sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of: Let-7b, mir-21, mir-23b, mir-25, miR-26a, mir-28, mir-29a, mir-31, miR-32, mir-30a-3p, mir-34a, mir-96, miR-98, mir-100, mir-101, mir-105, mir-108, miR-125b, miR-126, mir-126, mir-128, mir-137, miR-143, miR-155, mir-207, mir-214, mir-216, mir-223, mir-292-3p, mir-328, mir-335, mir-340, mir-341, mir-367, mir-368, mir-380-3p, and mir-410.

78. The method of definition 77, further comprising identifying a cell or a patient having the cell as in need of inhibiting apoptosis.

79. A method for treating cancer in a subject comprising administering to the subject an effective amount of one or more synthetic miRNA molecules and/or miRNA inhibitors corresponding to miR-21, miR-126, miR-143, miR-145, miR-188, miR-200b, miR-219, or miR-331.

80. The method of definition 79, wherein the cancer is breast cancer and the subject is administered 1) one or more miRNA inhibitors corresponding to miR-21, miR-15a, miR-16, miR-24, and/or miR-25, and/or 2) one or more miRNAs corresponding to miR-99, miR-100, miR-205, miR-197, miR-126, miR-143, miR-145 and/or miR-321.

81. The method of definition 79, wherein the cancer is colon cancer and the subject is administered 1) one or more miRNA inhibitors corresponding to miR-21, miR-106, miR-189, miR-200b, miR-223, miR-224, miR-31, and/or miR-17; and/or 2) one or more miRNAs corresponding to miR-145, miR-143, miR-133, miR-342, miR-125a, miR-195, miR-30a, miR-10a, miR-130, miR-130a, miR-192, miR-194, miR-215, miR-144, miR-23, miR-26a, miR-126, miR-199a, miR-188, miR-331, and/or miR-21.

82. The method of definition 79, wherein the cancer is thyroid cancer and the subject is administered 1) one or more miRNA inhibitors corresponding to miR-21, miR-125, miR-24, miR-200b, miR-29b, miR-221, miR-222, miR-224, miR-10a, and/or miR-183; and/or 2) one or more miRNAs corresponding to miR-145, miR-22, miR-331, miR-126, miR-30a, miR-199a, miR-223, and/or miR-321.

83. The method of definition 79, wherein the cancer is lung cancer and the subject is administered 1) one or more miRNA inhibitors corresponding to miR-223, miR-106, miR-21, miR-200b, miR-321, miR-182, miR-183, miR-17, and/or miR-205; and/or 2) one or more miRNAs corresponding to miR-130a, miR-145, miR-126, miR-331, miR-342, miR-143, Let-7, miR-30a, miR-16, miR-26a, miR-125a, miR-29b, miR-24, miR-328, miR-201, miR-195, miR-22, miR-181a, miR-331, and/or miR-321.

84. A method for treating cancer in a subject comprising administering to the subject an effective amount of one or more synthetic miRNA molecules and/or miRNA inhibitors corresponding to let-7, miR-10a, miR-16, miR-17, miR-21, miR-22, miR-23, miR-24, miR-26a, miR-29b, miR-30a, miR-106, miR-125a, miR-126, miR-130, miR-130a, miR-133, miR-143, miR-144, miR-145, miR-181a, miR-182, miR-183, miR-188, miR-189, miR-219, miR-192, miR-194, miR-195, miR-199a, miR-200b, miR-201, miR-205, miR-215, miR-223, miR-224, miR-321, miR-328, miR-331, or miR-342.

85. A method of treating cancer in a patient comprising administering to the patient the cancer therapeutic and an effective amount of at least one miRNA molecule that improves the efficacy of the cancer therapeutic or protects non-cancer cells.

86. The method of definition 85, wherein the miRNA molecule enhances the efficacy of the cancer therapeutic and is selected from the group consisting of ambi-miR-7100, mir-28, mir-101, mir-124, mir-125a, mir-126, mir-132, mir-136, mir-147, mir-155, mir-182, mir-186, mir-202, mir-206, mir-216, mir-221, mir-224, mir-291, mir-292-3p, mir-297, mir-302, mir-337, mir-372, mir-373, and mir-376b.

87. The method of definition 85, wherein the miRNA molecule protects non-cancer cells from the cancer therapeutic and is selected from the group consisting of mir-16, mir-24, mir-30a-3p, mir-125b, mir-152, mir-194, mir-197, mir-214, and mir-331.

88. A method for treating lupus in a subject comprising administering to the subject an effective amount of 1) one or more miRNA inhibitors corresponding to miR-21, miR-223, and/or miR-342 expression; and/or 2) one or more miRNAs corresponding to miR-95, miR-105, miR-137, miR-186, miR-188, miR-199, miR-211, miR-215, mu-miR-

290, miR-301, and/or miR-331.

89. A method for treating a prion disease in a subject comprising administering to the subject an effective amount of 1) one or more miRNA inhibitors corresponding miR-7, miR-9-as, miR-16, miR-24, miR-26A, miR-27A, miR-130A, and/or miR-239 expression; and/or 2) one or more miRNAs corresponding to miR-95 and/or miR-135A.

90. A method for preventing or treating ischemia in a subject comprising administering to the subject an effective amount of 1) one or more miRNA inhibitors corresponding to miR-28, miR-30A, miR-31, miR-138, miR-139, miR-140, miR-291-5P and/or miR-298 expression; and/or 2) one or more miRNAs corresponding to Let7F-2 and/or miR-16.

91. A method for inducing transformation in a cell comprising administering to the cell an effective amount of at least one miRNA selected from the group consisting of mir-192, mir-198, and mir-199.

92. A method for activating ERK in cells comprising providing or introducing into the cells an effective amount of one or more nucleic acids capable of being processed into a mature miRNA when it is inside the cell, wherein the mature miRNA is let-7, miR-19a, miR-25, miR-96, miR-125a, miR-134, miR-148, miR-152, miR-206, miR-207, miR-210, miR-212, miR-216, miR-217, miR-218, miR-223, mu-miR-294, mu-miR-295, miR-301, miR-328, mu-miR-329, miR-339, miR-370, or miR-372.

93. A method for activating hTert in a cell comprising introducing into the cell an effective amount of one or more nucleic acids capable of being processed into a mature miRNA inside the cell, wherein the mature miRNA is miR-15a, miR-16, miR-21, mir-24, miR-26a, miR-92, miR-105, miR-125a, miR-125b, miR-128, mir-147, miR-195, miR-207, miR-224, mu-miR-295, mir-301, miR-337, mir-368, or mir-371.

94. A method for identifying an miRNA that inhibits an hTert activating gene product comprising:

a) introducing into a cell a candidate miRNA into a cell;

b) assaying the level of hTert expression or hTert activity in the cell, wherein a reduction in hTert expression or activity compared to a cell lacking the miRNA identifies the miRNA as a potential inhibitor of an hTert activating gene product.

95. The method of definition 94, wherein the sequence of the candidate miRNA was previously evaluated for an ability to inhibit an hTert activating gene product.

96. The method of definition 87.7, wherein the hTert activating gene product is selected from the group consisting of ACOX1, AKT1, APAF1, COX-5B, COX6, COX7B, CPOX, DUOX2, GPX1, GPX2, GPX4, LPO, MAPK1, MAPK4, MTCO1, NOX3, NOX5, PAOX, PPOX, PRKCA, PRKCD, and TNFRSF6.

97. A method for inhibiting hTert in a cell comprising providing to the cell an effective amount of an miRNA selected from the group consisting of miR-26a, miR-147, mir-195, and mir-368.

98. A method for inhibiting stimulation of Stat3 in a cell comprising providing to the cell an effective amount of an miRNA selected from the group consisting of mir-93, mir-100, mir-134, mir-99a, mir-103, mir-128, mir-129, mir-181b, mir-193, mir-197, mir-212, mir-218, mir-219, mir-302, mir-323, mir-324-3p, mir-325, mir-330, mir-331, mir-340, mmu-mir-350, mir-425, mir-491, mir-518f, and mir-520a\*.

99. A kit for evaluating miRNA molecules comprising, in suitable containers, at least five RNA molecules of definition 1.

100. A kit for evaluating miRNA molecules comprising, in suitable containers, at least five miRNA inhibitor molecules, wherein each miRNA inhibitor molecule is between 17 and 25 nucleotides in length and comprises a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA.

101. A kit comprising, in suitable containers:

a) at least one synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5' to 3' is identical to a mature miRNA sequence, and a complementary region

whose sequence from 5' to 3' is between 60% and 100% complementary to the miRNA sequence; and

b) at least one miRNA inhibitor between 17 and 25 nucleotides in length and comprising a 5' to 3' sequence that is at least 90% complementary to the 5' to 3' sequence of a mature miRNA.

## Examples

[0290] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

[0291] Unless otherwise designated, catalog numbers refer to products available by that number from Ambion, Inc.®, The RNA Company.

### EXAMPLE 1:

#### Assay for measuring activity of precursor miRNAs (reporter)

[0292] A series of luciferase reporter vectors was created to measure the activities of synthetic miRNAs in cells. The reporter vectors were based on plasmids that had been used to monitor the activity of endogenous miRNAs (Tuschl paper). Briefly, a mammalian expression vector with the luciferase gene under the control of the CMV early promoter was created. Down-stream of the luciferase coding sequence, in the 3' UTR of the gene, sequences complementary to mature miR-1-2, miR-10, miR-124, miR-19a, and miR-130 were added. The reporter vectors were co-transfected into HeLa cells along with synthetic miRNAs designed to introduce one of the five miRNAs listed above. The transfections involved mixing 200 ng of reporter vector with 0.3, 1, and 3 pmoles of each corresponding synthetic miRNA. The reporter/miRNA mixture was mixed with 0.3  $\mu$ l of Lipofectamine 2000 (Invitrogen) and incubated for 5-15 minutes. Approximately 8,000 cells were added to each miRNA/reporter/transfection reagent complex in individual wells of a 96-well plate. HeLa cells were grown in D-MEM (GIBCO) supplemented with 10% fetal bovine serum (GIBCO) at 37°C and 5% CO<sub>2</sub>. 24-48 hrs post transfection, the cells were harvested and assayed using the Luciferase assay as described by the manufacturer (Promega). The level of luciferase expression in the cell populations was compared to cells transfected with the same reporter but a synthetic miRNA with a sequence that does not correspond to the vector. This non-targeting miRNA was referred to as the negative control miRNA.

[0293] Final analysis of the synthetic miRNA designs involved measuring the activity of both the active and complementary strands of our synthetic miRNAs. For these studies, reporter vectors with luciferase 3' UTR sequences were created that included regions complementary to both the active and the complementary strands of our synthetic miR-33 and let-7b miRNA designs. When co-transfected with malfunctioning synthetic miRNAs, the reporters with a sequence targeted by the complementary strand exhibit reduced luciferase expression because the complementary strand of the synthetic miRNAs are entering the miRNA pathway in addition to or even instead of the active strand that is desired. For these experiments, the co-transfection and reporter analysis protocols are identical to what is described above.

### EXAMPLE 2:

#### Assay for measuring activity of precursor miRNAs (Endogenous gene)

[0294] While the luciferase reporter constructs were extremely valuable in evaluating the synthetic miRNA designs, it was important to verify the findings of the reporter constructs by measuring the effects of the synthetic miRNAs on endogenous gene targets. For these studies, the expression of RAS and MYC in cells transfected with let-7 miRNAs was chosen for monitoring. Both RAS and MYC are down-regulated by the various members of the let-7 family in humans and *C. elegans* (publication pending). Using a microarray system specific to miRNAs, the inventors have found that HepG2 cells express undetectable levels of let-7. To test the activities of our various designs of our synthetic miRNAs, synthetic let-7 miRNAs were created and used to transfect HepG2 cells in 24-well plates using siPORT NeoFX (Ambion) according to the manufacturer's suggestions. Three days post-transfection, the cells were fixed with 4% paraformaldehyde, stained with DAPI to localize cell nuclei, and stained with FITC-conjugated antibodies specific to MYC or RAS (US Biological) according to the manufacturer's suggestions. The relative reduction in target protein expression in synthetic let-7 transfected cells was determined by comparing the staining intensity of MYC and RAS to cells transfected with a negative control miRNA using MetaMorph software.

**[0295]** To ensure that the results of our let-7 assays could be verified by additional miRNA interactions that are observed naturally in cells, we created assays for two additional miRNAs with verified targets. In the first, a real-time PCR™ assay was developed to measure the level of the HOXB8 mRNA in cells transfected with synthetic miR-196. It has been shown that miR-196 induces degradation of the HOXB8 mRNA in cells. When transfected into cultured cells using siPORT NeoFX according to the manufacturer's instructions, effective miR-196 synthetic miRNA designs reduce the levels of the HOXB8 mRNA.

**[0296]** To monitor the effectiveness of synthetic miR-1-2 miRNAs, a reporter vector was created wherein the 3' UTR of the G6PD gene was placed immediately down-stream of the luciferase coding region. An interaction between miR-1-2 and the G6PD 3' UTR has been published (Lewis, 2003). Synthetic miR-1-2 designs were co-transfected with the reporter vector and assayed as described in Example 1.

### EXAMPLE 3

#### **Effectiveness of partially complementary miRNAs**

**[0297]** Three general sequence designs were compared for miRNA activity. The first, referred to as the "miRNA design," featured an active strand identical to the mature miRNA found in animals and a complementary strand that was identical to the hairpin sequence that is predicted to exist in cells during the processing of the miRNA prior to activation of the miRNA (see below). The second design, referred to as the "mismatch design," was a hybrid of the same active strand as above with a complementary strand with a di-nucleotide, 3' overhang and two mismatches in the final five nucleotides that preceded the 3' overhang (see below). The third design, referred to as the "siRNA design," comprised the same active strand as above hybridized to a second RNA that was fully complementary except that it left 3' di-nucleotide overhangs at either end of the double-stranded molecule (two polynucleotides) (see below). The examples below involve or correspond to human miRNAs.

#### **miR-1-2**

*mature miR-1-2 sequence-* UGGAAUGUAAAGAAGUAUGUA (53-73 of SEQ ID NO:1)

miRNA design = CAUACUUCUUUAUAUGCCCAUA (SEQ ID NO:594) +

UGGAAUGUAAAGAAGUAUGUA (SEQ ID NO:595)

mismatch design = CAUACUUCUUACAUCUGTT (SEQ ID NO:596) +

UGGAAUGUAAAGAAGUAUGUA (SEQ ID NO:597)

siRNA design = CAUACUUCUUACAUCUCCATT (SEQ ID NO:598) +

UGGAAUGUAAAGAAGUAUGUA (SEQ ID NO:599)

#### **mir-124a-1**

*mature miR-124 sequence-* UUAAGGCACGCGGUGAAUGCCA (52-73 of SEQ ID NO:80)

miRNA design = GUGUUCACAGCGGACCUUGAUU (SEQ ID NO:600) +

UUAAGGCACGCGGUGAAUGCCA (SEQ ID NO:601)

mismatch design = GCAUUCACCGCGUGCCUUGGTT (SEQ ID NO:602) +

UUAAGGCACGCGGUGAAUGCCA (SEQ ID NO:603)

siRNA design = GCAUUCACCGCGUGCCUUAATT (SEQ ID NO:604) +

UUAAGGCACGCGGUGAAUGCCA (SEQ ID NO:605)

#### **miR-130a**

*mature miR-130 sequence* – CAGUGCAAUGUUAAAAGGGC (55-74 of SEQ ID NO:91)

miRNA design = UCUUUUCACAUUGUGCUAC (SEQ ID NO:606) +

CAGUGCAAUGUUAAAAGGGC (SEQ ID NO:607)

mismatch design = UAUUUUAACAUUGCACUGTT (SEQ ID NO:608) +

CAGUGCAAUGUUAAAAGGGC (SEQ ID NO:609)

siRNA design = CCUUUUAACAUUGCACUGTT (SEQ ID NO:610) +

CAGUGCAAUGUUAAAAGGGC (SEQ ID NO:611)

**miR-19a**

*mature miR-19a sequence* – UGUGCAAUCUAUGCAAACUGA (49-71 of SEQ ID NO:28)

miRNA design = AGUUUUGCAUAGUUGCACUA (SEQ ID NO:612) +

UGUGCAAUCUAUGCAAACUGA (SEQ ID NO:613)

mismatch design = ACAUUUGCAUAGAUUUGCACATT (SEQ ID NO:614) +

UGUGCAAUCUAUGCAAACUGA (SEQ ID NO:615)

siRNA design = AGUUUUGCAUAGAUUUGCACATT (SEQ ID NO:616) +

UGUGCAAUCUAUGCAAACUGA (SEQ ID NO:617)

**mmu-miR-10a-1 (mouse)**

*mature miR-10 sequence* – UACCCUGUAGAUCGAAUUUGUG (22-44 of SEQ ID NO:212)

miRNA design = CAAAUUCGUAUCUAGGGGAAUA (SEQ ID NO:618) +

UACCCUGUAGAUCGAAUUUGUG (SEQ ID NO:619)

mismatch design = AGAAUUCGGAUCUACAGGGUATT (SEQ ID NO:620) +

UACCCUGUAGAUCGAAUUUGUG (SEQ ID NO:621)

siRNA design = CAAAUUCGGAUCUACAGGGUATT (SEQ ID NO:622) +

UACCCUGUAGAUCGAAUUUGUG (SEQ ID NO:623)

**miR-33**

*mature miR-33 sequence* – GUGCAUUGUAGUUGCAUUG (6-24 of SEQ ID NO:57)

miRNA = AUGUUUCCACAGUGCAUCA (SEQ ID NO:624) + GUGCAUUGUAGUUGCAUUG (SEQ ID NO:625)

mismatch design = GUCCAACUACAAUGCACTT (SEQ ID NO:626) +  
GUGCAUUGUAGUUGCAUUG (SEQ ID NO:627)

siRNA design = AUGCAACUACAAUGCACTT (SEQ ID NO:628) + GUGCAUUGUAGUUGCAUUG (SEQ ID NO:629)

**let-7b**

*mature let-7b sequence* – UGAGGUAGUAGGUUGUGUGGUU (6-27 of SEQ ID NO:6)

miRNA design = CUAUACAACCUACUGCCUCC (SEQ ID NO:630) +

UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:631)

mismatch design = CCACACAACCUACUAUCUUATT (SEQ ID NO:632) +

UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:633)

siRNA design = CCACACAACCUACUACCUCATT (SEQ ID NO:634) +

UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:635)

**miR-196-2**

*mature miR-196 sequence* – UAGGUAGUUUCAUGUUGUUGG (7-27 of SEQ ID NO:143)

siRNA design = AACAAUGAAACUACCUATT (SEQ ID NO:636) +

UAGGUAGUUUCAUGUUGUUGG (SEQ ID NO:637)

miRNA design = CAAUUCGUAUCUAGGGGAAUA (SEQ ID NO:638) +

UAGGUAGUUUCAUGUUGUUGG (SEQ ID NO:639)

mismatch design = AAUACAUGAAACUACCUATT (SEQ ID NO:640) +

UAGGUAGUUUCAUGUUGUUGG (SEQ ID NO:641)

The assorted mir-1-2, mmu-miR-10a-1, miR-19a, mir-124a-1, and mir-130a synthetic miRNAs were tested for their capacity to reduce the expression of the reporter gene in vectors with appropriate miRNA target sites using the assay described in Example 1. All three designs were similarly capable of down-regulating the appropriate reporter vectors.

**[0298]** To assess whether there were differences between the various miRNA designs in their ability to affect the expression of endogenous genes, the following cells were transfected: HepG2 cells with three designs of the let-7 synthetic miRNAs, A549 with three designs of the miR-196 synthetic miRNAs, and HeLa with the G6PD reporter vector and three designs of the miR-1-2 synthetic miRNA. As with the reporter vectors, all three synthetic miRNA designs proved capable of reducing the expression of the target genes, though it is notable that the siRNA design performed most poorly.

**[0299]** As a final comparison of the three synthetic miRNA designs, synthetic miRNAs were co-transfected with reporter vectors that included target sites for the complementary strands of the synthetic miRNAs according to the procedure described in Example 1. In this assay, it was apparent that the siRNA design significantly affected the reporter vectors, indicating that the wrong strand of the miRNA was entering the miRNA pathway (FIG. 3). Because the complementary strand might impact the expression of genes that are not natural targets of the miRNA that is being studied, the siRNA design is inappropriate for effective synthetic miRNAs.

**EXAMPLE 4:****Effectiveness of chemically 5' end-modified synthetic miRNAs**

**[0300]** Although the siRNA design proved problematic in that it exhibited a high rate of complementary strand uptake by the miRNA pathway, it did have the advantage that it was easy to hybridize and easy to deliver to cells. For these reasons, ways to overcome the problems with complementary strand uptake were explored. The siRNA design was used to test the effects of chemical modifications at the 5' ends of the synthetic miRNAs. For these studies, several different complementary strands were synthesized with unique 5' ends. One featured four deoxyribose nucleotides at the 5' end; one was a combination of four deoxyribose nucleotides at the 5' end and a 5' NH<sub>2</sub>; one had a 5'NH<sub>2</sub>; one had a 5' NHCOCH<sub>3</sub> (see below).

**miR-33**

*mature miR-33 sequence* – GUGCAUUGUAGUUGCAUUG (6-24 of SEQ ID NO:57)

5 siRNA design = AUGCAACUACAAUGCACTT (SEQ ID NO:642) + GUGCAUUGUAGUUGCAUUG  
(SEQ ID NO:643)

10 5' amino design = (NH<sub>2</sub>)AUGCAACUACAAUGCACTT (SEQ ID NO:644) +  
GUGCAUUGUAGUUGCAUUG (SEQ ID NO:645)

5' acetyl design = (CH<sub>3</sub>OCNH)AUGCAACUACAAUGCACTT (SEQ ID NO:646) +  
GUGCAUUGUAGUUGCAUUG (SEQ ID NO:647)

15 5' DNA design = dAdUdGdCAACUACAAUGCACTT (SEQ ID NO:648) +  
GUGCAUUGUAGUUGCAUUG (SEQ ID NO:649)

20 5' amino DNA design = (NH<sub>2</sub>)dAdUdGdCAACUACAAUGCACTT (SEQ ID NO:650) +  
GUGCAUUGUAGUUGCAUUG (SEQ ID NO:651)

**let-7b**

25 *mature let-7b sequence* – UGAGGUAGUAGGUUGUGUGGUU (6-27 of SEQ ID NO:6)

siRNA design = CCACACAACCUACUACCUCATT (SEQ ID NO:652) +  
UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:653)

30 5' amino design = NH<sub>2</sub>CCACACAACCUACUACCUCATT (SEQ ID NO:654) +  
UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:655)

35 5' DNA design = dCdCdAdCACAACCUACUACCUCATT (SEQ ID NO:656) +  
UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:657)

5' amino DNA design = NH<sub>2</sub>dCdCdAdCACAACCUACUACCUCATT (SEQ ID NO:658) +  
UGAGGUAGUAGGUUGUGUGGUU (SEQ ID NO:659)

**miR-1-2**

45 *mature miR-1-2 sequence*- UGGAAUGUAAAGAAGUAUGUA (53-73 of SEQ ID NO:1)

siRNA design = CAUACUUCUUUACAUUCCATT (SEQ ID NO:660) +  
UGGAAUGUAAAGAAGUAUGUA (SEQ ID NO:661)

50 5' amino design = NH<sub>2</sub>CAUACUUCUUUACAUUCCATT (SEQ ID NO:662) +  
UGGAAUGUAAAGAAGUAUGUA (SEQ ID NO:663)

**miR-124a-1**

55

*mature miR-124 sequence*- UUAAGGCACGCGGUGAAUGCCA (52-73 of SEQ ID NO:80)

siRNA design = GCAUUCACCGCGUGCCUUAATT (SEQ ID NO:664) +

UUAAGGCACGCGGUGAAUGCCA (SEQ ID NO:665)

5' amino design = NH<sub>2</sub>GCAUUCACCGCGUGCCUUAATT (SEQ ID NO:666) +

UUAAGGCACGCGGUGAAUGCCA (SEQ ID NO:667)

#### **miR-130a**

*mature miR-130 sequence* – CAGUGCAAUGUAAAAGGGC (55-74 of SEQ ID NO:91)

siRNA design = CCUUUUAACAUUGCACUGTT (SEQ ID NO:668) +

CAGUGCAAUGUAAAAGGGC (SEQ ID NO:669)

5' amino design = NH<sub>2</sub>CCUUUUAACAUUGCACUGTT (SEQ ID NO:670) +

CAGUGCAAUGUAAAAGGGC (SEQ ID NO:671)

#### **miR-10a-1**

*mature miR-10 sequence* – UACCCUGUAGAUCGAAUUUGUG (22-44 of SEQ ID NO:212)

siRNA design = CAAAUUCGGAUCUACAGGGUATT (SEQ ID NO:672) +

UACCCUGUAGAUCGAAUUUGUG (SEQ ID NO:673)

5' amino design = NH<sub>2</sub>CAAAUUCGGAUCUACAGGGUATT (SEQ ID NO:674) +

UACCCUGUAGAUCGAAUUUGUG (SEQ ID NO:675)

The miR-33 and let-7b synthetic miRNAs were co-transfected into HeLa and HepG2 cells, respectively, with reporter vectors bearing target sites for the active and complementary strands of miR-33 and let-7b as described in Example 1. Luciferase expression from the active and complementary strand-specific reporter vectors was measured according to the manufacturer's (Promega) protocol. As shown in FIG. 3, the synthetic miRNA designs with the 5' NH<sub>2</sub> and 5' NHCOCH<sub>3</sub> provided higher active strand activity and significantly reduced complementary strand activity relative to the unmodified, synthetic miRNAs. This is ideal for synthetic miRNAs since the effects seen following transfection will be specific to the activity of the active strand of the synthetic miRNA. Furthermore, the high efficacy of the 5' modified designs will allow lower concentrations to be used for transfections and reduce toxicity that is often observed when transfecting cells with higher amounts of nucleic acid.

**[0301]** To confirm that the 5' amino modification is superior to the standard siRNA design for a broad set of synthetic miRNAs, the effectiveness of both synthetic miRNA designs was measured in cells co-transfected with reporter vectors with miRNA target sites. As seen in FIG. 4, the 5' NH<sub>2</sub> is reproducibly superior to the unmodified siRNA design.

#### **EXAMPLE 5:**

##### **Effectiveness of chemically internally modified synthetic miRNAs**

**[0302]** The siRNA design was also used to test the effects of chemical modifications at internal domains within the complementary strand. For these studies, 2'-O-Me modifications were placed at various locations along the length of the complementary strand. Below is provided an example of a series of synthetic miRNAs with chemically modified complementary strands.

miRNA Strand - 5'-UAU ACA AGA GAU GAA AUC CUC-3' (SEQ ID NO:676)

Complementary Strands -

Position 1 - 5'-**GGA** UUU CAU CUC UUG UAU AUt-3'  
 Position 2 - 5'-GGA **UUU** CAU CUC UUG UAU AUt-3'  
 Position 3 - 5'-GGA UUU **CAU** CUC UUG UAU AUt-3'  
 Position 4 - 5'-GGA UUU CAU **CUC** UUG UAU AUt-3'  
 Position 5 - 5'-GGA UUU CAU CUC **UUG** UAU AUt-3'  
 Position 6 - 5'-GGA UUU CAU CUC UUG **UAU** AUt-3'  
 Note - Positions that are 2'-O-Me are denoted in bold.

**[0303]** Synthetic miRNAs with the designs described above were tested for miRNA and complementary strand activity. Interestingly, complementary strand modifications at positions 1 and 5 significantly reduced complementary strand activity without altering the activity of the miRNA strand (FIG. 3).

#### EXAMPLE 6:

##### Synthetic miRNA library screen for miRNAs that influence cell proliferation

**[0304]** A hallmark of cancer is uncontrolled cell proliferation; cell proliferation assays are commonly used by researchers to study the influence of genes in oncogenesis. A cell proliferation assay was used in conjunction with the miRNA inhibitor library to identify miRNAs that influence cell proliferation.

**[0305]** The inventors transfected HeLa cells in triplicate with fifteen different synthetic miRNAs using siPORT NeoFX (Ambion) according to the manufacturer's instructions (FIG. 6). Transfected HeLa cells were analyzed using Alamar Blue (BioSource International, Inc., CA) at 24 hr intervals. Alamar Blue is a compound, that when reduced by cellular metabolism, changes from a non-fluorescent blue color to a fluorescent red form that is easily quantified. The amount of Alamar Blue reduced is directly proportional to the cell number, providing a rapid method for assessing cell proliferation. To perform the assay, the Alamar Blue reagent was added into the tissue culture media at a 10% final concentration. The mixture was incubated for 3-6 hr in growth conditions after which fluorescence was quantified using a Spectra Max™ GeminiXS™ (Molecular Devices, Sunnyvale, CA). Cells transfected with synthetic miR-124 and miR-106 exhibited significantly lower proliferation than negative control-transfected samples, as well as samples transfected with the other synthetic miRNAs.

#### EXAMPLE 7:

##### MiRNA inhibitor library screen for miRNAs that influence cell proliferation

**[0306]** A hallmark of cancer is uncontrolled cell proliferation. Cell proliferation assays are commonly used by researchers to study the influence of genes in oncogenesis. A cell proliferation assay was used in conjunction with our miRNA inhibitor library to identify miRNAs that influence cell proliferation.

**[0307]** Cells were transfected with a library of over 90 miRNA inhibitors to identify miRNAs that are involved in cell growth. HeLa cells (8000 cells/well of 96 well plate) were transfected in triplicate with 5 pmoles of miRNA inhibitors using siPORT™ NeoFX™ (Ambion). The media was changed 24 hrs after transfection. 72 hours post-transfection, we fixed cells with 4% paraformaldehyde, permeabilized with 0.1% TritonX 100, and stained with propidium iodide to look at total cell number. The plates were scanned using the TTP labtech Acumen Explorer. Cell number was plotted relative to cells transfected with a negative control miRNA inhibitor (FIG. 7). The red horizontal bars bracket normal variation in cell proliferation (20% variation). Insets: Specific miRNA inhibitors that either increased cell proliferation (left arrow) or did not affect cell proliferation (right arrow) were used in a second round of screening. HeLa cells were transfected with these miRNA inhibitors and cells were fixed and stained with anti b-actin antibody and DAPI to visualize cell morphology changes in response to specific miRNA function. Cells transfected with the miRNA inhibitor that increased cell proliferation show marked alteration in cell morphology (left inset) vs. normal morphology (right inset).

**[0308]** A group of nine miRNA inhibitors were identified that caused significant decreases (miR 31, 150, 187, 125a, 190, 191, 193, 204 and 218) in cell growth and two miRNA inhibitors that caused a significant increase (miR 24 and miR 21) in cell growth following transfection into HeLa cells (Table 4). MiRNA-31 inhibition also caused a distinct cellular morphology. A relative cut off of 20% above and below 100% was chosen as genes that were considered significantly changed. These results demonstrate the ability of individual human miRNAs to regulate important cellular processes. Furthermore, the diversity of the observed effects demonstrates the potential complexity of cellular outcomes of miRNA-mediated regulation of gene expression.

**Table 4. MiRNAs that affect cell proliferation  
Relative Impact on Cell**

miRNA	Proliferation
miR-31	Up regulation
miR-150	Up regulation
miR-187	Up regulation
miR-125a	Up regulation
miR-190	Up regulation
miR-191	Up regulation
miR-193	Up regulation
miR-204	Up regulation
miR218	Up regulation
miR-21	Down regulation
miR-24	Down regulation

**EXAMPLE 8:****Synthetic miRNA library screen for miRNAs that influence apoptosis**

**[0309]** Many diseases including cancer are characterized by an inability to institute programmed cell death, or apoptosis. A caspase 3/7 activity assay was used in conjunction with a library of synthetic miRNAs to identify miRNAs that are involved in regulating apoptosis.

**[0310]** A library of eighteen synthetic miRNAs was used to transfect A549 cells (8000 cells/well of 96 well plate) in triplicate using siPORT™ NeoFX™ (Ambion). Media was changed after 24 hrs and cells were visually inspected under a microscope to qualitatively inspect cell death 72 hours after transfection. The cells were measured for apoptosis by measuring caspase 3 activity as follows: 1) Cells were washed once with PBS and frozen at -80°C. 2) Cells were lysed by adding 40 µl of cold lysis buffer (50 mM HEPES pH 7.2, 40 mM NaCl, 0.5% NP40, 0.5 mM EDTA) to the wells and incubated for 20 min at 4°C. 3) Add 160 µl ICE buffer (50 mM HEPES pH 7.4, 0.1% CHAPS, 0.1 mM EDTA, 10% sucrose) + 5 mM DTT containing 20 µM DEVDafc substrate. 4) Measure fluorescence increase in one hour at 400 ex, 505 em.

**[0311]** Cells transfected with miR-1-2 and miR-33 synthetic miRNAs exhibited reduced caspase 3/7 activity and cells transfected with miR-20 exhibited much higher levels of apoptosis. These three miRNAs likely regulate genes that are involved in controlling apoptosis.

**EXAMPLE 9:****Screen for miRNAs that influence cell viability**

**[0312]** miRNA inhibitors were also used to identify miRNAs that influence cell viability. A library of over 90 miRNA inhibitors was used to transfect A549 cells (8000 cells/well of 96 well plate) in triplicate using siPORT™ NeoFX™ (Ambion). Media was changed after 24 hrs and cells were visually inspected under a microscope to qualitatively inspect cell death 72 hours after transfection. Cells were trypsinized and stained with ViaCount Flex Reagent, which distinguishes between viable and non-viable cells based on permeability of the DNA binding dyes in the reagent. Cells were analyzed using the Guava PCA-96 (Personal Cell Analysis).

**[0313]** Twenty-one miRNA inhibitors induced a significantly different ratio of live to dead cells than did the negative control miRNA inhibitor (FIG 8). Twelve reduced cell viability and nine increased cell viability (Table 5). Interestingly, there was little overlap in the miRNAs that affected cell viability in A549 cells and those that affected cell proliferation in HeLa cells, suggesting that different cells respond differently to have reduced miRNA activities or cell viability and cell proliferation are not affected by the same cellular pathways.

**Table 5. MiRNAs that affect cell viability**

miRNA	Relative Impact on Cell Viability
miR-7	Down
miR-19a	Down

(continued)

	miRNA	Relative Impact on Cell Viability
	miR-23	Down
5	miR-24	Down
	miR-27a	Down
	miR-31	Down
	miR-32	Down
10	miR-134	Down
	miR-140	Down
	miR-150	Down
	miR-192	Down
	miR-193	Down
15	miR-107	Up
	miR-133	Up
	miR-137	Up
	miR-152	Up
20	miR-155	Up
	miR-181a	Up
	miR-191	Up
	miR-203	Up
25	miR-215	Up

**EXAMPLE 10:****Screen for miRNAs That Influence Apoptosis**

30 **[0314]** Apoptosis is a natural cellular process that helps control cancer by inducing death in cells with oncogenic potential. Many oncogenes function by altering induction of apoptosis. To identify miRNAs that participate in apoptosis, an apoptosis assay was used with the miRNA inhibitor library.

35 **[0315]** Using a library of over 90 miRNA inhibitors, we screened for miRNAs that affect apoptosis. HeLa cells (8000 cells/well of 96 well plate) were transfected in triplicate with miRNA inhibitors (5 pmoles) using Ambion siPORT™ NeoFX™. The media was changed 24 hrs after transfection and processed cells 72 hours after transfection. The cells were measured for apoptosis by measuring caspase 3 activity as follows: 1) Cells were washed once with PBS and frozen at -80°C. 2) Cells were lysed by adding 40 µl of cold lysis buffer (50 mM HEPES pH 7.2, 40 mM NaCl, 0.5% NP40, 0.5 mM EDTA) to the wells and incubated for 20 min at 4°C. 3) Add 160 µl ICE buffer (50 mM HEPES pH 7.4, 0.1% CHAPS, 0.1 mM EDTA, 10% sucrose) + 5 mM DTT containing 20 µM DEVDafc substrate. 4) Measure fluorescence increase in one hour at 400 ex, 505 em.

40 **[0316]** Samples were also analyzed for cell number using a general esterase assay to normalize the caspase 3 results. FDA substrate (0.4 mg/ml fluorescein diacetate (FDA) in acetonitrile) was diluted 1:19 into dilution buffer (40 mM TrisCl pH 7.5, 20 mM NaCl, 0.5% NP-40, 0.02 mg/ml final conc). 40 µl buffer (40 mM TrisCl pH 7.5, 0.5% NP-40) was added to each sample well. Samples were incubated 10 min on ice. 160 µl of diluted FDA substrate was added to each well. 45 Fluorescence was measured for 30 min at 37°C (ex = 488, em = 529). The slope of fluorescence increase over time is a function of the cell number in the plate.

**[0317]** Normalized screening data are displayed in FIG. 9. miRNAs that affect apoptosis are listed in Table 6.

**Table 6. MiRNAs that affect apoptosis**  
**Relative Impact on Cell**

	miRNA	Proliferation
	miR-31	Down
	miR-214	Down
55	miR-7	Up
	miR-1-2	Up
	miR-148	Up

(continued)

**Relative Impact on Cell**

	<b>miRNA</b>	<b>Proliferation</b>
5	miR-195	Up
	miR-196	Up
	miR-199a	Up
	miR-204	Up
10	miR-210	Up
	miR-211	Up
	miR-212	Up
	miR-215	Up
	miR-216	Up
15	miR-218	Up
	miR-296	Up
	miR-321	Up

**EXAMPLE 11:****Expression Analyses Using Synthetic RNAs**

[0318] In addition to using phenotypic assays to identify miRNAs that influence gross cellular processes or cellular pathways, collections of synthetic miRNAs and/or miRNA inhibitors can be used to identify miRNAs that directly regulate the expression of a gene. A plasmid was created that had a luciferase gene immediately upstream of the 3'UTR of the G6PD gene. A549 cells were co-transfected with the reporter vector and eighteen different synthetic miRNAs. 24 hours post-transfection, luciferase activity in the various cell populations was measured. Interestingly, the miR-1-2 significantly reduced the expression of the luciferase/G6PD gene, indicating that this family of miRNAs regulates the expression of the G6PD gene. Similar experiments can be used to identify miRNAs that regulate the expression of such important genes as p53, BRCA1 and BRCA2, RAS, MYC, BCL-2, and others.

**EXAMPLE 12:****Oncogenic miRNAs-Differential Expression and Cancer Regulation**

[0319] As noted in previous examples, a number of miRNAs have been identified that are differentially expressed between tumor and normal adjacent tissue samples from the same cancer patients. Interestingly, there is significant overlap in the miRNAs that are differentially expressed between different cancers, suggesting there is a core set of miRNAs that influence cellular processes that when altered, lead to cancer. The following describes experiments aimed at developing a link between miRNA mis-regulation and cancer.

*miRNA Expression in Lung Cancer*

[0320] Twenty-two tumor and normal adjacent tissue (NAT) samples from lung cancer patients were analyzed using the miRNA array system described above. The arrays were analyzed and the relative expression of each miRNA was compared between the tumor and normal adjacent tissues from each patient. The various miRNAs were clustered based on their relative expression in tumors across different patients (FIG. 14). Six miRNAs (miR-126, 30a, 143, 145, 188, and 331) were expressed at significantly lower levels in the tumors of more than 70% of the patients. Two miRNAs (miR-21 and 200b) were expressed at significantly higher levels in the tumors of more than 70% of the patients. The differential expression of a number of these miRNAs was verified by Northern analysis (FIG. 15).

*miRNA Expression in Colon Cancer*

[0321] Twenty-five tumor and NAT samples from colon cancer patients were analyzed using our miRNA array process. Like the lung cancer comparisons, the various miRNAs were clustered based on their relative expression in tumors across the different colon cancer patients (FIG. 14). Five miRNAs (miR-143, 145, 195, 130a, and miR-331) were expressed at significantly lower levels in the tumors of more than 70% of the patients. Five miRNAs (miR-223, 21, 31, 17,

and 106) were expressed at significantly higher levels in the tumors of more than 70% of the patients.

#### miRNAs as Cancer Markers

5 **[0322]** It is interesting that eight different miRNAs were differentially expressed between the tumor and normal adjacent samples for most of the lung and colon patient samples that we analyzed (FIG. 16). These same miRNAs were also found to be differentially expressed in the breast, thymus, bladder, pancreatic, and prostate cancer patients that we analyzed, suggesting that these miRNAs might control cellular processes that when altered lead to cancer.

#### 10 miRNAs as Regulators of Oncogene Expression

**[0323]** To address whether specific miRNAs might be participating in cancer through the mis-regulation of oncogenes, we scanned the 3' untranslated regions (UTRs) of 150 well-known oncogenes for sequences with significant homology to the miRNAs identified in our microarray analysis. Potential target sites were selected based on two criteria:

15 (1) *Perfect complementarity between positions 2-9 of the miRNA and the oncogene.* This miRNA core sequence has been identified as critical to the activities of miRNAs and the known miRNA target sites have essentially 100% complementarity at this site (Doench *et al.* 2004).

20 (2) *Overall  $T_m$  of the miRNA/mRNA interaction.* In addition to the core sequence, overall binding stability between miRNAs and mRNAs has been shown to be an important indicator of miRNA activity (Doench *et al.*, 2004).

**[0324]** As seen in Table 8, potential target sites in the 3'UTRs of known oncogenes were identified for all of the miRNAs that were observed to be routinely differentially expressed in tumor samples. Interestingly, KRAS2, MYCL1, and CBL have multiple predicted miRNA binding sites which could provide the cooperative miRNA binding that has been implicated as an important factor in miRNA regulation (Doench *et al.* 2003); Zeng *et al.*, 2003). Many of the genes listed in Table 8 become oncogenic when they are over-expressed, thus it is conceivable that reduced expression of a miRNA could lead to up-regulation of one or more oncogenes and subsequently lead to oncogenesis.

**Table 8: Cancer-related miRNAs and their putative oncogene targets**

miRNA	Predicted Gene Target
let-7	RAS
let-7	C-MYC
miR-21	mutS homolog 2 (MSH2)
35 miR-21	v-ski sarcoma viral oncogene homolog (avian) (SKI)
miR-143	breakpoint cluster region (BCR)
miR-143	MCF.2 cell line derived transforming sequence (MCF2)
miR-143	von Hippel-Lindau tumor suppressor (VHL)
40 miR-143	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog (KRAS2)
miR-143	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog (KRAS2)
miR-143	Cas-Br-M (murine) ecotropic retroviral transforming sequence (CBL)
miR-143	Cas-Br-M (murine) ecotropic retroviral transforming sequence (CBL)
45 miR-145	v-myc myelocytomatosis viral related oncogene (MYCN)
miR-145	fibroblast growth factor receptor 2 (FGFR2)
miR-145	Cas-Br-M (murine) ecotropic retroviral transforming sequence (CBL)
miR-188	v-myc myelocytomatosis viral oncogene homolog 1 (MYCL1)
miR-200b	cadherin 13 (CDH13)
50 miR-200b	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT)
miR-219	v-myc myelocytomatosis viral oncogene homolog 1 (MYCL1)
miR-219	B-cell CLL/lymphoma 2 (BCL2)
miR-219	cadherin 1, type 1, E-cadherin (epithelial) (CDH1)
miR-331	vav 1 oncogene (VAV1)
55 miR-331	fibroblast growth factor receptor 1 (FGFR1)
miR-331	BCL2-antagonist/killer 1 (BAK1)
miR-331	retinoic acid receptor, alpha (RARA)

(continued)

miRNA	Predicted Gene Target
miR-331	v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC)

5

**EXAMPLE 13:****Measuring the Effect of miRNAs on Oncogene Expression**

10 **[0325]** Confirming miRNA target site predictions can be done in a variety of ways. In *Drosophila* and *C. elegans*, genetic approaches have been applied wherein mutations in the miRNA and the putative miRNA target site(s) are made and shown to result in similar phenotypes (Ha *et al.*, 1996; Vella *et al.*, 2004). In mammalian cells, where genetic approaches are far more difficult, reporter constructs have been used to show that the 3' UTRs of putative target genes are regulated in cells at levels that are disproportionate to reporter vector controls that contain mutations in the putative miRNA binding sites (Lewis *et al.* 2003). In addition, vectors and oligonucleotides have been used to introduce or inhibit miRNAs in cells to determine the effects on endogenous levels of putative target genes (Lewis *et al.*, 2003; Kiriakidou *et al.* 2004). The latter approach has been undertaken to validate the miRNA target site predictions.

15 **[0326]** Synthetic miRNAs and miRNA inhibitors have been developed that can be transfected into mammalian cells to either introduce miRNAs into cells or inhibit the activity of miRNAs in cells, respectively. See USN 60/627,171, which is hereby incorporated by reference. A synthetic miRNA and a miRNA inhibitor corresponding to let-7b were used to determine if the target site predictions were correct. In these experiments, cultured cells that express undetectable levels of the miRNA were transfected with the synthetic miRNA using siPORT™ NeoFX™ Transfection Agent (Ambion). Immunofluorescence assays were used to RAS and C-MYC in the transfected cells. The proteins from both oncogenes were expressed at almost three-fold lower levels in cells transfected with the synthetic miRNA than cells transfected with a Negative Control miRNA (Ambion). In a reciprocal experiment, cells that naturally express high levels of the miRNA were transfected with the let-7 miRNA inhibitor. As expected, the proteins from both oncogenes were higher in cells transfected with the miRNA inhibitor than in cells transfected with the Negative Control inhibitor (Ambion). These results are consistent with the model that the miRNA regulates the expression of the two oncogenes. These data suggest that mis-regulation of a key miRNA could participate in cancer progression by failing to regulate the expression of one or more oncogenes.

30

**EXAMPLE 14:****miRNAs in Lupus**

35

**[0327]** Systemic lupus erythematosus (SLE; Lupus) is a chronic inflammatory auto-immune disease that ultimately leads to immune complex-mediated end-organ failure. It is characterized by an over activation of CD4+ T helper cells and repression of CD8+ T cytotoxic activity, leading to an overproduction of natural antibodies and pathogenic autoantibodies. Recently several histone modifications were reported in peripheral blood mononuclear cells (PBMCs) isolated from lupus patients. Diagnosis of lupus is still frequently incorrect mainly because the symptoms vary so widely and they come and go frequently, and because the disease mimics so many other disorders. Furthermore, diagnosis does not indicate the particular therapy to be used. In the absence of a cure, present-day treatment of lupus is still primarily tailored to symptomatic relief and not to the diagnosis. A diagnostic assay with high specificity and sensitivity would be very important.

40

45 **[0328]** Samples were analyzed from 16 individuals, 8 with clinically verified lupus and 8 non-lupus patients that were age- and gender-matched with the lupus patients. Total RNA from these samples was isolated using the glass fiber filter method described above. The total RNA was fractionated by tube electrophoresis to recover the miRNAs. The miRNAs were fluorescently labeled with Cy3 or Cy5 using the two-step fluorescent labeling process described above. The labeled miRNAs were hybridized to miRNA probes arrayed on glass slides as described above. The signal from the hybridized miRNAs was quantified using a GenePix 4000B Scanner (Axon) and the lupus and normal sample signals were compared to identify differentially expressed miRNAs. Each array experiment included duplicate arrays.

50

55 **[0329]** Fourteen miRNAs were differentially expressed in all of the lupus samples relative to the matched samples. miR-301, miR-199, miR-95, miR-105, mu-miR-290, miR-215, miR-188, miR-186, miR-211, miR-331, and miR-137 were expressed at 50% or less in the lupus samples than the corresponding normal samples. miR-21, miR-223, and miR-342 were expressed at 50% or greater in the lupus samples than the corresponding normal samples. Several of the miRNAs were differentially expressed by as much as tenfold between the lupus and normal samples. These miRNAs represent targets for diagnostic assay of therapeutic development.

**EXAMPLE 15:****miRNAs and Prion Diseases**

5 **[0330]** Novel infectious particles, termed prions, composed largely and perhaps solely of a single protein, are the likely causative agents of a group of transmissible spongiform encephalopathies that produce lethal decline of cognitive and motor function. Evidence indicates that the responsible protein arrives at a pathogenic state by misfolding from a normal form that has ubiquitous tissue distribution.

10 **[0331]** Using two cell-based prion model systems, the identification of miRNAs that might be associated with the process was pursued. One model system comprises two cell lines, one of which is susceptible to prion formation and one that is not. The second model system involves cells before and after they have been infected with prions. Total RNA from prion-sensitive cells, prion-insensitive cells, and prion-infected cells was isolated using the glass fiber filter method described above. The total RNA was fractionated by tube electrophoresis to recover the miRNAs. The miRNAs were fluorescently labeled with Cy3 or Cy5 using the two-step fluorescent labeling process described above. The labeled  
15 miRNAs were hybridized to miRNA probes arrayed on glass slides as described above. The signal from the hybridized miRNAs was quantified using a GenePix 4000B Scanner (Axon) and the signal from each of the samples was compared to identify differentially expressed miRNAs.

20 **[0332]** As seen in FIG. 13, ten miRNAs were significantly up- or down-regulated in both prion-sensitive and prion-infected cells relative to prion resistant, uninfected cells. Arrays on multiple biological replicates for both model systems have confirmed these results. Based on their expression profiles, miR-95, 135a, 7, 9, 27a, 130a, 16, 26a, and 24 likely are involved directly or indirectly in prion infection and might represent diagnostic or therapeutic targets for prion disease.

**EXAMPLE 16:****Stroke-Associated miRNAs**

25 **[0333]** Stroke is a major cause of death and permanent disability in humans. They occur when blood flow to a region of the brain is obstructed and may result in death of brain tissue. There are two main types of stroke: ischemic and hemorrhagic. Ischemic stroke is caused by blockage in an artery that supplies blood to the brain, resulting in a deficiency  
30 in blood flow (ischemia). Hemorrhagic stroke is caused by the bleeding of ruptured blood vessels (hemorrhage) in the brain. Understanding miRNAs involved in stroke might enhance detection and/or treatment.

35 **[0334]** A stroke model system was used wherein mice are "preconditioned" by reducing oxygen flow to the brain (Kitagawa 1991). An equivalent set of six mice were used; three were preconditioned and three were untreated. 24 hours after pre-conditioning, the mice were sacrificed. Total RNA from these samples was isolated using the glass fiber filter method described above. The total RNA was fractionated by tube electrophoresis to recover the miRNAs. The miRNAs were fluorescently labeled with Cy3 or Cy5 using the two-step fluorescent labeling process described above. The labeled  
40 miRNAs were hybridized to miRNA probes arrayed on glass slides as described above. The signal from the hybridized miRNAs was quantified using a GenePix 4000B Scanner (Axon) and the preconditioned and normal sample signals were compared to identify differentially expressed miRNAs.

45 **[0335]** Analysis of the miRNA profiles of the preconditioned animals (labeled P1, P2, and P4) revealed 10 miRNAs that were expressed at significantly different levels in all three pre-conditioned animals relative to the three non-treated animals (FIG. 14). These miRNAs resulted from ischemic pre-conditioning and represent potential targets for stroke diagnosis, prevention, or treatment.

**EXAMPLE 16:****Synthetic miRNA Library Screens for miRNAs That Influence Cell Proliferation and Cell Viability in Various Cell Types**

50 **[0336]** A hallmark of cancer is uncontrolled cell proliferation; cell proliferation assays are commonly used by researchers to study the influence of genes in oncogenesis. A cell proliferation assay was used in conjunction with the miRNA inhibitor library to identify miRNAs that influence cell proliferation.

55 HeLa (human ovarian cancer) and A549 (human lung cancer) cells were transfected in triplicate with 150 synthetic miRNAs using siPORT NeoFX (Ambion) according to the manufacturer's instructions. The 150 are as follows: Let-7a, Let-7b, Let-7c, Let-7d, Let-7g, mir-1, mir-7, mir-9, mir-10a, mir-10b, mir-15a, mir-16, mir-18, mir-19a, mir-17-3p, mir-20, mir-21, mir-22, mir-23a, mir-23b, mir-24, mir-25, mir-26a, mir-27a, mir-28, mir-29a, mir-31, mir-32, mir-30a-3p, mir-34a, mir-92, mir-95, mir-96, mir-98, mir-99a, mir-100, mir-101, mir-103, mir-105, mir-107, mir-108, mir-122, mir-124, mir-125a, mir-125b, mir-126, mir-128, mir-129, mir-132, mir-133A, mir-133B, mir-134, mir-135, mir-136, mir-137, mir-139, mir-140,

mir-141, mir-142, mir-143, mir-144, mir-145, mir-146, mir-147, mir-148, mir-149, mir-150, mir-151, mir-152, mir-153, mir-155, mir-181a, mir-182, mir-183, mir-184, mir-186, mir-187, mir-188, mir-190, mir-191, mir-192, mir-193, mir-194, mir-195, mir-196, mir-197, mir-198, mir-199, mir-201, mir-203, mir-204, mir-205, mir-206, mir-207, mir-208, mir-210, mir-211, mir-212, mir-214, mir-215, mir-216, mir-217, mir-218, mir-219, mir-220, mir-221, mir-223, mir-224, mir-299, mir-301, mir-302, mir-320, mir-322, mir-323, mir-325, mir-324-3p, mir-328, mir-330, mir-331, mir-335, mir-337, mir-338, mir-339, mir-340, mir-345, mir-346, mir-367, mir-368, mir-369, mir-370, mir-371, mir-372, mir-373, mir-374, mu-mir-290, mu-mir-291, mu-mir-292-3p, mu-mir-293, mu-mir-294, mu-mir-295, mu-mir-297, mu-mir-298, mu-mir-329, mu-mir-341, mu-mir-344, mu-mir-351, mu-mir-376b, mu-mir-380-3p, mu-mir-409, mu-mir-411, mu-mir-412

**[0337]** The synthetic miRNAs were double stranded nucleic acid molecules composed of an active strand and a complementary strand. The active strand contained a sequence that was identical to the corresponding mature miRNA. The complementary strand contained a sequence that was 100% complementary to the relevant region of the mature miRNA sequence, but 1) lacking two nucleotides on its 3' end that were complementary to the mature miRNA sequence (at the 5' end of the active strand) and 2) having a dinucleotide overhang on its 5' end with respect to the active strand. In other words, the two strands were fully complementary to the other's sequence except that each strand has a dinucleotide 5' overhang with respect to the other strand. The same kind of synthetic miRNAs were used for Examples 17-20 as well. Any exceptions are described below. The miRNAs indicated in the tables identify the miRNA that corresponds to the provided synthetic sequence.

**[0338]** Jurkat cells (human leukemia cell) and primary human T-cells in triplicate were electroporated with the same set of synthetic miRNAs using siPorter-96 (Ambion) according to the manufacturer's instruction. All cells were analyzed for viable and non-viable cells 72 hours post-transfection using the PCA-96 (Guava) with the Viacount Assay. Viable cell number is the number of live cells in a well at the point of the assay. The numbers provided in the tables below are equal to the average number of viable cells in wells transfected with a particular miRNA divided by the number of viable cells in wells transfected with negative control synthetic miRNAs multiplied by 100 to yield the % Cell Viability of miRNA-transfected cells relative to negative control transfected cells.

**[0339]** Significance was assigned based on the average values of the negative control transfected samples. miRNAs that were significantly different than the negative controls were qualified as "significant" based on being at least two standard deviations above or below the negative control data.

**[0340]** The sequence ifmiRNA-325 is 5'- ccuaguagguguccaguaagugu-3'.

**TABLE 9**  
**miRNAs That Significantly Reduce Cell Viability of HeLa Cells**

	% Viability	std dev
mir-345	75	5.9
mir-346	77.8	8.2
mir-193	79.6	14.7
mir-206	79.6	6.5
mir-337	80.8	3.1
mmu-mir-293	82.6	1.7
mir-299	84.0	4.0
mmu-mir-329	84.5	4.5
mmu-mir-409	86	2.8
mmu-mir-292-3p	86.2	2.8
mir-210	86.4	5.1
mmu-mir-344	86.4	5.3
mmu-mir-298	86.7	4.2
mir-208	87.4	4.5
mir-197	87.6	7.5
mir-217	87.9	3.5
mir-1	88.2	9.0
mir-124	88.8	4.2

**TABLE 10**  
**miRNAs That Significantly Reduce Viable Cell Number of HeLa Cells**

		<b>Total Cell</b>	<b>std dev</b>
5	Let-7b	16.2	8.1
	Let-7g	22.7	8.2
	Let-7c	24.1	7.2
	mir-124	24.5	3.4
10	Let-7a	25.4	1.2
	Let-7d	37.3	2.3
	mir-337	37.5	16.9
	mir-1	38.7	2.2
	miR-299	38.9	4.2
15	mir-34a	40.5	13.3
	mmu-mir-292	41.2	8.3
	mir-122	41.2	6.5
	mir-346	41.9	4.3
20	mir-101	43.4	6.4
	mir-210	47.1	8.4
	mir-147	47.7	8.2
	mir-98	50.6	2.6
	mir-345	51.8	6.8
25	miR-92	52.4	6.8
	miR-96	53.2	0.9
	mir-7	54.0	5.3
	mir-133b	55.9	3.1
	mir-206	56.0	12.4
30	mmu-mir-297	56.0	5.7
	mir-19a	57.2	20.6
	mmu-mir-344	57.5	14.1
	mir-205	58.9	18.7
35	mir-208	60.5	11.1

**TABLE 11**  
**miRNAs That Significantly Increase Viable Cell Number of HeLa Cells**

		<b>Total Cell</b>	<b>Std dev</b>
40	mir-32	142.9	25.4
	mu-miR-290	143.5	17.6
	mir-212	143.5	10.4
45	mir-92	144.7	16.8
	mir-323	147.3	25.9
	mir-145	148.1	22.2
	mir-324	148.2	9.0
	mir-198	152.1	67.8
50	mir-27a	156.2	13.4
	mir-369	158.4	27.3
	mir-31	159.3	16.1
	mir-335	161.7	20.8
55	mmu-mir-351	162.3	6.9
	mir-370	164.3	4.5
	mir-325	169.6	19.8

(continued)

**miRNAs That Significantly Increase Viable Cell Number of HeLa Cells**

	<b>Total Cell</b>	<b>Std dev</b>
5 mir-331	172.5	24.0
mir-139	181.3	11.2

**TABLE 12****miRNAs That Significantly Reduce Cell Viability of A549 Cells**

	<b>% Viability</b>	<b>St dev</b>
15 mir-193	92.4	2.5
mir-224	92.5	1.4
mir-96	92.6	0.1
mir-346	93.9	1.6
mmu-mir-293	94.9	0.7
mir-34a	95	0.2
20 mir-216	95.1	1.0
mmu-mir-380	95.2	0.8
mir-182	95.6	0.8
mir-301	95.6	1.0
mmu-mir-344	95.8	0.2
25 mmu-mir-409	95.8	0.6
mir-369	95.9	0.7

**TABLE 13****miRNAs That Significantly Reduce Viable Cell Number in A549 Cells**

	<b>Cell Number</b>	<b>St Dev</b>
35 mir-124	44.3	2.2
mir-16	52.9	1.3
mir-337	54.7	7.0
mir-195	59.3	6.7
mir-34a	60.8	2.1
mir-15a	60.9	3.7
40 mir-28	61.3	0.8
Let-7g	61.9	0.8
mmu-mir-292	62.2	2.3
mmu-mir-344	62.6	9.1
45 mir-7	62.9	4.6
mir-193	63.7	3.3
mir-137	63.9	1.3
mir-147	64.8	0.5
mir-29a	67.0	3.8
50 mir-129	67.2	3.3
mir-22	67.5	3.4
mir-126	68.0	2.6
mir-345	69.2	7.4
55 mir-192	69.5	5.9
Let-7b	70.2	2.2
Let-7d	70.5	2.7
mir-346	70.9	7.1

**TABLE 14**  
**miRNAs That Significantly Increase Viable Cell Number in A549**

	<b>Total cell</b>	<b>Std dev</b>	
5	mir-373	110.4	7.9
	mir-25	111.8	6.0
	mmu-mir-294	112.1	5.9
10	mir-32	120.8	4.3
	mir-92	122.4	4.0

**TABLE 15**  
**miRNAs That Significantly Reduce Cell Viability of Jurkats Cells**

	<b>% Viability</b>	<b>St Dev</b>	
	let-7a	20.54	0.70
	miR-10b	35.98	2.92
20	let-7b	48.79	5.08
	miR-17-3p	61.55	15.63
	miR-30a-3p	64.36	26.60
	miR-34a	65.45	20.44
25	miR-122	65.63	17.80
	miR-29a	66.44	7.14
	miR-101	67.44	29.56
	miR-133a	71.51	17.82
	miR-19a	71.77	23.79
30	miR-32	75.59	11.69
	miR-1	75.74	12.92
	miR-132	76.32	16.22
	miR-28	77.07	16.58
	miR-20	77.60	15.23
35	miR-134	78.96	1.75

**TABLE 16**  
**miRNAs That Significantly Increase Cell Viability in Jurkat Cells**

	<b>Total cell</b>	<b>Std dev</b>	
40	miR-181-a	122.77	22.40
	miR-9	124.63	9.98
	miR-141	126.08	24.03
45	miR-98	126.24	11.90
	miR-10a	126.86	8.93
	miR-125b	128.71	3.50
	miR-126	130.69	18.20
50	miR-100	130.77	14.60
	miR-23b	132.18	3.50
	miR-140	135.73	4.08
	miR-155	142.57	22.40
	miR-15a	143.01	11.29
55	miR-129	146.94	9.92
	miR-25	150.25	17.85
	miR-143	158.74	1.86

(continued)

**miRNAs That Significantly Increase Cell Viability in Jurkat Cells**

	Total cell	Std dev
5 miR-26a	166.09	13.65

**TABLE 17****miRNAs that Significantly Reduce Cell Viability in Primary T-Cells**

	% Viability	St Dev
miR-184	61.04	12.16
miR-145	68.98	11.23
15 miR-186	69.64	6.99
miR-139	69.85	0.29
miR-134	71.90	22.42
miR-190	75.59	2.43
miR-144	77.13	4.18
20 miR-183	77.71	2.86
miR-147	78.09	0.33
miR-140	78.70	5.81
miR-155	79.26	10.68

**TABLE 18****miRNAs that Significantly Increase Cell Viability of Primary T-Cells**

	% Viability	St Dev
30 miR-126	120.81	40.08
miR-10b	121.28	18.86
miR-17	122.46	3.71
miR-10a	124.11	9.46
35 miR-20	124.75	13.60
let-7c	124.81	4.00
miR-125a	125.66	5.13
miR-15a	129.07	10.96
let-7b	130.11	13.48
40 let-7a	130.88	16.16
miR-18	131.73	1.75

**[0341]** It is interesting to note that the miRNAs that affect one cell type often fail to affect other cell types. This is likely due to the fact that the cellular processes that are active vary between different cell types. This can be vitally important when considering the potential of miRNA-based therapeutics. Abnormal (disease) cells are different from normal cells owing to the fact that different cellular processes are active in the two cell types. Identifying miRNAs that have differential effects on normal and abnormal cells would be ideal since they could be delivered globally and expected to have an effect on only disease cells. When the cell viability data were compared for the leukemia (cancerous T-cell) cells and primary T-cells, it was noted that let-7a, let-7b, and miR-10b all significantly reduce the percentage of viable cells in the leukemia cells while essentially having no effect on the corresponding normal T-cells. These miRNAs are candidates for leukemia drugs.

**EXAMPLE 17****Synthetic miRNA library screen for miRNAs that influence ERK activation**

**[0342]** In order for cancer cells to proliferate they must subvert both the machinery that controls the cell division cycle

and the process of programmed cell death (apoptosis). This is frequently achieved by mutation of specific proto-oncogenes such as *Ras* or tumor suppressors such as *p53*. The Ras-family of membrane associated GTPases transmit signals into the interior of the cell by the activation of a number of cytosolic signal transduction pathways such as the Raf>MEK>ERK MAP kinase signaling pathway. Disregulation of the Ras/Raf/MEK/ERK pathway plays a major role in cancer pathogenesis (Meijer).

**[03443]** To identify miRNAs that affect ERK activation, HeLa cells were transfected in a 96-well plate format with 150 different synthetic miRNAs. Prior to transfection, the HeLa cells were trypsinized to remove adherent cells and diluted in normal growth medium to 10<sup>5</sup> cells/mL. 0.5 µl of siPort NeoFX in 9.5 µl of Optimem I medium was added to the cells and incubated for 10 minutes at room temp (10 µL for each sample). miRNAs were rehydrated with 10 µl of diluted siPORT NeoFX. The samples were incubated at 37 °C and then the transfected samples were evaluated 72 hours after transfection.

**[03444]** The controls for ERK activation were performed by depriving the wells of a phosphate source for detection of ERK phosphorylation. 100 µl of serum-free media (DMEM) to 37°C was added per well and the cells were incubated for 4 hours at 37 °C to attain basal phosphorylation levels. For the positive control wells, serum-free media was aspirated from wells and 100 µL of 100 ng/mL EGF was added before incubating the cells for 7.5 minutes at 37 °C.

**[03445]** Media from all wells was removed by aspiration and the cells were immediately fixed in 150 µL of 3.7% Formaldehyde in 1X PBS for 20 minutes at room temp with no shaking. Fixing solution was removed to an appropriate waste container. The fixed cells were washed three times with 1X PBS. The wells were then washed three times with 200 µL of 1X PBS containing 0.1% Triton X-100 for 5 minutes per wash, with shaking at room temp.

**[03446]** Cells were blocked by adding 150 µL of Li-COR Odyssey Blocking Buffer to each well. The solution was moved carefully by pipetting down the sides of the wells to avoid detaching the cells. Blocking was for 90 minutes at room temp with moderate shaking on a rotator and the two primary antibodies were added to a tube containing Odyssey Blocking Buffer. The primary antibody was incubated for 2 hours with gentle shaking at room temp (Phospho-ERK (Rabbit, 1:100 dilution; Cell Signaling Technology 9101). Total ERK2 (Mouse; 1:75 dilution; Santa Cruz Biotechnology SC-1647)). The wells were washed three times with 1X PBS + 0.1% Tween-20 for 5 minutes at room temp with gentle shaking, using a generous amount of buffer. The fluorescently labeled secondary antibody was diluted in Odyssey Blocking Buffer (Goat anti-rabbit Alexa Fluor 680 (1:200 dilution; Molecular Probes) Goat anti-mouse IRDye 800CW (1:800 dilution; Rockland Immunochemicals)). The antibody solutions were mixed well and 50 µL of the secondary antibody solution was added to each well. The antibody solution was incubated for 60 minutes with gentle shaking at room temp. The plate was washed three times with 1X PBS + 0.1% Tween-20 for 5 minutes at room temp with gentle shaking, using a generous amount of buffer. After a final wash, wash solution was completely removed from wells. The plates were scanned with the Odyssey Infrared Imaging System (700 nm detection for Alexa Fluor 680 antibody and 800 nm detection for IRDye 800CW antibody). Negative control transfected cells yield 100% erk activation (meaning background levels of active erk). Transfecting cells with some of our miRNAs alters the level of active erk.

**TABLE 19**  
**miRNAs That Activate ERK**

miR	% Activation	Std Dev
mir-218	312.96	22.91
mir-210	291.74	38.23
mir-217	273.49	26.84
mir-152	265.54	35.82
mir-148	264.38	43.55
mir-223	264.15	39.72
mir-301	261.36	61.77
mir-328	259.48	45.87
mir-206	255.51	55.53
mir-125a	252.46	27.34
mmu-mir-329	243.38	5.43
mir-19a	241.52	31.33
mir-25	238.90	44.94
mmu-mir-294	235.51	24.60
mir-212	231.36	23.61
mmu-mir-295	221.47	14.05
mir-370	220.60	22.88

(continued)

**miRNAs That Activate ERK**

	<b>miR</b>	<b>% Activation</b>	<b>Std Dev</b>
5	mir-216	219.17	25.98
	mir-96	213.93	57.07
	mir-339	213.9	42.25
	mir-134	211.15	12.84
10	mir-372	211.13	5.67
	Positive Control	245.36	10.76

**EXAMPLE 18****15 Screen for miRNAs that influence apoptosis**

**[0347]** Apoptosis is a natural cellular process that helps control cancer by inducing death in cells with oncogenic potential. Many oncogenes function by altering induction of apoptosis. To identify miRNAs that participate in apoptosis, an apoptosis assay was used with the miRNA inhibitor library.

20 **[0348]** HeLa cells (8000 cells/well of 96 well plate) were transfected in triplicate with more than 150 synthetic miRNAs (described above) (3 pmoles) using Ambion siPORTTM NeoFX™. The media was changed 24 hrs after transfection and cells were processed 72 hrs after transfection. The cells were measured for apoptosis by measuring caspase 3 activity as follows: 1) Cells were washed once with PBS and frozen at -80°C. 2) Cells were lysed by adding 40 µl of cold lysis buffer (50 mM HEPES pH 7.2, 40 mM NaCl, 0.5% NP40, 0.5 mM EDTA) to the wells and incubated for 20 min at 25 4°C. 3) Add 160 µl ICE buffer (50 mM HEPES pH 7.4, 0.1% CHAPS, 0.1 mM EDTA, 10% sucrose) + 5 mM DTT containing 20 µM DEVDafc substrate. 4) Measure fluorescence increase in one hour at 400 ex, 505 em.

**[0349]** Samples were also analyzed for cell number using a general esterase assay to normalize the caspase 3 results. FDA substrate (0.4 mg/ml fluorescein diacetate (FDA) in acetonitrile) was diluted 1:19 into dilution buffer (40 mM TrisCl pH 7.5, 20 mM NaCl, 0.5% NP-40, 0.02 mg/ml final conc). 40 µl buffer (40 mM TrisCl pH 7.5, 0.5% NP-40) was added to each sample well. Samples were incubated 10 min on ice. 160 µl of diluted FDA substrate was added to each well. Fluorescence was measured for 30 min at 37 deg (ex = 488, em = 529). The slope of fluorescence increase over time is a function of the cell number in the plate.

30 **[0350]** miRNAs that affect apoptosis are listed in the table below. These miRNAs apparently regulate pathways that lead to apoptosis. Mis-regulation of these miRNAs could induce cells to undergo apoptosis or might keep the cells from undergoing apoptosis. Introducing or inhibiting these miRNAs in cancer (or other disease) cells that have overcome apoptotic signaling pathways or Parkinson's (or other disease) cells that have prematurely induced apoptosis could be used to treat the diseases.

**TABLE 20****miRNAs that Significantly Increase the Percentage of Apoptotic Cells**

		<b>Relative change in apoptotic cells</b>	<b>St Dev</b>
	mir-338	773.46	69.82
	mir-27a	607.24	150.08
45	mir-128	594.42	260.06
	mir-23a	473.44	208.82
	mir-324	442.99	101.03
	mir-22	439.13	62.59
	mir-181a	409.97	65.14
50	mmu-mir-293	403.86	53.41
	mmu-mir-412	402.27	42.04
	mir-196	378.13	28.15
	mir-31	373.90	61.39
55	Let-7d	369.10	88.94
	mir-23b	360.68	81.97
	mu-miR-290	354.90	46.63

(continued)

**miRNAs that Significantly Increase the Percentage of Apoptotic Cells**

		<b>Relative change in apoptotic cells</b>	<b>St Dev</b>
5	mir-217	347.38	56.49
	mir-199	345.75	67.55
	mir-24	317.43	62.85
	mir-214	312.25	7.38
10	mir-198	303.24	44.25

**TABLE 21****miRNAs that Significantly Decrease the Percentage of Apoptotic Cells**

		<b>Relative change in apoptotic cells</b>	<b>St Dev</b>
15	mir-105	39.97	8.91
	mir-34a	37.75	8.41
	mir-96	31.89	13.40
20	mmu-mir-292	30.72	4.27
	mir-126	28.71	4.24
	mir-137	12.69	11.80
	mir-101	7.50	6.91

**EXAMPLE 19****Synthetic miRNA library screen for miRNAs that influence hTert expression**

**[0351]** Telomerase is a complex of proteins and RNA that maintains the ends of chromosomes by appending telomeres. With rare exceptions, terminally differentiated cells lack active telomerase. One of the exceptions is cancer cells. More than 90% of human cancer samples have active telomerase (reviewed in Dong *et al.* 2005). The hTert gene encodes the catalytic domain of telomerase. The expression of hTert correlates with telomerase activity in cells making it a good surrogate for telomerase activity. An RT-PCR based assay for monitoring hTert mRNA expression in telomerase negative cells has been developed and used to identify miRNAs that participate in the regulation of telomerase. The miRNAs that regulate telomerase activity represent intervention points for cancer therapeutics.

**[0352]** BJ cells are normal human foreskin fibroblasts that lack hTert mRNA and telomerase activity. BJ cells were trypsinized and diluted to 13,000 cells/ml in normal growth media. 0.3  $\mu$ l of lipofectamine 2000 agent was diluted into 40  $\mu$ l of OPTI-MEM and incubated for five minutes. The diluted transfection reagent was added to the wells of 96-well plates that contained 150 synthetic miRNAs (as described above) as well as two different negative control synthetic miRNAs. Each well housed a different synthetic miRNA. The synthetic miRNAs and transfection agent were incubated for 15 minutes at room temperature and then 200  $\mu$ l (2,600 cells) were added on top of the lipid/miRNA complex. Cells were placed in an incubator and RNA was isolated 72 hours later. RNA was isolated from the cells in each well using RNAqueous™-MagMAX96 Total RNA Isolation kit (Cat#1830) standard protocol (lyse cells in wells). Reverse transcription was done using the RETROscript reaction by adding 11  $\mu$ l of total RNA (20-100 ng/ $\mu$ l) to 1 ul of random decamers and incubated in 70°C water bath for 3 minutes then place on ice. Next, 8ul of the cocktail containing Nuc-free water 3.8  $\mu$ l, 10X Reverse Transcription buffer 2.0ul, 2.5mM dNTPs 2.0ul, RNase Inhibitor Protein (40U/ul), 0.1ul MMLV-RT (100 U/ $\mu$ l), and incubated at 42°C for 1 hour, then 92°C for 10 minutes.

**[0353]** Real time PCR reactions were assembled to quantify hTert mRNA and 18S rRNA in each of the samples. Nuclease-free water, 10X Complete PCR buffer/SYBR, 25mM MgCl<sub>2</sub>, 2.5mM dNTPs, 50X ROX, 18S- or hTert-specific primers (for & rev mix 3uM), cDNA from the various samples, and Super taq polymerase into a PCR tube. The reaction was heated to 95°C for 5 minutes and then subjected to 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, 72°C for 30 seconds. The amplification products were monitored using the ABI 7600 (Applied Biosystems). BJ cells ordinarily fail to yield amplification products with the hTert primers. Those miRNA-transfected samples that yielded a hTert PCR product were also analyzed for 18S rRNA levels to ensure that there were not significantly more cells in the samples that might have contributed to the amount of hTert in the samples.

**[0354]** The hTert mRNA was detected in duplicate transfections of each of the miRNAs listed below. These miRNAs presumably affect pathways that regulate the expression of the hTert gene. Over-expression of any of these miRNAs

might contribute to cancer by activating telomerase. Regulating the activities of these miRNAs in cancer cells could limit their transformation and overcome oncogenesis.

**TABLE 22**  
**hTert Activators**

---

mmu-mir-295
mir-92
mir-337
mir-26a
mir-224
mir-21
mir-195
mir-16
mir-15a
mir-128
mir-125b
mir-125a
mir-105

**EXAMPLE 20**

**Synthetic miRNA library screens for miRNAs that influence cell cycle**

**[0355]** The adult human body consists of about 50-100 trillion cells. Each day, several billion of these cells divide in two to replace the billions of cells that die and are removed. In the course of an average lifetime, this adds up to an astronomical number of cell divisions, most of which go perfectly well. Errors do occur, however, and if they are not corrected they may lead to cancer. Cell growth and division are normally controlled by an intricate system of checks and balances. But occasionally a cell will start to proliferate wildly, dividing again and again and defying all normal restraints on its growth. That is the beginning of most common forms of cancer.

**[0356]** The inventors transfected 4,000 BJ cells/well in triplicate with 46 synthetic miRNAs using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The

- let7a
- let7a
- mir1
- mir1
- mir105
- mir125a
- mir128
- mir142
- mir145
- mir146
- mir147
- mir150
- mir15a
- mir16
- mir186
- mir187
- mir188
- mir191
- mir195
- mir20
- mir206
- mir21
- mir211

mir223  
 mir224  
 mir26a  
 mir320  
 5 mir324-  
 3p  
 mir325  
 mir335  
 mir337  
 10 mir338  
 mir345  
 mir371  
 mir373  
 mir92  
 15 mmu201  
 mmu207  
 mmu290  
 mmu291-  
 3p  
 20 mmu294  
 mmu295  
 mmu297  
 mmu322  
 mmu376b  
 25 mmu409

[0357] 24 hours post-transfection, half of the BJ cells from each well were removed to fresh medium. 72 hrs post-transfection, the cells were fixed with 4%paraformaldehyde at a final concentration of 2%. The fixed cells were stained with propidium iodide (TTP LabTech protocol) and assessed using the TTP LabTech cell scanner. Propidium iodide stains DNA and the relative DNA content in a cell corresponds with its position in the cell cycle. The cell scanner measured propidium iodide staining in each cell and assigned its position in the cell cycle. The percentage of cells in each stage of cell cycle was calculated and compared to cells transfected with negative control synthetic miRNAs. The relative change in cells in each stage was calculated for each miRNA that was used. Those synthetic miRNAs that induced a significant shift toward or away from a specific stage of cell cycle are listed below. These represent miRNAs that regulate key points in the cell cycle and offer key intervention points for cancer-related therapeutic development.

**TABLE 23**  
**miRNAs that significantly reduce the percentage of BJ cells in G1 phase of the cell cycle**

miRNA	% Diff in Cells in G1	St. Dev.
mir-21	54.4	4.2
mir-20	63.6	9.3
mir-1	65.3	9.5
mir-206	66.8	9.0
45 mir-373	72.6	5.7
mir-26a	78.0	4.0

**TABLE 24**  
**miRNAs that significantly increase the percentage of BJ cells in G1 phase of the cell cycle**

miRNA	% Diff in Cells in G1	St. Dev.
rno-mir-325	121.7	5.3
55 mmu-409	123.2	13.7
mir-324	123.7	4.9
mir-195	125.1	2.5

(continued)

**miRNAs that significantly increase the percentage of BJ cells in G1 phase of the cell cycle**

	<b>miRNA</b>	<b>% Diff in Cells in G1</b>	<b>St. Dev.</b>
5	mmu-376b	126.5	3.1
	mir-142	127.0	13.0
	mir-371	128.9	2.8
	let-7a	131.5	4.5
10	mir-146	141.5	7.7
	mir-128	143.0	2.4

**TABLE 25****miRNAs that significantly reduce the percentage of BJ cells in S phase of the cell cycle**

	<b>miRNA</b>	<b>% Diff in Cells in S</b>	<b>St. Dev.</b>
15	mir-128	55.5	3.8
	let-7a	57.6	8.7
20	mir-142	59.5	24.7
	mir-146	63.5	16.8
	mmu-297	65.0	14.1
	mir-337	65.3	11.3
25	mir-195	65.6	0.1
	mmu-376b	69.1	11.6
	mir-324	72.2	9.4
	mir-187	72.3	10.9
30	mir-186	72.8	6.1

**TABLE 26****miRNAs that significantly increase the percentage of BJ cells in S phase of the cell cycle**

	<b>miRNA</b>	<b>% Diff in Cells in S</b>	<b>St. Dev.</b>
35	mir-92	132.0	14.7
	mir-15a	134.8	13.9
	mir-191	135.9	29.1
40	mir-26a	136.0	7.6
	mir-20	139.7	17.6
	mmu-290	141.0	11.7
	let-7a	141.1	19.9
	mir-345	143.3	45.8
45	mir-16	150.1	24.8
	mir-224	150.6	9.8

**TABLE 26****miRNAs that significantly reduce the percentage of BJ cells in G2/M phase of the cell cycle**

	<b>miRNA</b>	<b>% Diff in Cells in G2/M</b>	<b>St. Dev.</b>
50	mir-147	51.2	6.1
	mir-371	52.8	2.7
55	mir-146	57.2	5.3
	mir-195	58.9	4.4
	mir-128	65.4	2.7

(continued)

**miRNAs that significantly reduce the percentage of BJ cells in G2/M phase of the cell cycle**

	miRNA	% Diff in Cells in G2/M	St. Dev.
5	mir-15a	67.4	13.7
	let-7a	69.1	2.8

TABLE 27

**miRNAs that significantly increase the percentage of BJ cells in G2/M phase of the cell cycle**

	miRNA	% Diff in Cells in G2/M	St. Dev.
	mir-26a	130.2	5.8
15	mir-187	132.0	4.3
	mir-145	136.8	13.7
	mir-373	137.9	5.2
	mir-20	143.0	10.6
20	mir-21	160.3	7.1

TABLE 28

**miRNAs that significantly increase the percentage of BJ cells with greater than 2X amount of DNA**

	miRNA	% Diff in Cells w/>2X DNA	St. Dev.
25	mir-20	157.9	23.4
	mir-1	161.9	13.6
	mir-345	176.1	17.4
30	mir-373	177.9	32.7
	mir-337	195.0	52.1
	mir-21	209.4	45.7

**EXAMPLE 21****Synthetic miRNA library screen for miRNAs that influence cell proliferation**

[0358] Cell proliferation assays were used in conjunction with our synthetic miRNA library to identify miRNAs that influence cell proliferation in a broad range of cells, including those from lung, breast, prostate, skin, cervix, T-cell, and foreskin tissues.

[0359] Cervical (HeLa), lung (A549, CRL-5826, and HTB-57), breast (MCF12A and BT549), prostate (22Rv1), T-cells (Jurkat and primary normal), and skin (TE354T, TE353SK, and BJ) cells were transfected in triplicate with each of the more than 150 synthetic miRNAs in our library. With the exceptions of Jurkats and Primary T-cells, each cell type was transfected with 5 picomoles of each of the miRNAs in the synthetic miRNA library using siPORT™ NeoFX™ (Ambion) at a plating density of approximately 8000 cells/well of 96 well plate. The Jurkats and primary T-cells were mixed at a rate of approximately 50,000 cells/well with 500 picomoles of each of the synthetic miRNAs. The media was changed 24 hrs after transfection. 72 hours post-transfection, cell number was estimated by one of three methods:

(1) Alamar blue was added to each well and the 96-well plates were analyzed using a plate reader. Alamar blue is a substrate for a metabolic enzyme in cells and the reaction product is fluorescent. The fluorescence in each well correlates with the total number of cells in each well.

(2) ViaCount Flex Reagent (Guava), a dye that fluoresces when it interacts with DNA, was added to each well and fluorescence was quantified using the Guava PCA-96 according to the manufacturer's instructions.

(3) Propidium iodide, a dye that fluoresces when it interacts with DNA, was added to each well and the total number of cells in the well was estimated by counting unique sites of stained DNA using the TTP LabTech Cell Scanner

according to the manufacturer's instructions.

The impact of each miRNA on cell proliferation was assessed by dividing the cell number reading of each well by the average cell number reading for wells transfected with a negative control (NC) miRNA.

5 **[0360]** Presented in FIG. 15A-C are synthetic miRNAs that significantly reduced the proliferation of the various cell types that were analyzed. These miRNAs represent molecules that could be used for therapeutics, diagnostics, creating cell lines with interesting research properties, and inducing differentiation.

10 **[0361]** Approximately 10% of the miRNAs significantly reduced cell proliferation for at least four different cell types. These miRNAs (presented in ranked order in the table below) are provided below and can be implemented in methods and compositions of the invention.

**Table 29**  
**Common Anti-Proliferation miRNAs**

miRNA	# Positives
miR-124	7
miR-16	6
miR-101	6
miR-126	6
miR-147	6
miR-15a	5
miR-96	5
miR-105	5
miR-142	5
miR-215	5
miR-346	4
miR-206	4
miR-192	4
miR-194	4

35 **[0362]** Among the cells that were used in the synthetic miRNA library screens are matched pairs of cancer and non-cancer cells from breast, skin, and T-cell. Interestingly, many synthetic miRNAs differentially affected proliferation in the cell pairs (see table below).

**Table 30**

**Breast**

miRNA	Cancer		Non-Cancer	
	%NC	% Std Dev	%NC	% Std Dev
mir-201	79	14	103	17
mir-192	81	3	95	17
mir-92	85	11	104	24

**Skin**

pre-MIR	Cancer		Normal	
	% of NC	%ST DEV	% of NC	%ST DEV
mir-154	51	5	93	10
mir-195	58	3	87	5
mu-mir- 376b	65	3	99	8
mir-201	67	8	106	4
mir-26a	69	12	97	17
mir-193	69	4	105	10

(continued)

T-Cell		Leukemia		Normal	
		%NC	% St Dev	%NC	% St Dev
5	let-7a	21	1	137	15
	let-7b	50	5	136	13
	miR-101	69	30	95	5
10	miR-10b	37	3	115	18
	miR-122	67	18	104	18
	miR-17-3p	63	16	116	4
	miR-29a	68	7	111	8
	miR-30a-3p	66	27	97	18
15	miR-34a	67	21	100	1

Presented in FIG.16 are synthetic miRNAs that significantly increase the proliferation of the various cell types that were analyzed.

## 20 **EXAMPLE 22**

### **miRNA inhibitor library screens identify miRNAs that influence cell proliferation**

25 **[0363]** A cell proliferation assay was used in conjunction with our synthetic miRNA library to identify miRNAs that influence cell proliferation in a broad range of cells, including those from lung, breast, prostate, skin, cervix, T-cell, and foreskin tissues.

30 **[0364]** Breast (MCF12A), prostate (22Rv1), lung (A549), and skin (TE354T) cells were transfected in triplicate with each of the more than 150 miRNA inhibitors in our library. Each cell type was transfected with 10 picomoles of each of the miRNA inhibitors in the library using siPORT™ NeoFX™ (Ambion) at a plating density of approximately 8000 cells/well of 96 well plate. 72 hours post-transfection, cell number was estimated by one of three methods:

(1) Alamar blue was added to each well and the 96-well plates were analyzed using a plate reader. Alamar blue is a substrate for a metabolic enzyme in cells and the reaction product is fluorescent. The fluorescence in each well correlates with the total number of cells in each well.

35 (2) ViaCount Flex Reagent (Guava), a dye that fluoresces when it interacts with DNA, was added to each well and fluorescence was quantified using the Guava PCA-96 according to the manufacturer's instructions.

40 (3) Propidium iodide, a dye that fluoresces when it interacts with DNA, was added to each well and the total number of cells in the well was estimated by counting unique sites of stained DNA using the TTP LabTech Cell Scanner according to the manufacturer's instructions.

**[0365]** The impact of each miRNA inhibitor on cell proliferation was assessed by dividing the cell number reading of each well by the average cell number reading for wells transfected with a negative control (NC) miRNA.

45 **[0366]** Presented in FIG. 17 are miRNAs whose inhibition significantly reduced the proliferation of the various cell types that were analyzed. These miRNAs represent molecules that could be used for therapeutics, diagnostics, creating cell lines with interesting research properties, and inducing differentiation.

50 **[0367]** Presented in FIG. 18 are miRNA inhibitors that significantly increase the proliferation of the various cell types that were analyzed. These miRNAs represent molecules that could be used for therapeutics, diagnostics, creating cell lines with interesting research properties, and inducing differentiation.

## **EXAMPLE 23**

### **Synthetic miRNA library screen for miRNAs that influence cell viability**

55 **[0368]** The basis for most human diseases is the subversion of one or more cells to function in ways that are outside what they normally do. For instance, cancer initiates with the immortalization and transformation of a single cell which then divides repeatedly to form a tumor. Compounds that reduce the viability of disease cells are used routinely to treat

patients with cancer and other diseases.

**[0369]** Cervical (HeLa), lung (A549), and T-cells (Jurkat and primary normal) were transfected in triplicate with each of the more than 150 synthetic miRNAs in our library. With the exceptions of Jurkats and Primary T-cells, each cell type was transfected with 5 picomoles of each of the miRNAs in the synthetic miRNA library using siPORT™ NeoFX™ (Ambion) at a plating density of approximately 8000 cells/well of 96 well plate. The Jurkats and primary T-cells were mixed at a rate of approximately 50,000 cells/well with 500 picomoles of each of the synthetic miRNAs. For the HeLa and A549 cells, the media was changed 24 hrs after transfection. 72 hours post-transfection, cell viability was estimated by one of two methods:

(1) ViaCount Flex Reagent (Guava), which includes a dye that can only enter dead cells and that fluoresces when it interacts with DNA, was added to each well and fluorescence was quantified using the Guava PCA-96 according to the manufacturer's instructions. The percentage of viable cells was measured by dividing the number of non-dead and non-apoptotic cells in the sample by the total number of cells in the well and multiplying by 100.

(2) Propidium iodide, a dye that fluoresces when it interacts with DNA, was added to each well. Each cell was analyzed using the TTP LabTech Cell Scanner according to the manufacturer's instructions to detect cells with staining patterns consistent with cell death or apoptosis. The percentage of viable cells was measured by dividing the number of non-dead and non-apoptotic cells in the sample by the total number of cells in the well and multiplying by 100.

**[0370]** Presented in FIG. 19 are synthetic miRNAs that significantly decrease or increase viability in the various cell types that were analyzed. A comparison of the viability of jurkat and primary T-cells, which represent the leukemic and normal forms of T-cells, let-7, miR-10, miR-101, miR-17-3p, miR-19, and miR-34a severely reduced the viability of the leukemia cells without affecting the normal T-cells.

#### **EXAMPLE 24**

##### **Synthetic miRNA library screen for miRNAs that influence apoptosis**

**[0371]** To identify miRNAs that participate in apoptosis, an apoptosis assay was used with the miRNA inhibitor library.

**[0372]** Approximately 8000 cervical (HeLa), prostate (22Rv1), T-cell (Jurkat), and skin (TE354T) cells per well were transfected in triplicate with each of the more than 150 synthetic miRNAs in our library using siPORT™ NeoFX™ (Ambion). Media was changed after 24 hrs and cells were visually inspected under a microscope to qualitatively inspect cell death 72 hours after transfection. The cells were measured for apoptosis by measuring caspase 3 activity as follows:

1) Cells were washed once with PBS and frozen at -80°C. 2) Cells were lysed by adding 40 µl of cold lysis buffer (50 mM HEPES pH 7.2, 40 mM NaCl, 0.5% NP40, 0.5 mM EDTA) to the wells and incubated for 20 min at 4°C. 3) Add 160 µl ICE buffer (50 mM HEPES pH 7.4, 0.1% CHAPS, 0.1 mM EDTA, 10% sucrose) + 5 mM DTT containing 20 µM DEVDafc substrate. 4) Measure fluorescence increase in one hour at 400 ex, 505 em. Samples were also analyzed for cell number using a general esterase assay to normalize the caspase 3 results. FDA substrate (0.4 mg/ml fluorescein diacetate (FDA) in acetonitrile) was diluted 1:19 into dilution buffer (40 mM TrisCl pH 7.5, 20 mM NaCl, 0.5% NP-40, 0.02 mg/ml final conc). 40 µl buffer (40 mM TrisCl pH 7.5, 0.5% NP-40) was added to each sample well. Samples were incubated 10 min on ice. 160 µl of diluted FDA substrate was added to each well. Fluorescence was measured for 30 min at 37 deg (ex = 488, em = 529). The slope of fluorescence increase over time is a function of the cell number in the plate.

**[0373]** The impact of each miRNA on apoptosis was assessed by dividing the caspase 3 reading of each well by the average caspase 3 reading for wells transfected with a negative control (NC) miRNA.

**[0374]** As seen in FIG. 20, many different miRNAs were able to increase or decrease apoptosis in the four cell types that were analyzed. A few miRNAs (miR-126, miR-26a, miR-1, miR-149, and let-7g) affected apoptosis in multiple cell types suggesting that they regulate apoptosis via genes that are common in multiple cell types.

#### **EXAMPLE 25**

##### **Synthetic miRNA library screen for miRNAs that induce transformation**

**[0375]** Transformation is necessary for tumor formation as it overcomes the cell's natural response to stop dividing when placed in a crowded environment. To identify miRNAs that participate in transformation, a transformation assay featuring NIH3T3 cells was used with the synthetic miRNA library. NIH 3T3 cells are used in transformation assays as they lack the capacity to form colonies when plated in soft agar. Modulation of cell processes that inhibit transformation can be readily detected because they induce NIH3T3 cells to begin forming colonies when plated in soft agar.

**[0376]** Approximately 8000 NIH 3T3 cells were transfected in duplicate with each of the more than 150 synthetic miRNAs in our library using siPORTTM NeoFX™ (Ambion). Media was changed after 24 hrs and the cells were transferred to 24-well dishes containing soft agar. The soft agar limits mobility and ensures that sister cells must remain in contact following cell division. Close contact with other cells typically induces the NIH 3T3 cells to stop dividing. The total number of cells in each well was measured by taking an absorbance reading at 495 nm. The absorbance reading for each well was divided by the average absorbance reading for cells transfected with negative control miRNAs and multiplied by 100 to get the percent change in transformation. An initial screen revealed miR-10, miR-23, miR-24, miR-198, miR-192, and miR-199 as miRNAs that increased transformation relative to cells transfected with negative control. A repeat of the experiment with the initial candidates yielded the following hit as shown below:

Table 31

miRNA	%NC	%SD
198	103	2.07
192	108	5.7
199	113	5.59

## **EXAMPLE 26**

### **MiRNAs that affect the efficacy of therapeutic compounds**

**[0377]** Many compounds have been tested in clinical trials for their capacity to positively affect the outcome of patients. In some cases, these compounds meet the standards set for by the FDA and they become therapeutics. Unfortunately, very few therapeutics are 100% effective. Enhancing the activities of therapeutic compounds provides a significant opportunity within the medical industry. The two most common methods that are used to enhance therapeutics are modifying the chemical structure of the compounds or using multiple therapeutic compounds simultaneously. Whether it would be beneficial to introduce miRNAs in advance of adding compounds that are known to significantly reduce the viability of cancer cells was evaluated. One of the anti-cancer compounds that was introduced was TRAIL, a compound that binds at least two different receptors and activates the apoptosis pathway to induce cell death primarily in cancer cells. The second compound that was tested in combination with synthetic miRNAs was etoposide, a topoisomerase II inhibitor that activates the apoptosis pathway of cancer and normal cells alike by reducing the repair of DNA damage within the cells.

**[0378]** Approximately 8000 cervical (HeLa) and lung (A549, HTB-57, and CRL-5826) cells per well were transfected in triplicate with synthetic miRNAs from our library using siPORTTM NeoFX™ (Ambion). Media was changed after 24 hrs and etoposide and TRAIL were introduced at a final concentration of approximately 25 μM after 48 hours. The cells were visually inspected under a microscope to qualitatively inspect cell death 64 hours after transfection.

**[0379]** The cells treated with etoposide were measured for apoptosis by measuring caspase 3 activity as follows: 1) Cells were washed once with PBS and frozen at -80°C. 2) Cells were lysed by adding 40 μl of cold lysis buffer (50 mM HEPES pH 7.2, 40 mM NaCl, 0.5% NP40, 0.5 mM EDTA) to the wells and incubated for 20 min at 4°C. 3) Add 160 μl ICE buffer (50 mM HEPES pH 7.4, 0.1% CHAPS, 0.1 mM EDTA, 10% sucrose) + 5 mM DTT containing 20 μM DEVDafc substrate. 4) Measure fluorescence increase in one hour at 400 ex, 505 em. Samples were also analyzed for cell number using a general esterase assay to normalize the caspase 3 results. FDA substrate (0.4 mg/ml fluorescein diacetate (FDA) in acetonitrile) was diluted 1:19 into dilution buffer (40 mM TrisCl pH 7.5, 20 mM NaCl, 0.5% NP-40, 0.02 mg/ml final conc). 40 μl buffer (40 mM TrisCl pH 7.5, 0.5% NP-40) was added to each sample well. Samples were incubated 10 min on ice. 160 μl of diluted FDA substrate was added to each well. Fluorescence was measured for 30 min at 37 deg (ex = 488, em = 529). The slope of fluorescence increase over time is a function of the cell number in the plate.

**[0380]** The cells treated with TRAIL were assessed for cell viability by adding alamar blue each well and analyzing fluorescence using a plate reader. Alamar blue is a substrate for a metabolic enzyme in cells and the reaction product is fluorescent. The fluorescence in each well correlates with the total number of cells in each well.

**[0381]** The effect of each miRNA on the treatments was measured by dividing the caspase 3 or alamar blue reading of the cells transfected with miRNAs and treated with TRAIL or etoposide by the same readings for cells that were only transfected with the miRNAs. The change in caspase 3 activity or alamar blue staining for each miRNA was then divided by the differences observed for two negative control miRNAs and multiplied by 100 to calculate the relative effect induced by the combination of each miRNA and the therapeutic compound. These values are listed as %NC in Figure G.

**[0382]** As shown in FIG. 21, a number of miRNAs significantly increased the capacity of the two therapeutic compounds to induce cell death in the cancer cells that were treated. Interestingly, mir-292-3p, mir-132, mir-124, and mir-28 all worked extremely well in combination with both TRAIL and etoposide.

**EXAMPLE 27****Synthetic miRNA library screen for miRNAs that affect cell cycle**

5 **[0383]** The adult human body consists of about 50-100 trillion cells. Each day, several billion of these cells divide in two to replace the billions of cells that die and are removed. In the course of an average lifetime, this adds up to an astronomical number of cell divisions, most of which go perfectly well. Errors do occur, however, and if they are not corrected they may lead to cancer. Cell growth and division are normally controlled by an intricate system of checks and balances. But occasionally a cell will start to proliferate wildly, dividing again and again and defying all normal restraints on its growth. That is the beginning of most common forms of cancer.

10 **[0384]** Approximately 8000 cervical (HeLa) and 4000 skin (BJ) cells per well were transfected in triplicate with each of the more than 150 synthetic miRNAs in our library. HeLa cells were transfected using siPORTTM NeoFX™ (Ambion) and BJ cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. 24 hours post-transfection, half of the cells from each well were removed to fresh medium. 72 hrs post-transfection, the cells were fixed with 4% paraformaldehyde at a final concentration of 2%. The fixed cells were stained with propidium iodide (TTP LabTech protocol) and assessed using the TTP LabTech cell scanner. Propidium iodide stains DNA and the relative DNA content in a cell corresponds with its position in the cell cycle. The cell scanner measured propidium iodide staining in each cell and assigned its position in the cell cycle. The percentage of cells in each stage of cell cycle was calculated and compared to cells transfected with negative control synthetic miRNAs. The relative change in cells in each stage was calculated for each miRNA that was used. Those synthetic miRNAs that induced a significant shift toward or away from a specific stage of cell cycle are listed below. These represent miRNAs that regulate key points in the cell cycle and offer key intervention points for cancer-related therapeutic development.

20 **[0385]** As seen in FIG. 22, many different miRNAs significantly altered the percentage of cells in the various stages of cell cycle in the two cell types that were analyzed.

25

**EXAMPLE 28****Synthetic miRNA library screen for miRNAs that influence ERK activity**

30 **INVENTORS: IS THIS THE SAME AS EXAMPLE 17?**

**[0386]** In order for cancer cells to proliferate they must subvert both the machinery that controls the cell division cycle and the process of programmed cell death (apoptosis). This is frequently achieved by mutation of specific proto-oncogenes such as *Ras* or tumor suppressors such as *p53*. The Ras-family of membrane associated GTPases transmit signals into the interior of the cell by the activation of a number of cytosolic signal transduction pathways such as the Raf>MEK>ERK MAP kinase signaling pathway. Disregulation of the Ras/Raf/MEK/ERK pathway plays a major role in cancer pathogenesis (reviewed in Meijer *et al.*).

35 **[0387]** To identify miRNAs that affect ERK activation, HeLa cells were transfected in a 96-well plate format with 160 different synthetic miRNAs. Prior to transfection, the HeLa cells were trypsinized to remove adherent cells and diluted in normal growth medium to 10<sup>5</sup> cells/mL. 0.5 μl of siPort NeoFX in 9.5 μl of OptiMEM I medium was added to the cells and incubated for 10 minutes at room temp (10 μL for each sample). miRNAs were rehydrated with 10 μl of diluted siPORT NeoFX. The samples were incubated at 37 °C and then the transfected samples were evaluated 72 hours after transfection.

40 **[0388]** The controls for ERK activation were performed by depriving the wells of a phosphate source for detection of ERK phosphorylation. 100 μl of serum-free media (DMEM) to 37°C was added per well and the cells were incubated for 4 hours at 37 °C to attain basal phosphorylation levels. For the positive control wells, serum-free media was aspirated from wells and 100 μL of 100 ng/mL EGF was added before incubating the cells for 7.5 minutes at 37 °C.

45 **[0389]** Media from all wells was removed by aspiration and the cells were immediately fixed in 150 μL of 3.7% Formaldehyde in 1X PBS for 20 minutes at room temp with no shaking. Fixing solution was removed to an appropriate waste container. The fixed cells were washed three times with 1X PBS. The wells were then washed three times with 200 μL of 1X PBS containing 0.1% Triton X-100 for 5 minutes per wash, with shaking at room temp.

50 **[0390]** Cells were blocked by adding 150 μL of Li-COR Odyssey Blocking Buffer to each well. The solution was moved carefully by pipetting down the sides of the wells to avoid detaching the cells. Blocking was for 90 minutes at room temp with moderate shaking on a rotator and the two primary antibodies were added to a tube containing Odyssey Blocking Buffer. The primary antibody was incubated for 2 hours with gentle shaking at room temp (Phospho-ERK (Rabbit, 1:100 dilution; Cell Signaling Technology 9101). Total ERK2 (Mouse; 1:75 dilution; Santa Cruz Biotechnology SC-1647)). The wells were washed three times with 1X PBS + 0.1% Tween-20 for 5 minutes at room temp with gentle shaking, using a generous amount of buffer. The fluorescently labeled secondary antibody was diluted in Odyssey Blocking Buffer (Goat

55

## EP 2 808 390 A1

anti-rabbit Alexa Fluor 680 (1:200 dilution; Molecular Probes) Goat anti-mouse IRDye 800CW (1:800 dilution; Rockland Immunochemicals)). The antibody solutions were mixed well and 50  $\mu$ L of the secondary antibody solution was added to each well. The antibody solution was incubated for 60 minutes with gentle shaking at room temp. The plate was washed three times with 1X PBS + 0.1% Tween-20 for 5 minutes at room temp with gentle shaking, using a generous amount of buffer. After a final wash, wash solution was completely removed from wells. The plates were scanned with the Odyssey Infrared Imaging System (700 nm detection for Alexa Fluor 680 antibody and 800 nm detection for IRDye 800CW antibody).

Table 32

### miRNAs That Activate ERK

miRNA	% NC	%StDev
let-7	250	25
mir-125a	252	27
mir-134	211	13
mir-148	264	44
mir-152	266	36
mir-19a	242	31
mir-206	256	56
mir-207	224	3
mir-210	292	38
mir-212	231	24
mir-216	219	26
mir-217	273	27
mir-218	313	23
mir-223	264	40
mir-25	239	45
mir-294	236	25
mir-295	221	14
mir-301	261	62
mir-328	259	46
mir-329	243	5
mir-339	214	42
mir-370	221	23
mir-372	211	6
mir-96	214	57
Positive Control	245	11

### **EXAMPLE 29**

#### **Synthetic miRNA library screen for miRNAs that influence hTert expression**

**[0391]** Telomerase is a complex of proteins and RNA that maintains the ends of chromosomes by appending telomeres. With rare exceptions, terminally differentiated cells lack active telomerase. One of the exceptions is cancer cells. More than 90% of human cancer samples have active telomerase (reviewed in Dong *et al.*, 2005). The hTert gene encodes the catalytic domain of telomerase. The expression of hTert correlates with telomerase activity in cells making it a good surrogate for telomerase activity. We have developed and used an RT-PCR based assay for monitoring hTert mRNA expression in telomerase negative cells to identify miRNAs that participate in the regulation of telomerase. The miRNAs that regulate telomerase activity represent intervention points for cancer therapeutics.

**[0392]** BJ cells are normal foreskin fibroblasts that lack hTert mRNA and telomerase activity. BJ cells were trypsinized and diluted to 13,000 cells/ml in normal growth media. 0.3  $\mu$ l of lipofectamine 2000 agent was diluted into 40  $\mu$ l of OPTI-MEM and incubated for five minutes. The diluted transfection reagent was added to the wells of 96-well plates that contained 151 synthetic miRNAs as well as two different negative control synthetic miRNAs. Each well housed a different synthetic miRNA. The synthetic miRNAs and transfection agent were incubated for 15 minutes at room temperature and then 200  $\mu$ l (2,600 cells) were added on top of the lipid/miRNA complex. Cells were placed in an incubator and RNA

## EP 2 808 390 A1

was isolated 72 hours later. RNA was isolated from the cells in each well using RNAqueous™-MagMAX96 Total RNA Isolation kit (Cat#1830) standard protocol (lyse cells in wells). Reverse transcription was done using the RETROscript reaction by adding 11 ul of total RNA (20-100 ng/ $\mu$ l) to 1  $\mu$ l of random decamers and incubated in 70°C water bath for 3 minutes then place on ice. Next, 8  $\mu$ l of the cocktail containing Nuc-free water 3.8  $\mu$ l, 10X Reverse Transcription buffer 2.0  $\mu$ l, 2.5 mM dNTPs 2.0  $\mu$ l, RNase Inhibitor Protein (40 U/ $\mu$ l), 0.1  $\mu$ l MMLV-RT (100 U/ $\mu$ l), and incubated at 42°C for 1 hour, then 92°C for 10 minutes.

**[0393]** Real time PCR reactions were assembled to quantify hTert mRNA and 18S rRNA in each of the samples. Nuclease-free water, 10X Complete PCR buffer/SYBR, 25 mM MgCl<sub>2</sub>, 2.5 mM dNTPs, 50X ROX, 18S- or hTert-specific primers (for & rev mix 3  $\mu$ M), cDNA from the various samples, and Super taq polymerasewere placed into a PCR tube. The reaction was heated to 95°C for 5 minutes and then subjected to 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, 72°C for 30 seconds. The amplification products were monitored using the ABI 7600 (Applied Biosystems). BJ cells ordinarily fail to yield amplification products with the hTert primers. Those miRNA-transfected samples that yielded a hTert PCR product were also analyzed for 18S rRNA levels to ensure that there were not significantly more cells in the samples that might have contributed to the amount of hTert in the samples.

**[0394]** The hTert mRNA was detected in duplicate transfections of each of the miRNAs listed below. These miRNAs presumably affect pathways that regulate the expression of the hTert gene. Over-expression of any of these miRNAs might contribute to cancer by activating telomerase. Regulating the activities of these miRNAs in cancer cells could limit their transformation and overcome oncogenesis.

Table 33

### hTert miRNA Activators

miRNA	Log(2) hTert Expression
mir-147	3.14
mir-195	4.25
miR-21	1.55
mir-24	4.68
mir-26a	4.35
mir-301	4.14
mir-368	5.30
mir-371	2.43

**[0395]** The telomerase activity screen was repeated using a series of siRNAs targeting kinases, phosphatases, GPCRs, transcription factors, and assorted other genes. Targeting the genes below with siRNAs resulted in increased hTert expression. Interestingly, many of these genes are predicted to be targets for the miRNAs that we found to be hTert regulators (see table below).

Table 34

### hTert Gene Activators

Gene	Log(2) hTert Expression
ACOX1	3.44
AKT1	1.80
APAF1	3.40
COX-5B	2.78
COX6	2.28
COX7B	3.95
CPOX	4.66
DUOX2	3.80
GPX1	1.85
GPX2	2.56
GPX4	3.17
LPO	3.37
MAPK1	3.07
MAPK4	3.61
MTCO1	1.58

(continued)

**hTert Gene Activators**

	Gene	Log(2) hTert Expression
5	NOX3	2.30
	NOX5	2.54
	PAOX	1.72
	PPOX	2.09
10	PRKCA	2.24
	PRKCD	4.39
	TNFRSF6	2.25

**EXAMPLE 30**

15

**Effect of miRNA primary sequence on function**

[0396] Many miRNAs appear to be very closely related to others based on their primary sequences. For instance, let-7a is a member of the let-7 gene family, which includes 7 unique genes within the human genome. The let-7 genes encode miRNAs that vary by as little as a single nucleotide and as many as four nucleotides. In our synthetic miRNA and miRNA inhibitor libraries, we have five different human let-7 miRNAs. These miRNAs have been used in many different cell types in screens designed to identify miRNAs involved in a variety of different cellular processes. In many of the screens, the various let-7 miRNAs generate similar phenotypes. FIG. 223 provides two examples wherein all of the let-7 family members yield similar responses. In contrast, there are some screens wherein the various let-7 family miRNAs yield significantly different results (FIG. 23).

25

**EXAMPLE 31**

30

**Synthetic miRNA library screen for miRNAs that influence inflammation**

[0397] Inflammation is the body's natural protective response to an injury or infection. It is designed to hyper-stimulate biological pathways that initiate tissue repair or attack invading pathogens. This response is a delicate balance of both pro- and anti-inflammatory genes and their proteins. If the inflammatory response is maintained too long it can lead to tissue destruction, organ failure or inflammatory diseases such as Rheumatoid arthritis, Psoriasis, Asthma, Inflammatory bowel disease (Crohn's disease and related conditions), Multiple Sclerosis, coronary obstructive pulmonary disease (COPD), Allergic rhinitis (hay fever), and Cardiovascular disease.

35

[0398] Stat3 is the subject of intense scientific investigation, because it's known to be an important transcription factor that turns on genes required for the cell division, induction and suppression of apoptosis, and cell motility. Many STAT3 target genes are known, including those encoding the anti-apoptotic proteins Bcl-xl, Mcl-1, and Bcl-2, the proliferation-associated proteins Cyclin D1 and Myc, and the pro-angiogenic factor VEGF. The inflammatory disease psoriasis is characterized by lesions, which contain epidermal keratinocytes that express high levels of activated Stat3. Stat3 has also recently been discovered to play an important role as an anti-inflammatory regulator. In normal mice, the immune system is initially upregulated in response to bacterial protein challenge creating systemic inflammation followed by down regulation of the initiating factors. Mice with a deletional mutation for Stat3-beta lacked the ability to down regulate the initial inflammatory reaction after bacterial protein challenge which lead to irreversible damage to the animals' own tissues and finally to animal death.

45

[0399] A stat3 response assay was used to identify miRNAs that regulate cellular inflammatory response. The stable Stat3-luciferase reporter cell line from Panomics, which contains a chromosomal integration of a luciferase reporter construct regulated by 3 copies of the Stat1 response element was used for this purpose. The chemical agent Phorbol-12-myristate 13 acetate (PMA) is known to induce an inflammatory response in exposed cells and was used to stimulate inflammation in this experiment. These cells were transfected in triplicate with each of the more than 206 synthetic miRNAs in our library using siPORT™ NeoFX™ (Ambion) at a plating density of approximately 6000 cells/well of 96 well plate.. The media was changed 24h post transfection and exposed to 100nM PMA for 6 hours starting at 67 hours post transfection. The cells were assayed for changes in total cell number by alamarBlue as previously described and finally harvested at 72 hours post initial transfection. A luciferase assay was performed on all sample lysates to measure Stat3 responsiveness to the procedure. The data was normalized to total cell number using the alamar Blue data and compared to cells transfected with a negative control miRNA that underwent the same procedure.

55

## EP 2 808 390 A1

[0400] The following miRNA were able to reduce the ability of PMA to stimulate Stat3.

		% of NC	% STDEV
5	mir-93	34	74
	mir-100	13	10
	mir-134	50	18
	mir-99a	38	96
	mir-103	38	40
10	mir-128	49	115
	mir-129	44	112
	mir-181b	11	21
	mir-193	42	92
	mir-197	36	78
15	mir-212	42	92
	mir-218	38	84
	mir-219	39	86
	mir-302	40	87
20	mir-323	22	49
	mir-324-3p	29	63
	mir-325	29	63
	mir-330	21	47
	mir-331	39	86
25	mir-340	34	75
	mmu-mir-350	11	22
	mir-425	24	49
	mir-491	25	49
30	mir-518f	26	52
	mir-520a*	28	55

[0401] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods, and in the steps or in the sequence of steps of the methods, described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

## REFERENCES

[0402] The following references are specifically incorporated by reference to the extent they relate to topics and subject matter discussed herein.

U.S. Patent 4,337,063  
U.S. Patent 4,404,289  
U.S. Patent 4,405,711  
50 U.S. Patent 4,659,774  
U.S. Patent 4,682,195  
U.S. Patent 4,683,202  
U.S. Patent 4,684,611  
U.S. Patent 4,704,362  
55 U.S. Patent 4,816,571  
U.S. Patent 4,828,979  
U.S. Patent 4,849,513

U.S. Patent 4,910,300  
U.S. Patent 4,952,500  
U.S. Patent 4,959,463  
U.S. Patent 5,141,813  
5 U.S. Patent 5,143,854  
U.S. Patent 5,202,231  
U.S. Patent 5,214,136  
U.S. Patent 5,221,619  
U.S. Patent 5,223,618  
10 U.S. Patent 5,242,974  
U.S. Patent 5,264,566  
U.S. Patent 5,268,486  
U.S. Patent 5,288,644  
U.S. Patent 5,302,523  
15 U.S. Patent 5,322,783  
U.S. Patent 5,324,633  
U.S. Patent 5,378,825  
U.S. Patent 5,384,253  
U.S. Patent 5,384,261  
20 U.S. Patent 5,405,783  
U.S. Patent 5,412,087  
U.S. Patent 5,424,186  
U.S. Patent 5,428,148  
U.S. Patent 5,429,807  
25 U.S. Patent 5,432,049  
U.S. Patent 5,436,327  
U.S. Patent 5,445,934  
U.S. Patent 5,446,137  
U.S. Patent 5,464,765  
30 U.S. Patent 5,466,786  
U.S. Patent 5,468,613  
U.S. Patent 5,470,710  
U.S. Patent 5,470,967  
U.S. Patent 5,472,672  
35 U.S. Patent 5,480,980  
U.S. Patent 5,492,806  
U.S. Patent 5,503,980  
U.S. Patent 5,510,270  
U.S. Patent 5,525,464  
40 U.S. Patent 5,525,464  
U.S. Patent 5,527,681  
U.S. Patent 5,529,756  
U.S. Patent 5,532,128  
U.S. Patent 5,538,877  
45 U.S. Patent 5,538,880  
U.S. Patent 5,545,531  
U.S. Patent 5,547,839  
U.S. Patent 5,550,318  
U.S. Patent 5,554,501  
50 U.S. Patent 5,554,744  
U.S. Patent 5,556,752  
U.S. Patent 5,561,071  
U.S. Patent 5,563,055  
U.S. Patent 5,563,055  
55 U.S. Patent 5,571,639  
U.S. Patent 5,573,913  
U.S. Patent 5,574,146  
U.S. Patent 5,580,726

U.S. Patent 5,580,732  
U.S. Patent 5,580,859  
U.S. Patent 5,583,013  
U.S. Patent 5,589,466  
5 U.S. Patent 5,591,616  
U.S. Patent 5,593,839  
U.S. Patent 5,599,672  
U.S. Patent 5,599,695  
U.S. Patent 5,602,240  
10 U.S. Patent 5,602,244  
U.S. Patent 5,610,042  
U.S. Patent 5,610,287  
U.S. Patent 5,610,289  
U.S. Patent 5,614,617  
15 U.S. Patent 5,623,070  
U.S. Patent 5,624,711  
U.S. Patent 5,631,134  
U.S. Patent 5,637,683  
U.S. Patent 5,639,603  
20 U.S. Patent 5,645,897  
U.S. Patent 5,652,099  
U.S. Patent 5,654,413  
U.S. Patent 5,656,610  
U.S. Patent 5,658,734  
25 U.S. Patent 5,661,028  
U.S. Patent 5,665,547  
U.S. Patent 5,667,972  
U.S. Patent 5,670,663  
U.S. Patent 5,672,697  
30 U.S. Patent 5,681,947  
U.S. Patent 5,695,940  
U.S. Patent 5,700,637  
U.S. Patent 5,700,922  
U.S. Patent 5,702,932  
35 U.S. Patent 5,705,629  
U.S. Patent 5,708,154  
U.S. Patent 5,714,606  
U.S. Patent 5,728,525  
U.S. Patent 5,736,524  
40 U.S. Patent 5,744,305  
U.S. Patent 5,763,167  
U.S. Patent 5,777,092  
U.S. Patent 5,780,448  
U.S. Patent 5,789,215  
45 U.S. Patent 5,792,847  
U.S. Patent 5,800,992  
U.S. Patent 5,807,522  
U.S. Patent 5,830,645  
U.S. Patent 5,837,196  
50 U.S. Patent 5,847,219  
U.S. Patent 5,858,988  
U.S. Patent 5,859,221  
U.S. Patent 5,871,928  
U.S. Patent 5,872,232  
55 U.S. Patent 5,876,932  
U.S. Patent 5,886,165  
U.S. Patent 5,919,626  
U.S. Patent 5,945,100

U.S. Patent 5,981,274  
 U.S. Patent 5,994,624  
 U.S. Patent 6,004,755  
 U.S. Patent 6,087,102  
 5 U.S. Patent 6,251,666  
 U.S. Patent 6,262,252  
 U.S. Patent 6,368,799  
 U.S. Patent 6,376,179  
 U.S. Patent 6,383,749  
 10 U.S. Patent 6,617,112  
 U.S. Patent 6,638,717  
 U.S. Patent 6,720,138  
 U.S. Patent 6,723,509  
 U.S. Patent Ser 60/649,584  
 15 U.S. Patent Ser 60/575,743  
 British Appln. 1,529,202  
 European Appl. 266,032  
 European Appl. 373 203  
 European Appl. 785 280  
 20 European Appl. 799 897  
 PCT Appln. WO 94/09699  
 PCT Appln. WO 95/06128  
 PCT Appln. WO 0138580  
 PCT Appln. WO 0168255  
 25 PCT Appln. WO 03020898  
 PCT Appln. WO 03022421  
 PCT Appln. WO 03023058  
 PCT Appln. WO 03029485  
 PCT Appln. WO 03040410  
 30 PCT Appln. WO 03053586  
 PCT Appln. WO 03066906  
 PCT Appln. WO 03067217  
 PCT Appln. WO 03076928  
 PCT Appln. WO 03087297  
 35 PCT Appln. WO 03091426  
 PCT Appln. WO 03093810  
 PCT Appln. WO 03100448A1  
 PCT Appln. WO 04020085  
 PCT Appln. WO 04027093  
 40 PCT Appln. WO 09923256  
 PCT Appln. WO 09936760  
 PCT Appln. WO 93/17126  
 PCT Appln. WO 95/11995  
 PCT Appln. WO 95/21265  
 45 PCT Appln. WO 95/21944  
 PCT Appln. WO 95/21944  
 PCT Appln. WO 95/35505  
 PCT Appln. WO 96/31622  
 PCT Appln. WO 97/10365  
 50 PCT Appln. WO 97/27317  
 PCT Appln. WO 9743450  
 PCT Appln. WO 99/35505  
 PCT Appln. WO03100012  
 UK 8 803 000;  
 55 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\\_uids=15766527&query\\_hl=1](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15766527&query_hl=1)  
 Agrawal and Zamecnik, *Nucleic Acids Research*, 18(18):5419-5423, 1990.  
 Allen et al., *Biochemistry*, 28:4601-4607, 1989.

- Ambros, Cell, 107(7):823-826, 2001.
- Baglioni and Nilson, Interferon, 5:23-42, 1983.
- Bayer and Wilchek, Methods of Biochemical Analysis, 26:1-45, 1980.
- Bayer et al, Analytical Biochemistry, 149:529-536, 1985.
- 5 Beaucage, and Lyer, Tetrahedron, 48:2223-2311, 1992.
- Bernstein et al., Nature, 409: 363-366, 2001.
- Bijsterbosch et al., Biochem. Pharmacol., 62(5):627-633, 2001.
- Blackie et al., Bioorg. Med. Chem. Lett., 12(18):2603-2606, 2002.
- 10 Bobo et al., In: Diagnosis of Chlamydia trachomatis Cervical Infection by Detection of Amplified DNA with an Enzyme Immunoassay, 1990.
- Borlakoglu et al., Biochem. Pharmacol., 40(2):265-272, 1990.
- Bosher and Labouesse, Nat. Cell Biol., 2:E31-E36, 2000.
- Brennecke et al., Cell, 113:25-36, 2003.
- Brumbaugh et al., Proc Natl Acad Sci USA, 85(15):5610-5614, 1988.
- 15 Brummelkamp et al., Science, 296(5567):550-553, 2002
- Calin et al., Proc. Natl. Acad. Sci. USA, 99:15524-15529, 2002.
- Caplen et al., Proc Natl Acad Sci USA, 98: 9742-9747, 2001.
- Cardullo et al., Proc Natl Acad Sci USA, 85(23):8790-8794, 1988
- Carrington et al. Science, 301(5631):336-338, 2003.
- 20 Chang et al., Nature, 430(7001):785-789, 2004.
- Chen and Okayama, Mol. Cell Biol., 7(8):2745-2752, 1987.
- Chen et al., Science, 303(5654):83-86, 2004.
- Cogoni, C., and Macino, Science, 286:342-2344, 1999.
- Cogoni. and Macino, Nature, 399:166-169, 1999.
- 25 Conway et al., Nucleic Acids Res. Symposium Series, 21:43-44, 1989.
- Crooke, In: Antisense Drug Technology, Marcel Dekker and Co, Basel, Switzerland, Chapter 6, 2001.
- Cummins et al., In: IRT: Nucleosides and nucleosides, La Jolla CA, 72, 1996.
- Dalmay et al. EMBO J, 20:2069-2078, 2001.
- Dalmay et al., Cell, 101:543-553,2000.
- 30 Denli et al., Trends Biochem. Sci., 28:196, 2003.
- Dewanjee et al., Biotechniques, 5: 844-846, 1994.
- Didenko, Biotechniques, 31(5):1106-16, 1118, 1120-1,2001.
- Doench et al., Genes & Dev. 17: 438-442, 2003.
- Doench et al., Genes Dev. 18(5):504-11, 2004.
- 35 Dong et al., Crit Rev Oncol Hematol. 54(2):85-93, 2005.
- Dostie et al., RNA, 9:180-186, 2003.
- Draper and Gold, Biochemistry, 19:1774-1781, 1980.
- Elbashir et al., Nature, 411:494-498, 2001.
- Emptage et al., : Neuron, 2001 Jan;29(1):197-208, 2001.
- 40 Fechheimer et al., Proc. Natl. Acad. Sci. USA, 84:8463-8467, 1987.
- Fire et al., Nature, 391:806-811, 1998.
- Forster et al. Nucleic Acids Res., 13(3):745-761, 1985.
- Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348-3352, 1979.
- Froehler et al., Nucleic Acids Res., 14(13):5399-5407, 1986.
- 45 Gillam et al., J. Biol. Chem., 253:2532, 1978.
- Gillam et al., Nucleic Acids Res., 6:2973, 1979.
- Gopal, Mol. Cell Biol., 5:1188-1190, 1985.
- Graham and Van Der Eb, Virology, 52:456-467, 1973.
- Griffey et al., J Mass Spectrom, 32(3):305-13, 1997.
- 50 Grishok et al., Cell, 106: 23-34, 2001.
- Ha et al., Genes Dev., 10, 3041-3050, 1996.
- Hamilton and Baulcombe, Science, 286:950-952, 1999.
- Hammond et al., Nat. Rev. Genet., 2(2):110-9, 2001.
- Haralambidis et al., Nucleic Acids Res., 18(3):493-9, 1990.
- 55 Harland and Weintraub, J. Cell Biol., 101:1094-1099, 1985.
- Holtke and Kessler, Nucleic Acids Res., 18(19):5843-51, 1990.
- Hutvagner and Zamore, Science, 297(5589):2056-2060, 2002.
- Hutvagner et al., PLoS Biol. 2(4):E98, 2004.

- Hutvagner et al., *Science*, 293:834-838, 2001.  
Itakura and Riggs, *Science*, 209:1401-1405, 1980.  
Itakura et al., *J. Biol. Chem.*, 250:4592, 1975.  
5 Jablonski et al., *Nucleic Acids Res.*, 14(15):6115-6128, 1986.  
Kaepler et al., *Plant Cell Reports*, 9: 415-418, 1990.  
Kaneda et al., *Science*, 243:375-378, 1989.  
Kato et al., *J. Biol. Chem.*, 266:3361-3364, 1991.  
Keller et al., *Analytical Biochemistry*, 170:441-450, 1988.  
10 Ketting et al., *Cell*, 99:133-141, 1999.  
Khorana, *Science*, 203, 614 1979.  
Kimura et al., *Cancer Research*, 55:1379-1384, 1995.  
Kiriakidou et al. *Genes Dev.* 18(10):1165-78, 2004.  
Kitagawa et al., *Brain Res.*, 561:203-11, 1991.  
Klostermeier and Millar, *Biopolymers*, 61(3):159-79, 2001-2002  
15 Knight et al., *Science*, 2:2, 2001.  
Kornberg and Baker, In: *DNA Replication*, 2d Ed., Freeman, San Francisco, 1992.  
Kuhnast et al., *Bioconjug Chem*, 5:627-636, 2000.  
Lagos-Quintana et al., *Science*, 294(5543):853-858, 2001.  
Langer et al., *Proc. Natl. Acad. Sci. USA*, 78(11):663-6637, 1981.  
20 Lau et al., *Science*, 294(5543):858-862, 2001.  
Lee and Ambros, *Science*, 294(5543):862-864, 2001.  
Lee et al., *Nature*, 425(6956):415-419 2003.  
Lee, *EMBO J.*, 21(17):4663-4670 2002.  
Leonetti et al., *Bioconjugate Chem.*, 1:149-153, 1990.  
25 Lewis, *Cell*, 115(7):787-798 2003.  
Lin and Avery, *Nature*, 402:128-129, 1999.  
Liu et al., *Anal. Biochem.*, 289:239-245, 2001.  
Lorenz et al., *Bioorg. Med. Chem. Lett.* 14(19):4975-4977, 2004.  
MacKellar et al., *Nucl. Acids Res.*, 20:3411-3417, 1992.  
30 Manoharan, *Antisense Nucleic Acid Drug Dev.*, 12(2):103-128, 2002.  
Martin et al., *RNA*, 4(2):226-20, 1998.  
Meijer et al., *Progress in Cell cycle research Vol 5*, 219-224. (Meijer, L., Jezequel, A., and Roberge, M. eds), Chapter 22.  
Meister et al., *RNA*, 10(3):544-50, 2004.  
35 Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 95:155-2-15507, 1998.  
Mourrain et al., *Cell*, 101:533,2000.  
Nicolau and Sene, *Biochim. Biophys. Acta*, 721:185-190, 1982.  
Nicolau et al., *Methods Enzymol.*, 149:157-176, 1987.  
Nykanen et al., *Cell*, 107(3):309-321, 2001.  
40 Olsen et al., *Dev. Biol.*, 216:671, 1999.  
Omirulleh et al., *Plant Mol. Biol.*, 21(3):415-428, 1993.  
Oravcova et al., *Blood Press Suppl.*, 1:61-64, 1994.  
Pasquinelli and Ruvkun, *Ann. Rev. Cell Dev. Biol.*, 18:495-513, 2002.  
Piutlle et al., *Gene*, 112(1):101-5, 1992.  
45 Plasterk and Ketting, *Curr. Opin. Genet. Dev.*, 10:562-567, 2000.  
Potrykus et al., *Mol. Gen. Genet.*, 199(2):169-77, 1985.  
Regnier and Preat, *Pharm Res*, 10:1596-602, 1998.  
Reinhart et al., *Nature*, 403:901-906, 2000.  
Reisfeld et al. *Biochem Biophys Res Comm*, 142(2):519-526, 1987.  
50 Richardson and Gumpert, *Nucleic Acids Res*, 11(18):6167-84, 1983.  
Richardson and Macy, *Biochemistry*, 20(5):1133-9, 1981.  
Rippe et al., *Mol. Cell Biol.*, 10:689-695, 1990.  
Roychoudhury and Kossel, *Eur J Biochem*, 22(3):310-20, 1971.  
Rump et al., *Biochem Pharmacol* 59(11): 1407-16, 2000.  
55 Rusckowski et al., *Antisense Nucleic Acid Drug Dev.*, 5:333-345, 2000.  
Rusconi et al., *Nat. Biotechnol.*, 22(11):1423-1428, 2004.  
Saiki et al. *Science*, 230:1350-1354, 1985  
Sambrook et al., In: *DNA microarrays: a molecular cloning manual*, Cold Spring Harbor Laboratory Press, Cold

- Spring Harbor, NY, 2003.
- Sambrook et al., In: *Molecular cloning: a laboratory manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- 5 Sambrook et al., In: *Molecular cloning: a laboratory manual*, 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.
- Scheit, In: *Synthesis and Biological Function*, Wiley-Interscience, New York, 171-172, 1980.
- Schwarze et al., *Trends in Cell Biol.*, 10:290-295, 2000.
- Sedelnikova et al., *Antisense Nucleic Acid Drug Dev.*, 6:443-452, 2000.
- 10 Seggerson et al., *Dev. Biol.*, 243:215, 2002.
- Sharp and Zamore, *Science*, 287:2431-2433, 2000.
- Smardon et al., *Curr. Biol.*, 10:169-178, 2000.
- Sodja et al., *Nucleic Acids Res.*, 5(2):385-401, 1978.
- Soutschek et al., *Nature*, 432(7014):173-178, 2004.
- Sproat et al., *Nucleic Acids Res.*, 17(9):3373-3386, 1989.
- 15 Stalnacke et al., *Eur. J. Nucl. Med.*, 5:166-170, 1985.
- Sui et al., *Proc. Natl. Acad. Sci. USA*, 99(8):5515-5520, 2002.
- Tabara et al., *Cell*, 99:123-132, 1999.
- Takeda and Ikeda, *Nucl. Acids Res.*, 15:101-104, 1984.
- Tuschl, *Chembiochem*, 2:239-245, 2001.
- 20 Uhlenbeck et al., *Nucleic Acids Res.*, 10(11):3341-52, 1982.
- Urdea et al., *Clinical Chemistry*, 35(8):1571-1575, 1989.
- Vella et al., *Genes Dev.* 18(2):132-7, 2004.
- Viscidi et al., *J. Clinical Microbiology*, 23(2):311-317, 1986.
- Vyas et al., *Crit. Rev. Ther. Drug Carrier Syst.*, 18:1-76, 2001.
- 25 Waterhouse et al., *Nature*, 411:834-842, 2001.
- Weeks et al., *Clin. Chem.*, 29(8):1474-1479, 1983.
- Williams et al., *Int. J. Dev. Biol.*, 41(2):359-364, 1997.
- Winter and Brownlee, *Nucleic Acids Res.*, 5(9):3129-39, 1978.
- Wong et al., *Gene*, 10:87-94, 1980.
- 30 Wu et al., *Eur. J. Pharm. Sci.*, 3:179-186, 2000.
- Wu-Scharf et al., *Science*, 290:1159-1162, 2000.
- Xu et al., *Curr. Biol.*, 13:790-795, 2003.
- Yoo et al., *Nucleic Acids Res.*, 21:4225-4231, 2000.
- Zamore et al., *Cell*, 101:25-33, 2000.
- 35 Zamore, *Nat. Struct. Biol.*, 8:746-750, 2001.
- Zeng et al., *Mol Cell*, 9, 1327-33, 2002.
- Zeng et al., *Proc. Natl. Acad. Sci.* 100: 9779-9784, 2003.
- Zhang et al., *Eur. J. Nucl. Med.*, 11:1700-1707, 2000.
- Zhang et al., *J. Mol. Neurosci.*, 1:13-28, 1996.
- 40 Zhang et al., *J. Nucl. Med.*, 11:1660-1669, 2001.
- Ziauddin and Sabatini, *Nature*, 411(6833):107-110, 2001.

45

50

55

EP 2 808 390 A1

SEQUENCE LISTING

<110> ASURAGEN, INC.

5 <120> METHODS AND COMPOSITIONS INVOLVING MODIFIED MIRNA  
MOLECULES AND MIRNA INHIBITOR MOLECULES

<130> R 65977

10 <150> PCT/US2005/041162  
<151> 2005-11-14

<150> 60/683,736  
<151> 2005-05-23

15 <150> 60/649,634  
<151> 2005-02-03

<150> 60/627,171  
<151> 2004-11-12

20 <160> 803

<170> PatentIn Ver. 2.1

<210> 1  
<211> 85  
25 <212> RNA  
<213> Homo sapiens

<400> 1  
30 accuacucag aguacauacu ucuuuaugua ccacauaugaa cauacaaugc uauggaaugu 60  
aaagaaguau guauuuuugg uaggc 85

<210> 2  
<211> 71  
35 <212> RNA  
<213> Homo sapiens

<400> 2  
40 ugggaaacau acuucuuuau augcccacuuu ggaccugcua agcuauaggaa uguaaagaag 60  
uanguaucuc a 71

<210> 3  
<211> 80  
45 <212> RNA  
<213> Homo sapiens

<400> 3  
50 ugggaugagg uaguagguug uauaguuuua gggucacacc caccacuggg agauaacuau 60  
acaauacuacuc gucuuuccua 80

<210> 4  
<211> 72  
55 <212> RNA  
<213> Homo sapiens

<400> 4  
agguugaggu aguagguugu auaguuuuga auuacaucaa gggagauaac uguacagccu 60  
ccuagcuuuc cu 72

EP 2 808 390 A1

<210> 5  
 <211> 74  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 5  
 gggugaggua guagguugua uaguuugggg cucugcccug cuaugggaua acuauacaau 60  
 cuacugucuu uccu 74  
 10  
 <210> 6  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 6  
 cggggugagg uaguagguug ugugguuuca gggcagugau guugcccuc ggaagauaac 60  
 uauacaaccu acugccuucc cug 83  
 20  
 <210> 7  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 7  
 gcauccgggu ugagguagua gguuguaugg uuuagaguua caccucggga guuaacugua 60  
 caaccuucua gcuuuccuug gagc 84  
 30  
 <210> 8  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 8  
 ccuaggaaga gguaguaggu ugcauaguuu uagggcaggg auuuugccca caaggaggua 60  
 acuaucgac cugcugccuu ucuuagg 87  
 40  
 <210> 9  
 <211> 79  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 9  
 cccgggcuga gguaggaggu uguauaguug aggaggacac ccaaggagau cacuaucgg 60  
 ccuccuagcu uccccagg 79  
 50  
 <210> 10  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 10  
 ucagagugag guaguagauu guauaguugu gggguaguga uuuuaccug uucaggagau 60  
 aacuaucua ucuaugccu ucccuga 87  
 <210> 11

EP 2 808 390 A1

<211> 83  
 <212> RNA  
 <213> Homo sapiens

5

<400> 11  
 ugugggauga gguaguagau uguauaguuu uagggucaua ccccaucuug gagauaacua 60  
 uacagucucac ugucuuuccc acg 83

10

<210> 12  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

15

<400> 12  
 uuggauguug gccuaguucu guguggaaga cuagugauuu uguuguuuuu agauaacuaa 60  
 aucgacaaca aaucacaguc ugccauaugg cacaggccau gccucucacag 110

20

<210> 13  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

25

<400> 13  
 cuggauacag aguggaccgg cuggccccaau cuggaagacu agugauuuug uuguugucuu 60  
 acugcgcuca acaacaaauc ccagucucacc uaauggugcc agccaucgca 110

30

<210> 14  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

35

<400> 14  
 agauuagagu ggcugugguc uagugcugug uggaagacua gugauuuugu uguucugaug 60  
 uacuacgaca acaagucaca gccggccuca uagcgcagac ucccuucgac 110

40

<210> 15  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

45

<400> 15  
 aggcugaggu aguaguuuugu acaguuuagag ggucuaugau accaccgggu acaggagaua 60  
 acuguacagg ccacugccuu gccca 84

50

<210> 16  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

55

<400> 16  
 cuggcugagg uaguaguuuug ugcuguuggu cggguuguga cauugcccgc uguggagaua 60  
 acugcgcaag cuacugccuu gcua 84

<210> 17  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 17  
 cggggguuggu uguuauuuuu gguuauuuuu cuguauuuuu gguguggagu cuucauuuag 60  
 cuaguuuacc gaaaguuuuu auuacccca 89

5

<210> 18  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

10

<400> 18  
 ggaagcaggu uguuauuuuu gguuauuuuu cuguauuuuu guuuuggucu ucauuuagcu 60  
 aguuuaccga aaguuuuuuu uccuuca 87

15

<210> 19  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens

20

<400> 19  
 ggaggcccggu uucucuuuuu gguuauuuuu cuguauuuuu gccacagagc cgucauuuag 60  
 cuaguuuacc gaaaguuuuu auguuuucu 90

25

<210> 20  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

30

<400> 20  
 gaucugucug ucuucuuuuu auaccuuuuu gaucuuuuuu uguguuuuuu auuuuugggu 60  
 cacuuuuuucg uauuuuuuuu aauuuuuuuu ugacuuuuuu acuccuuuuu 110

35

<210> 21  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

40

<400> 21  
 ccagagguug uaacuuuuuu uuuuuuuuuu cuguuuuuuu gaauuuuuuu gguuuuuuuu 60  
 uaguuuuuuu uuuuuuuuuu ggguuuuuuu ugguuuuuuu aaaaauuuuu 110

45

<210> 22  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens

50

<400> 22  
 ccuuggaguu aaguuuuuuu acuuuuuuuu uuuuuuuuuu uuuuuuuuuu caguuuuuuu 60  
 uuuuuuuuuu cuuuuuuuuu agg 83

55

<210> 23  
 <211> 98  
 <212> RNA  
 <213> Homo sapiens

<400> 23  
 uuuuuuuuuu aauuuuuuuu aguuuuuuuu cuuuuuuuuu auuuuuuuuu cauuuuuuuu 60

aucauuuuuu gcugcucuag aaauuuuagg aaauucau 98

5  
 <210> 24  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

10  
 <400> 24  
 gucagcagug ccuuagcagc acguaaaauu uggcguaaag auucuaaaaau uaucuccagu 60  
 auuaacugug cugcugaagu aagguugac 89

15  
 <210> 25  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens

20  
 <400> 25  
 guuccacucu agcagcacgu aaauauuggc guagugaaaau auauuuuuuu caccauuuu 60  
 acugugcugc uuuaguguga c 81

25  
 <210> 26  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

30  
 <400> 26  
 gucagaauaa ugucaaagug cuuacagugc agguagugau augugcaucu acugcaguga 60  
 aggcacuugu agcauuauug ugac 84

35  
 <210> 27  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens

40  
 <400> 27  
 uguucuaagg ugcaucuagu gcagauagug aaguagauua gcaucuacug ccuaagugc 60  
 uccuucuggc a 71

45  
 <210> 28  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

50  
 <400> 28  
 gcaguccucu guuaguuuug cauaguugca cuacaagaag aauguaguug ugcaaaucua 60  
 ugcaaaacug augguggccu gc 82

55  
 <210> 29  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

55  
 <400> 29  
 cacuguucua ugguuaguuu ugcagguuug cauccagcug ugugauuuuc ugcugugcaa 60  
 auccaugcaa aacugacugu gguagug 87

EP 2 808 390 A1

<210> 30  
 <211> 96  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 30  
 acauugcuac uuacaauuag uuuugcaggu uugcauuuca gcguauauau guauaugugg 60  
 cugugcaaa ccaugcaaaa cugauuguga uaaugu 96  
 10  
 <210> 31  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 31  
 guagcacuaa agugcuuaua gugcagguag uguuuaguua ucuacugcau uaugagcacu 60  
 uaaaguacug c 71  
 20  
 <210> 32  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 32  
 ugucggguag cuuauacagac ugauguugac uguugaauacu cauggcaaca ccagucgaug 60  
 ggucugucuga ca 72  
 30  
 <210> 33  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 33  
 ggcugagccg caguaguucu ucaguggcaa gcuuuauuguc cugacccagc uaaagcugcc 60  
 aguugaagaa cuguugcccu cugcc 85  
 40  
 <210> 34  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 34  
 ggccggcugg gguuccuggg gaugggauuu gcuuccuguc acaaaucaca uugccagggg 60  
 uuuccaaccg acc 73  
 50  
 <210> 35  
 <211> 97  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 35  
 cucaggugcu cuggcugcuu gguuccugg caugcugauu ugugacuuaa gauuaaauc 60  
 acauugccag ggauuaccac gcaaccacga ccuuggc 97  
 55  
 <210> 36  
 <211> 68  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens  
 <400> 36  
 5 cuccggugcc uacugagcug auaucaguuc ucauuuuaca cacuggcuca guucagcagg 60  
 aacaggag 68

<210> 37  
 <211> 73  
 <212> RNA  
 10 <213> Homo sapiens

<400> 37  
 15 cucugccucc cgugccuacu gagcugaaac acaguugguu uguguacacu ggcucaguuc 60  
 agcaggaaca ggg 73

<210> 38  
 <211> 84  
 <212> RNA  
 20 <213> Homo sapiens

<400> 38  
 25 ggccaguguu gagaggcga gacuugggca auugcuggac gcugcccugg gcauugcacu 60  
 ugucucgguc ugacagugcc ggcc 84

<210> 39  
 <211> 77  
 <212> RNA  
 30 <213> Homo sapiens

<400> 39  
 35 guggccucgu ucaaguaauc caggauaggc ugugcagguc ccaaugggcc uauucuuggu 60  
 uacuugcacg gggacgc 77

<210> 40  
 <211> 77  
 <212> RNA  
 40 <213> Homo sapiens

<400> 40  
 45 ccgggaccca guucaagua uucaggauag guugugugcu guccagccug uucuccauua 60  
 cuuggcucgg ggaccgg 77

<210> 41  
 <211> 84  
 <212> RNA  
 50 <213> Homo sapiens

<400> 41  
 55 ggcuguggcu ggauucaagu aauccaggau aggcuguuuc caucugugag gccuauucuu 60  
 gauuacuugu uucuggaggc agcu 84

<210> 42  
 <211> 78  
 <212> RNA  
 <213> Homo sapiens

<400> 42

EP 2 808 390 A1

cugaggagca gggcuuagcu gcuugugagc aggguccaca ccaagucgug uucacagugg 60  
cuaaguuccg ccccccag 78

5 <210> 43  
<211> 97  
<212> RNA  
<213> Homo sapiens

10 <400> 43  
accucucuaa caaggugcag agcuuagcug auuggugaac agugauuggu uuccgcuuug 60  
uucacagugg cuaaguucug caccugaaga gaaggug 97

15 <210> 44  
<211> 86  
<212> RNA  
<213> Homo sapiens

20 <400> 44  
gguccuugcc cucaaggagc ucacagucua uugaguuacc uuucugacuu ucccacuaga 60  
uugugagcuc cuggagggca ggcacu 86

25 <210> 45  
<211> 64  
<212> RNA  
<213> Homo sapiens

30 <400> 45  
augacugauu ucuuuuggug uucagaguca auauuuuuu cuagcaccau cugaaaucgg 60  
uuau 64

35 <210> 46  
<211> 81  
<212> RNA  
<213> Homo sapiens

40 <400> 46  
cuucaggaag cugguuucac auggugguuu agauuuuuu agugauuguc uagcaccau 60  
ugaaaucagu guucuugggg g 81

45 <210> 47  
<211> 81  
<212> RNA  
<213> Homo sapiens

50 <400> 47  
cuucuggaag cugguuucac augguggcuu agauuuuuu aucuuuguau cuagcaccau 60  
uugaaaucag uguuuuagga g 81

55 <210> 48  
<211> 88  
<212> RNA  
<213> Homo sapiens

<400> 48  
aucucuuaa caggcugacc gauuucuccu gguguucaga gucuguuuuu gucuagcacc 60  
auuugaaauc gguaugaug uaggggga 88

EP 2 808 390 A1

<210> 49  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 49  
 gcgacuguaa acauccucga cuggaagcug ugaagccaca gaugggcuuu cagucggaug 60  
 uuugcagcug c 71  
 10  
 <210> 50  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 50  
 agauacugua acauccuac acucucagcu guggaaagua agaaagcugg gagaaggcug 60  
 uuuacucuuu cu 72  
 20  
 <210> 51  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 51  
 guuguuguaa acauccccga cuggaagcug uaagacacag cuaagcuuuc agucagaugu 60  
 uugcugcuac 70  
 30  
 <210> 52  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 52  
 accaaguuuc aguucaugua acauccuac acucagcugu aauacaugga uuggcuggga 60  
 gguggauguu uacuucagcu gacuugga 88  
 40  
 <210> 53  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 53  
 accaugcugu agugugugua acauccuac acucucagcu gugagcucaa gguggcuggg 60  
 agaggguugu uuacuccuuc ugccaugga 89  
 50  
 <210> 54  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 54  
 cuguaaacau ccuugacugg aagcuguaag guguucagag gagcuuucag ucggauguuu 60  
 acag 64

EP 2 808 390 A1

<212> RNA  
 <213> Homo sapiens  
  
 <400> 55  
 5 ggagaggagg caaugcug gcaugcugu ugaacuggga accugcuaug ccaacauauu 60  
 gccaucuuuc c 71  
  
 <210> 56  
 <211> 70  
 10 <212> RNA  
 <213> Homo sapiens  
  
 <400> 56  
 15 ggagauauug cacauuacua aguugcaugu ugucacggcc ucaaugcaau uuagugugug 60  
 ugauauuuuc 70  
  
 <210> 57  
 <211> 69  
 20 <212> RNA  
 <213> Homo sapiens  
  
 <400> 57  
 25 cuguggugca uuguaguugc auugcauguu cuggugguac ccaugcaaug uuuccacagu 60  
 gcaucacag 69  
  
 <210> 58  
 <211> 110  
 <212> RNA  
 30 <213> Homo sapiens  
  
 <400> 58  
 35 ggccagcugu gaguguuucu uuggcagugu cuuagcuggu uguugugagc aauguaaagg 60  
 aagcaucag caaguauacu gcccuagaag ugcugcacgu uguggggccc 110  
  
 <210> 59  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
  
 40 <400> 59  
 gugcucgguu uguaggcagu gucauuagcu gauuguacug uggugguuac aaucacuaac 60  
 uccacugcca ucaaaacaag gcac 84  
  
 <210> 60  
 <211> 77  
 <212> RNA  
 <213> Homo sapiens  
  
 45 <400> 60  
 50 agucuaguua cuaggcagug uaguuagcug auugcuaaau guaccaauca cuaaccacac 60  
 ggccagguaa aaagauu 77  
  
 <210> 61  
 <211> 78  
 <212> RNA  
 55 <213> Homo sapiens

EP 2 808 390 A1

<400> 61  
 cuuucuacac agguugggau cgguugcaau gcuguguuuc uguaugguau ugcacuuguc 60  
 ccggccuguu gaguuugg 78

5

<210> 62  
 <211> 75  
 <212> RNA  
 <213> Homo sapiens

10

<400> 62  
 ucaucccugg guggggauuu guugcauuac uuguguucua uauaaaguau ugcacuuguc 60  
 ccggccugug gaaga 75

15

<210> 63  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens

20

<400> 63  
 cugggggcuc caaagugcug uucgugcagg uagugugauu acccaaccua cugcugagcu 60  
 agcacuuccc gagcccccg 80

25

<210> 64  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens

30

<400> 64  
 aacacagugg gcacucaaua aaugucuguu gaauugaaau gcguuacauu caacggguau 60  
 uauaugagca cccacucugu g 81

35

<210> 65  
 <211> 78  
 <212> RNA  
 <213> Homo sapiens

40

<400> 65  
 uggccgauuu uggcacuagc acauuuuugc uugugucucu ccgcucugag caaucaugug 60  
 cagugccaau augggaaa 78

45

<210> 66  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens

50

<400> 66  
 gugagguagu aaguuguauu guugugggggu agggauauua ggccccauu agaagauaac 60  
 uauacaacuu acuacuuucc 80

55

<210> 67  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens

<400> 67  
 cccauuggca uaaacccgua gauccgaucu uguggugaag uggaccgcac aagcucgcu 60  
 cuaugggucu gugucagugu g 81

EP 2 808 390 A1

<210> 68  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 68  
 ggcacccacc cguagaaccg accuugcggg gccuucgccg cacacaagcu cgugucugug 60  
 gguccguguc 70  
 10  
 <210> 69  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 69  
 ccuguugcca caaacccgua gauccgaacu ugugguauua guccgcacaa gcuuguaucu 60  
 auagguaugu gucuguuagg 80  
 20  
 <210> 70  
 <211> 75  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 70  
 ugcccuggcu caguuaucac agugcugaug cugucuauc uaaagguaca guacugugau 60  
 aacugaagga uggca 75  
 30  
 <210> 71  
 <211> 79  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 71  
 acuguccuuu uucgguuauc augguaccga ugcuguauau cugaaaggua caguacugug 60  
 auaacugaag aaugguggu 79  
 40  
 <210> 72  
 <211> 78  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 72  
 uugugcuuuc agcuucuua cagugcugcc uuguagcauu caggucaagc agcauuguac 60  
 agggcuaua aagaacca 78  
 50  
 <210> 73  
 <211> 78  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 73  
 uacugcccuc ggcuucuua cagugcugcc uuguugcaua uggaucaagc agcauuguac 60  
 agggcuaua aggcuuug 78  
 <210> 74

EP 2 808 390 A1

<211> 81  
 <212> RNA  
 <213> Homo sapiens

5

<400> 74  
 ugugcaucgu ggucaaaugc ucagacuccu gugguggcug cucaugcacc acggauguuu 60  
 gagcaugugc uacggugucu a 81

10

<210> 75  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens

15

<400> 75  
 ugugcaucgu ggucaaaugc ucagacuccu gugguggcug cuuauugcacc acggauguuu 60  
 gagcaugugc uauggugucu a 81

20

<210> 76  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens

25

<400> 76  
 ccuuggccau guaaaagugc uuacagugca gguagcuuuu ugagaucucac ugcaauguaa 60  
 gcacuucuua cauaccaug g 81

30

<210> 77  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

35

<400> 77  
 ccugccgggg cuaaagugcu gacagugcag auaguggucc ucuccgugcu accgcacugu 60  
 ggguaacuugc ugcuccagca gg 82

40

<210> 78  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens

45

<400> 78  
 cucucugcuu ucagcuucuu uacaguguug ccuuguggca uggaguucuaa gcagcauugu 60  
 acagggcuau caaagcacag a 81

50

<210> 79  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

55

<400> 79  
 ccuuagcaga gcuguggagu gugacaaugg uguuuguguc uaaacuauca aacgccauua 60  
 ucacacuaaa uagcuacugc uaggc 85

<210> 80  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 80  
 aggccucucu cuccguguuc acagcggacc uugauuuaaa uguccauaca auuaaggcac 60  
 gcggugaaug ccaagaaugg ggcug 85

5

<210> 81  
 <211> 109  
 <212> RNA  
 <213> Homo sapiens

10

<400> 81  
 aucaagauua gaggcucugc ucuccguguu cacagcggac cuugauuuua ugucauacaa 60  
 uuaaggcacg cggugaaugc caagagcggga gccuacggcu gcacuugaa 109

15

<210> 82  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

20

<400> 82  
 ugagggcccc ucugcuguguu cacagcggac cuugauuuua ugucuauaca auuaaggcac 60  
 gcggugaaug ccaagagagg cgccucc 87

25

<210> 83  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens

30

<400> 83  
 ugcgcuccuc ucagucccug agaccguaac uugugauguu uaccguuuua auccacgggu 60  
 uaggcucuug ggagcugcga gucgugcu 88

35

<210> 84  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

40

<400> 84  
 ugccagucuc uaggucccug agaccuuua accugugagg acauccaggg ucacagguga 60  
 gguucuuggg agccuggcgu cuggcc 86

45

<210> 85  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

50

<400> 85  
 accagacuuu uccuaguccc ugagaccua acuugugagg uauuuuagua acaucacaag 60  
 ucaggcucuu gggaccuagg cggagggga 89

55

<210> 86  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

<400> 86  
 cgcuggcgcac gggacauuau uacuuuuggu acgcgcugug acacuucaaa cucguaccgu 60

gaguaauauu gcgccgucca cggca 85

5 <210> 87  
<211> 97  
<212> RNA  
<213> Homo sapiens

<400> 87  
10 ugugaucacu gucuccagcc ugcugaagcu cagagggcuc ugauucagaa agaucaucgg 60  
auccgucuga gcuuggcugg ucggaagucu caucauc 97

15 <210> 88  
<211> 82  
<212> RNA  
<213> Homo sapiens

<400> 88  
20 ugagcuguug gauucggggc cguagcacug ucugagaggu uuacauuucu cacagugaac 60  
cggucucuuu uucagcugcu uc 82

25 <210> 89  
<211> 84  
<212> RNA  
<213> Homo sapiens

<400> 89  
30 ugugcagugg gaaggggggc cgaucacacug uacgagagug aguagcaggu cucacaguga 60  
accggucucu uucccuacug uguc 84

35 <210> 90  
<211> 90  
<212> RNA  
<213> Homo sapiens

<400> 90  
40 ugcccuucgc gaauuuuuu gcgucuggg cuugcuguac auaacucaau agccggaagc 60  
ccuuaaccca aaaagcauuu gcgaggggcg 90

45 <210> 91  
<211> 89  
<212> RNA  
<213> Homo sapiens

<400> 91  
50 ugcugcuggc cagagcucu uucacauugu gcuacugucu gcaccuguca cuagcagugc 60  
aauguuaaaa gggcauuggc cguguagug 89

55 <210> 92  
<211> 82  
<212> RNA  
<213> Homo sapiens

<400> 92  
ggccugcccg acacucuuuc ccuguugcac uacuauaggc cgcugggaag cagugcaaug 60  
augaaagggc aucggucagg uc 82

EP 2 808 390 A1

<210> 93  
 <211> 101  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 93  
 ccgccccgc gucuccaggg caaccguggc uuucgauugu uacuguggga acuggaggua 60  
 acagucuaca gccauggucg ccccgagca cggccacgcg c 101  
 10  
 <210> 94  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 94  
 acaaugcuuu gcuagagcug guaaaaugga accaaucgc cucuucuaug gauuuggucc 60  
 ccuucacca gcuguagcua ugcauuga 88  
 20  
 <210> 95  
 <211> 102  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 95  
 gggagccaaa ugcuuugcua gagcugguaa aauggaacca aaucgacugu ccaugggau 60  
 uggucuccuu caaccagcug uagcugugca uugauggcgc cg 102  
 30  
 <210> 96  
 <211> 119  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 96  
 ccucagaaga aaugcuccc cugcucuggc uggucuaacg gaaccaaguc cgucuuuccug 60  
 agagguuugg uccccucaa ccagcuacag cagggcuggc aaugcccagu ccuuggaga 119  
 40  
 <210> 97  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 97  
 cagggugugu gacugguuga ccagaggggc augcacugug uucaccugug gggccaccua 60  
 gucaccaacc cuc 73  
 50  
 <210> 98  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 98  
 aggccucgcu guucucuauug gcuuuuuuuu ccuaugugau ucuacugcuc acucauauag 60  
 ggauuggagc cguggcgcac ggcggggaca 90

EP 2 808 390 A1

<213> Homo sapiens

<400> 99  
 5 agauaaaauuc acucuagugc uuuauuggcuu uuuaauuccua ugugauagua auaaagucuc 60  
 auguagggau ggaagccaug aaauacauug ugaaaaauca 100

<210> 100  
 <211> 97  
 <212> RNA  
 10 <213> Homo sapiens

<400> 100  
 cacucugcug uggccuauagg cuuuucauuc cuaugugauu gcugucccaa acucauguag 60  
 15 ggcuaaaaagc caugggcuac agugaggggc gagcucc 97

<210> 101  
 <211> 82  
 <212> RNA  
 20 <213> Homo sapiens

<400> 101  
 ugagcccucg gaggacucca uuuguuuuga ugauggauuc uuaugcucca ucaucgucuc 60  
 25 aaaugagucu ucagaggguu cu 82

<210> 102  
 <211> 102  
 <212> RNA  
 <213> Homo sapiens

<400> 102  
 30 gguccucuga cucucuucgg ugacggguau ucuugggugg auaauacgga uuacguuguu 60  
 auugcuuaag aaucgcgua gucgaggaga guaccagcgg ca 102

<210> 103  
 <211> 84  
 <212> RNA  
 35 <213> Homo sapiens

<400> 103  
 40 cguugcugca gcugguguug ugaaucaggc cgacgagcag cgcauccucu uacccggcua 60  
 uuucacgaca ccaggguugc auca 84

<210> 104  
 <211> 99  
 <212> RNA  
 45 <213> Homo sapiens

<400> 104  
 cccuggcaug gugugguggg gcagcuggug uugugaauca ggccguugcc aaucagagaa 60  
 50 cggcuacuuc acaacaccag ggccacacca cacuacagg 99

<210> 105  
 <211> 68  
 <212> RNA  
 55 <213> Homo sapiens

<400> 105

EP 2 808 390 A1

1 guguauucua cagugcacgu gucuccagug uggcucggag gcuggagacg cggcccuguu 60  
 ggaguaac 68

5 <210> 106  
 <211> 100  
 <212> RNA  
 <213> Homo sapiens

10 <400> 106  
 ugugucucuc ucuguguccu gccagugguu uuaccuauug guagguuacg ucaugcuguu 60  
 cuaccacagg guagaaccac ggacaggaua ccggggcacc 100

15 <210> 107  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

20 <400> 107  
 cggccggccc uggguccauc uuccaguaca guguuggaug gucuaauugu gaagcuccua 60  
 acacugucug guaaagaugg cucccgggug gguuc 95

25 <210> 108  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

30 <400> 108  
 gacagugcag ucacccauaa aguagaaagc acuacuaaca gcacuggagg guguauguu 60  
 uccuacuuua uggaugagug uacugug 87

35 <210> 109  
 <211> 106  
 <212> RNA  
 <213> Homo sapiens

40 <400> 109  
 gcgcagcgc cugucuccca gccugaggug cagugcugca ucucugguca guugggaguc 60  
 ugagaugaag cacuguagcu caggaagaga gaaguuguuc ugcagc 106

45 <210> 110  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

50 <400> 110  
 uggggcccug gcugggauau caucauauac uguaaguug cgaugagaca cuacaguaua 60  
 gaugauguac uaguccgggc accccc 86

55 <210> 111  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens

<400> 111  
 caccuugucc ucacggucca guuuucccag gaaucccuua gaugcuaaga uggggauucc 60  
 uggaaauacu guucuugagg ucauguu 88

EP 2 808 390 A1

<210> 112  
 <211> 99  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 112  
 ccgaugugua uccucagcu ugagaacuga auuccauggg uugugucagu gucagaccuc 60  
 ugaaauucag ucuucagcu gggauaucuc ugucaucgu 99  
 10  
 <210> 113  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 113  
 aaucuaaaga caacauuucu gcacacacac cagacuaugg aagccagugu guggaaaugc 60  
 uucugcuaga uu 72  
 20  
 <210> 114  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 114  
 gaggcaaagu ucugagacac uccgacucug aguaugauag aagucagugc acuacagaac 60  
 uuugucuc 68  
 30  
 <210> 115  
 <211> 99  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 115  
 caagcacgau uagcauuuga ggugaaguuc uguuauacac ucaggcugug gcucucugaa 60  
 agucagugca ucacagaacu uugucucgaa agcuuucua 99  
 40  
 <210> 116  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 116  
 gccggcgccc gagcucuggc uccgugucuu cacucuccgug cuuguccgag gagggagggg 60  
 gggacggggg cugugcuggg gcagcugga 89  
 50  
 <210> 117  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 117  
 cucccaugg cccugucucc caaccuugu accagugcug ggcucagacc cugguacagg 60  
 ccugggggac agggaccugg ggac 84

EP 2 808 390 A1

<212> RNA  
 <213> Homo sapiens  
  
 <400> 118  
 5 uuuccugccc ucgaggagcu cacagucuag uaugucucau ccccuacuag acugaagcuc 60  
 cuugaggaca gggauuguca uacucaccuc 90  
  
 <210> 119  
 <211> 87  
 10 <212> RNA  
 <213> Homo sapiens  
  
 <400> 119  
 15 uguccecccc ggcccagguu cugugauaca cuccgacucg ggcucuggag cagucaguc 60  
 augacagaac uugggcccgg aaggacc 87  
  
 <210> 120  
 <211> 90  
 20 <212> RNA  
 <213> Homo sapiens  
  
 <400> 120  
 cucacagcug ccagugucau uuuugugauc ugcagcuagu auucucacuc caguugcaua 60  
 25 gucacaaaag ugaucuuugg cagguguggc 90  
  
 <210> 121  
 <211> 87  
 <212> RNA  
 30 <213> Homo sapiens  
  
 <400> 121  
 agcggugggcc agugucauuu uugugauguu gcagcuagua auaugagccc aguugcauag 60  
 ucacaaaagu gaucauugga aacugug 87  
  
 <210> 122  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 35  
  
 <400> 122  
 40 gugguacuug aagauagguu auccguguug ccuucgcuuu auuugugacg aaucuacac 60  
 gguugaccua uuuucagua ccaa 84  
  
 <210> 123  
 <211> 65  
 <212> RNA  
 <213> Homo sapiens  
 45  
  
 <400> 123  
 50 cuguuaaugc uaaucgugau agggguuuuu gccuccaacu gacuccuaca uauuagcauu 60  
 aacag 65  
  
 <210> 124  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 55

EP 2 808 390 A1

<400> 124  
 agaagggcua ucagggcagc cuucagagga cuccaaggaa cauuccaacgc ugucggugag 60  
 uuugggauuu gaaaaaacca cugaccguug acuguaccuu ggggucuuua 110

5

<210> 125  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

10

<400> 125  
 ccugugcaga gauuauuuuu uaaaagguca caaucaacau ucauugcugu cgguggguug 60  
 aacugugugg acaagcucac ugaacaauga augcaacugu ggccccgcuu 110

15

<210> 126  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

20

<400> 126  
 cgaaaaauuu gccaaaggguu ugggggaaca uucaaccugu cggugaguuu gggcagcuca 60  
 ggcaaaccuau cgaccguuga guggaccug aggccuggaa uugccaucuu 110

25

<210> 127  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

30

<400> 127  
 cugauggcug cacucaacau ucauugcugu cgguggguuu gagucugaau caacucacug 60  
 aucaaugaau gcaaacugcg gaccaaaca 89

35

<210> 128  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

40

<400> 128  
 gagcugcuug ccuc(cccccg) uuuuuggcaa ugguagaacu cacacuggug agguaacagg 60  
 auccgguggu ucuaagacuug ccaacuauug ggcgaggacu cagccggcac 110

45

<210> 129  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

50

<400> 129  
 ccgcagagug ugacuccugu ucuguguaug gcacugguag aaucacugu gaacagucuc 60  
 agucagugaa uuaccgaagg gccauaaaca gagcagagac agauccacga 110

55

<210> 130  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

<400> 130  
 ccagucacgu ccccuuauca cuuuuccagc ccagcuuugu gacuguaagu guuggacgga 60  
 gaacugauaa gguuagguga uuga 84

EP 2 808 390 A1

<210> 131  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 131  
 agggggcgag ggauuggaga gaaaggcagu uccugauggu cccucuccca ggggcuggcu 60  
 uuccucuggu ccuuccucc ca 82  
 10  
 <210> 132  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 132  
 ugcuuguaac uuuccaaaga auucucuuu ugggcuuuc gguuuuuuu uaagcccaa 60  
 ggugaauuu uugggaagu ugagcu 86  
 20  
 <210> 133  
 <211> 109  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 133  
 ggucgggcuc accaugacac agugugagac cucgggcuac aacacaggac cggggcgug 60  
 cucugacccc ucgugucuug uguugcagcc ggagggacgc agguccgca 109  
 30  
 <210> 134  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 134  
 ugcucccucu cucacaucuu uugcauggug gagggugagc uuucugaaaa cccucuccac 60  
 augcaggguu ugcaggaugg cgagcc 86  
 40  
 <210> 135  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 135  
 ugcaggccuc ugugugauau guuugauau uuagguugu auuuauuca acuaauauc 60  
 aaacauauuc cuacaguguc uugcc 85  
 50  
 <210> 136  
 <211> 92  
 <212> RNA  
 <213> Homo sapiens  
 <400> 136  
 cggcuggaca gcgggcaacg gaaucccaa agcagcuguu gucuccagag cauuccagcu 60  
 gcgcuuggau uucgucuccu gcucuccugc cu 92  
 55  
 <210> 137

EP 2 808 390 A1

<211> 110  
 <212> RNA  
 <213> Homo sapiens

5

<400> 137  
 gccgagaccg agugcacagg gcucugaccu augaaugac agccagugcu cucgucucc 60  
 cucuggcugc caauuccaau ggucacaggu auguucgccu caaugccagc 110

10

<210> 138  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens

15

<400> 138  
 cgaggauagg agcugagggc ugggucuuug cgggcgagau gagggugucg gaucaacugg 60  
 ccuacaaagu cccaguucuc ggcccccg 88

20

<210> 139  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

25

<400> 139  
 augguguuau caaguguaac agcaacucca uguggacugu guaccaauuu ccaguggaga 60  
 ugcuguuacu uuugaugguu accaa 85

30

<210> 140  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

35

<400> 140  
 ugguucccgc cccuguaac agcaacucca uguggaagug cccacugguu ccaguggggc 60  
 ugcuguuauuc uggggcgagg gccag 85

40

<210> 141  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

45

<400> 141  
 agcuucccug gcucuagcag cacagaaaau uggcacagg gaagcgaguc ugccaauuu 60  
 ggucugugcug cuccaggcag gguggug 87

50

<210> 142  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens

55

<400> 142  
 gugaauuagg uaguuucaug uuguugggcc ugguuucug aacacaaca cauuuaacca 60  
 cccgauucac 70

<210> 143  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 143  
 ugcucgcuca gcugaucugu ggcuuaggua guuucauguu guugggauug aguuuugaac 60  
 ucggcaacaa gaaacugccu gaguuacauc agucgguuuu cgucgagggc 110

5

<210> 144  
 <211> 75  
 <212> RNA  
 <213> Homo sapiens

10

<400> 144  
 ggcugugccg gguagagagg gcagugggag guaagagcuc uucacccuuc accaccuucu 60  
 ccaccagca uggcc 75

15

<210> 145  
 <211> 62  
 <212> RNA  
 <213> Homo sapiens

20

<400> 145  
 ucauuggucc agaggggaga uagguuccug ugauuuuucc uucuucucua uagaauaaa 60  
 ga 62

25

<210> 146  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens

30

<400> 146  
 gccaacccag uguucagacu accuguucag gaggcucuca auguguacag uagucugcac 60  
 auugguuagg c 71

35

<210> 147  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

40

<400> 147  
 aggaagcuuc uggagauccu gcuccgucgc cccaguguuc agacuaccug uucaggacaa 60  
 ugccguugua caguagucug cacauugguu agacugggca agggagagca 110

45

<210> 148  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

50

<400> 148  
 ccagaggaca ccuccacucc gucuaccag uguuuagacu aucuguucag gacucccaaa 60  
 uuquacagua gucugcacau ugguuaggcu gggcuggguu agaccucgg 110

55

<210> 149  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

<400> 149  
 ccagcucggg cagccguggc caucuucug ggcagcauug gauggaguca ggucucuaau 60

acugccuggu aaugaugacg gcggagcccu gcacg 95

5 <210> 150  
<211> 68  
<212> RNA  
<213> Homo sapiens

10 <400> 150  
cccucgucuu acccagcagu guuugggugc gguugggagu cucuaauacu gccggguaau 60  
gauggagg 68

15 <210> 151  
<211> 90  
<212> RNA  
<213> Homo sapiens

20 <400> 151  
ccgggccccu gugagcaucu uaccggacag ugcuggauuu cccagcuuga cucuaacacu 60  
gucugguaac gauguucaa ggugacccgc 90

25 <210> 152  
<211> 110  
<212> RNA  
<213> Homo sapiens

30 <400> 152  
guguugggga cucgcgcgcu ggguccagug guucuuaaca guucaacagu ucuguagcgc 60  
aaugugaaa uguuuaggac cacuagacc gccgggcgcg gcgacagcga 110

35 <210> 153  
<211> 110  
<212> RNA  
<213> Homo sapiens

40 <400> 153  
ggcuacaguc uuucuucaug ugacucgugg acuucccuuu gucauccuau gccugagaau 60  
auaugaagga gccugggaag gcaaaggac guucaauugu caucacuggc 110

45 <210> 154  
<211> 110  
<212> RNA  
<213> Homo sapiens

50 <400> 154  
aaagauccuc agacaaucca ugugcuucuc uuguccuua uuccaccgga gucugucuca 60  
uacccaacca gauucagug gagugaagu caggaggcau ggagcugaca 110

55 <210> 155  
<211> 86  
<212> RNA  
<213> Homo sapiens

<400> 155  
ugcuucccga ggccacaugc uucuuuauau ccccauugg auuacuugc uauggaangu 60  
aaggaagugu gugguuucg caagug 86

EP 2 808 390 A1

<210> 156  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 156  
 ugacgggcga gcuuuuggcc cggguuauac cugaugcuca cguauaagac gagcaaaaag 60  
 cuuguugguc a 71  
 10  
 <210> 157  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 157  
 acccggcagu gccuccaggc gcagggcagc ccugcccac cgcacacugc gcugcccag 60  
 acccacugug cgugugacag cggcugaucu gugccugggc agcgcgaccc 110  
 20  
 <210> 158  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 158  
 ucaccuggcc augugacuug ugggcuuccc uuugucaucc uucgccuagg gcucugagca 60  
 gggcagggac agcaaagggg ugcucaguug ucacuuccca cagcacggag 110  
 30  
 <210> 159  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 159  
 cggggcaccc cgcccggaca gcgcgccggc accuuggcuc uagacugcuu acugcccggg 60  
 ccgccucag uaacagucuc cagucacggc caccgacgcc uggccccgcc 110  
 40  
 <210> 160  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 160  
 ugaguuuuga gguugcuuca gugaacauuc aacgcugucg gugaguugg aaauaaauc 60  
 aaaaccaucg accguugauu guaccuauug gcuaaccauc aucuacucca 110  
 50  
 <210> 161  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 161  
 ggccuggcug gacagaguug ucaugugucu gccugucuac acuugcugug cagaacauc 60  
 gcucaccugu acagcaggca cagacaggca gucacaugac aaccagccu 110  
 <210> 162  
 <211> 110  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens

<400> 162

aucauucaga aaugguauac aggaaaauga ccuaugaauu gacagacaau auagcugagu 60  
 uugucuguca uuucuuuagc ccaauauucu guaugacugu gcuacuucua 110

<210> 163

<211> 110

<212> RNA

<213> Homo sapiens

<400> 163

gauggcugug aguuggcuua aucucagcug gcaacuguga gauguucaua caaucccua 60  
 caguggucuc ugggauuaug cuaaacagag caauuuccua gccucacga 110

<210> 164

<211> 110

<212> RNA

<213> Homo sapiens

<400> 164

aguauaaaua uuacauaguu uuugaugucg cagauacugc aucaggaacu gauuggauaa 60  
 gaucaguca ccaucaguuc cuaaugcauu gccuucagca ucuaaacaag 110

<210> 165

<211> 110

<212> RNA

<213> Homo sapiens

<400> 165

gugauaaugu agcgagauuu ucuguugugc uugaucuaac caugugguug cgagguauga 60  
 guaaaacaug guuccgucaa gcaccaugga acgucacgca gcuuucuaca 110

<210> 166

<211> 110

<212> RNA

<213> Homo sapiens

<400> 166

gaccagucgc ugcggggcuu uccuuugugc uugaucuaac cauguggugg aacgauggaa 60  
 acggaacaug guucugucuaa gcaccgcgga aagcaccgug cucuccugca 110

<210> 167

<211> 110

<212> RNA

<213> Homo sapiens

<400> 167

ccgccccggg ccgcggcucc ugauugucca aacgcaauuc ucgagucuau ggcuccggcc 60  
 gagaguugag ucuggacguc ccgagccgcc gcccccaaac cucgagcggg 110

<210> 168

<211> 97

<212> RNA

<213> Homo sapiens

<400> 168

EP 2 808 390 A1

acucaggggc uucgccacug auuguccaaa cgcaauucuu guacgagucu gcgccaacc 60  
gagaauugug gcuggacauc uguggcugag cuccggg 97

5 <210> 169  
<211> 110  
<212> RNA  
<213> Homo sapiens

10 <400> 169  
gacagugugg cauuguaggg cuccacaccg uaucugacac uuugggagagg ggcaccaugc 60  
ugaagguguu caugaugcgg ucugggaacu ccucacggau cuuacugaug 110

15 <210> 170  
<211> 110  
<212> RNA  
<213> Homo sapiens

20 <400> 170  
ugaacaacca ggucuggggc augaaccugg cauacaaugu agauuucugu guucguuagg 60  
caacagcuac auugucugcu ggguuucagg cuaccuggaa acauguucuc 110

25 <210> 171  
<211> 110  
<212> RNA  
<213> Homo sapiens

30 <400> 171  
gcugcuggaa gguguaggua cccucaaugg cucaguagcc aguguagauc cugucuuucg 60  
uaaucagcag cuacaucugg cuacuggguc ucugauggca ucuucuaagcu 110

35 <210> 172  
<211> 110  
<212> RNA  
<213> Homo sapiens

40 <400> 172  
ccuggccucc ugcagugcca cgcuccgugu auuugacaag cugaguugga cacuccaugu 60  
gguagagugu caguuuuguca aaaucccaaa gugcggcaca ugcuuaccag 110

45 <210> 173  
<211> 81  
<212> RNA  
<213> Homo sapiens

50 <400> 173  
gggcuuucuaa gucacuagug guuccguuua guagaugauu gugcauuguu ucaaaauggu 60  
gcccuaguga cuacaaagcc c 81

55 <210> 174  
<211> 80  
<212> RNA  
<213> Homo sapiens

60 <400> 174  
aggacccuuc cagagggccc ccccucauc cuguugugcc uaauucagag gguugggugg 60  
aggcucuccu gaagggcucu 80

EP 2 808 390 A1

<210> 175  
 <211> 63  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 175  
 aagaaauggu uuaccguccc acauacauuu ugaauaugua ugugggaugg uaaaccgcuu 60  
 cuu 63  
 10  
 <210> 176  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 176  
 acugcuaacg aaugcucuga cuuuauugca cuacugua cuuacagcuag cagugcaaua 60  
 guauugucua agcaucugaa agcagg 86  
 20  
 <210> 177  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 177  
 ccaccacuua aacguggaug uacuugcuuu gaaacuaaaag aaguaagugc uuccauguuu 60  
 uggugaugg 69  
 30  
 <210> 178  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 178  
 gcuucgcucc ccuccgccuu cucuucccg g uucuucccg agucgggaaa agcuggguug 60  
 agagggcgaa aaaggaugag gu 82  
 40  
 <210> 179  
 <211> 59  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 179  
 uuggccuccu aagccaggga uuguggguuc gagucccacc cgggguaaag aaaggccga 59  
 50  
 <210> 180  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 180  
 uugguacuug gagagaggug guccguggcg cguucgcuuu auuuauuggcg cacauuacac 60  
 ggucgaccuc uuugcaguau cuaaac 86  
 <210> 181  
 <211> 83  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens  
 <400> 181  
 5 cugacuaugc cuctcccgcau ccccuagggc auugguguaa agcuggagac ccacugcccc 60  
 aggugcugcu gggguugua guc 83

<210> 182  
 <211> 95  
 <212> RNA  
 10 <213> Homo sapiens

<400> 182  
 15 cucaucuguc uguugggcug gaggcagggc cuuugugaag gcggguggug cucagaucgc 60  
 cucugggccc uuccuccagc cccgagggcg auuca 95

<210> 183  
 <211> 75  
 <212> RNA  
 20 <213> Homo sapiens

<400> 183  
 uggagugggg gggcaggagg ggcucagggg gaaagugcau acagccccug gccucucug 60  
 cccuuccguc ccug 75

<210> 184  
 <211> 94  
 <212> RNA  
 25 <213> Homo sapiens

<400> 184  
 30 cuuuggcgau cacugccucu cugggccugu gucuuaggcu cugcaagauc aaccgagcaa 60  
 agcacacggc cugcagagag gcagcgcucu gcc 94

<210> 185  
 <211> 94  
 <212> RNA  
 35 <213> Homo sapiens

<400> 185  
 40 gaguuugguu uuguuugggu uuguucuagg uaugguccca gggaucccag aucaaaccag 60  
 gccccugggc cuauccuaga accaaccuaa gcuc 94

<210> 186  
 <211> 94  
 <212> RNA  
 45 <213> Homo sapiens

<400> 186  
 50 uguuuugagc ggggucaag agcaauaacg aaaaanguuu gucauaaacg guuuuucauu 60  
 auugcuccug accuccucuc auuugcuaua uuca 94

<210> 187  
 <211> 93  
 <212> RNA  
 55 <213> Homo sapiens

<400> 187

EP 2 808 390 A1

guagucagua guuggggggu gggaacggcu ucauacagga guugaugcac aguuauccag 60  
 cucuauaug augccuuucu ucauccccuu caa 93

5 <210> 188  
 <211> 67  
 <212> RNA  
 <213> Homo sapiens

10 <400> 188  
 ucuccaacia uauccuggug cugagugaug acucagggga succagcauc agugauuuug 60  
 uugaaga 67

15 <210> 189  
 <211> 94  
 <212> RNA  
 <213> Homo sapiens

20 <400> 189  
 cggggcggcc gcucuccug uccuccagga gcucacgugu gccugccugu gagcgccucg 60  
 acgacagagc cggcgccugc cccagugucu ggcg 94

25 <210> 190  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

30 <400> 190  
 uuguaccugg ugugauuaa aagcaaugag acugauuguc auaugucguu ugugggaucc 60  
 gucucaguua cuuuauagcc auaccuggua ucuua 95

35 <210> 191  
 <211> 99  
 <212> RNA  
 <213> Homo sapiens

40 <400> 191  
 gaaacugggc ucaaggugag gggugcuauc ugugauugag ggacaugguu aauggaauug 60  
 ucucacacag aaaucgcacc cgucaccuug gccuacuua 99

45 <210> 192  
 <211> 77  
 <212> RNA  
 <213> Homo sapiens

50 <400> 192  
 gcuugggaca cauacuucu uauaugccca uaugaaccug cuaagcuauug gaauguaaag 60  
 aaguauguau uucaggc 77

55 <210> 193  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens

<400> 193  
 ucagagcaca uacuucuuua uguacccaua ugaacauuca gugcuauuga auguaaagaa 60  
 guaugauuu ug 72

EP 2 808 390 A1

<210> 194  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 194  
 ccaggcugag guaguaguuu guacaguuuug agggucuaug auaccacccg guacaggaga 60  
 uaacuguaca ggccacugcc uugccagg 88  
 10  
 <210> 195  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 195  
 cuggcugagg uaguaguuuug ugcuguuggu cggguuguga cauugcccgc uguggagaua 60  
 acugcgcaag cuacugccuu gcuag 85  
 20  
 <210> 196  
 <211> 103  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 196  
 aauggguucc uaggaagagg uaguagguug cauaguuuua gggcagagau uuugcccaca 60  
 aggaguuaac uauacgaccu gcugccuuuc uuagggccuu auu 103  
 30  
 <210> 197  
 <211> 94  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 197  
 uucacugugg gaugagguag uagguuguau aguuuuaggg ucacaccac cacugggaga 60  
 uaacuaaaca aucuacuguc uuuccuaagg ugau 94  
 40  
 <210> 198  
 <211> 96  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 198  
 cugcauguuc ccagguugag guaguagguu guauaguua gaguacauc aagggagaua 60  
 acuguacagc cuccuagcuu uccuugggac uugcac 96  
 50  
 <210> 199  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 199  
 gcagggugag guaguagguu gugugguuuc agggcaguga uguugcccuu ccgaagauaa 60  
 cuauacaacc uacugccuuc ccuga 85

EP 2 808 390 A1

<212> RNA  
 <213> Homo sapiens  
  
 <400> 200  
 5 ugugugcauc cggguugagg uaguagguug uaugguuuag aguuacaccc ugggaguuaa 60  
 cuguacaacc uucuagcuuu ccuuggagca cacu 94  
  
 <210> 201  
 <211> 95  
 10 <212> RNA  
 <213> Homo sapiens  
  
 <400> 201  
 15 acggccuuug gggugaggua guagguugua ugguuuuggg cucugccccg cucugcggua 60  
 acuaauacaau cuacugucuu uccugaagug gccgc 95  
  
 <210> 202  
 <211> 93  
 20 <212> RNA  
 <213> Homo sapiens  
  
 <400> 202  
 25 cgcgcccccc gggcugaggu aggagguugu auaguugagg aagacacccg aggagaucac 60  
 uauacggccu ccuagcuuuc cccaggcugc gcc 93  
  
 <210> 203  
 <211> 89  
 30 <212> RNA  
 <213> Homo sapiens  
  
 <400> 203  
 aucagaguga gguaguagau uguauaguug ugggguagug auuuuacccu guuuaggaga 60  
 uaacuaauaca aucuaaugcc uucccugag 89  
  
 <210> 204  
 <211> 83  
 35 <212> RNA  
 <213> Homo sapiens  
  
 <400> 204  
 40 ugugggauga gguaguagau uguauaguuu uagggucaua ccccaucuug gagauaacua 60  
 uacagucuac ugucuuuccc acg 83  
  
 <210> 205  
 <211> 108  
 45 <212> RNA  
 <213> Homo sapiens  
  
 <400> 205  
 50 uuggauguug gccuaguucu guguggaaga cuagugauuu uguuguuuuu agauaacuaa 60  
 aacgacaaca aaucacaguc ugccauaugg cacaggccac cucuacag 108  
  
 <210> 206  
 <211> 97  
 55 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 206  
 ggucgggcca gccccguuug gaagacuagu gauuuuguug uugugucucu guauccaaca 60  
 acaaguccca gucugccaca uggugcuggu cauuuca 97

5

<210> 207  
 <211> 111  
 <212> RNA  
 <213> Homo sapiens

10

<400> 207  
 aggagcggag uacgugagcc agugcuaugu ggaagacuug ugauuuuguu guucugauau 60  
 gauaugacia caagucacag ccagccucau agcguggacu ccuaucaccu u 111

15

<210> 208  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens

20

<400> 208  
 guuguuauucu uugguuauucu agcuguauga guguauggu cuucauaaag cuagauaacc 60  
 gaaaguaaaa ac 72

25

<210> 209  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

30

<400> 209  
 cgggguuggu uguuaucuuu gguuaucuag cuguaugagu gguguggagu cuucauaaag 60  
 cuagauaacc gaaaguaaaa auaacccca 89

35

<210> 210  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens

40

<400> 210  
 ggaggccccgu uucucucuuu gguuaucuag cuguaugagu gccacagagc cgucauaaag 60  
 cuagauaacc gaaaguagaa augacucuca 90

45

<210> 211  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

50

<400> 211  
 uauauaccu guagaaccga auuugugugg uaccacaua gucacagauu cgauucuagg 60  
 ggaauaua 68

55

<210> 212  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

<400> 212  
 gaucugucug ucuucuguau auaccugua gauccgaauu uguguaagga auuuuguggu 60  
 caaaauucg uaucuagggg aauauguagu ugacauaaac acuccgcuca 110

EP 2 808 390 A1

<210> 213  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 213  
 gaccugucug ucuucuguau auaccugua gauccgaauu uguguaagga auuuuguggu 60  
 cacaaaucg uaucuagggg aauauguagu ugacauaaac acuccgcuca 110  
 10  
 <210> 214  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 214  
 cuguagcagc acaucauggu uuacauacua cagucaagau gcgaaucuu auuugcugcu 60  
 cuag 64  
 20  
 <210> 215  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 215  
 ccuuggagu aaaguagcag cacauaaugg uuuguggaug uugaaaaggu gcaggccaau 60  
 cugugcugcc ucaaaauaca agga 84  
 30  
 <210> 216  
 <211> 93  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 216  
 augucagcgg ugccuuagca gcacguaaa auuggcgua agauucugaa auuaccucca 60  
 guauugacug ugcugcugaa guaagguugg caa 93  
 40  
 <210> 217  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 217  
 caugcuuguu ccacucuagc agcacguaaa uauuggcgua gugaaauaaa uauuaaacac 60  
 cauuuuuuu gugcugcuuu agugugacag ggaua 95  
 50  
 <210> 218  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 218  
 gucagaauaa ugucaaagug cuuacagugc agguagugau gugugcaucu acugcaguga 60  
 gggcacuugu agcauuagc ugac 84  
 <210> 219

EP 2 808 390 A1

<211> 96  
 <212> RNA  
 <213> Homo sapiens

5

<400> 219  
 ugcgugcuuu uuguucuaag gugcaucuag ugcagauagu gaaguagacu agcaucuacu 60  
 gcccaagug cuccuucugg cauaagaagu uauguc 96

10

<210> 220  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

15

<400> 220  
 acuuacgauu aguuuugcag auuugcaguu cagcguaauu gugaaauauu ggcugugcaa 60  
 auccaugcaa aacugauugu gggga 84

20

<210> 221  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

25

<400> 221  
 gcagcccucu guuaguuuug cauaguugca cuacaagaag aauguaguug ugcaaaucua 60  
 ugcaaaacug augguggccu gc 82

30

<210> 222  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

35

<400> 222  
 cacuggucua ugguuaguuu ugcagguuug cauccagcug uauaaauuuc ugcugugcaa 60  
 auccaugcaa aacugacugu gguggug 87

40

<210> 223  
 <211> 107  
 <212> RNA  
 <213> Homo sapiens

45

<400> 223  
 gugugaugug acagcuucug uagcacuaaa gugcuuauag ugcagguagu gugugagccau 60  
 cuacugcauu acgagcacuu aaaguacugc cagcuguaga acuccag 107

50

<210> 224  
 <211> 92  
 <212> RNA  
 <213> Homo sapiens

55

<400> 224  
 uguaccaccu ugucggauag cuuauacagac ugauguugac uguugaaucu cauggcaaca 60  
 gcagucgaug ggcugucuga cauuuuggua uc 92

<210> 225  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 225  
 accuggcuga gccgcaguag uucuucagug gcaagcuua uguccugacc cagcuaaagc 60  
 ugccaguuga agaacuguug cccucugccc cuggc 95

5

<210> 226  
 <211> 74  
 <212> RNA  
 <213> Homo sapiens

10

<400> 226  
 ggcugcuugg guuccuggca ugcugauuug ugacuugaga uaaaaaucac auugccaggg 60  
 auuaccacgc aacc 74

15

<210> 227  
 <211> 75  
 <212> RNA  
 <213> Homo sapiens

20

<400> 227  
 cggacggcug gggguuccugg ggaugggauu ugaugccagu cacaaaucac auugccaggg 60  
 auuuccaacu gaccc 75

25

<210> 228  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

30

<400> 228  
 cuccggugcc uacugagcug auaucaguuc ucauuucaca cacuggcuca guucagcagg 60  
 aacaggag 68

35

<210> 229  
 <211> 107  
 <212> RNA  
 <213> Homo sapiens

40

<400> 229  
 gccucucucc gggcuccgcc ucccuggccu acugagcuga aacaguugau uccagugcac 60  
 uggcucaguu cagcaggaac aggaguccag ccccuagga gcuggca 107

45

<210> 230  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

50

<400> 230  
 ggccaguguu gagagggcga gacuugggca auugcuggac gcugcccugg gcauugcacu 60  
 ugucucgguc ugacagugcc ggcc 84

55

<210> 231  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens

<400> 231  
 aaggccgugg ccucguuca gaauccagg auaggcugug cagguccaa ggggccuauu 60

cuugguuacu ugcacgggga cgcgggccug 90

5 <210> 232  
<211> 85  
<212> RNA  
<213> Homo sapiens

<400> 232  
10 ugcccgggac ccaguucaag uaaucagga uagguugugg ugcugaccag ccuguucucc 60  
auuacuuggc ucgggggccg gugcc 85

15 <210> 233  
<211> 84  
<212> RNA  
<213> Homo sapiens

<400> 233  
20 ggcugcggcu ggauucaagu aaucaggau aggcuguguc cguccaugag gccuguucuu 60  
gauuacuugu uucuggaggc agcg 84

25 <210> 234  
<211> 73  
<212> RNA  
<213> Homo sapiens

<400> 234  
30 aggucgagag cuuagcugau uggugaacag ugauugguuu ccgcuuuguu cacaguggcu 60  
aaguucugca ccu 73

35 <210> 235  
<211> 87  
<212> RNA  
<213> Homo sapiens

<400> 235  
40 uggccugagg agcagggcuu agcugcuugu gagcaagguc cacagcaaag ucguguucac 60  
aguggcuaag uuccgcccc uggaacc 87

45 <210> 236  
<211> 86  
<212> RNA  
<213> Homo sapiens

<400> 236  
50 ggucccuacc uucaaggagc ucacagucua uugaguugcc uuucugauuc ucccacuaga 60  
uugugagcug cuggagggca ggcacu 86

55 <210> 237  
<211> 71  
<212> RNA  
<213> Homo sapiens

<400> 237  
aggaagcugg uuucuuagg ugguuuagau uaaaauagug auugucuagc accauuugaa 60  
aucaguguuc u 71

EP 2 808 390 A1

<210> 238  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 238  
 accccuuaga ggaugacuga uuucuuuugg uguucagagu caauagaauu uucuagcacc 60  
 aucugaaauc gguuauaauug auugggga 88  
 10  
 <210> 239  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 239  
 aucucuuaaca caggcugacc gauuucuccu gguguucaga gucuguuuuu gucuagcacc 60  
 auuugaaauc gguuauaug uaggggga 88  
 20  
 <210> 240  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 240  
 cuucuggaag cugguuucac augguggcuu agauuuuucc aucuuuguau cuagcacc 60  
 uuugaaucag uguuuuagga g 81  
 30  
 <210> 241  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 241  
 gcgacuguaa acauccucga cuggaagcug ugaagccaca aaugggcuu cagucggau 60  
 uuugcagcug c 71  
 40  
 <210> 242  
 <211> 60  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 242  
 auguaaaca cuacacuca gcugucauac augcguuggc ugggaugugg auguuuacgu 60  
 50  
 <210> 243  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 243  
 cuguaaaca ccuugacugg aagcuguaag guguugagag gagcuucag ucggauguuu 60  
 acag 64  
 <210> 244  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 244  
 accauguugu agugugugua aacauccuac acucucagcu gugagcucaa gguggcuggg 60  
 agagggguugu uuacuccuuc ugccaugga 89

5

<210> 245  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

10

<400> 245  
 gagugacaga uauuguaaac auccuacacu cucagcugug aaaaguaaga aagcuggggag 60  
 aaggcuguuu acucucucug ccuu 84

15

<210> 246  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

20

<400> 246  
 aagucugugu cuguaaaacau ccccgacugg aagcuguaag ccacagccaa gcuuucaguc 60  
 agauguuugc ugcuaucggc uc 82

25

<210> 247  
 <211> 106  
 <212> RNA  
 <213> Homo sapiens

30

<400> 247  
 ugcuccugua acucggaacu ggagaggagg caaugcug gcuaugcugu ugaacugaga 60  
 accugcuaug ccaacauauu gccaucuuuc cugucugaca gcagcu 106

35

<210> 248  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens

40

<400> 248  
 ggagauauug cacauuacua aguugcaugu ugucacggcc ucaaugcaau uuagugugug 60  
 ugauauuuuc 70

45

<210> 249  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens

50

<400> 249  
 cuguggugca uuguaguugc auugcaugu cuggcaauac cugugcaaug uuuccacagu 60  
 gcaucacgg 69

55

<210> 250  
 <211> 77  
 <212> RNA  
 <213> Homo sapiens

<400> 250  
 agucuaguua cuaggcagug uaguugcug auugcuaaua guaccaauca cuaaccacac 60

agccagguaa aaagacu

77

&lt;210&gt; 251

&lt;211&gt; 84

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 251

gugcucgguu uguagggcagu gaaauuagcu gauuguagug cggugcugac aaucacuaac 60

uccacugcca ucaaaacaag gcac 84

&lt;210&gt; 252

&lt;211&gt; 102

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 252

ccagcuguga gaaauucuuu ggcagugucu uagcugguug uugugaguau uagcuaagga 60

agcaaucagc aaguaucug ccuagaagu gcugcacauu gu 102

&lt;210&gt; 253

&lt;211&gt; 91

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 253

ugcccuuca uccacaggug gggauuggug gcauuacuug uguuagauau aaaguaaugc 60

acuuguccg gccugaggaa gaaagaggu u 91

&lt;210&gt; 254

&lt;211&gt; 80

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 254

cuuucuacac agguugggau uugucgcaau gcuguguuuc ucuguauggu auugcacuug 60

ucccgccug uugaguugg 80

&lt;210&gt; 255

&lt;211&gt; 88

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 255

agucaugggg gcuccaaagu gcuguucgug cagguagugu aauuaccuga ccuacugcug 60

agcuagcacu ucccgagccc ccaggaca 88

&lt;210&gt; 256

&lt;211&gt; 106

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 256

ccaguaccuu cugcuuggcc gauuuuggca cuagcacauu uuugcuugug ucucuccgcu 60

gugagcauc auguguagug ccaauuggg aaaagcgggc ugcugc 106

EP 2 808 390 A1

<210> 257  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 257  
 gugagguagu aaguuguauu guuguggggu agggauuuua ggccccagua agaagauaac 60  
 uauacaacuu acuacuuucc 80  
 10  
 <210> 258  
 <211> 65  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 258  
 cauaaacccg uagaucggau cuugugguga aguggaccgc gcaagcucgu uucuaugggu 60  
 cugug 65  
 20  
 <210> 259  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 259  
 ggcaccacc cguagaaccg accuugcggg gccuucgccg cacacaagcu cgugucugug 60  
 gguccguguc 70  
 30  
 <210> 260  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 260  
 ccuguugcca caaacccgua gauccgaacu ugugcugauu cugcacacaa gcuugugucu 60  
 auagguaugu gucuguuagg 80  
 40  
 <210> 261  
 <211> 57  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 261  
 ucaguuauca cagugcugau gcuguccauu cuaaagguac aguacuguga uacuga 57  
 50  
 <210> 262  
 <211> 97  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 262  
 aucugagacu gaacugcccu uuucgguaa ucaugguacc gaugcuguag cucugaaagg 60  
 uacaguacug ugauagcuga agaauggcgg ugccauc 97  
 <210> 263  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 263  
 uucuuacugc ccucggcuuc uuuacagugc ugccuuguug cauauggauc aagcagcauu 60  
 guacagggcu augaaggcau ugagac 86

5

<210> 264  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

10

<400> 264  
 gucuucgugc uuucagcuuc uuuacagugc ugccuuguag cauucagguc aagcagcauu 60  
 guacagggcu augaaagaac caagaa 86

15

<210> 265  
 <211> 65  
 <212> RNA  
 <213> Homo sapiens

20

<400> 265  
 augucaaagu gcuaacagug cagguagcuu uuugaguucu acugcagugc cagcacuucu 60  
 uacau 65

25

<210> 266  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

30

<400> 266  
 ccugcuggga cuaaagugcu gacagugcag auaguggucc ucucugugcu accgcacugu 60  
 ggguaacuugc ugcuccagca gg 82

35

<210> 267  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

40

<400> 267  
 uucucugugc uuucagcuuc uuuacagugu ugccuugugg cauggaguuc aagcagcauu 60  
 guacagggcu aucaaagcac agagagc 87

45

<210> 268  
 <211> 66  
 <212> RNA  
 <213> Homo sapiens

50

<400> 268  
 agcuguggag ugugacaaug guguuugugu ccaaaccauc aaacgccauu aucacacuaa 60  
 auagcu 66

55

<210> 269  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

<400> 269  
 cucugcgugu ucacagcgga ccuugauuuu augucuauc aaauaaggca cgcggugaau 60

gccaagag

68

5  
 <210> 270  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

10  
 <400> 270  
 aggccucucu cuccguguuc acagcggacc uugauuuaaa uguccauaca auuaaggcac 60  
 gcgugaaug ccaagaaugg ggcug 85

15  
 <210> 271  
 <211> 109  
 <212> RNA  
 <213> Homo sapiens

20  
 <400> 271  
 aucaagauga gagacucugc ucuccguguu cacagcggac cuugauuuuaa ugucauacaa 60  
 uuaaggcacg cggugaaugc caagagcgga gccuacggcu gcacuugaa 109

25  
 <210> 272  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

30  
 <400> 272  
 cugggucccu gagacccuuu aaccugugag gacguccagg gucacaggug agguucuugg 60  
 gagccugg 68

35  
 <210> 273  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens

40  
 <400> 273  
 gccuaguccc ugagaccua acuugugagg uauuuuagua acaucacaag ucagguucu 60  
 gggaccuagg c 71

45  
 <210> 274  
 <211> 77  
 <212> RNA  
 <213> Homo sapiens

50  
 <400> 274  
 ugcgcucucc ucagucccug agaccuaac uugugauguu uaccguuuua auccacgggu 60  
 uaggcucuug ggagcug 77

55  
 <210> 275  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens

60  
 <400> 275  
 ugacagcaca uuauuacuuu ugguacgcgc ugugacacuu caaacucgua ccgugagua 60  
 uaaugcgcgg uca 73

EP 2 808 390 A1

<210> 276  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 276  
 ccagccugcu gaagcucaga gggcucugau ucagaaagau caucggaucc gucugagcuu 60  
 ggcuggucgg 70  
 10  
 <210> 277  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 277  
 guuggauucg gggccguagc acugucugag agguuuacau uucucacagu gaaccggucu 60  
 cuuuuucagc 70  
 20  
 <210> 278  
 <211> 76  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 278  
 cagugggaag gggggccgau gcacuguaag agagugagua gcaggucuca cagugaaccg 60  
 gucucuuucc cuacug 76  
 30  
 <210> 279  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 279  
 uggaucuuuu ugcggucugg gcuugcuguu cucucgacag uagucaggaa gccuuaccc 60  
 caaaaaguau cua 73  
 40  
 <210> 280  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 280  
 ugccuuucgc gaaucuuuuu gcggucuggg cuugcuguac auaacucaau agccggaagc 60  
 ccuuacccca aaaagcauuc gcggagggcg 90  
 50  
 <210> 281  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 281  
 gagcucuuuu cacauuguc uacugucuaa cguguaccga gcagugcaau guuaaaaggg 60  
 cauc 64  
 <210> 282  
 <211> 82  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens  
 <400> 282  
 5 ggcuuuguugg acacucuuuc ccuguugcac uacugugggc cucugggaag cagugcaaug 60  
 augaaagggc aucugucggg cc 82

<210> 283  
 <211> 66  
 <212> RNA  
 10 <213> Homo sapiens

<400> 283  
 15 gggcaaccgu ggcuuucgau uguuacugug ggaaccggag guaacagucu acagccaugg 60  
 ucgccc 66

<210> 284  
 <211> 68  
 <212> RNA  
 20 <213> Homo sapiens

<400> 284  
 gcuaaagcug guaaaaugga accaaaucgc cucuucaaug gauuuggucc ccuucaacca 60  
 gcuguagc 68

25 <210> 285  
 <211> 104  
 <212> RNA  
 <213> Homo sapiens

30 <400> 285  
 agaagccaaa ugcuuugcug aagcugguaa aauggaacca aaucagcugu uggauggauu 60  
 ugguccccuu caaccagcug uagcugcgca uugaucacgc cgca 104

35 <210> 286  
 <211> 119  
 <212> RNA  
 <213> Homo sapiens

40 <400> 286  
 ccuccaaagg gaguggcccc cugcucuggc uggucaaacg gaaccaaguc cguciuuccug 60  
 agagguuugg uccccuucuaa ccagcuacag cagggcuggc aaagcucaau auuuggaga 119

45 <210> 287  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens

50 <400> 287  
 agggugugug acugguugac cagaggggcg ugcacucugu ucaccucugug ggccaccuag 60  
 ucaccaacc u 71

55 <210> 288  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens

<400> 288

EP 2 808 390 A1

aggccucacu guucucuauug gcuuuuuauu ccuaugugau ucuaauugcuc gcucauauag 60  
 ggauuuggagc cguggcguac ggugaggaua 90

5 <210> 289  
 <211> 97  
 <212> RNA  
 <213> Homo sapiens

10 <400> 289  
 cgcucugcugc uggccuaugg cuuuucauuc cuaugugauu gcugcuccga acucauguag 60  
 ggcuaaaaagc caugggcuac agugaggggc aagcucc 97

15 <210> 290  
 <211> 100  
 <212> RNA  
 <213> Homo sapiens

20 <400> 290  
 agauaaaauc acucuagugc uuuauuggcu uuuauuccua ugugaucgua aaaaagucuc 60  
 auguagggau ggaagccaug aaauacauug ugaaaauua 100

25 <210> 291  
 <211> 62  
 <212> RNA  
 <213> Homo sapiens

30 <400> 291  
 gaggacucca uuuguuuuga ugauggauuc uuaagcucca ucaucgucuc aaaugagucu 60  
 uc 62

35 <210> 292  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens

40 <400> 292  
 cuucggugac ggguaauucuu ggguggauaa uacggauuac guuguuauug cuuaagaaua 60  
 cgcguagucg agg 73

45 <210> 293  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens

50 <400> 293  
 cagcuggugu ugugaauacag gccgacgagc agcgcauccu cuuacccggc uauuucacga 60  
 caccaggguu g 71

55 <210> 294  
 <211> 99  
 <212> RNA  
 <213> Homo sapiens

60 <400> 294  
 cucuagcaug guguuugugg acagcuggug uugugaauca ggccguugcc aaucagagaa 60  
 cggcuacuuc acaacaccag ggccacacug cacugcaag 99

EP 2 808 390 A1

<210> 295  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 295  
 guguaucua cagugcacgu gucuccagug uggcucggag gcuggagacg cggcccuguu 60  
 ggaguaac 68  
 10  
 <210> 296  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 296  
 ccugccagug guuuuacccu augguagguu acgucaugcu guucuaccac aggguagaac 60  
 cacggacagg 70  
 20  
 <210> 297  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 297  
 ggguccaucu uccagugcag uguuggaugg uugaaguaug aagcuccuaa cacugucugg 60  
 uaaagauggc cc 72  
 30  
 <210> 298  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 298  
 acccauaaag uagaaagcac uacuaacagc acuggagggg guaguguuuc cuacuuuauug 60  
 gaug 64  
 40  
 <210> 299  
 <211> 63  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 299  
 ccugaggugc agugcugcau cucuggucag uugggagucu gagaugaagc acuguagcuc 60  
 agg 63  
 50  
 <210> 300  
 <211> 66  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 300  
 ggcuggggaau ucaucauaau cuguaaguuu gugaugagac acuacaguau agaugaugua 60  
 cuaguc 66

EP 2 808 390 A1

<212> RNA  
<213> Homo sapiens

5 <400> 301  
cucacggucc aguuuuucca ggaaucccuu ggaugcuaag auggggauuc cuggaaauac 60  
uguucuugag 70

10 <210> 302  
<211> 65  
<212> RNA  
<213> Homo sapiens

15 <400> 302  
agcucugaga acugaauucc auggguuaua ucaaugucag accugugaaa uucaguucuu 60  
cagcu 65

20 <210> 303  
<211> 99  
<212> RNA  
<213> Homo sapiens

25 <400> 303  
agccaguuug gucuuuugag acaaaguucu gagacacucc gacucugagu augauagaag 60  
ucagugcacu acagaacuuu gucucuagag gcugugguc 99

30 <210> 304  
<211> 66  
<212> RNA  
<213> Homo sapiens

35 <400> 304  
ggcucuggcu ccgugucuuc acucccgugu uuguccgagg agggagggag ggacgggggc 60  
ggugcu 66

40 <210> 305  
<211> 65  
<212> RNA  
<213> Homo sapiens

45 <400> 305  
cccugucucc caaccuuugu accagugcug ugccucagac ccugguacag gccuggggga 60  
uaggg 65

50 <210> 306  
<211> 68  
<212> RNA  
<213> Homo sapiens

55 <400> 306  
ccugcccucg aggagcucac agucuaguau gucuccuccc uacuagacug aggcuccuug 60  
aggacagg 68

60 <210> 307  
<211> 73  
<212> RNA  
<213> Homo sapiens

EP 2 808 390 A1

<400> 307  
 ccgggccuag guucugugau acacuccgac ucgggcucug gagcagucag ugcaugacag 60  
 aacuugggcc cgg 73

5

<210> 308  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens

10

<400> 308  
 cggugucauu uuugugacgu ugcagcuagu aauaugagcc caguugcaua gucacaaaag 60  
 ugaucuuug 69

15

<210> 309  
 <211> 66  
 <212> RNA  
 <213> Homo sapiens

20

<400> 309  
 gaagauaggu uauccguguu gccuucgcuu uauucgugac gaaucauaca cgguugaccu 60  
 auuuuu 66

25

<210> 310  
 <211> 65  
 <212> RNA  
 <213> Homo sapiens

30

<400> 310  
 cuguuaaugc uaaugugau agggguuuug gccucugacu gacuccuacc uguuagcauu 60  
 aacag 65

35

<210> 311  
 <211> 76  
 <212> RNA  
 <213> Homo sapiens

40

<400> 311  
 ccauggaaca uucaacgcug ucggugaguu uggaaucaaa aaacaaaaaa accaccgacc 60  
 guugacugua ccuugg 76

45

<210> 312  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens

50

<400> 312  
 aggucaacaau caacauucau ugcugucggu gggguugaacu guguaaaaa gcucacugaa 60  
 caaugaaugc aacuguggcc 80

55

<210> 313  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

<400> 313  
 gccaaagguu ugggggaaca uucaaccugu cggugaguuu gggcagcuca gacaaaccuu 60  
 cgaccguuga guggaccccg aggccugga 89

EP 2 808 390 A1

<210> 314  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 314  
 uugauggcug cacucaacau ucauugcugu cgguggguuu gaaugucaac caacucacug 60  
 aucaaugaa gcaaacugcg ggccaaaaa 89  
 10  
 <210> 315  
 <211> 75  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 315  
 accauuuuug gcaaugguag aacucacacc gguaagguaa ugggacccgg ugguucuaga 60  
 cuugccaacu auggu 75  
 20  
 <210> 316  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 316  
 cuguguaugg cacugguaga auucacugug aacagucuca gucagugaau uaccgaaggg 60  
 ccauaaacag 70  
 30  
 <210> 317  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 317  
 ccuuuccuua ucacuuuucc agccagcuuu gugacucuaa guguuggacg gagaacugau 60  
 aaggguaagg 69  
 40  
 <210> 318  
 <211> 65  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 318  
 agggauugga gagaaaggca guuccugaug guccccuccc aggggcuggc uuuccucugg 60  
 uccuu 65  
 50  
 <210> 319  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 319  
 acuuuccaaa gaauucuccu uuugggcuuu cucauuuuau uuaagcccu aaggugaau 60  
 uuugggaag u 71  
 <210> 320

EP 2 808 390 A1

<211> 61  
 <212> RNA  
 <213> Homo sapiens

5  
 <400> 320  
 ucaggcuaca acacaggacc cgggcgcugc ucugaccccu cgugucuugu guugcagccg 60  
 g 61

10  
 <210> 321  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

15  
 <400> 321  
 ucucacaucc cuugcauggu ggagggugag cucucugaaa accccuccca caugcagggg 60  
 uugcagga 68

20  
 <210> 322  
 <211> 67  
 <212> RNA  
 <213> Homo sapiens

25  
 <400> 322  
 cugugugaua uguuugauau auuagguugu uauuuauucc aacuauauau caagcauauu 60  
 ccuacag 67

30  
 <210> 323  
 <211> 74  
 <212> RNA  
 <213> Homo sapiens

35  
 <400> 323  
 agcgggcaac ggaaucccaa aagcagcugu ugucuccaga gcauuccagc ugcacuugga 60  
 uuucguuccc ugcu 74

40  
 <210> 324  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

45  
 <400> 324  
 cgugcacagg gcucugaccu augaaugac agccaguacu cuuuucucuc cucuggcugc 60  
 caauuccaaua ggucacaggu auguucacc 89

50  
 <210> 325  
 <211> 66  
 <212> RNA  
 <213> Homo sapiens

55  
 <400> 325  
 gagagcuggg ucuuugcggg caagaugaga gugucaguuc aacuggccua caaaguccca 60  
 guccuc 66

<210> 326  
 <211> 67  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 326  
 aucgggugua acagcaacuc cauguggacu gugcucggau uccaguggag cugcuguuac 60  
 uucugau 67

5

<210> 327  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

10

<400> 327  
 guggcuccca cccucuguaa cagcaacucc auguggaagu gccacuggu uccagugggg 60  
 cugcuguuau cugggguggc ggcuaag 86

15

<210> 328  
 <211> 58  
 <212> RNA  
 <213> Homo sapiens

20

<400> 328  
 uagcagcaca gaaauauugg cauggggaag ugagucugcc aaauuuggcu gugcugcu 58

25

<210> 329  
 <211> 102  
 <212> RNA  
 <213> Homo sapiens

30

<400> 329  
 ugagccggga cuguugagug aaguagguag uuucauguug uugggccugg cuuucugaac 60  
 acaacgacau caaaccaccu gauucauggc aguuacugcu uc 102

35

<210> 330  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

40

<400> 330  
 agcugaucug uggcuuaggu aguuucaugu uguugggauu gaguuuugaa cucggcaaca 60  
 agaaacugcc ugaguuacau caguc 85

45

<210> 331  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens

50

<400> 331  
 gccauccag uguucagacu accuguucag gaggcuggga cauguacagu agucugcaca 60  
 uugguuaggc 70

55

<210> 332  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

<400> 332  
 uggaagcuuc aggagauccu gcuccgucgc cccaguguuc agacuaccug uucaggacaa 60  
 ugccguugua caguagucug cacauugguu agacugggca agggccagca 110

EP 2 808 390 A1

<210> 333  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 333  
 ccagaggaua ccuccacucc gucuaccag uguuuagacu accuguucag gacucccaa 60  
 uuguacagua gucugcacau ugguuaggcu gggcuggguu agaccucgg 110  
 10  
 <210> 334  
 <211> 70  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 334  
 gccguggcca ucuuacuggg cagcauugga uagugucuga ucucuaauac ugccugguaa 60  
 ugaugacggc 70  
 20  
 <210> 335  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 335  
 cugggccucu gugggcaucu uaccggacag ugcuggauuu cuuggcuuga cucuaacacu 60  
 gucugguaac gauguucaa ggugaccac 90  
 30  
 <210> 336  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 336  
 cccucgucuu acccagcagu guuugggugc ugguugggag ucucuaauac ugccggguaa 60  
 ugauggagg 69  
 40  
 <210> 337  
 <211> 66  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 337  
 uaccuuacuc aguaaggcau uguucuucua uauuaauaaa ugaacagugc cuuucugugu 60  
 agggua 66  
 50  
 <210> 338  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 338  
 guuccuuuuu ccuaugcaua uacuucuuug uggaucuggu cuaaagaggu auagcgcaug 60  
 ggaagaugga gc 72  
 <210> 339

EP 2 808 390 A1

<211> 76  
 <212> RNA  
 <213> Homo sapiens

5

<400> 339  
 gccuggucca gugguucuug acaguucaac aguucuguag cacaaugug aauguuuag 60  
 gaccacuaga cccggc 76

10

<210> 340  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

15

<400> 340  
 uggacuuccc uuugucaucc uaugccugag aaauaugaa ggaggcuggg aaggcaaagg 60  
 gacguuca 68

20

<210> 341  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens

25

<400> 341  
 cucuuguccu ucauuccacc ggagucuguc uuaugccaac cagauuucag uggagugaag 60  
 cucaggag 68

30

<210> 342  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens

35

<400> 342  
 ccaggccaca ugcuucuuua uauccucaua gauaucucag cacuauggaa uguaaggaag 60  
 ugugugguuu ugg 73

40

<210> 343  
 <211> 79  
 <212> RNA  
 <213> Homo sapiens

45

<400> 343  
 aaggcagggg ugaggggcug cgggaggagc cgggcggagg cugcggcuug cgcuucuccu 60  
 ggcucuccuc ccucucuuu 79

50

<210> 344  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens

55

<400> 344  
 uuccuuugac gggugagcuu uuggcccggg uuauaccuga cacucacgua uaagacgagc 60  
 aaaaagcuug uggucagag gag 83

<210> 345  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 345  
 ccggggcagu cccuccaggc ucaggacagc cacugcccac cgcacacugc guugcuccgg 60  
 acccacugug cgugugacag cggcugaucu gucccugggc agcgcgaacc 110

5

<210> 346  
 <211> 106  
 <212> RNA  
 <213> Homo sapiens

10

<400> 346  
 cugcuuggac cugugaccug ugggcuuccc uuugucaucc uuugccuagg ccucugagug 60  
 aggcaaggac agcaaagggg ggcucagugg ucaccucuaac ugcaga 106

15

<210> 347  
 <211> 91  
 <212> RNA  
 <213> Homo sapiens

20

<400> 347  
 gggcagcgcg cgggcaccuu ggcucuagac ugcuuacugc cggggccgcc uucaguaaca 60  
 gucuccaguc acggccaccg acgccuggcc c 91

25

<210> 348  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

30

<400> 348  
 gguugcuuca gugaacauuc aacgcugucg gugaguuuug aauucaaaau aaaaccaucg 60  
 accguugauu guaccuaua gcuaacc 87

35

<210> 349  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

40

<400> 349  
 ggccuggcug gacagaguug ucaugugucu gccugucuac acuugcugug cagaacauc 60  
 gcucaccugu acagcaggca cagacaggca gucacaugac aaccagccu 110

45

<210> 350  
 <211> 112  
 <212> RNA  
 <213> Homo sapiens

50

<400> 350  
 agcucucagc aucaacggug uacaggagaa ugaccuauga uuugacagac cgugcagcug 60  
 uguaugucug ucauucugua ggccaauauu cuguauguca cugcuacuua aa 112

55

<210> 351  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens

<400> 351  
 uugguuuau cucagcuggc aacugugaga uguccuauc auuccucaca guggucucug 60

ggauuaugcu aa

72

5 <210> 352  
 <211> 108  
 <212> RNA  
 <213> Homo sapiens

10 <400> 352  
 aaacauaguc auuacaguuu uugauguugc agauacugca ucaggaacug acuggauaag 60  
 acuaaauccc caucaguucc uaugcauug ccuucagcau cuaaaca 108

15 <210> 353  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

20 <400> 353  
 gaccaguugc cgcggggcuu uccuuugugc uugaucuaac cauguggugg aacgauggaa 60  
 acggaacaug guucugucaa gcaccgcgga aagcaucgcu cucuccugca 110

25 <210> 354  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens

30 <400> 354  
 ccgucccggg ccgcgccucc ugauugucca aacgcaauuc ucgagucucu ggcuccggcc 60  
 gagaguugcg ucuggacguc ccgagccgcc gccccaaac cucgaggggg 110

35 <210> 355  
 <211> 97  
 <212> RNA  
 <213> Homo sapiens

40 <400> 355  
 acucaggggc uucgccacug auuguccaaa cgcaauucuu guacgagucu gcgcccaacc 60  
 gagaauugug gcuggacauc ugugguugag cuccggg 97

45 <210> 356  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

50 <400> 356  
 auccaggucu ggggcaugaa ccuggcauac aauguagauu ucuguguuug uuaggcaaca 60  
 gcuacauugu cugcuggguu ucaggcuacc uggaa 95

55 <210> 357  
 <211> 79  
 <212> RNA  
 <213> Homo sapiens

<400> 357  
 cccucagugg cucaguagcc aguguagauc cugucuuugg uaucagcag cuacaucugg 60  
 cuacuggguc ucuggggc 79

EP 2 808 390 A1

<210> 358  
 <211> 110  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 358  
 ucuggccauc ugcaguguca cgcuccgugu auuugacaag cugaguugga cacucugugu 60  
 gguagagugu caguuuuguca aaauaccccaa guguggcuca ugccuauacag 110  
 10  
 <210> 359  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 359  
 gggcuuuuaa gucacuagug guuccguuaa guagaugguu ugugcauugu uucaaaaugg 60  
 ugcccuagug acuacaaagc cc 82  
 20  
 <210> 360  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 360  
 cucaucuugc gguacucaaa cuaugggggc acuuuuuuuu uucuuuaaaa agugccgccu 60  
 aguuuaagc cccgccgguu gag 83  
 30  
 <210> 361  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 361  
 ccuauguagc ggccaucaaa guggaggccc ucucuugagc cugaaugaga aagugcuucc 60  
 acuuugugug ccacugcaug gg 82  
 40  
 <210> 362  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 362  
 cagccuguga uacucaaaacu gggggcucuu uuggauuuuc aucggaagaa aagugccgcc 60  
 agguuuugag ugucaccggu ug 82  
 50  
 <210> 363  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 363  
 uucaaucugu gguacucaaa cugugugaca uuuuguucuu uguaagaagu gccgcagagu 60  
 uuguaguguu gccgauugag 80  
 55  
 <210> 364  
 <211> 84  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens  
 <400> 364  
 5 uuccauauag ccuacucuaa aauggaggcc cuaucuaagc uuuuaagugg aaagugcuuc 60  
 ccuuuugugu guugccaugu ggag 84

<210> 365  
 <211> 69  
 <212> RNA  
 10 <213> Homo sapiens

<400> 365  
 15 ggugagacuc aaaugugggg cacacuucug gacuguacau agaaagugcu acuacuuuug 60  
 agucucucc 69

<210> 366  
 <211> 79  
 <212> RNA  
 20 <213> Homo sapiens

<400> 366  
 25 gggccuuucu ggagggcccc ccucuaaucc uguugugcuc gcuucagagg guugggugga 60  
 ggcucuccug aaggugucc 79

<210> 367  
 <211> 76  
 <212> RNA  
 <213> Homo sapiens

30 <400> 367  
 auauguaugu auguauguau gugugcaugu gcaugugcau guaugcauau uguauguaua 60  
 uauuaugcau acaugu 76

<210> 368  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens

40 <400> 368  
 uguaugugca ugcauugug cucaugugug uguacaugua ugugugcaug ugcauguaua 60  
 uaug 64

<210> 369  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

50 <400> 369  
 ccaggccuuu ggcagaggag ggcuguucuu ccuugaguu uuaugacugg gaggaacuag 60  
 ccuucucuca gcuuaggagu gg 82

<210> 370  
 <211> 63  
 <212> RNA  
 55 <213> Homo sapiens

<400> 370

EP 2 808 390 A1

aagaaauggu uuaccguccc acauacauuu ugaguaugua ugugggacgg uaaaccgcuu 60  
 cuu 63

5 <210> 371  
 <211> 79  
 <212> RNA  
 <213> Homo sapiens

10 <400> 371  
 gcuacuugaa gagagguuau ccuuugugug uuugcuuuac gcgaaaugaa uaugcaaggg 60  
 caagcucucu ucgaggagc 79

15 <210> 372  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

20 <400> 372  
 ccugcuaacg gcugcucuga cuuuauugca cuacuguacu uuacagcgag cagugcaaua 60  
 guauuguaaa agcauccgag agcagg 86

25 <210> 373  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens

30 <400> 373  
 ccaccacuua aacgugguug uacuugcuuu agaccuaaga aaguaagugc uuccauguuu 60  
 uggugaugg 69

35 <210> 374  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

40 <400> 374  
 gccucgccgc ccuccgccuu cucuucccgg uucuucccgg agucgggaaa agcuggguug 60  
 agagggcgaa aaaggaugug gg 82

45 <210> 375  
 <211> 59  
 <212> RNA  
 <213> Homo sapiens

<400> 375  
 uuggccuccu aagccagga uuguggguuc gagucccacc cgggguaaug agguguuuu 59

50 <210> 376  
 <211> 86  
 <212> RNA  
 <213> Homo sapiens

55 <400> 376  
 uugguacuug gagagaggug guccguggcg cguucgcuuc auuuauuggcg cacauuacac 60  
 ggucgaccuc uuugcgguau cuaauc 86

EP 2 808 390 A1

<210> 377  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 377  
 aacugacuau gccuccucgc auctccuagg gcauuggugu aaagcuggag acccacugcc 60  
 ccaggugcug cuggggguug uagucugac 89  
 10  
 <210> 378  
 <211> 98  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 378  
 auauagugcu ugguuccuag uaggugcuca gaaaguguuu gugacauau ucguuuauug 60  
 agcaccuccu aucaaucaag cacugugcua ggcucugg 98  
 20  
 <210> 379  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 379  
 cucaucuguc uguugggcug ggggcagggc cuuugugaag gcggguuauug cucagaucgc 60  
 cucugggccc uuccuccagu cccgaggcag auuuu 95  
 30  
 <210> 380  
 <211> 97  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 380  
 cugucucgga gccuggggca ggggggcagg aggggcucag ggagaaagua ucuacagccc 60  
 cuggcccucu cugcccuucc gucccuguc cccaagu 97  
 40  
 <210> 381  
 <211> 97  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 381  
 uguucgcuuc ugguaccgga agagagguuu ucugggucuc uguuucuuug augagaauga 60  
 aacacaccca gcuaaccuuu uuuucaguau caaaucc 97  
 50  
 <210> 382  
 <211> 98  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 382  
 gaccuuugg cgaucucugc cucucugggc cugugucuua ggcucucaa gauccaacga 60  
 gcaaagcaca gggccugcag agagguagcg cucugcuc 98  
 60  
 <210> 383  
 <211> 96  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens  
 <400> 383  
 5 gagucugguu uuguuugggu uuguucuagg uaugguccca gggaucccag aucaaaccag 60  
 gccccugggc cuauccuaga accaaccuaa acccgu 96

<210> 384  
 <211> 97  
 <212> RNA  
 10 <213> Homo sapiens

<400> 384  
 15 caguguagug agaaguuggg gggugggaac ggcgucaugc aggaguugau ugcacagcca 60  
 uucagcuccu auaugaugcc uuucuucacc cccuua 97

<210> 385  
 <211> 98  
 <212> RNA  
 20 <213> Homo sapiens

<400> 385  
 25 caacgcugca caggccgucc ucccacaaca uauccuggug cugagugggu gcacagugac 60  
 uccagcauca gugauuuugu ugaagagggc agcugcca 98

<210> 386  
 <211> 96  
 <212> RNA  
 30 <213> Homo sapiens

<400> 386  
 35 acgggguggc cacuaucuu guccuccagg agcucacgua ugccugccug ugagcggccuc 60  
 ggcgacagag ccggugucca cccuggcacu guccac 96

<210> 387  
 <211> 98  
 <212> RNA  
 40 <213> Homo sapiens

<400> 387  
 45 caauuguacu uggugugauu auaaagcaau gagacugauu gucauuguc guuuguggga 60  
 uccgucucag uuacuuuaua gccauaccug guaucuaa 98

<210> 388  
 <211> 96  
 <212> RNA  
 50 <213> Homo sapiens

<400> 388  
 55 aaaaugauga ugucaguugg ccggucggcc gaucgcucgg ucugucaguc agucggucgg 60  
 ucgaucgguc ggucggucag ucggcuuccu gucuuc 96

<210> 389  
 <211> 99  
 <212> RNA  
 60 <213> Homo sapiens

<400> 389

EP 2 808 390 A1

gaaaauaggc ucaaggugag gggugcuauc ugugauugag ggacaugguc aauggaaauug 60  
 ucucacacag aaaucgcacc cgucacccuug gccugcuga 99

5 <210> 390  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

10 <400> 390  
 cugcagccag gguuuuuacc agucagggcuc cuggcuagau uccagguacc agcugguacc 60  
 ugaucuagcc aaagccugac uguaagcccu gaaca 95

15 <210> 391  
 <211> 96  
 <212> RNA  
 <213> Homo sapiens

20 <400> 391  
 acccaagucc aggccugcug accccuaguc cagugcuugu gguggcuacu gggcccugaa 60  
 cuaggggucuu ggagaccugg guuugaucuc cacagg 96

25 <210> 392  
 <211> 98  
 <212> RNA  
 <213> Homo sapiens

30 <400> 392  
 ucuguguugg gcgucugucu gcccagaguc cugccucucu guugcucuga aggaggcagg 60  
 ggcugggccu gcagcugccu gggcagagcu gcuccuuc 98

35 <210> 393  
 <211> 99  
 <212> RNA  
 <213> Homo sapiens

40 <400> 393  
 agaugccuug cuccuacaag aguaaagugc augcgcuuug ggacagugag gaaaauaauug 60  
 uucacaaagc ccauacacuu ucacccuuua ggagaguug 99

45 <210> 394  
 <211> 98  
 <212> RNA  
 <213> Rattus norvegicus

50 <400> 394  
 ugggcuccua ggaagaggua guagguugca uaguuuuagg gcagagauuu ugcccacaag 60  
 gaguaaacia uacgaccugc ugccuuucuu agggccuu 98

55 <210> 395  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

60 <400> 395  
 uguuggccua guucugugug gaagacuagu gauuuuguug uuuuuagaua acuaagacga 60  
 caacaaauca cagucugcca uauggcacag gccaccu 97

EP 2 808 390 A1

<210> 396  
 <211> 94  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 396  
 uucacugugg gaugagguag uagguuguau aguuuuaggg ucacaccac cacugggaga 60  
 uaacuauaca aucuacuguc uuuccuaagg ugau 94  
 10  
 <210> 397  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 397  
 cggcaugcuc ccaggcugag guaguagguu guauaguua gaguuacaac aaggagaua 60  
 acuguacagc cuccuagcuu uccuugggac uugcac 96  
 20  
 <210> 398  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 398  
 gcggggugag guaguagguu gugugguuuc agggcaguga ugucgccccu ccgaagaua 60  
 cuauacaacc uacugccuuc ccuga 85  
 30  
 <210> 399  
 <211> 94  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 399  
 ugugugcauc cggguugagg uaguagguug uagguuuag aguuacacc ugggaguua 60  
 cuguacaacc uucuagcuuu ccuuggagca cacu 94  
 40  
 <210> 400  
 <211> 95  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 400  
 acggccuuug gggugaggua guagguugua ugguuuuggg cucugccccg cucugcgua 60  
 acuauacaau cuacugucu uccugaagug gccgc 95  
 50  
 <210> 401  
 <211> 93  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 401  
 cgcgcccccc gggcugaggu aggagguugu auaguugagg aagacaccg aggagauca 60  
 uauacggccu ccuagcuuuc cccaggcugc gcc 93  
 <210> 402  
 <211> 89

EP 2 808 390 A1

<212> RNA  
 <213> Rattus norvegicus  
  
 <400> 402  
 5 aucagaguga gguaguagau uguauaguug uggguagug auuuuacccu guuuaggaga 60  
 uaacuaauaca aucuaugcc uucccugag 89  
  
 <210> 403  
 <211> 83  
 10 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 403  
 15 ugugggauga gguaguagau uguauaguuu uagggucaua ccccaucuug gagauaacua 60  
 uacagucuaac ugucuuuccc acg 83  
  
 <210> 404  
 <211> 85  
 20 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 404  
 25 cuggcugagg uaguaguuuug ugcuguuggu cggguuguga cauugcccgc uguggagaua 60  
 acugcgcaag cuacugccuu gcuag 85  
  
 <210> 405  
 <211> 95  
 30 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 405  
 ggacagacca gccugucug gaagacuagu gauuuuguug uugugucugu guccaacaac 60  
 aagucccagu cugccacaug guguugguca cauca 95  
  
 35 <210> 406  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus  
  
 40 <400> 406  
 aggccagaac acaugagcca augcuauugug gaagacuugu gauuuuguug uucugauaug 60  
 auaugacaac aagucacagc cagccucaua gaguggacuc ccaucaccuu 110  
  
 45 <210> 407  
 <211> 89  
 <212> RNA  
 <213> Rattus norvegicus  
  
 50 <400> 407  
 cggguuguggu uguuaucuuu gguuaucuaug cuguaugagu gguguggagu cuucauaaag 60  
 cuagauaacc gaaaguaaaa auaacccca 89  
  
 55 <210> 408  
 <211> 90  
 <212> RNA  
 <213> Rattus norvegicus

EP 2 808 390 A1

<400> 408  
 ggaggcccgu uucucucuuu gguuauacuag cuguauagagu gccacagagc cgucauaaag 60  
 cuagauaacc gaaaguagaa augacucuaa 90

5

<210> 409  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus

10

<400> 409  
 ggaagcgagu uguuauuuu gguuauacuag cuguauagagu guauuggucu ucauaaagcu 60  
 aguaaccga aaguaaaaac uccuua 87

15

<210> 410  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus

20

<400> 410  
 gaccugucug ucuucuguau auaccugua gaucgaaau uguguaagga auuuuguggu 60  
 cacaaaucg uaucuagggg aauauguagu ugacuaaaac acuccgcua 110

25

<210> 411  
 <211> 109  
 <212> RNA  
 <213> Rattus norvegicus

30

<400> 411  
 ccaaaguugu aacguugucu auauauaccc uguagaaccg aauuugugug guaccacau 60  
 agucacagau ucgauucug ggaauauau ggucgaugca aaaacuua 109

35

<210> 412  
 <211> 98  
 <212> RNA  
 <213> Rattus norvegicus

40

<400> 412  
 uuggaacuu aaaguacugu agcagcatau caugguuuac auacuacagu caagaugcga 60  
 aucuuuuuu gcugcucuag aaauuuuagg aaauuca 98

45

<210> 413  
 <211> 95  
 <212> RNA  
 <213> Rattus norvegicus

50

<400> 413  
 cauacuuguu ccgcucuagc agcacguaaa uauuggcgua gugaaauaaa uauuaaacac 60  
 cauuuuuuu gugcugcuuu agugugacag ggaua 95

55

<210> 414  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus

<400> 414  
 gucaggauaa ugucaaagug cuuacagugc agguaguggu gugugcaucu acugcaguga 60  
 aggcacuugu ggcauugugc ugac 84

EP 2 808 390 A1

<210> 415  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 415  
 ugcgugcuuu uuguucuaag gugcaucuag ugcagauagu gaaguagacu agcaucuacu 60  
 gccuaagug cucuucugg cauaagaagu uauguc 96  
 10  
 <210> 416  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 416  
 cacuggucua ugguuaguuu ugcagguuug cauccagcug uauaauauuc ugcugugcaa 60  
 auccaugcaa aacugacugu gguggug 87  
 20  
 <210> 417  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 417  
 acauugcuac uuacgguuag uuuugcagau uugcaguuca gcguauaugu ggauauaugg 60  
 cugugcaau ccaugcaaaa cugauuguga ugaugu 96  
 30  
 <210> 418  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 418  
 gcagcccucu guucguuuug cauaguugca cuacaagaag aauguaguug ugcaaaucua 60  
 ugcaaaacug augguggccu gc 82  
 40  
 <210> 419  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 419  
 cagcuucugu agcacuaaag ugcuuauagu gcagguagug ugucgucauc uacugcauua 60  
 cgagcacuua caguacugcc agcug 85  
 50  
 <210> 420  
 <211> 92  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 420  
 uguaccaccu ugucggguag cuuauacagac ugauguugac uguugaauuc cauggcaaca 60  
 gcagucgaug ggcugucuga cauuuuggua uc 92  
 <210> 421

EP 2 808 390 A1

<211> 95  
 <212> RNA  
 <213> Rattus norvegicus

5

<400> 421  
 accuggcuga gccgcaguag uucuucagug gcaagcuuaa uguccugacc cagcuaaagc 60  
 ugccaguuga agaacuguug cccucugcca cuggc 95

10

<210> 422  
 <211> 75  
 <212> RNA  
 <213> Rattus norvegicus

15

<400> 422  
 cggccggcug ggguuuccugg ggaugggauu ugaugccagu cacaaaucac auugccaggg 60  
 auuuccaacu gacct 75

20

<210> 423  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

25

<400> 423  
 cucaccugcu cuggcugcuu ggguuuccugg caugcugauu ugugacuuga gauuaaauc 60  
 acauugccag ggauuaccac gcaaccauga ccuuggc 97

30

<210> 424  
 <211> 68  
 <212> RNA  
 <213> Rattus norvegicus

35

<400> 424  
 cuccggugc uacugagcug auaucaguuc ucauuucaca cacuggcuca guucagcagg 60  
 aacaggag 68

40

<210> 425  
 <211> 108  
 <212> RNA  
 <213> Rattus norvegicus

45

<400> 425  
 gccucuccu gggcuccgcc uccugugccu acugagcuga aacaguugau uccagugcac 60  
 uggcucaguu cagcaggaac aggaguccag ccccauagg agcuggca 108

50

<210> 426  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus

55

<400> 426  
 ggccaguguu gagagggcga gacacgggca auugcuggac gcugcccugg gcauugcacu 60  
 ugucucgguc ugacagugcc ggcc 84

<210> 427  
 <211> 90  
 <212> RNA  
 <213> Rattus norvegicus

EP 2 808 390 A1

<400> 427  
 aaggccgugg ccuuguucaa guaauccagg auaggcugug cagguccaa ggggccuauu 60  
 cuugguuacu ugcacgggga cgcgggccug 90

5

<210> 428  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus

10

<400> 428  
 ugcccgggac ccaguucaag uaaucagga uagguugugg ugcuggccag ccuguucucc 60  
 auuacuuggc ucgggggccg gugcc 85

15

<210> 429  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

20

<400> 429  
 accucucuaa caaggugcag agcuuagcug auuggugaac agugauuggu uuccgcuuug 60  
 uucacagugg cuaaguucug caccugaaga gaaggug 97

25

<210> 430  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus

30

<400> 430  
 uggccugugg agcagggcuu agcugcuugu gagcaagguc uacagcaaag ucguguucac 60  
 aguggcuaag uuccgccccc uggaccc 87

35

<210> 431  
 <211> 86  
 <212> RNA  
 <213> Rattus norvegicus

40

<400> 431  
 ggucccuacc cgcaaggagc ucacagucua uugaguuccu uuucugauuc ucccacuaga 60  
 uugugagcuc cuggagggca ggcacu 86

45

<210> 432  
 <211> 81  
 <212> RNA  
 <213> Rattus norvegicus

50

<400> 432  
 cuucuggaag cugguuucac augguggcuu agauuuuucc aucuuuguau cuagcaccu 60  
 uugaaaucag uguuuuagga g 81

55

<210> 433  
 <211> 88  
 <212> RNA  
 <213> Rattus norvegicus

<400> 433  
 accccuuga ggaugacuga uuucuuuugg uguucagagu cauagaauu uucugacc 60

aucugaaauc gguuauaaug auugggga 88  
  
 5 <210> 434  
 <211> 81  
 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 434  
 10 cuucaggaag cugguucau auggugguuu agauuuuuuu agugauuguc uagcaccuu 60  
 ugaaaucagu guucuuggug g 81  
  
 <210> 435  
 <211> 88  
 15 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 435  
 20 aucucuuaa caggcugacc gauuucuccu gguguucaga gucuguuuuu gucuagcacc 60  
 auuugaaauc gguuauaug uaggggga 88  
  
 <210> 436  
 <211> 89  
 25 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 436  
 30 accauguugu agugugugua aacaucuuac acucucagcu gugagcucaa gguggcuggg 60  
 agagggguugu uuacuccuuc ugccaugga 89  
  
 <210> 437  
 <211> 64  
 35 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 437  
 40 cuguaaaca ccuugacugg aagcuguaag guguugagag gagcuuucag ucggauuuuu 60  
 acag 64  
  
 <210> 438  
 <211> 87  
 45 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 438  
 cagaguuuca guucauguaa acaucuuaca cucagcuguc auacaugagu uggcuggggu 60  
 guggauuuuu acgucagcug ucuugga 87  
  
 <210> 439  
 <211> 82  
 50 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 439  
 55 aagucugugu cuguaaaca ccccgacugg aagcuguaag ccacagccaa gcuuucaguc 60  
 agauguuugc ugcuaucugg uc 82

EP 2 808 390 A1

<210> 440  
 <211> 71  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 440  
 gcaacuguaa acauccucga cuggaagcug ugaagccaca aaugggcuuu cagucggaug 60  
 uuugcagcug c 71  
 10  
 <210> 441  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 441  
 gagugacaga uacuguaaac auccuacacu cucagcugug aaaaguaaga aagcugggag 60  
 aaggcuguuu acucucucug ccuu 84  
 20  
 <210> 442  
 <211> 106  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 442  
 ugcuccugaa acuuggaacu ggagaggagg caagaugcug gcauagcugu ugaacugaga 60  
 accugcuaug ccaacauauu gccaucuuuc cugucugaca gcagcu 106  
 30  
 <210> 443  
 <211> 70  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 443  
 ggggauauug cacauuacua aguugcaugu ugucacggcc ucaaugcaau uuagugugug 60  
 ugauauucuc 70  
 40  
 <210> 444  
 <211> 69  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 444  
 ccguggugca uuguaguugc auugcauguu cuggcaguac cugugcaaug uuuccacagu 60  
 gcaucacgg 69  
 50  
 <210> 445  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 445  
 gugcucgguu uguaggcagu guaauuagcu gauuguagug cggugcugac aaucacuaac 60  
 uccacugcca ucaaaaacaag gcac 84  
 55  
 <210> 446  
 <211> 77  
 <212> RNA

EP 2 808 390 A1

<213> Rattus norvegicus  
 <400> 446  
 5 agucuaguua cuaggcagug uaguuagcug auugcuaaua guaccaauca cuaaccacac 60  
 agccagguaa aaagacu 77

<210> 447  
 <211> 102  
 <212> RNA  
 10 <213> Rattus norvegicus

<400> 447  
 15 ccggcuguga gaaauucuuu ggcagugucu uagcugguug uugugaguau uagcuaagga 60  
 agcaaucagc aaguauacug ccuagaagu gcugcacguu gu 102

<210> 448  
 <211> 78  
 <212> RNA  
 20 <213> Rattus norvegicus

<400> 448  
 25 cuuucuaacac agguugggau uugucgcaau gcuguguuuc uguauaguau ugcacuuguc 60  
 ccggccuguu gaguuugg 78

<210> 449  
 <211> 92  
 <212> RNA  
 30 <213> Rattus norvegicus

<400> 449  
 35 ugcccuuca uccacaggug gggauuagug ccuuuacuug uguuagauaa aaaguauugc 60  
 acuugucccg gccugaggaa gaaaagaggg uu 92

<210> 450  
 <211> 87  
 <212> RNA  
 40 <213> Rattus norvegicus

<400> 450  
 45 agucaugggg gcuccaaagu gcuguucgug cagguagugc auugccugac cuacugcuga 60  
 gcuagcacuu cccgagcccc caggaca 87

<210> 451  
 <211> 106  
 <212> RNA  
 50 <213> Rattus norvegicus

<400> 451  
 55 ccaguaccuau cugcuuggcc gauuuuggca cuagcacauu uuugcuugug ucucuccgcu 60  
 cugagcaauc augugcagug ccaauauggg aaaagcgggc ugcugc 106

<210> 452  
 <211> 80  
 <212> RNA  
 55 <213> Rattus norvegicus

<400> 452

EP 2 808 390 A1

gugagguagu aaguuguauu guugugggggu agggauuuua ggccccaaaua agaagauaac 60  
 uauacaacuu acuacuuucc 80

5 <210> 453  
 <211> 81  
 <212> RNA  
 <213> Rattus norvegicus

10 <400> 453  
 cccauuggca uaaacccgua gauccgaucu uguggugaag uggaccgcac aagcucguuu 60  
 cuaugggucu guggcagugu g 81

15 <210> 454  
 <211> 70  
 <212> RNA  
 <213> Rattus norvegicus

20 <400> 454  
 ggcacccacc cguagaaccg accuugcggg gccuucgccg cacacaagcu cgugucugug 60  
 gguccguguc 70

25 <210> 455  
 <211> 80  
 <212> RNA  
 <213> Rattus norvegicus

30 <400> 455  
 ccuguugcca caaacccgua gauccgaacu ugugcugacc augcacacaa gcuugugucu 60  
 auagguaugu gucuguuagg 80

35 <210> 456  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

40 <400> 456  
 aucugagacu gaacuguccu uuucggguu ucaugguacc gaugcuguag aucugaaagg 60  
 uacaguacug ugauagcuga agaauggugg ugccauc 97

45 <210> 457  
 <211> 75  
 <212> RNA  
 <213> Rattus norvegicus

50 <400> 457  
 ugcccuggcu caguuaucac agugcugaug cuguccauuc uaaagguaca guacugugau 60  
 aacugaagga uggca 75

55 <210> 458  
 <211> 86  
 <212> RNA  
 <213> Rattus norvegicus

60 <400> 458  
 gucuucgugc uuucagcuuc uuucagugc ugccuuguag caucagguc aagcagcauu 60  
 guacagggcu augaaagaac caagaa 86

EP 2 808 390 A1

<210> 459  
 <211> 86  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 459  
 uucuacugc ccucggcuuc uuuacagugc ugccuuguug cauauggauc aagcagcauu 60  
 guacagggcu augaaggcau ugagac 86  
 10  
 <210> 460  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 460  
 ccugcuggga cuaaagugcu gacagugcag auaguggucc ucucugugcu accgcacugu 60  
 ggguaacuugc ugcuccagca gg 82  
 20  
 <210> 461  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 461  
 uucucucugc uuuaagcuuc uuuacagugu ugccuugugg cauggaguuc aagcagcauu 60  
 guacagggcu aucaaagcac agagagc 87  
 30  
 <210> 462  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 462  
 ccuuagcaga gcucuggagu gugacaaugg uguuuguguc caaaacauga aacgccauca 60  
 ucacacuaaa cagcuacugc uaggc 85  
 40  
 <210> 463  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 463  
 ugagggccc ucugcguguu cacagcggac cuugauuuuaa ugucuauaca auuaaggcac 60  
 gcgguagaug ccaagagagg cgccucc 87  
 50  
 <210> 464  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 464  
 aggccucucu cuccguguuc acagcggacc uugauuuuaa uguccauaca auuaaggcac 60  
 gcgguagaug ccaagaagg ggcug 85  
 <210> 465  
 <211> 109

EP 2 808 390 A1

<212> RNA  
 <213> Rattus norvegicus  
  
 <400> 465  
 5 aucaagauca gagacucugc ucuccguguu cacagcggac cuugauuuua ugucauacaa 60  
 uuaaggcacg cggugaaugc caagagcggg gccuacggcu gcacuugaa 109  
  
 <210> 466  
 <211> 85  
 10 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 466  
 15 ugccggccuc ugggucccug agaccuuua accugugagg acguccaggg ucacagguga 60  
 gguucuuggg agccuggcgc cuggc 85  
  
 <210> 467  
 <211> 87  
 20 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 467  
 25 ugcgcucucc ucagucccug agaccuaac uugugauguu uaccguuuua auccacgggu 60  
 uaggcucuug ggagcugcga gucgugc 87  
  
 <210> 468  
 <211> 88  
 30 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 468  
 35 accagacuuu uccuaguccc ugagaccua acuugugagg uauuuuagua acaucacaag 60  
 ucaggcucu ugggaccuagg cggagagg 88  
  
 <210> 469  
 <211> 73  
 40 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 469  
 45 ugacagcaca uuauuacuuu ugguacgcgc ugugacacuu caaacucgua cggugagua 60  
 uaaugcgugg uca 73  
  
 <210> 470  
 <211> 97  
 50 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 470  
 55 uuugaucacu gucuccagcc ugcugaagcu cagagggcuc ugauucagaa agaucaucgg 60  
 auccgucuga gcuuggcugg ucggaagucu caucauc 97  
  
 <210> 471  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus

EP 2 808 390 A1

<400> 471  
 ugagcuguug gauucggggc cguagcacug ucugagaggu uuacauuucu cacagugaac 60  
 cggucucuuu uucagcugcu uc 82

5

<210> 472  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus

10

<400> 472  
 ugugcagugg gaaggggggc cgaugcacug uaagagagug aguagcaggu cucacaguga 60  
 accggucucu uucccuacug uguc 84

15

<210> 473  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

20

<400> 473  
 agacugcccu ucgcgaaucu uuuugcgguc ugggcuugcu guacauaacu caauagccgg 60  
 aagcccuuac cccaaaaagc auucgcggag ggcgcgc 97

25

<210> 474  
 <211> 72  
 <212> RNA  
 <213> Rattus norvegicus

30

<400> 474  
 ugggucuuuu ugcggucugg gcuugcuguu cucuccacag uagucaggaa gcccuaccc 60  
 caaaaaguau cu 72

35

<210> 475  
 <211> 88  
 <212> RNA  
 <213> Rattus norvegicus

40

<400> 475  
 ugcugcuggc cggagcucu uucacauugu gcuacugucu acacguguac cgagcagugc 60  
 aauguuaaaa gggcaucggc cuuguagu 88

45

<210> 476  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus

50

<400> 476  
 ggcuugcugg acacucuuc ccuguugcac uacuguggc cucugggaag cagugcaaug 60  
 augaaagggc auccgucagg cc 82

55

<210> 477  
 <211> 101  
 <212> RNA  
 <213> Rattus norvegicus

<400> 477  
 ccgccccgc gucuccagg caaccguggc uuucgauugu uacuguggga accggaggua 60  
 acagucuaca gccauggucg ccccgagca cgcccacgcu c 101

EP 2 808 390 A1

<210> 478  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 478  
 caaugcuug cuaaagcugg uaaauggaa ccaaaucgcc ucuucaaugg auuuggucc 60  
 cuucaaccag cuguagcuau gcauuga 87  
 10  
 <210> 479  
 <211> 73  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 479  
 cagggugugu gacugguuga ccagaggggc gugcacuuug uucaccugu gggccaccua 60  
 gucaccaacc cuc 73  
 20  
 <210> 480  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 480  
 cgcucugcug uggccuaugg cuuuucauuc cuaugugauu gcuguuccga acucauguag 60  
 ggcuaaaagc caugggcuac agugaggggc aagcucc 97  
 30  
 <210> 481  
 <211> 100  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 481  
 agauaaaauc acucuagugc uuuauggcuu uuuaauccua ugugaucgua auaaagucuc 60  
 auguagggau ggaagccaug aaauacauug ugaaaauua 100  
 40  
 <210> 482  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 482  
 ugagcccucg gaggacucca uuuguuuuga ugauggauuc uuaagucca ucaucgucuc 60  
 aaaugagucu ucagaggguu cu 82  
 50  
 <210> 483  
 <211> 102  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 483  
 ggcccucuga cucucuucgg ugacggguau ucuugggugg auaauacgga uuacguuguu 60  
 auugcuuaag aaucgcgua gucgaggaga guaccagcgg ca 102  
 <210> 484

EP 2 808 390 A1

<211> 82  
 <212> RNA  
 <213> *Rattus norvegicus*

5  
 <400> 484  
 guugcugcag cugguguugu gaucaggcc gacgagcaac gcauccucuu acccgguau 60  
 uucacgacac cagguugca cc 82

10  
 <210> 485  
 <211> 99  
 <212> RNA  
 <213> *Rattus norvegicus*

15  
 <400> 485  
 cucuggcaug guguuguggg acagcuggug uugugaauca ggccguugcc aaucagagaa 60  
 cggcuacuuc acaacaccag ggucucacug cacugcagg 99

20  
 <210> 486  
 <211> 68  
 <212> RNA  
 <213> *Rattus norvegicus*

25  
 <400> 486  
 gugauucua cagugcacgu guccagug uggcucggag gcuggagacg cggcccuguu 60  
 ggaguaac 68

30  
 <210> 487  
 <211> 99  
 <212> RNA  
 <213> *Rattus norvegicus*

35  
 <400> 487  
 gugucucucu cuguguccug ccagugguuu uaccuauagg uagguuacau caugcuguuc 60  
 uaccacaggg uagaaccacg gacaggauac uggagcacc 99

40  
 <210> 488  
 <211> 94  
 <212> RNA  
 <213> *Rattus norvegicus*

45  
 <400> 488  
 ggcugacucu gaguccaucu uccagugcag uguuggaugg uugaaguacg aagcuccuaa 60  
 cacugucugg uaaauggc ccccgguca guuc 94

50  
 <210> 489  
 <211> 87  
 <212> RNA  
 <213> *Rattus norvegicus*

55  
 <400> 489  
 gacagugcag ucaccuaaa aguagaaagc acuacuaaca gcacuggagg guguaguguu 60  
 uccuacuuua uggaugagug uacugug 87

<210> 490  
 <211> 105  
 <212> RNA  
 <213> *Rattus norvegicus*

EP 2 808 390 A1

<400> 490  
 gcggagcggc ugucuccag ccugaggugc agugcugcau cucuggucag uugggagucu 60  
 gagaugaagc acuguagcuc aggaagggag aagauguucu gcagc 105

5

<210> 491  
 <211> 83  
 <212> RNA  
 <213> Rattus norvegicus

10

<400> 491  
 gggccuuggc ugggauauca ucauauacug uaaguuugug augagacacu acaguauaga 60  
 ugauguacua gucuggguac ccc 83

15

<210> 492  
 <211> 88  
 <212> RNA  
 <213> Rattus norvegicus

20

<400> 492  
 caccuugucc ucacggucca guuuucccag gaaucccuug gaugcuaaga uggggauucc 60  
 uggaaauacu guucuugagg ucauggcu 88

25

<210> 493  
 <211> 95  
 <212> RNA  
 <213> Rattus norvegicus

30

<400> 493  
 uguguauucc cagcucugag aacugaauc cauggguuau agcaauguca gaccugugaa 60  
 guucaguucu uuagcuggga uagcucuauc gucau 95

35

<210> 494  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

40

<400> 494  
 caggcacucu uagcauuuga ggugaaguuc uguuauacac ucaggcugug gcucugaaag 60  
 ucagugcauc acagaacuuu gucucgaaag cuuucua 97

45

<210> 495  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus

50

<400> 495  
 cuucucaagg ccugucucc caaccuugu accagugcug ugccucagac ccugguacag 60  
 gccuggggga cagggacuug gggac 85

55

<210> 496  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

<400> 496  
 agcgcuuucc ugcccucgag gaggcucag ucuaguaugu cuccuccua cuagacugag 60

gcuccuugag gacagggauC gucauacuca ccucccg 97

5 <210> 497  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus

<400> 497  
 10 uguuccccgg gccagguuc ugugauacac uccgacucgg gcucuggagc agucagugca 60  
 ugacagaacu ugggcccggu aggac 85

15 <210> 498  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus

<400> 498  
 20 agcgguggcc agugucauuu uugugauguu gcagcuagua auaugagccc aguugcauag 60  
 ucacaaaagu gaucauugga aacugug 87

25 <210> 499  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus

<400> 499  
 30 gcgugucuu g aagauagguu auccguguug ccuucgcuuu auucgugacg aaucacacac 60  
 gguugaccua uuuuucagua ccaa 84

35 <210> 500  
 <211> 106  
 <212> RNA  
 <213> Rattus norvegicus

<400> 500  
 40 agaacuugcc aaggguuugg gggaaacauuc aaccugucgg ugaguuuuggg cagcucagac 60  
 aaaccaucga ccguugagug gaccccgagg ccuggaacug ccaccc 106

45 <210> 501  
 <211> 117  
 <212> RNA  
 <213> Rattus norvegicus

<400> 501  
 50 agaugggcaa ccaaggcagc cuuaagagga cuccauggaa cauucacgc ugucggugag 60  
 uuugggauuc aaaaacaaa aaaaccacca accguugacu guaccuuggg auucuua 117

55 <210> 502  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus

<400> 502  
 ccugugcaga gaugauguuu acaaagguca caucaacau ucauugcugu cgguggguug 60  
 aacuguguag aaaagcucac ugaacaauga augcaacugu ggccccgcuu 110

EP 2 808 390 A1

<210> 503  
 <211> 88  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 503  
 ugauggcugc acucaacauu cauugcuguc gguggguuug aaugucaacc aacucacugg 60  
 ucaaugaaug caaacugcgg gccaaaaa 88  
 10  
 <210> 504  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 504  
 ccagagagug ugacuccugu ccuguguaug gcacugguag aaucacugu gaacagucuc 60  
 ggucagugaa uuaccgaagg gccauaaaca gagcagagac agauccgcga 110  
 20  
 <210> 505  
 <211> 77  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 505  
 cacuuucccu uaucaguuuu ccagccagcu uugugacugu aaauguugga cggagaacug 60  
 auaaggguaa gugacug 77  
 30  
 <210> 506  
 <211> 80  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 506  
 gggggugagg gauuggagag aaaggcaguu ccugaugguc cccucccagg ggcuggcuuu 60  
 ccucuggucc uucucuccca 80  
 40  
 <210> 507  
 <211> 86  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 507  
 ugcuuacaac uuuccaaaga auucuccuuu ugggcuuucu cauuuuuuu uaagcccaaa 60  
 ggugaauuuu uugggaaguu ugagcu 86  
 50  
 <210> 508  
 <211> 104  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 508  
 gggcucacag gacacaaugc ggauccucag gcuacaacac aggacccggg cgcugcucug 60  
 accccucgug ucuuguguug cagccggagg gacgcagguc ugca 104  
 55  
 <210> 509  
 <211> 85  
 <212> RNA

EP 2 808 390 A1

<213> Rattus norvegicus  
 <400> 509  
 5 ugcaggccuc ugugugauau guuugauaua uuagguuguu auuuaucca acuauauauc 60  
 aagcauauuc cuacaguguc uugcc 85  
  
 <210> 510  
 <211> 91  
 <212> RNA  
 10 <213> Rattus norvegicus  
  
 <400> 510  
 ggcuggacag cgggcaacgg aaucacaaa gcagcuguug ucuccagagc auuccagcug 60  
 cacuuggauu ucguucccug cucuccugcc u 91  
 15  
  
 <210> 511  
 <211> 110  
 <212> RNA  
 20 <213> Rattus norvegicus  
  
 <400> 511  
 gucaagaugg agugcacagg gcucugaccu augaaauugac agccaguacu cugaucucgc 60  
 cucuggcugc caguuccaua ggucacaggu auguucgccu caaugccagc 110  
 25  
  
 <210> 512  
 <211> 86  
 <212> RNA  
 <213> Rattus norvegicus  
 30  
  
 <400> 512  
 gcgagcggga gcugagagcu gggucuuugc gggcaagaug agggugucag uucaacuggc 60  
 cuacaaaguc ccaguccucg gcuccc 86  
 35  
  
 <210> 513  
 <211> 83  
 <212> RNA  
 <213> Rattus norvegicus  
 40  
  
 <400> 513  
 auggagucan cacguguaac agcaacucca uguggacugu gcacagauc caguggagcu 60  
 gcuguaucuu uugauggccu cca 83  
 45  
  
 <210> 514  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus  
 50  
  
 <400> 514  
 uggcuccac cccuguaac agcaacucca uguggaagug cccacugauu ccaguggggc 60  
 ugcuguauc ugggguggag gcugg 85  
 55  
  
 <210> 515  
 <211> 87  
 <212> RNA  
 <213> Rattus norvegicus  
  
 <400> 515

EP 2 808 390 A1

aacucuccug gcucuagcag cacagaaaua uuggcacggg uaagugaguc ugccaauauu 60  
ggcugugcug cuccaggcag gguggug 87

5 <210> 516  
<211> 110  
<212> RNA  
<213> Rattus norvegicus

10 <400> 516  
uguuugcuca gcugaucugu ggcuuaggua guuucauguu guugggauug aguuuugaac 60  
ucggcaacaa gaaacugccu gaguuacauc agucgguuuu cgucgagggc 110

15 <210> 517  
<211> 110  
<212> RNA  
<213> Rattus norvegicus

20 <400> 517  
uggaagcuuc uggagauccu gcuccgucgc cccaguguuc agacuaccug uucaggacaa 60  
ugccguugua caguagucug cacauugguu agacugggca agggccagca 110

25 <210> 518  
<211> 69  
<212> RNA  
<213> Rattus norvegicus

30 <400> 518  
cccucgucuu acccagcagu guuugggugc uggguuggag ucucuaauac ugccggguaa 60  
ugauggagg 69

35 <210> 519  
<211> 89  
<212> RNA  
<213> Rattus norvegicus

40 <400> 519  
cuggggccucu gugggcaucu uaccggacag ugcuggauuu cuuggcuuga cucuaacacu 60  
gucugguaac gauguucaa ggugacca 89

45 <210> 520  
<211> 95  
<212> RNA  
<213> Rattus norvegicus

50 <400> 520  
ccaacuuggg cagccguggc caucuacug ggcagcauug gauagugucu gaucucuaau 60  
acugccuggu aaugaugacg gcggagcccu gcacg 95

55 <210> 521  
<211> 97  
<212> RNA  
<213> Rattus norvegicus

60 <400> 521  
gcgcgccugg uccagugguu cuuaacaguu caacaguucu guagcgcaau ugugaaaugu 60  
uuaggaccac uagacccggc gcgcacggca gcggcga 97

EP 2 808 390 A1

<210> 522  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 522  
 ggcuacagcc cuucucaug ugacucgugg acuucccuu gucauccuau gccugagaau 60  
 auaugaagga ggcuggggaag gcaaagggac guucaauugu caucacuggc 110  
 10  
 <210> 523  
 <211> 108  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 523  
 aaacagcccc agacaaucca uggguccucc uguccuucan uccaccggag ucugucuau 60  
 gccaacaga uuucagugga gugaagcuca ggaggcaugg agcugcca 108  
 20  
 <210> 524  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 524  
 cuuccccagg ccacaugcuu cuuuauaucc ucauagauau cacugcgcua uggaauguaa 60  
 ggaagugugu gguuuuggca agug 84  
 30  
 <210> 525  
 <211> 83  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 525  
 uuccuugac gggugagcuu uuggcccggg uuauaccuga cucucacgua uaagacgagc 60  
 aaaaagcuug uuggucagag gag 83  
 40  
 <210> 526  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 526  
 ccggggcagu ccuccaggc ucaggacagc cacugcccac agcacacugc guugcuccgg 60  
 acccacugug cgugugacag cggcugaucu gucccugggc agcgcgaacc 110  
 50  
 <210> 527  
 <211> 106  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 527  
 cagcuuggac cugugaccuc ugggcuuccc uuugucaucc uuugccuagg ccucugagug 60  
 gggcaaggac agcaaagggg ggcucagugg ucaccucuac ugcaga 106  
 <210> 528  
 <211> 111

EP 2 808 390 A1

<212> RNA  
<213> Rattus norvegicus

<400> 528  
5 cgggauaucc cgcgccgggc agcgcgccgg caccuuggcu cuagacugcu uacugcccgg 60  
gccgcccuca guaacagucu ccagucacgg ccaccgacgc cuggccccgc c 111

<210> 529  
10 <211> 100  
<212> RNA  
<213> Rattus norvegicus

<400> 529  
15 agguugcuuc agugaacauu caacgcuguc ggugaguuuug gaauucaauu aaaaaccauc 60  
gaccguugau uguacccuau agcuaaccu uaucuacucc 100

<210> 530  
20 <211> 110  
<212> RNA  
<213> Rattus norvegicus

<400> 530  
25 guccuggaug gacagaguug ucaugugucu gccugucuac acuugcugug cagaacauc 60  
gcucaccugu acagcaggca cagacaggca gucacaugac aaccagccu 110

<210> 531  
30 <211> 106  
<212> RNA  
<213> Rattus norvegicus

<400> 531  
35 guuagcuau aguuaguuuu aucucagcug gcaacuguga gauguccua ucauuccua 60  
caguggucuc ugggauuau cuaaacagag cauuuccuu gaccuc 106

<210> 532  
40 <211> 105  
<212> RNA  
<213> Rattus norvegicus

<400> 532  
45 accacaguca uuguaguuuu gaugucgcag auacugcauc aggaacugac uggauaagac 60  
ucagucacca ucaguuccua augcauugcc uucagcaucu aaaca 105

<210> 533  
50 <211> 110  
<212> RNA  
<213> Rattus norvegicus

<400> 533  
55 gaccaguugc cgcggggcuu uccuuuguc uugaucuaac cauguggugg aacgauggaa 60  
acggaacaug guucugucua gcaccgcgga aagcaucgcu cucuccugca 110

<210> 534  
55 <211> 110  
<212> RNA  
<213> Rattus norvegicus

EP 2 808 390 A1

<400> 534  
 gugauaacgu agcgagauuu ucuguugugc uugaucuaac caugugcuug cgagguauga 60  
 guaaaacaug guuccgucaa gcaccaugga acgucacgca gcuuucuaca 110

5

<210> 535  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus

10

<400> 535  
 cugucccggg ccgcgccucc ugauugucca aacgcaauuc ucgagucucu ggcuccggcc 60  
 gagaguugcg ucuggacguc ccgagccgcc gccccc aaac cucgaggggg 110

15

<210> 536  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus

20

<400> 536  
 acucaggggc uucaccacug auuguccaaa cgcaauucuu guacgagucu gcgccaacc 60  
 gagaauugug gcuggacauc ugugguugag cuccgg 96

25

<210> 537  
 <211> 109  
 <212> RNA  
 <213> Rattus norvegicus

30

<400> 537  
 ugaauaucca ggucuggggc augaaccugg cauacaaugu agauuucugu guuuguuagg 60  
 caacagcuac auugucugcu ggguuucagg cuaccuggaa gcauuucuc 109

35

<210> 538  
 <211> 103  
 <212> RNA  
 <213> Rattus norvegicus

40

<400> 538  
 aaggauuagg gugcccucag uggcucagua gccaguguag auccugucuu ugguaaucag 60  
 cagcuacauc uggcuacugg gucucugaug gcaucaucua gcu 103

45

<210> 539  
 <211> 110  
 <212> RNA  
 <213> Rattus norvegicus

50

<400> 539  
 ucuggccuuc ugcaguguua cgcuccgugu auuugacaag cugaguugga cacucugugu 60  
 gguagagugu caguuuuguca aauaccccaa guguggcuca ugcuuaucag 110

55

<210> 540  
 <211> 81  
 <212> RNA  
 <213> Rattus norvegicus

<400> 540  
 ucaucuugcg guucucaaac uaugggggca cuuuuuuuuu cuuuuuuuuu ugccgccagg 60  
 uuuuagggcc ugccgguuga g 81

EP 2 808 390 A1

<210> 541  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 541  
 ccgguguagu agccaucaaa guggaggccc ucucuugggc ccgagcuaga aagugcuucc 60  
 acuuugugug ccacugcaug gg 82  
 10  
 <210> 542  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 542  
 caaccuguga uacucaaacu gggggcucuu uuggguuuuc uuuggaagaa aagugccgcc 60  
 agguuuugag uguuaccgau ug 82  
 20  
 <210> 543  
 <211> 78  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 543  
 ggaccuuucu ggagggcccc ccucuaaucc uguugugcuc gcuucagagg guugggugga 60  
 ggcucuccug aagguguc 78  
 30  
 <210> 544  
 <211> 68  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 544  
 uauguaugua ugauguaug uaugcaugua ugugugcaug uaugcaugca ugcauguaug 60  
 uauguaug 68  
 40  
 <210> 545  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 545  
 ccaggccuuc ggcagaggag ggcuguucuu ccuuggguu uuaugacugg gaggaacuag 60  
 ccuucucucu gcuuaggagu gg 82  
 50  
 <210> 546  
 <211> 63  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 546  
 aagaaauggu uuaccguccc acauacauuu ugaguaugua ugugggacgg uaaaccgcuu 60  
 cuu 63  
 <210> 547

EP 2 808 390 A1

<211> 79  
 <212> RNA  
 <213> Rattus norvegicus

5 <400> 547  
 gcuacuugaa gagagguuau ccuugugug uuugcuuuac gcgaaaugaa uaugcaaggg 60  
 caagcucucu ucgaggagc 79

10 <210> 548  
 <211> 100  
 <212> RNA  
 <213> Rattus norvegicus

15 <400> 548  
 ccugcuggcu acugcugagc acugcucuga cuuuauugca cuacuguacu guacagcuag 60  
 cagugcaaua guauuguaa agcauccggg agcaggcuac 100

20 <210> 549  
 <211> 82  
 <212> RNA  
 <213> Rattus norvegicus

25 <400> 549  
 gccucgcugu ccuccgccuu cucuucccgg uucuucccgg agucgggaaa agcuggguug 60  
 agagggcgaa aaaggauaug gg 82

30 <210> 550  
 <211> 59  
 <212> RNA  
 <213> Rattus norvegicus

<400> 550  
 uuggccuccu aagccaggga uuguggguuc gaguccacc cgggguaaga gguuguguu 59

35 <210> 551  
 <211> 95  
 <212> RNA  
 <213> Rattus norvegicus

40 <400> 551  
 ccucgcugac uccgaaggga ugcagcagca auucauguuu uggaguauug ccaagguuca 60  
 aaacaugaag cgcugcaaca ccccuucgug ggaaa 95

45 <210> 552  
 <211> 86  
 <212> RNA  
 <213> Rattus norvegicus

50 <400> 552  
 uugguacuug gagagaggug guccguggcg cguucgcuuc auuuauuggcg cacauuacac 60  
 ggucgaccuc uuugcggguau cuaauc 86

55 <210> 553  
 <211> 83  
 <212> RNA  
 <213> Rattus norvegicus

EP 2 808 390 A1

<400> 553  
 cugacuaugc cuccucgcau ccccuagggc auugguguaa agcuggagac ccacugcccc 60  
 aggugcugcu ggggguugua guc 83

5

<210> 554  
 <211> 98  
 <212> RNA  
 <213> Rattus norvegicus

10

<400> 554  
 auauagugcu ugguuccuag uaggugcuca gaaaguguuu gugacauaa ucguuuauug 60  
 agcaccuccu aucaaucaag cacugugcua ggcucugg 98

15

<210> 555  
 <211> 95  
 <212> RNA  
 <213> Rattus norvegicus

20

<400> 555  
 cucaucuguc uguggggug ggggcagggc cuuugugaag gcggguuauug cucagaucgc 60  
 cucugggccc uuccuccagu cccgaggcag auuuu 95

25

<210> 556  
 <211> 84  
 <212> RNA  
 <213> Rattus norvegicus

30

<400> 556  
 uggggcaggg gggcaggagg ggcucagggg gaaagcaucu acagccccug gccucucug 60  
 cccuuccguc cccuguccc aaau 84

35

<210> 557  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

40

<400> 557  
 uguucgcuuc ugguaccgga agagagguuu ucugggucuc uguuucuuug augagaauga 60  
 aacacacca gcuaaccuuu uuuucaguau caaaucc 97

45

<210> 558  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

50

<400> 558  
 acccuuuggc gaucucugcc ucucugggcc ugugucuuaug gcucuuaag aucuaacgag 60  
 caaagcacag ggccugcaga gagguagcgc ucugcuc 97

55

<210> 559  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus

<400> 559  
 gagucugguc uuguuugggu uuguucuagg uaugguccca gggaucccag aucaaaccag 60  
 gccccugggc cuauccuaga accaaccuaa acccau 96

EP 2 808 390 A1

<210> 560  
 <211> 95  
 <212> RNA  
 <213> Rattus norvegicus  
 5  
 <400> 560  
 ccccgugga accacguggu gugcuaguua cuuuugggcu ggagagacgg cucagggguu 60  
 aagagcacag acugcucuuc cagagguccu gaguu 95  
 10  
 <210> 561  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 561  
 augugaccgu gccucucacc cuuccauauc uagucucuga gaaaaaugaa gacuggauuc 60  
 caugaaggga ugugaggccu ggaaacugga gcuuua 96  
 20  
 <210> 562  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <400> 562  
 aguguaguga gaaguugggg ggugggaacg gcgucaugca ggaguugauu gcacagccau 60  
 ucaguccua uaugaugccu uucuucaccc ccuuaa 97  
 30  
 <210> 563  
 <211> 66  
 <212> RNA  
 <213> Rattus norvegicus  
 35  
 <400> 563  
 uccccaacaa uauccuggug cugagugggu gcacagugac uccagcauca gugauuuugu 60  
 ugaaga 66  
 40  
 <210> 564  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 45  
 <400> 564  
 acggggugga caccguccu guccuccagg agcucacgua ugccugccug ugagcgccuc 60  
 gacgacagag ccagagucca cccugcacu gcccaa 96  
 50  
 <210> 565  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 55  
 <400> 565  
 aaaaugauga ugucaguugg ccggucggcc gaucgcucgg ucugucaguc agucggucgg 60  
 ucgaucgguc ggucggucag ucggcuuccu gucuuc 96  
 <210> 566

EP 2 808 390 A1

<211> 99  
 <212> RNA  
 <213> Rattus norvegicus

5

<400> 566  
 gaaaauugggc ucaaggugag gggugcuauc ugugauugag ggacaugguc aauggaaauug 60  
 ucucacacag aaaucgcacc cgucaccuug gccugcuga 99

10

<210> 567  
 <211> 98  
 <212> RNA  
 <213> Rattus norvegicus

15

<400> 567  
 cugcagccag aguuuuuacc agucaggcuc cuggcuagau uccagguacc aacugguacc 60  
 ugaucuagcc aaagccugac cguaaagcugc aaaagaaa 98

20

<210> 568  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus

25

<400> 568  
 acccaagucc aggccugcug accccuaguc cagugcuugu gguggcuacu gggcccugaa 60  
 cuaggggucuu ggagaccugg guuugaucuc cacagg 96

30

<210> 569  
 <211> 98  
 <212> RNA  
 <213> Rattus norvegicus

35

<400> 569  
 ucuguguugg gcaucugucu gccugagugc cugccucucu guugcucuga aggaggcagg 60  
 ggcugggccu gcagcugccu gggcagagcu gcuccuuc 98

40

<210> 570  
 <211> 97  
 <212> RNA  
 <213> Rattus norvegicus

45

<400> 570  
 gaagacucua gcauguaagg uugggggagg gggcuguguc uagcaagucu ucuuuuuuuu 60  
 cagcccugcu gucuuaaccu cuagguguuc cggcucc 97

50

<210> 571  
 <211> 99  
 <212> RNA  
 <213> Rattus norvegicus

55

<400> 571  
 agaugccuug cuccuacaag aguaaagugc acgugcuuug ggacagugag gaaaauaaug 60  
 uucacaaagc ccauacacuu ucacccuuua ggagaguug 99

<210> 572  
 <211> 81  
 <212> RNA  
 <213> Rattus norvegicus

EP 2 808 390 A1

<220>

<223> Description of Combined DNA/RNA Molecule:c

<400> 572

5 cauggcaccu ccauuucccu gaggagcccu uugagccuga ggugaaaaa aacagguca 60  
agaggcgccu gggaacugga g 81

<210> 573

<211> 98

10

<212> RNA

<213> Homo sapiens

<400> 573

15 acccaaacc uaggucugcu gacuccuagu ccagggcucg ugauggcugg ugggccuga 60  
acgagggguc uggaggccug gguuugaaua ucgacagc 98

<210> 574

<211> 86

20

<212> RNA

<213> Homo sapiens

<400> 574

25 gucugucugc ccgcaugccu gccucucugu ugcucugaag gaggcagggg cugggccugc 60  
agcugccugg gcagagcggc uccugc 86

<210> 575

<211> 68

30

<212> RNA

<213> Homo sapiens

<400> 575

35 ccauuacugu ugcuaauaug caacucuguu gaauauaaau uggaauugca cuuuagcaau 60  
ggugaugg 68

<210> 576

<211> 66

40

<212> RNA

<213> Homo sapiens

<400> 576

45 aaaaggugga uauuccuucu auguuuangu uauuuuggu uaaacauaga ggaaaucca 60  
cguuuu 66

<210> 577

<211> 70

50

<212> RNA

<213> Homo sapiens

<400> 577

55 uugaagggag aucgaccgug uuauauucgc uuuauugacu ucgaauaaua caugguugau 60  
cuuuucucag 70

<210> 578

<211> 75

55

<212> RNA

<213> Homo sapiens

EP 2 808 390 A1

<400> 578  
 agacagagaa gccaggucac gucucugcag uuacacagcu cacgagugcc ugcuggggug 60  
 gaaccugguc ugucu 75

5

<210> 579  
 <211> 67  
 <212> RNA  
 <213> Homo sapiens

10

<400> 579  
 guggcacuca aacugugggg gcacuuucug cucucuggug aaagugccgc caucuuuuga 60  
 guguuac 67

15

<210> 580  
 <211> 67  
 <212> RNA  
 <213> Homo sapiens

20

<400> 580  
 guggggccuca aauguggagc acuaauucuga uguccaagug gaaagugcug cgacauuuga 60  
 gcgucac 67

25

<210> 581  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens

30

<400> 581  
 gggauacuca aaaugggggc gcuuuccuuu uugucuguac uggaagugc uucgauuuug 60  
 ggguguccc 69

35

<210> 582  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens

40

<400> 582  
 uacaucggcc auuauaauc aaccugauaa guguuauagc acuaucaga uuguauugua 60  
 auugucugug ua 72

45

<210> 583  
 <211> 99  
 <212> RNA  
 <213> Mus musculus

50

<400> 583  
 cauggcaccu ccguuucccu gaggagcccu uugagccugg agugaaaaa aaaaacaggu 60  
 caagaggcgc cugggaacug gagaagagug uaaaacuuc 99

55

<210> 584  
 <211> 79  
 <212> RNA  
 <213> Mus musculus

<400> 584  
 agacggagag accaggucac gucucugcag uuacacagcu caugagugcc ugcuggggug 60

gaaccugguu ugucugucu

79

&lt;210&gt; 585

&lt;211&gt; 68

&lt;212&gt; RNA

&lt;213&gt; Mus musculus

&lt;400&gt; 585

5  
 10  
 uaaaagguag auucuccuuc uaugaguaca auauuaauga cuaaucguag aggaaaaucc 60  
 acguuuuc 68

&lt;210&gt; 586

&lt;211&gt; 82

&lt;212&gt; RNA

&lt;213&gt; Mus musculus

&lt;400&gt; 586

15  
 20  
 ugguauuuaa aagguggaua uuccuucuau gguuacgugc uuccuggaua aucauagagg 60  
 aacauccacu uuucaguau ca 82

&lt;210&gt; 587

&lt;211&gt; 61

&lt;212&gt; RNA

&lt;213&gt; Mus musculus

&lt;400&gt; 587

25  
 30  
 aagaugguug accauagaac augcgcuacu ucugugucgu auguaguaug guccacaucu 60  
 u 61

&lt;210&gt; 588

&lt;211&gt; 79

&lt;212&gt; RNA

&lt;213&gt; Mus musculus

&lt;400&gt; 588

35  
 40  
 ugguacucgg agagagguua cccgagcaac uuugcaucug gaggacgaau guugcucggu 60  
 gaacccuuu ucgguauca 79

&lt;210&gt; 589

&lt;211&gt; 81

&lt;212&gt; RNA

&lt;213&gt; Mus musculus

&lt;400&gt; 589

45  
 50  
 gguacuuga ggagagguug ucugugauga guucgcuua uuaaugacga auauaacaca 60  
 gauggccugu uucaauacc a 81

&lt;210&gt; 590

&lt;211&gt; 82

&lt;212&gt; RNA

&lt;213&gt; Mus musculus

&lt;400&gt; 590

55  
 ugguacuugg agagauagua gaccguauag cguacgcuuu aucugugacg uauguaacac 60  
 gguccacuaa ccucaguau ca 82

EP 2 808 390 A1

<210> 591  
 <211> 80  
 <212> RNA  
 <213> Mus musculus  
 5  
 <400> 591  
 ggguauggga cggauugucg accagcugga aaguaauugu uucuaaugua cuucaccugg 60  
 uccacuagcc gucggugccc 80  
 10  
 <210> 592  
 <211> 96  
 <212> RNA  
 <213> Rattus norvegicus  
 15  
 <400> 592  
 guacauaugu ugaagauuau uauauauag aguggguguu guggugguag uaugauaugu 60  
 agaguaguag guugcauagu acgauguagu guauga 96  
 20  
 <210> 593  
 <211> 79  
 <212> RNA  
 <213> Rattus norvegicus  
 25  
 <220>  
 <223> Description of Combined DNA/RNA Molecule:c  
 <400> 593  
 cacacuguag gccucauuaa auguuuguug aaugaaaaa ugaaucauca acagacauua 60  
 auugggcgcc ugcucugug 79  
 30  
 <210> 594  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 35  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 <400> 594  
 cauacuucuu uauaugccca ua 22  
 40  
 <210> 595  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 45  
 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 50  
 <400> 595  
 uggaauguaa agaaguaugu a 21  
 55  
 <210> 596  
 <211> 21

EP 2 808 390 A1

<212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 5  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 596  
 10 cauacuucuu uacauucgt t 21  
  
 <210> 597  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
  
 <220>  
 20 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 597  
 25 uggaauguaa agaaguaugu a 21  
  
 <210> 598  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 30  
 <220>  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 35 Primer  
  
 <400> 598  
 cauacuucuu uacauccat t 21  
  
 <210> 599  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 45  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 599  
 50 uggaauguaa agaaguaugu a 21  
  
 <210> 600  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 55

EP 2 808 390 A1

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

5

<400> 600  
guguucacag cggaccuuga uu 22

10

<210> 601  
<211> 22  
<212> RNA  
<213> Artificial Sequence

15

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

20

<400> 601  
uuaaggcacg cggugaaugc ca 22

25

<210> 602  
<211> 22  
<212> RNA  
<213> Artificial Sequence

30

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35

<400> 602  
gcauucaccg cgugccuugg tt 22

40

<210> 603  
<211> 22  
<212> RNA  
<213> Artificial Sequence

45

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50

<400> 603  
uuaaggcacg cggugaaugc ca 22

55

<210> 604  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<220>

EP 2 808 390 A1

<223> Description of Artificial Sequence: Synthetic  
Primer

5 <400> 604  
gcauucaccg cgugccuuaa tt 22

10 <210> 605  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

15 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

20 <400> 605  
uuaaggcacg cggugaaugc ca 22

25 <210> 606  
<211> 19  
<212> RNA  
<213> Artificial Sequence

<220>

30 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35 <400> 606  
ucuuuucaca uugugcuac 19

40 <210> 607  
<211> 20  
<212> RNA  
<213> Artificial Sequence

<220>

45 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50 <400> 607  
cagugcaaug uuaaaagggc 20

55 <210> 608  
<211> 20  
<212> RNA  
<213> Artificial Sequence

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

EP 2 808 390 A1

<400> 608  
 uauuuuaaca uugcacugtt 20

5 <210> 609  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

10 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

15 <400> 609  
 cagugcaaug uaaaaagggc 20

20 <210> 610  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

25 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

30 <400> 610  
 ccuuuuuaaca uugcacugtt 20

35 <210> 611  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

40 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

45 <400> 611  
 cagugcaaug uaaaaagggc 20

50 <210> 612  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

55 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

55 <400> 612  
 aguuuugcau aguugcacua 20

EP 2 808 390 A1

5  
 <210> 613  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 10  
 <400> 613  
 ugugcaaauc uaugcaaaac uga 23

15  
 <210> 614  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 20  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 25  
 <400> 614  
 acauuugcau agauuugcac att 23

30  
 <210> 615  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 35  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 <400> 615  
 40  
 ugugcaaauc uaugcaaaac uga 23

45  
 <210> 616  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 50  
 <400> 616  
 aguuuugcau agauuugcac att 23

55  
 <210> 617  
 <211> 23

<212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 5  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 617  
 10 ugugcaaauc uaugcaaaac uga 23  
  
 <210> 618  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
  
 <220>  
 20 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 618  
 25 caaaauucgua ucuaggggaa ua 22  
  
 <210> 619  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
 30  
 <220>  
  
 <220>  
 35 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 619  
 uacccuguag auccgaauiu gug 23  
  
 <210> 620  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 45  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 620  
 50 agaauucgga ucuacaggu att 23  
  
 <210> 621  
 <211> 23  
 <212> RNA  
 <213> Artificial Sequence  
 55

EP 2 808 390 A1

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

5

<400> 621  
uaccuguag auccgaauuu gug 23

10

<210> 622  
<211> 23  
<212> RNA  
<213> Artificial Sequence

15

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

20

<400> 622  
caauucgga ucuacaggu att 23

25

<210> 623  
<211> 23  
<212> RNA  
<213> Artificial Sequence

30

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35

<400> 623  
uaccuguag auccgaauuu gug 23

40

<210> 624  
<211> 19  
<212> RNA  
<213> Artificial Sequence

45

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50

<400> 624  
auguuuccac agugcauca 19

55

<210> 625  
<211> 19  
<212> RNA  
<213> Artificial Sequence

<220>

<220>

EP 2 808 390 A1

<223> Description of Artificial Sequence: Synthetic  
Primer

5 <400> 625  
gugcauugua guugcauug 19

<210> 626  
<211> 19  
10 <212> RNA  
<213> Artificial Sequence

<220>

<220>  
15 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 626  
guccaacuac aaugcactt 19

20 <210> 627  
<211> 19  
<212> RNA  
25 <213> Artificial Sequence

<220>

<220>  
30 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 627  
gugcauugua guugcauug 19

35 <210> 628  
<211> 19  
<212> RNA  
40 <213> Artificial Sequence

<220>

<220>  
45 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 628  
augcaacuac aaugcactt 19

<210> 629  
<211> 19  
50 <212> RNA  
<213> Artificial Sequence

<220>

<220>  
55 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 629  
 gugcauugua guugcauug 19

5 <210> 630  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence

10 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

15 <400> 630  
 cuauacaacc uacugccuuc c 21

20 <210> 631  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence

25 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

30 <400> 631  
 ugagguagua gguugugugg uu 22

35 <210> 632  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence

40 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

45 <400> 632  
 ccacacaacc uacuaucuua tt 22

50 <210> 633  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence

55 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

<400> 633  
 ugagguagua gguugugugg uu 22

5 <210> 634  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 10 Primer  
 <400> 634  
 ccacacaacc uacuaccuca tt 22

15 <210> 635  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 20 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 25 <400> 635  
 ugagguagua gguugugugg uu 22

30 <210> 636  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 35 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 40 <400> 636  
 aacaacauga aacuaccuat t 21

45 <210> 637  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 50 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 <400> 637  
 uagguaguuu cauguuguug g 21

55 <210> 638  
 <211> 22

<212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 5  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 638  
 10 caaauucgua ucuagggaa ua 22  
  
 <210> 639  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
  
 <220>  
 20 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 639  
 25 uagguaguuu cauguuguug g 21  
  
 <210> 640  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 30  
 <220>  
  
 <220>  
 35 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 640  
 aauaacauga aacuaccuat t 21  
  
 <210> 641  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 40  
 <220>  
 45  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 641  
 50 uagguaguuu cauguuguug g 21  
  
 <210> 642  
 <211> 19  
 <212> RNA  
 <213> Artificial Sequence  
 55

EP 2 808 390 A1

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

5

<400> 642  
augcaacuac aaugcactt 19

10

<210> 643  
<211> 19  
<212> RNA  
<213> Artificial Sequence

15

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

20

<400> 643  
gugcaugua guugcaug 19

25

<210> 644  
<211> 19  
<212> RNA  
<213> Artificial Sequence

30

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35

<400> 644  
augcaacuac aaugcactt 19

40

<210> 645  
<211> 19  
<212> RNA  
<213> Artificial Sequence

45

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50

<400> 645  
gugcaugua guugcaug 19

55

<210> 646  
<211> 19  
<212> RNA  
<213> Artificial Sequence

<220>

<220>

EP 2 808 390 A1

<223> Description of Artificial Sequence: Synthetic  
Primer

5 <400> 646  
augcaacuac aaugcactt 19

<210> 647  
<211> 19  
10 <212> RNA  
<213> Artificial Sequence

<220>

<220>  
15 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 647  
gugcauugua guugcauug 19

20 <210> 648  
<211> 19  
<212> RNA  
25 <213> Artificial Sequence

<220>

<220>  
30 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 648  
augcaacuac aaugcactt 19

35 <210> 649  
<211> 19  
<212> RNA  
<213> Artificial Sequence

40 <220>

<220>  
45 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 649  
gugcauugua guugcauug 19

<210> 650  
<211> 19  
50 <212> RNA  
<213> Artificial Sequence

<220>

<220>  
55 <223> Description of Artificial Sequence: Synthetic  
Primer

<400> 650  
 augcaacuac aaugcactt 19

5 <210> 651  
 <211> 19  
 <212> RNA  
 <213> Artificial Sequence

10 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

15 <400> 651  
 gugcauugua guugcauug 19

20 <210> 652  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence

25 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

30 <400> 652  
 ccacacaacc uacuaccuca tt 22

35 <210> 653  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence

40 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

45 <400> 653  
 ugagguagua gguugugugg uu 22

50 <210> 654  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence

55 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

<400> 654  
 ccacacaacc uacuaccuca tt 22

5 <210> 655  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 <220>  
 10 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 <400> 655  
 ugagguagua gguugugugg uu 22

15 <210> 656  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 20 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 25 <400> 656  
 ccacacaacc uacuaccuca tt 22

30 <210> 657  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 35 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 40 <400> 657  
 ugagguagua gguugugugg uu 22

45 <210> 658  
 <211> 22  
 <212> RNA  
 <213> Artificial Sequence  
 <220>  
 50 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer  
 <400> 658  
 ccacacaacc uacuaccuca tt 22

55 <210> 659  
 <211> 22

<212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 5  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 659  
 10 ugagguagua gguugugugg uu 22  
  
 <210> 660  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
  
 <220>  
 20 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 660  
 25 cauacuucuu uacauccat t 21  
  
 <210> 661  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 30  
 <220>  
  
 <220>  
 35 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 661  
 uggaauguaa agaaguaugu a 21  
  
 <210> 662  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
  
 <220>  
 45  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
     Primer  
  
 <400> 662  
 50 cauacuucuu uacauccat t 21  
  
 <210> 663  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 55

EP 2 808 390 A1

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

5

<400> 663  
uggaauguaa agaaguaugu a 21

10

<210> 664  
<211> 22  
<212> RNA  
<213> Artificial Sequence

15

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

20

<400> 664  
gcAUCaccg cgugccuuaa tt 22

25

<210> 665  
<211> 22  
<212> RNA  
<213> Artificial Sequence

30

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35

<400> 665  
uuAaggcacg cggugaaugc ca 22

40

<210> 666  
<211> 22  
<212> RNA  
<213> Artificial Sequence

45

<220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50

<400> 666  
gcAUCaccg cgugccuuaa tt 22

55

<210> 667  
<211> 22  
<212> RNA  
<213> Artificial Sequence

<220>

<220>

EP 2 808 390 A1

<223> Description of Artificial Sequence: Synthetic  
 Primer

5 <400> 667  
 uuaaggcacg cggugaaugc ca 22

10 <210> 668  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

<220>

15 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

20 <400> 668  
 ccuuuuuaca uugcacugtt 20

25 <210> 669  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

<220>

30 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

35 <400> 669  
 cagugcaaug uuaaaaagggc 20

40 <210> 670  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

<220>

45 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

50 <400> 670  
 ccuuuuuaca uugcacugtt 20

<210> 671  
 <211> 20  
 <212> RNA  
 <213> Artificial Sequence

<220>

55 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

<400> 671  
cagugcaaug uaaaaagggc 20

5 <210> 672  
<211> 23  
<212> RNA  
<213> Artificial Sequence

10 <220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

15 <400> 672  
caaaauucgga ucuacagggg att 23

20 <210> 673  
<211> 23  
<212> RNA  
<213> Artificial Sequence

<220>

25 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

30 <400> 673  
uaccucguag auccgaauuu gug 23

35 <210> 674  
<211> 23  
<212> RNA  
<213> Artificial Sequence

<220>

40 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 674  
caaaauucgga ucuacagggg att 23

45 <210> 675  
<211> 23  
<212> RNA  
<213> Artificial Sequence

50 <220>

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

55 <400> 675  
uaccucguag auccgaauuu gug 23

EP 2 808 390 A1

<210> 676  
 <211> 21  
 <212> RNA  
 <213> Artificial Sequence  
 5  
 <220>  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 10  
 Primer  
 <400> 676  
 uauacaagag augaaauccu c 21  
 <210> 677  
 <211> 64  
 <212> RNA  
 <213> Homo sapiens  
 <400> 677  
 20  
 ccccgcgagc agccccucgc acaaaccgga ccugagcguu uuguucguuc ggcucgcgug 60  
 aggc 64  
 <210> 678  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens  
 <400> 678  
 30  
 uaaaagguag auucuccuuc uaugaguaca uuauuuuga uuaaucuag aggaaaaucc 60  
 acguuuuc 68  
 <210> 679  
 <211> 69  
 <212> RNA  
 <213> Homo sapiens  
 <400> 679  
 40  
 uugagcagag guugcccuug gugaauucgc uuauuuuug uugaucaca caaaggcaac 60  
 uuuuguuug 69  
 <210> 680  
 <211> 66  
 <212> RNA  
 <213> Homo sapiens  
 <400> 680  
 45  
 agggcuccug acuccagguc cuguguguua ccuagaaaua gcacuggacu uggagucaga 60  
 aggccu 66  
 <210> 681  
 <211> 67  
 <212> RNA  
 <213> Homo sapiens  
 <400> 681  
 55  
 agagauggua gacuauggaa cguaggcguu augauuuucug accuauguaa caugguccac 60  
 uaacucu 67

EP 2 808 390 A1

<210> 682  
 <211> 61  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 682  
 aagaugguug accauagaac augcgcuauuc ucugugucgu auguaauaug guccacaucu 60  
 u 61  
 10  
 <210> 683  
 <211> 75  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 683  
 uacuuuaagc gagguugccc uuuguauauu cgguuuauug acauggaaua uacaagggca 60  
 agcucucugu gagua 75  
 20  
 <210> 684  
 <211> 76  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 684  
 uacuugaaga gaaguuguuc gugguggauu cgcuuuacuu augacgaauc auucacggac 60  
 aacacuuuuu ucagua 76  
 30  
 <210> 685  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 685  
 succucagau cagaagguga uuguggcuuu ggguggauau uaucagcca cagcacugcc 60  
 uggucagaaa gag 73  
 40  
 <210> 686  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 686  
 uguuuuuuuaa ggaauuuuaa acaauuccua gacaauaugu auaauguua uaagucuuuc 60  
 cuagaaaauug uucauaaugc cuguaaca 88  
 50  
 <210> 687  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 687  
 gagagaagca cuggacuuag ggucagaagg ccugagucuc ucugcugcag augggcucuc 60  
 ugucuccugag ccaagcuuug uccucccugg 90  
 <210> 688

EP 2 808 390 A1

<211> 94  
 <212> RNA  
 <213> Homo sapiens

5  
 <400> 688  
 auaaaaggaag uuaggcugag gggcagagag cgagacuuuu cuauuuucca aaagcucggu 60  
 cugaggcccc ucagucuugc uuccuaaccc ggc 94

10  
 <210> 689  
 <211> 98  
 <212> RNA  
 <213> Homo sapiens

15  
 <400> 689  
 cgagggggaug cagcagcaau ucauguuuug aaguguucua aaugguuca aacgugaggg 60  
 gcugcuauac cccucgugg ggaagguaga aggugggg 98

20  
 <210> 690  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

25  
 <400> 690  
 gaaagcgcuu uggaaugaca cgaucacucc cguugagugg gcacccgaga agccaucggg 60  
 aaugucgugu ccgcccagug cucuuuc 87

30  
 <210> 691  
 <211> 111  
 <212> RNA  
 <213> Homo sapiens

35  
 <400> 691  
 gccgggaggu ugaacaucuu gcauagugcu gccaggaaau cccuauuuca uauaagaggg 60  
 ggcuggcugg uugcauauug aggauguccc aucucccagc ccacuucguc a 111

40  
 <210> 692  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens

45  
 <400> 692  
 cgccggccga ugggcgucuu accagacaug guuagaccug gccucuguc uauacuguc 60  
 ugguaaaacc guccaucgcg ugc 83

50  
 <210> 693  
 <211> 91  
 <212> RNA  
 <213> Homo sapiens

55  
 <400> 693  
 cuguguguga ugagcuggca guguauguu agcugguuga auaugugaau ggcaucggcu 60  
 aacaugcaac ugcugucuua uugcauauac a 91

<210> 694  
 <211> 91  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 694  
 aaacgauacu aaacuguuuu ugcgauugugu uccuaauaug cacuaauaaau auauugggaa 60  
 cauuuugcau guauaguuuu guaucaauau a 91

5

<210> 695  
 <211> 85  
 <212> RNA  
 <213> Mus musculus

10

<400> 695  
 aaagugcuuu ggaaugacac gaucacucucc guugaguggg cacccaagaa gccaucggga 60  
 augucguguc cgcccagugc ucuuu 85

15

<210> 696  
 <211> 112  
 <212> RNA  
 <213> Mus musculus

20

<400> 696  
 acgaggaggu ugaacaucuu gcauagugcu gccaggaaau cccuacuua uacuaagagg 60  
 gggcuggcug guugcauau uaggauugc caucuccugg cccacuucgu ca 112

25

<210> 697  
 <211> 83  
 <212> RNA  
 <213> Mus musculus

30

<400> 697  
 ccugcugaug gaugucuua cagacauggu ugaucugga ugcaucuguc uaauacuguc 60  
 ugguaaugcc guccaaccac ggc 83

35

<210> 698  
 <211> 91  
 <212> RNA  
 <213> Mus musculus

40

<400> 698  
 cuguguguga uggcuuggca guguauguu agcugguuga guaugugagc ggcaccagcu 60  
 aacaugcgac ugcucuccua uugcacacac a 91

45

<210> 699  
 <211> 91  
 <212> RNA  
 <213> Mus musculus

50

<400> 699  
 gagagauacu gagcuguuuu ugcgauugugu uccuaauaug ugcuaauaaau auauugggaa 60  
 cauuuugcau aaauagcuuu gugucaauac a 91

55

<210> 700  
 <211> 112  
 <212> RNA  
 <213> Rattus norvegicus

<400> 700  
 acggggaggu ugaacaucuu gcauagugcu gccaggaaau cccuacuua uacuaagagg 60

EP 2 808 390 A1

gggcuggcug guugcauauug uaggaugucc caucucccg cccacuucgu ca 112

5 <210> 701  
 <211> 85  
 <212> RNA  
 <213> Rattus norvegicus

10 <400> 701  
 ugccugcuga uggaugucuu accagacaug guuagaucug gauguaucug ucuaauacug 60  
 ucugguaaug ccguccaucc auggc 85

15 <210> 702  
 <211> 91  
 <212> RNA  
 <213> Rattus norvegicus

20 <400> 702  
 cugugugcga ugguuggca guguauguu agcugguuga guaanguaaa ggcaccagcu 60  
 acaaugcaac ugcucuccua uugcacauc a 91

25 <210> 703  
 <211> 91  
 <212> RNA  
 <213> Rattus norvegicus

30 <400> 703  
 gagagaugcg gagcuguuuu ugcgauuguu uccuaaugug ugcuaacaau auauugggaa 60  
 cauuugcau aaauaguuu acaucgacac a 91

35 <210> 704  
 <211> 100  
 <212> RNA  
 <213> Homo sapiens

40 <400> 704  
 ccaaagaaag augcuaaacu auuuuugcga uguguuccua auauguaau uaaauguaau 60  
 ggggacauuu ugcauucua guuuuguauc aauaauugg 100

45 <210> 705  
 <211> 72  
 <212> RNA  
 <213> Homo sapiens

50 <400> 705  
 cuugggaaug gcaaggaaac cguuaccuu acugaguuaa gaaugguaa ugguucucuu 60  
 gcuauaccga ga 72

55 <210> 706  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

60 <400> 706  
 gcuaagcacu uacaacuguu ugcagaggaa acugagacuu uguaacuaug ucucagucuc 60  
 aucugcaaag aaguaagugc uuugc 85

EP 2 808 390 A1

<210> 707  
 <211> 22  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 707  
 gagguugucc guggugaguu cg 22  
  
 <210> 708  
 <211> 96  
 <212> RNA  
 <213> Homo sapiens  
 10  
 <400> 708  
 ucccuggcgu gaggguaugu gccuuuggac uacaucgugg aagccagcac caugcagucc 60  
 augggcauau acacuugccu caaggccuau gucauc 96  
  
 <210> 709  
 <211> 76  
 <212> RNA  
 <213> Homo sapiens  
 20  
 <400> 709  
 gagggggaag acgggaggaa agaagggagu gguuccauca cgccuccuca cuccucuccu 60  
 cccgucuucu ccucuc 76  
 25  
  
 <210> 710  
 <211> 63  
 <212> RNA  
 <213> Homo sapiens  
 30  
 <400> 710  
 gucaggcuca guccccucc gauaaacccc uaaaauagga cuuuccggg gggugacccu 60  
 ggc 63  
 35  
  
 <210> 711  
 <211> 73  
 <212> RNA  
 <213> Homo sapiens  
 40  
 <400> 711  
 acuuggagag aggcuggccg ugaugaauc gauucauca agcgagucan acacggcucu 60  
 ccucucuuiu agu 73  
 45  
  
 <210> 712  
 <211> 68  
 <212> RNA  
 <213> Homo sapiens  
 50  
 <400> 712  
 guauccugua cugagcugcc ccgagcuggg cagcaugaag ggccucgggg cagcucagua 60  
 caggaugc 68  
 55  
  
 <210> 713  
 <211> 80  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 713  
 gguacuugaa gagugguuau cccugcugug uucgcuuau uuaugacgaa ucacacaggg 60  
 acauccaguu uuucaguauc 80

5

<210> 714  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens

10

<400> 714  
 gagaaucauc ucucccagau aauggcacuc ucaaacaagu uuccaaaauug uuugaaaggc 60  
 uauuuuuggg ucagaugacu cuc 83

15

<210> 715  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

20

<400> 715  
 guggcagcuu gguggucgua ugugugacgc cauuuacuug aaccuuuagg agugacauca 60  
 cauauacggc agcuaaacug cuac 84

25

<210> 716  
 <211> 128  
 <212> RNA  
 <213> Homo sapiens

30

<400> 716  
 uggaggccuu gcugguuugg aaagucauu guucgacacc auggaucucc agguggguca 60  
 aguuuagaga ugcaccaacc uggaggacuc caugcuguug agcuguucac aagcagcggg 120  
 cacuucca 128

35

<210> 717  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

40

<400> 717  
 uugacuuagc ugguuagugg ggaacccuuc caugaggagu agaacacucc uuaugcaaga 60  
 uucccuucua ccuggcuggg uugg 84

45

<210> 718  
 <211> 116  
 <212> RNA  
 <213> Homo sapiens

50

<400> 718  
 caacuacagc cacuacuaca ggaccaucga ggaccugcgg gacaagauuc uuggugccac 60  
 cauugagaac gccaggauug uccugcagau caacaaugcu caacuggcug cagaug 116

55

<210> 719  
 <211> 89  
 <212> RNA  
 <213> Homo sapiens

<400> 719

EP 2 808 390 A1

cuggccucca gggcuuugua caugguaggc uuucauucac ucguuugcac auucggugaa 60  
 ggucuacugu gugccaggcc cugugccag 89

5 <210> 720  
 <211> 24  
 <212> RNA  
 <213> Homo sapiens

10 <400> 720  
 ugaacaauac acgggaaacc ucuu 24

15 <210> 721  
 <211> 82  
 <212> RNA  
 <213> Homo sapiens

20 <400> 721  
 ugguaaccuga aaagaaguug cccauguuau uuucgcuuaa uaugugacga aacaacaug 60  
 gugcacuucu uuucgguau ca 82

25 <210> 722  
 <211> 17  
 <212> RNA  
 <213> Homo sapiens

<400> 722  
 auuacauggc caaucuc 17

30 <210> 723  
 <211> 21  
 <212> RNA  
 <213> Homo sapiens

35 <400> 723  
 cagcagcaca cugugguuug u 21

40 <210> 724  
 <211> 124  
 <212> RNA  
 <213> Homo sapiens

45 <400> 724  
 aaccuccuu gggaagugaa gcucaggcug ugauuucacg ccagggggcg uuuuucuaaa 60  
 acuggaugaa aagcaccucc agagcuugaa gcucacaguu ugagagcaau cgucuaagga 120  
 aguu 124

50 <210> 725  
 <211> 122  
 <212> RNA  
 <213> Homo sapiens

55 <400> 725  
 gcccgucucc cugugccuug ggcggggcggc uguuaagacu ugcagugaug uuuaacuccu 60  
 cuccacguga acaucacagc aagucugugc ugcuucccggu ccuacgcug ccugggcagg 120  
 gu 122

EP 2 808 390 A1

<210> 726  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 726  
 gcucuuuuuu ucuaauccuu gcuaccuggg ugagagugcu gucugaaugc aaugcaccug 60  
 ggcaaggauu cugagagcga gagc 84  
 10  
 <210> 727  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 727  
 gcucuuccuc ucuaauccuu uguccuggg ugagagugcu uucugaaugc aaugcaccug 60  
 ggcaaggauu cugagagggg gagc 84  
 20  
 <210> 728  
 <211> 55  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 728  
 auccuugcua ucugggugcu agugcuggcu caaugcaaug caccugggca aggau 55  
 30  
 <210> 729  
 <211> 71  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 729  
 ugcccuagca gcggaacag uucugcagug agcgaucggg gcucuggggu auuguuuccg 60  
 cugccagggg a 71  
 40  
 <210> 730  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 730  
 gcugcuguug ggagaccug gucugcacuc uaucuguauu cuuacugaag ggagugcagg 60  
 gcaggguuuc ccuacagag ggc 83  
 50  
 <210> 731  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 731  
 gaugcaccca gugggggagc caggaaguau ugauguuucu gccaguuuag cgucaacacu 60  
 ugcugguuuc cucucuggag cauc 84  
 <210> 732  
 <211> 124  
 <212> RNA  
 <213> Homo sapiens

EP 2 808 390 A1

<400> 732  
 gccaccacca ucagccauac uauguguagu gccuuauuca ggaagguguu acuuauuaga 60  
 uaaauuuug uaaggcacc uucugaguag aguaaugugc aacauggaca acuuuugugg 120  
 uggc 124  
 5

<210> 733  
 <211> 94  
 <212> RNA  
 <213> Homo sapiens  
 10

<400> 733  
 gugcugugug uagugcuuca cuucaagaag ugccaugcau gugucuagaa auauguuuug 60  
 caccuuuugg agugaaaua ugcacaacag auac 94  
 15

<210> 734  
 <211> 115  
 <212> RNA  
 <213> Homo sapiens  
 20

<400> 734  
 ccaccuucag cugaguguag ugcccuacuc cagagggcgu cacucaugua aacuaaaaca 60  
 ugauuguagc cuuuuggagu agaguaauac acaucacgua acgcauuuu ggugg 115  
 25

<210> 735  
 <211> 94  
 <212> RNA  
 <213> Homo sapiens  
 30

<400> 735  
 caugcugugu gugguacccu acugcagaca guggcaauca uguauaaaua aaaaugauug 60  
 guacgucugu gguagagua cugcaugaca caug 94  
 35

<210> 736  
 <211> 74  
 <212> RNA  
 <213> Homo sapiens  
 40

<400> 736  
 gugguguccu acucaggaga guggcaauca cauguaaua ggugugauug aaaccucuaa 60  
 gaguggagua acac 74  
 45

<210> 737  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens  
 50

<400> 737  
 caauagacac ccaucguguc uuuugcucug cagucaguaa auauuuuuuu gugaaugugu 60  
 agcaaaagac agauggugg uccaug 87  
 55

<210> 738  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens  
 <400> 738

EP 2 808 390 A1

caauagacac ccaucguguc uuuugcucug cagucaguaa auauuuuuuu gugaaugugu 60  
 agcaaaagac agaugggug ucgauug 87

5 <210> 739  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens

10 <400> 739  
 ucucagucug uggcacucag ccuugagggc acuuucuggu gccagaauga aagugcuguc 60  
 auagcugagg uccaugacu gagg 84

15 <210> 740  
 <211> 98  
 <212> RNA  
 <213> Homo sapiens

20 <400> 740  
 gguacuucuc agucuguggc acucagccuu gagggcacuu ucuggugcca gaaugaaagu 60  
 gcugucgauag cugaggucca augacugagg cgagcacc 98

25 <210> 741  
 <211> 129  
 <212> RNA  
 <213> Homo sapiens

30 <400> 741  
 ggaugccac auucagccau ucagcguaca gugccuuuca caggaggug ucauuuauug 60  
 gaacuaaaau uaaaauuca ccuuucugag aaggguuauug uacagcaugc acugcauauug 120  
 ugguguccc 129

35 <210> 742  
 <211> 127  
 <212> RNA  
 <213> Homo sapiens

40 <400> 742  
 ggaugccaca uucagccau cagugugcag ugccuuucac agggaggugu cauuuauug 60  
 aacuaaaau uaaaauuca cuuucugaga aggguaauug acagcaugc cugcauauug 120  
 ggugucc 127

45 <210> 743  
 <211> 58  
 <212> RNA  
 <213> Homo sapiens

50 <400> 743  
 cuacucugga gagugacaau cauguauau uaaaauuugau ugacacuucu gugaguag 58

55 <210> 744  
 <211> 58  
 <212> RNA  
 <213> Homo sapiens

55 <400> 744  
 cuacucugga gagugacaau cauguauaac uaaaauuugau ugacacuucu gugaguag 58

EP 2 808 390 A1

<210> 745  
 <211> 58  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 745  
 cuacucugga gagugacaau cauguauaac uaaauuugau ugacacuucu gugaguag 58

<210> 746  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens  
 10  
 <400> 746  
 15 ucucaugcag ucauucucca aaagaaagca cuuucuguug ucugaaagca gagugccuuc 60  
 uuuuggagcg uuacuguuug aga 83

<210> 747  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens  
 20  
 <400> 747  
 25 ucucaugcag ucauucucca aaagaaagca cuuucuguug ucugaaagca gagugccuuc 60  
 uuuuggagcg uuacuguuug aga 83

<210> 748  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 30  
 <400> 748  
 35 ucucaggcug ugaccuucuc gaggaaagaa gcacuuucug uugucugaaa gaaaagaaag 60  
 ugcuuccuuu cagaggguaa cgguuugaga 90

<210> 749  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 40  
 <400> 749  
 45 ucucagguug ugaccuucuc gaggaaagaa gcacuuucug uugucugaaa gaaaagaaag 60  
 ugcuuccuuu cagaggguaa cgguuugaga 90

<210> 750  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 50  
 <400> 750  
 55 ucucaugaug ugaccaucug gagguaagaa gcacuuugug uuuugugaaa gaaagugcuu 60  
 ccuucagag gguuacucuu ugaga 85

<210> 751  
 <211> 90  
 <212> RNA

EP 2 808 390 A1

<213> Homo sapiens  
 <400> 751  
 ucucaggcug ugaccaucug gagguaagaa gcacuuucug uuuugugaaa gaaaagaaag 60  
 5 ugcuuccuuu cagaggguaa cucuuugaga 90

<210> 752  
 <211> 87  
 <212> RNA  
 10 <213> Homo sapiens

<400> 752  
 ucucaggcag ugaccucua gauggaagca cugucuguug uauaaaagaa aagaucgugc 60  
 15 auccuuuag aguguuacug uuugaga 87

<210> 753  
 <211> 67  
 <212> RNA  
 20 <213> Homo sapiens

<400> 753  
 gugaccucu agauggaagc acugucuguu gucuaagaaa aagaucgugca uccuuuuga 60  
 25 guguuac 67

<210> 754  
 <211> 95  
 <212> RNA  
 <213> Homo sapiens

30 <400> 754  
 gaagaucuca ggcagugacc cucuagaugg aagcacuguc uguugucuaa gaaaagaucg 60  
 ugcauccuuu uagaguguua cuguuugaga aaauc 95

<210> 755  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

35 <400> 755  
 ucucaagcug ugacugcaaa ggaagcccu uucuguuguc ugaaagaaga gaaagcgcuu 60  
 40 cccuuugcug gauuacgguu ugaga 85

<210> 756  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

45 <400> 756  
 ucucaagcug ugggucugca aaggaagcc cuuucuguug ucuaaaagaa gagaaagcgc 60  
 50 uuccuuugc uggauuacgg uuugaga 87

<210> 757  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens

55 <400> 757

EP 2 808 390 A1

ucaugcugug gccuccaga ggggaagcgc uucuguuguc ugaaagaaa caaagcguc 60  
 cccuuuagag guuuacgguu uga 83

5 <210> 758  
 <211> 101  
 <212> RNA  
 <213> Homo sapiens

10 <400> 758  
 gcgagaagau cucaugcugu gacucucugg agggaagcac uuucuguugu cugaaagaaa 60  
 acaaaagcgcu ucucuuuaga guguuacggu uugagaaaag c 101

15 <210> 759  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

20 <400> 759  
 ucccaugcug ugacccucua gagggaagca cuuucuguug ucugaaagaa accaaagcgc 60  
 uuccuuuugg agcguuacgg uuugaga 87

25 <210> 760  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens

30 <400> 760  
 ucucaggcug ugacccucua gagggaagcg cuuucuguug gcuaaaagaa aagaaagcgc 60  
 uuccuuucag aguguuaacg cuuugaga 88

35 <210> 761  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

40 <400> 761  
 ucucaugcug ugacccucua gagggaagca cuuucucuug ucuaaaagaa aagaaagcgc 60  
 uucucuuuag aggauuacuc uuugaga 87

45 <210> 762  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

50 <400> 762  
 cucaggcugu gacacucua gagggaagcgc uuucuguugu cugaaagaaa ggaaagugca 60  
 uccuuuuaga guguuacugu uugag 85

55 <210> 763  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

60 <400> 763  
 ucucaggcug uguccucua cagggaagcg cuuucuguug ucugaaagaa aggaaagugc 60  
 auccuuuuag aguguuacug uuugaga 87

EP 2 808 390 A1

<210> 764  
 <211> 81  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 764  
 caugcuguga cccucuagag ggaagcgcuu ucuguugucu gaaagaaaag aaagugcauc 60  
 cuuuuagagg uuucacuguuu g 81  
 10  
 <210> 765  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 765  
 ucucagccug ugacccucua gagggagcg cuuucuguug ucugaaagaa aagaaagugc 60  
 aucuuuuuag aggauuacag uuugaga 87  
 20  
 <210> 766  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 766  
 ucccaugcug ugacccucca aagggagcg cuuucuguuu guuuucucuu aaacaaagug 60  
 ccuccuuua gaguguuacc guuuggga 88  
 30  
 <210> 767  
 <211> 84  
 <212> RNA  
 <213> Homo sapiens  
 35  
 <400> 767  
 ucucaugcag ucauucucca aaagggagca cuuucuguuu gaaagaaaac aaagugccuc 60  
 cuuuuagagu guuacuguuu gaga 84  
 40  
 <210> 768  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 45  
 <400> 768  
 cucaggcugu gacccuccag agggaguac uuucuguugu cugagagaaa agaaagugcu 60  
 uccuuugga cuguuucggu uugag 85  
 50  
 <210> 769  
 <211> 61  
 <212> RNA  
 <213> Homo sapiens  
 55  
 <400> 769  
 cccucuacag ggaagcgcuu ucuguugucu gaaagaaaag aaagugcuuc cuuuuagagg 60  
 g 61

EP 2 808 390 A1

<212> RNA  
 <213> Homo sapiens  
  
 <400> 770  
 5 ucucaggcug ucguccucua gagggaagca cuuucuguug ucugaaagaa aagaaagugc 60  
 uuccuuuuag aggguuaccg uuugaga 87  
  
 <210> 771  
 <211> 87  
 10 <212> RNA  
 <213> Homo sapiens  
  
 <400> 771  
 15 ucucaagcug ugagucuaca aaggggaagcc cuuucuguug ucuaaaagaa aagaaagugc 60  
 uucucuuugg ugguuacgg uuugaga 87  
  
 <210> 772  
 <211> 87  
 20 <212> RNA  
 <213> Homo sapiens  
  
 <400> 772  
 ucuccugcug ugaccucuaa gauggaagca guuucuguug ucugaaagga aagaaagugc 60  
 uuccuuuuug aggguuacug uuugaga 87  
 25  
  
 <210> 773  
 <211> 87  
 <212> RNA  
 30 <213> Homo sapiens  
  
 <400> 773  
 ucucaggcug ugaccucua aaggggaagcg cuuucugugg ucagaaagaa aagcaagugc 60  
 uuccuuuuag aggguuaccg uuuggga 87  
 35  
  
 <210> 774  
 <211> 90  
 <212> RNA  
 <213> Homo sapiens  
 40  
  
 <400> 774  
 ucccaugcug ugaccucua gaggaagcac uuucuguuug uugucugaga aaaaacaaag 60  
 ugcuuccuu uagaguuua ccguuuggga 90  
  
 <210> 775  
 <211> 88  
 <212> RNA  
 <213> Homo sapiens  
 45  
  
 <400> 775  
 50 ucccaugcug ugaccucua gaggaagcac uuucuguuug uugucugaga aaaaacaaag 60  
 ugcuuccuu uagaguua cuuuggga 88  
  
 <210> 776  
 <211> 87  
 <212> RNA  
 55 <213> Homo sapiens

EP 2 808 390 A1

<400> 776  
 ucucaggcug ugacccucca aaggaagaa cuuucuguug ucuaaaagaa aagaacgcac 60  
 uucccuuuag aguguuaccg ugugaga 87

5

<210> 777  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

10

<400> 777  
 ucucgggcug ugacucucca aaggaagaa uuuucucuug ucuaaaagaa aagaacgcac 60  
 uucccuuuag aguguuaccg ugugaga 87

15

<210> 778  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

20

<400> 778  
 ucucaggcug ugucccucia gaggaagcg cuuucuguug ucugaaagaa aagaaaugg 60  
 uucccuuuag aguguuaccg uuugaga 87

25

<210> 779  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

30

<400> 779  
 ucucaugcug ugacccucia gaggaagcg cuuucuguug ucugaaagaa aagaacgcgc 60  
 uucccuauag agguuaccg uuugaga 87

35

<210> 780  
 <211> 87  
 <212> RNA  
 <213> Homo sapiens

40

<400> 780  
 ucucaugcug ugacccuaca aaggaagca cuuucucuug ucuaaagaa aagaaggcgc 60  
 uucccuuugg aguguuaccg uuugaga 87

45

<210> 781  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

50

<400> 781  
 cucaagcugu gacucuccag aggaugcac uuucucuau gugaaaaaa agaaggcgc 60  
 uccuuuuga gcguuaccgu uuggg 85

55

<210> 782  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens

<400> 782  
 cucaggcugu gaccucucag aggaagcac uuucuguugc uugaaagaag agaaagcgc 60  
 uccuuuuga ggauuacucu uugag 85

EP 2 808 390 A1

<210> 783  
 <211> 65  
 <212> RNA  
 <213> Homo sapiens  
 5  
 <400> 783  
 gugaccucuc agaggggaagc acuuucuguu gaaagaaaag acaugcauc cuuucagagg 60  
 guuac 65  
 10  
 <210> 784  
 <211> 83  
 <212> RNA  
 <213> Homo sapiens  
 15  
 <400> 784  
 ucaggcugug acccucuuga ggggaagcacu uucuguuguc ugaaagaaga gaaagugcuu 60  
 ccuuuuagag gcuuacuguc uga 83  
 20  
 <210> 785  
 <211> 85  
 <212> RNA  
 <213> Homo sapiens  
 25  
 <400> 785  
 ucucaagcug ugacugcaaa ggggaagcccu uucuguuguc uaaaagaaaa gaaagugcuu 60  
 ccuuuuggug aauuacgguu ugaga 85  
 30  
 <210> 786  
 <211> 72  
 <212> RNA  
 <213> Mus musculus  
 35  
 <400> 786  
 cuugggaaug gcgaggaaac cguuaccuu acugaguuaa guaaugguua cgguucucuu 60  
 gcugcuccca ca 72  
 40  
 <210> 787  
 <211> 85  
 <212> RNA  
 <213> Mus musculus  
 45  
 <400> 787  
 gcuaagcagu uacaacuguu ugcagaggaa acugagacuu uuaacuaug ucucagucuc 60  
 aucugcaaag agguaagugc uuugc 85  
 50  
 <210> 788  
 <211> 75  
 <212> RNA  
 <213> Mus musculus  
 55  
 <400> 788  
 cuuuaccuaa uuuguugucc aucauguaaa acauaaauga ugauagacac cauauaaggu 60  
 agaggaaggu ucacu 75  
 <210> 789

EP 2 808 390 A1

<211> 71  
 <212> RNA  
 <213> Mus musculus

5

<400> 789  
 accuuguuau gggggucugg gguaaggagu ggucaucagg ggguacuacc aaguuuuuuc 60  
 ugugagauag a 71

10

<210> 790  
 <211> 74  
 <212> RNA  
 <213> Mus musculus

15

<400> 790  
 gcccuuuuuu gaauggcacu gaugugauaa aauiuuuuuu ugaucagggc cuuucuaagu 60  
 agaguaaggc uuac 74

20

<210> 791  
 <211> 73  
 <212> RNA  
 <213> Mus musculus

25

<400> 791  
 uauauguguu uaugugugug uacauguaca uaugugaaua ugauauccau auacauacac 60  
 gcacacauaa gac 73

30

<210> 792  
 <211> 71  
 <212> RNA  
 <213> Mus musculus

35

<400> 792  
 gugccugugu gcguaagugc cugcauguau augcguguau auuuuauugca uauacauaca 60  
 cacaccuaca c 71

40

<210> 793  
 <211> 78  
 <212> RNA  
 <213> Mus musculus

45

<400> 793  
 auaagaaacu uggcgugucg ugacugaugu acugauaaga aacucagugu gauaugacug 60  
 augugcgugu gucugucu 78

50

<210> 794  
 <211> 74  
 <212> RNA  
 <213> Mus musculus

55

<400> 794  
 cgcggugccu cuuucuuuga ucuugguguc cucauuuuga aagccaagga agaggugggg 60  
 ggcgugguag ccuu 74

<210> 795  
 <211> 75  
 <212> RNA  
 <213> Mus musculus

EP 2 808 390 A1

<400> 795  
 cagugcucuu cuuggacugg cacuggugag uaaaacuaaa uacaaccagu accuucuga 60  
 gaagaguaaa gcuca 75

5

<210> 796  
 <211> 67  
 <212> RNA  
 <213> Mus musculus

10

<400> 796  
 gugcuuuacg uaguauagug cuuuucacau uaaacaaaaa gugaaaggug ccuacuauug 60  
 uauagga 67

15

<210> 797  
 <211> 73  
 <212> RNA  
 <213> Mus musculus

20

<400> 797  
 gagggggaag acgggagaag agaagggagu gguuuuuggg ugccucacuc cuccccuccc 60  
 gucuuguucu cuc 73

25

<210> 798  
 <211> 58  
 <212> RNA  
 <213> Mus musculus

30

<400> 798  
 gucaggcuca gucccccucc gauaaaccuc aaaaauagguu cuuaccuagg gggcuggc 58

35

<210> 799  
 <211> 73  
 <212> RNA  
 <213> Mus musculus

40

<400> 799  
 acuuggagag aggcuggccg ugaugaauuc gauucaucua aacgagucua acacggcucu 60  
 ccucucuucu agu 73

45

<210> 800  
 <211> 65  
 <212> RNA  
 <213> Mus musculus

50

<400> 800  
 gcauccugua cugagcugcc ccgagcugag cacagugaag gaccucgggg cagcucagua 60  
 cagga 65

55

<210> 801  
 <211> 72  
 <212> RNA  
 <213> Rattus norvegicus

<400> 801  
 uuugggaaug gcgaggaaac cguuaccauu acugaguuaa gaaugguaa ugguucucu 60  
 gcugcucca ca 72

<210> 802  
 <211> 73  
 <212> RNA  
 <213> Rattus norvegicus

5

<400> 802  
 gagggggaag acgggagaag agaagggagu gguuuuuggg ugccucacuc cuccccuccc 60  
 gucuuguucu cuc 73

10

<210> 803  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

15

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

20

<400> 803  
 tcatcgtctc aatgagtct 20

**Claims**

- 25 1. A synthetic RNA molecule having a sequence that is 80%-100% identical to a mature miR-34b sequence or to a mature miR-34c sequence, for use in treating cancer.
- 30 2. A synthetic RNA molecule for the use of claim 1, further defined as a 17-125 residue oligonucleotide comprising:  
 an miRNA region having a sequence that is 80%-100% identical to the mature miR-34b or miR-34c sequence; and  
 a complementary region having a sequence that is 60%-100% complementary to the miRNA region.
- 35 3. A synthetic RNA molecule for the use of any of claims 1-2, having a sequence that is 80%-100%, 85%-100%, 90%-100%, 95%-100%, or 100% identical to the mature miR-34b sequence (residues 14-35 of SEQ ID NO:59, 13-34 of SEQ ID NO:251, 13-35 of SEQ ID NO:245).
- 40 4. A synthetic RNA molecule for the use of any of claims 1-2, having a sequence that is 80%-100%, 85%-100%, 90%-100%, 95%-100%, or 100% identical to the mature miR-34c sequence (residues 13-34 of SEQ ID NO:60, 13-34 of SEQ ID NO:250, 13-35 of SEQ ID NO:246).
- 45 5. A synthetic RNA molecule for the use of any of claims 1-4, wherein the synthetic RNA molecule comprises two separate oligonucleotides.
6. A synthetic RNA molecule for the use of any of claims 1-4, wherein the synthetic RNA molecule comprises a hairpin oligonucleotide.
7. A synthetic RNA molecule for the use of any of claims 1-6, for use in administration to a cell or subject identified as needing a cancer treatment.
- 50 8. A synthetic RNA molecule for the use of any of claims 1-7, wherein the cancer is lung cancer, cervical cancer, prostate cancer, skin cancer, or leukemia, preferably human lung cancer, cervical cancer, prostate cancer, skin cancer, or leukemia.
- 55 9. A synthetic RNA for use as a medicament, the synthetic RNA comprising:  
 a first 17-30 residue oligonucleotide having a sequence that is 80%-100% identical to a mature miR-34b sequence or to a mature miR-34c sequence; and  
 a separate, second 17-30 residue oligonucleotide having a sequence that is 60%-100% complementary to the

first oligonucleotide.

5 **10.** A synthetic RNA molecule for the use of claim 9, wherein the first oligonucleotide has a sequence that is 80%-100%, 85%-100%, 90%-100%, 95%-100%, or 100 % identical to the mature miR-34b sequence (residues 14-35 of SEQ ID NO:59, 13-34 of SEQ ID NO:251, 13-35 of SEQ ID NO:245).

10 **11.** A synthetic RNA molecule for the use of claim 9, wherein the first oligonucleotide has a sequence that is 80%-100%, 85%-100%, 90%-100%, 95%-100%, or 100 % identical to the mature miR-34c sequence (residues 13-34 of SEQ ID NO:60, 13-34 of SEQ ID NO:250, 13-35 of SEQ ID NO:246).

**12.** A synthetic RNA molecule for the use of any of claims 9-11, further comprising at least one of:

i) a replacement group for the phosphate or the hydroxyl of the nucleotide at the 5' end of the second oligonucleotide,

15 ii) one or more sugar modifications in the first or last 1-6 residues of the second oligonucleotide, and

iii) a noncomplementarity between one or more nucleotides in the last 1-5 residues at the 3' end of the second oligonucleotide and the corresponding nucleotides of the first oligonucleotide,

20 preferably comprising two of i), ii), and iii), more preferably comprising i), ii), and iii).

25 **13.** A synthetic RNA molecule for the use of any of claims 9-12, comprising a replacement group for the phosphate or the hydroxyl of the nucleotide at the 5' end of the second oligonucleotide, preferably wherein the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2'O-Me, DMTO, fluoroscein, a thiol, or acridine, preferably:

wherein the phosphate of the nucleotide at the 5' end of the second oligonucleotide is replaced, preferably wherein the replacement group is a lower alkylamine group,

wherein the hydroxyl of the nucleotide at the 5' end of the second oligonucleotide is replaced,


30 and/or

35 comprising one or more sugar modifications in the first or last 1-6 residues of the second oligonucleotide, preferably (i) wherein the sugar modification is a 2'O-Me modification, (ii) comprising one or more sugar modifications in the first 1-6 residues of the second oligonucleotide, (iii) comprising one or more sugar modifications in the last 1-6 residues of the second oligonucleotide, or (iv) comprising one or more sugar modifications in the first or last 2 to 4 residues of the second oligonucleotide.

40 **14.** A synthetic RNA molecule for the use of any of claims 9-13, comprising a noncomplementarity between one nucleotide in the last 1-5 residues at the 3' end of the second oligonucleotide and the corresponding nucleotides of the first oligonucleotide, or comprising a noncomplementarity between two or more nucleotides in the last 1-5 residues at the 3' end of the second oligonucleotide and the corresponding nucleotides of the first oligonucleotide.



45 **15.** A synthetic RNA molecule according to any of claims 1-14 for use in reducing cell viability, decreasing cell proliferation, or inducing apoptosis in a cancer cell, with the proviso that methods of medical treatment of the human or animal body by therapy are excluded.

Fig. 1



# Fig. 2




## Vector Expression



Correct strand uptake  
Low transfection efficiency






## siRNA Design



High transfection efficiency  
Off-strand uptake



## miRNA Design



High transfection efficiency  
Correct strand uptake



**Fig. 3**

Active strand reporter                      Complementary-strand reporter








Fig. 4




**Fig. 5**

**Synthetic miRNAs in multiple cell types**




**Effect of Synthetic miRNAs on endogenous targets**

# Fig. 6



# Fig. 7












FIG. 11




FIG. 12




FIG. 13




FIG. 14

<b>Breast BT549</b>			<b>Breast MCF12A</b>			<b>Cervical HeLa</b>			<b>Prostate 22 Rv1</b>		
miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev
mir-101	87	3	mir-126	88	32	mir-1	20	2	mir-126	63	3
mir-105	88	2	mir-142	87	27	mir-101	12	2	mir-101	77	9
mir-124	88	5	mir-147	87	33	mir-124	16	4	mir-103	75	10
mir-126	82	2	mir-206	86	12	mir-192	13	3	mir-105	75	12
mir-129	85	1	mir-208	87	12	mir-193	5	2	mir-107	84	22
mir-132	87	4	mir-210	86	11	mir-195	21	7	mir-124	77	6
mir-142	87	4	mir-211	83	7	mir-201	26	7	mir-128	81	4
mir-192	81	3	mir-214	85	19	mir-206	12	6	mir-129	81	4
mir-201	79	14	mir-215	70	10	mir-208	21	12	mir-132	84	10
mir-215	82	1	mir-219	88	10	mir-210	23	4	mir-135	79	4
mir-27a	87	4	mir-220	85	7	mir-215	33	21	mir-137	81	4
mir-346	88	1	mir-221	88	7	mir-299	20	18	mir-141	85	2
mir-92	85	11	mir-223	87	10	mir-337	18	3	mir-142	69	4
mir-96	87	9	mir-331	88	12	mir-339	31	2	mir-147	66	4
mir-98	87	1	mir-345	88	10	mir-340	31	7	mir-15a	85	9
mir-99a	88	1	mir-346	82	12	mir-345	31	21	mir-16	74	6
			mir-297	78	15	mir-34a	35	7	mir-27a	83	7
			mir-329	82	17	mir-367	31	12	mir-28	82	9
			mir-409	86	11	mir-292-3p	29	21	mir-30a-3p	80	8
			mir-411	86	7	mir-293	26	30	mir-34a	72	8
						mir-297	19	16	mir-297	84	5
						mir-344	32	1			
						mir-409	30	16			

FIG. 15A

Skin TE354T			Skin TE353SK			BJ cells			Lung A549		
miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev
mir-1	53	7	mir-101	63	11	miR-206	19	7	mir-124	44	0
mir-101	49	6	mir-105	42	40	let7a	69	10	Let-7b	70	0
mir-124	64	10	mir-124	70	8	mir1	38	2.65	Let-7d	71	0
mir-136	59	4	mir-126	56	8	miR-105	65	5	Let-7g	62	1
mir-154	51	5	mir-128	53	46	miR-147	35	7	mir-126	68	0
mir-15a	63	4	mir-132	66	8	miR-15a	43	8	mir-129	67	1
mir-16	58	5	mir-133A	56	49	miR-16	51	4	mir-137	64	0
mir-192	62	7	mir-136	27	24	miR-195	48	10	mir-147	65	0
mir-193	69	4	mir-137	55	13	miR-297	46	6.85	mir-15a	61	0
mir-195	58	3	mir-141	62	23	miR-324-3p	68	8.84	mir-16	53	1
mir-201	67	8	mir-142	60	19	miR-337	27	7.26	mir-192	70	2
mir-206	51	4	mir-144	65	22	miR-376b	63	6.53	mir-193	64	3
mir-215	59	6	mir-15a	57	20				mir-195	59	0
mir-221	62	8	mir-16	59	9				mir-22	68	1
mir-26a	69	12	mir-181a	65	23				mir-28	61	0
mir-28	60	18	mir-20	47	41				mir-292-3p	62	0
mir-346	67	6	mir-206	67	15				mir-29a	67	1
mir-34a	65	5	mir-215	68	11				mir-337	55	0
mir-7	63	1	mir-223	56	49				mir-344	63	0
mir-96	60	8	mir-302	63	1				mir-345	69	1
mir-329	60	4	mir-330	66	59				mir-34a	61	0
mir-376b	65	3	mir-346	59	52				mir-7	63	1
			mir-373	66	7						
			mir-96	65	16						
			mir-291	48	17						
			mir-329	68	62						
			mir-380-3p	64	55						
			mir-411	54	47						

FIG. 15B

Lung CRL5826			Lung HTB-57			Jurkats			Primary T-cells		
miRNA	% of NC	STDEV	miRNA	% of NC	STDEV	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev
ambi-mir7100	63	21	mir-108	79		let-7a	21	1	miR-107	89	15
mir-101	70	20	mir-122	79		let-7b	50	5	miR-134	75	23
mir-105	74	11	mir-124	79		miR-101	69	30	miR-135	88	13
mir-124	63	8	mir-125a	77	11	miR-10b	37	3	miR-139	87	0
mir-125b	74	11	mir-126	78	2	miR-122	67	18	miR-141	89	1
mir-126	61	3	mir-132	59	7	miR-133a	73	18	miR-145	86	12
mir-128	71	13	mir-133A	77	7	miR-17-3p	63	16			
mir-132	73	18	mir-136	78	13	miR-29a	68	7			
mir-141	74	5	mir-147	72	4	miR-30a-3p	66	27			
mir-142	67	5	mir-151	67	10	miR-34a	67	21			
mir-147	75	7	mir-152	73	13						
mir-149	71	9	mir-16	79	6						
mir-188	67	11	mir-182	63	9						
mir-223	68	14	mir-183	72	9						
mir-28	74	19	mir-186	69	17						
mir-29a	74	14	mir-188	67	20						
mir-337	74	17	mir-28	79	16						
mir-346	72	13	mir-377	79	3						
mir-96	74	6	mir-526b*	79	0						
			mir-96	76	10						

FIG. 15C

Cervical HeLa			Prostate 22 Rv1			Skin TE354T			Skin TE353SK		
miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev
Let-7a	119	15	Let-7a	124	6	mir-139	117	20	mir-138	126	7
Let-7b	124	12	Let-7b	127	27	mir-141	120	52	mir-196	134	7
Let-7c	114	21	mir-127	127	11	mir-143	122	35	mir-197	135	8
Let-7d	113	29	mir-154	123	10	mir-145	156	71	mir-198	144	4
Let-7g	114	27	mir-181a	124	11	mir-146	143	85	mir-199	135	9
mir-145	111	29	mir-194	132	16	mir-188	117	37	mir-204	125	6
mir-155	114	17	mir-198	126	10	mir-190	131	55	mir-216	136	13
mir-181a	113	21	mir-199	146	18	mir-198	119	3	mir-410	134	7
mir-186	111	29	mir-201	125	24	mir-204	125	8			
mir-190	114	21	mir-369	130	9	mir-410	133	3			
mir-191	116	22	mir-93	129	16	mir-412	125	11			
mir-199	118	14									
mir-9	112	27									

BJ cells			Lung Cancer A549			Jurkats			Primary T-cells		
miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev	miRNA	% of neg cont	St Dev
miR-26a	130	17	mir-25	112	0	miR-100	134	15	let-7a	151	17
miR-128	131	24	mir-294	112	1	miR-125b	132	4	let-7b	150	14
miR-223	134	14	mir-32	121	0	miR-126	134	19	let-7c	159	4
miR-188	139	19	mir-92	122	0	miR-129	150	10	let-7d	142	10
miR-125a	140	10				miR-140	139	4	let-7g	141	7
miR-201	153	18				miR-143	162	2	miR-10a	130	10
miR-291-3p	155	30				miR-155	146	23	miR-10b	127	20
miR-145	161	2				miR-15a	146	12	miR-125a	131	5
miR-294	165	21				miR-23b	135	4	miR-126	126	42
miR-150	171	7				miR-25	154	18	miR-15a	135	11
miR-322	212	19.93				miR-26a	170	14	miR-17-3p	128	4
miR-295	215	40.78							miR-18	138	2
miR-187	246	19							miR-182	126	18
miR-373	268	41.39							miR-19a	126	5
									miR-20	130	14
									miR-7	126	1

CRL5826			HTB-57		
miRNA	% of NC	STDEV	miRNA	% of NC	STDEV
mir-130a	126	27	mir-135	121	8
mir-145	112	8	mir-216	126	7
mir-30e-5p	122	11	mir-293	121	4
mir-333	112	35	mir-338	122	14
mir-335	114	33	mir-341	118	22
mir-369	111	8			
mir-350	111	5			
mir-412	123	14			

FIG. 16

<b>Prostate 22Rv1</b>			<b>Skin TE354T</b>			<b>Breast MCF12a</b>			<b>Lung A549</b>		
miRNA	% NC	St Dev	miRNA	% NC	St Dev	miRNA	% NC	St Dev	miRNA	% NC	St Dev
mir-100	59	26	mir-210	67	13	mir-216	92	9	mir-129	90	5
mir-130a	58	16	mir-216	53	1	mir-217	95	14	mir-326	88	2
mir-211	54	7				mir-294	93	23	mir-331	92	2
mir-212	58	1							mir-338	91	2
mir-213	57	11							mir-341	89	5
mir-215	59	8							mir-370	91	0
mir-224	49	30							mir-92	88	0
mir-292	59	4									
mir-320	58	6									
mir-324	55	6									
mir-325	59	10									
mir-330	58	28									
mir-338	55	10									
mir-369	57	6									
mir-370	54	16									
mir-99a	58	15									

FIG. 17

<b>Prostate 22Rv1</b>			<b>Skin TE354T</b>			<b>Breast MCF12a</b>			<b>Lung A549</b>		
miRNA	% NC	St Dev	miRNA	% NC	St Dev	miRNA	% NC	St Dev	miRNA	% NC	St Dev
mir-10b	104	27	Let-7a	139	9	let7a	180	35	let7a-1	116	5
mir-152	111	20	Let-7b	148	8	let7b-1	176	36	mir-133a-2	126	2
			Let-7g	133	8	let7c	177	21	mir-142	112	4
			mir-10a	135	10	let7d	172	37	mir-187	110	6
			mir-10b	140	10	mir-10a	178	22	mir-199a-1	111	4
			mir-133B	135	8	mir-10b	190	18	mir-206	110	4
			mir-155	138	3	mir-133a	182	33	mir-211	110	6
			mir-15a	142	12	mir-152	175	33	mir-222	111	2
			mir-16	134	8	mir-153	178	27	mir-223	112	2
			mir-181a	138	6	mir-155	186	24	mir-23b	118	6
			mir-182	133	9	mir-16	174	30	mir-298	111	1
			mir-193	134	12	mir-181a	172	26	mir-328	115	1
			mir-194	137	28	mir-183	184	15	mir-342	118	0
			mir-196	133	6	mir-184	177	14	mir-371	122	2
			mir-204	135	9	mir-186	176	16			
			mir-23a	133	16	mir-191	174	11			
			mir-24	132	11	mir-200b	179	8			
			mir-25	142	13	mir-412	174	24			
			mir-92	132	11	mir-9	178	24			
			mir-95	137	5						

FIG. 18

<b>Jurkat</b>			<b>Primary T-cell</b>			<b>HeLa</b>			<b>A549</b>		
<b>Cell Viability</b>			<b>Cell Viability</b>			<b>Cell Viability</b>			<b>Cell Viability</b>		
miRNA	% NC	%SD	miRNA	% NC	%SD	miRNA	% NC	%STDEV	miRNA	%NC	%SD
<b>miRNAs that Decrease Cell Viability</b>											
let-7a	21	1	miR-107	89	15	mir-1	20	2	mir-193	80	15
let-7b	50	5	miR-134	75	23	mir-101	12	2	mir-206	80	7
miR-101	69	30	miR-135	88	13	mir-124	16	4	mir-210	86	5
miR-108	75	18	miR-139	87	0	mir-192	13	3	mir-292-3p	86	3
miR-10b	37	3	miR-141	89	1	mir-193	5	2	mir-293	83	2
miR-122	67	18	miR-145	86	12	mir-195	21	7	mir-299	84	4
miR-133a	73	18				mir-206	12	6	mir-329	85	5
miR-17-3p	63	16				mir-208	21	12	mir-337	81	3
miR-19a	73	24				mir-210	23	4	mir-345	75	6
miR-29a	68	7				mir-297	19	16	mir-346	78	8
miR-30a-3p	66	27				mir-299	20	18	mir-409	86	3
miR-34a	67	21				mir-337	18	3			
<b>miRNAs that Increase Cell Viability</b>											
miR-129	150	10	let-7a	151	17	mir-128	128	18			
miR-143	162	2	let-7b	150	14	mir-139	133	12			
miR-155	146	23	let-7c	159	4	mir-23a	159	13			
miR-15a	146	12	let-7d	142	10	mir-23b	155	12			
miR-25	154	18	let-7g	141	7	mir-24	132	20			
miR-26a	170	14	miR-10a	130	10	mir-32	133	20			
			miR-10b	127	20	mir-331	128	13			
			miR-125a	131	5						
			miR-126	126	42						
			miR-15a	135	11						
			miR-17-3p	128	4						
			miR-18	138	2						
			miR-182	126	18						
			miR-19a	126	5						
			miR-20	130	14						

FIG. 19

<b>Prostate 22Rv1</b>			<b>Skin TE354T</b>			<b>Jurkat</b>			<b>HeLa</b>		
<b>Synthetic miRNAs that Increase Apoptosis</b>											
miRNA	%NC	St Dev	miRNA	%NC	St Dev	miRNA	%NC	St Dev	miRNA	%NC	St Dev
Let-7g	164	17	mir-149	179	22	let-7b	201	41	let-7b	369	89
mir-1	192	20	mir-154	252	15	let-7g	152	19	let-7g	594	260
mir-10a	205	15	mir-195	174	16	miR-1	170	11	miR-1	410	65
mir-149	169	14	mir-208	189	18	miR-10b	198	24	miR-10b	378	28
mir-184	166	19	mir-214	187	14	miR-122	154	29	miR-122	303	44
mir-186	166	23	mir-217	177	21	miR-17-3p	171	12	miR-17-3p	346	68
mir-188	197	12	mir-293	234	19	miR-19a	153	6	miR-19a	312	7
mir-192	182	26	mir-299	193	12	miR-28	154	20	miR-28	347	56
			mir-328	198	17	miR-29a	155	15	miR-29a	439	63
			mir-344	204	8	miR-32	156	30	miR-32	473	209
						miR-34a	181	39	miR-34a	361	82
									let-7b	317	63
									let-7g	607	150
									miR-1	355	47
									miR-10b	404	53
									miR-122	374	61
									miR-17-3p	443	101
									miR-19a	773	70
									miR-28	402	42
<b>Synthetic miRNAs that Decrease Apoptosis</b>											
mir-128	54	27	Let-7b	56	10	miR-125b	75	2	miR-32	8	7
mir-21	47	23	mir-100	55	11	miR-126	66	11	mir-105	40	9
mir-216	48	37	mir-101	44	9	miR-143	68	3	mir-108	39	12
mir-223	54	36	mir-126	38	11	miR-155	67	22	mir-126	29	4
mir-23b	46	44	mir-207	59	8	miR-23b	70	14	mir-137	13	12
mir-328	22	29	mir-25	59	9	miR-26a	68	11	mir-292-3p	31	4
mir-335	40	26	mir-28	41	7	miR-98	74	27	mir-34a	38	8
mir-340	51	11	mir-29a	39	8				mir-96	32	13
mir-367	37	34	mir-30a-3p	30	6						
mir-368	53	36									
mir-380-3p	30	42									
mir-410	50	47									
mir-341	53	0									

FIG. 20

A549 +/- TRAIL		A549 +/- etoposide		HTB-57 +/- etoposide		CRL-5826 +/- etoposide		HeLa +/- etoposide	
<b>miRNAs that reduce cell viability in the presence of a therapeutic</b>									
miRNA	%NC	miRNA	% NC	miRNA	% NC	miRNA	% NC	miRNA	% NC
mir-101	135	mir-28	319	mir-126	171	mir-132	142	mir-124	162
mir-124	158	mir-124	139	mir-132	201	mir-182	134	mir-126	161
mir-125a	134	mir-126	141	mir-28	176	mir-28	154	mir-132	170
mir-132	147	mir-147	120	mir-337	217	mir-292-3p	212	mir-147	171
mir-136	178	mir-216	108	mir-292-3p	268			mir-216	199
mir-155	181	mir-292-3p	489	miR-7100	227			mir-28	169
mir-182	153	mir-337	251					mir-292-3p	208
mir-186	176							mir-337	285
mir-202	152								
mir-206	138								
mir-221	143								
mir-224	129								
mir-28	136								
mir-291	145								
mir-292-3p	169								
mir-297	140								
mir-302	134								
mir-372	125								
mir-373	169								
mir-376b	145								
<b>miRNAs that increase cell viability in the presence of a therapeutic</b>									
mir-125b	83								
mir-152	73								
mir-16	90								
mir-194	78								
mir-197	82								
mir-214	82								
mir-24	87								
mir-30a-3p	63								
mir-331	73								

FIG. 21

Figure 22. miRNAs that Affect Cell Cycle

BJ Cells				HeLa Pre-miR			
	G1	S	G2/M	>2N	G1	S	G2/M
miRNA	%NC %SD	miRNA %NC %SD	miRNA %NC %SD	miRNA %NC %SD	miRNA %NC %SD	miRNA %NC %SD	miRNA %NC %SD
let7a	90 22	mir128 46 7	mir128 69 4	mir125a 50 22	mir-1 43.5 3.3	mir-108 76.6 1.1	mir-122 38.6 7.2
mir1	87 12	mir142 49 41	mir146 61 9	mir128 31 29	mir-192 44.1 1.4	mir-122 66.3 1.7	mir-124 58.4 10.4
mir20	67 15	mir146 53 27	mir147 54 12	mir142 59 36	mir-193 32.1 1.4	mir-129 75.3 0.6	mir-126 55.7 13.5
mir206	70 13	mir186 60 8	mir15a 71 20	mir146 40 45	mir-206 27.4 2.6	mir-137 62.8 1.7	mir-129 66.0 4.9
mir21	57 8	mir187 60 15	mir195 62 7	mir16 49 21	mir-220 29.3 1.9	mir-147 76.8 3.3	mir-137 46.1 13.1
mir26a	82 5	mir195 54 0	mir371 56 5	mir191 56 40	mir-329 38.0 0.5	mir-324-3p 71.7 0.4	mir-147 60.0 4.0
mir290	85 2	mir297 54 22		mir201 59 27	mir-371 47.0 3.6	mir-337 64.3 3.9	mir-18 62.5 12.2
mir294	84 17	mir324-3p 60 13		mir224 53 17	mir-409 38.9 3.6	mir-219 64.2 1.9	mir-219 64.2 1.9
mir373	76 8	mir337 54 17		mir324-3p 46 33	mir-7d 57.0 0.5	mir-337 66.7 1.0	mir-337 66.7 1.0
		mir376b 57 17		mir92 41 20			
mir125a	120 3	let7a 117 14	mir145 145 10	mir1 171 9	mir-108 143.9 0.7	mir-197 163.8 1.7	mir-1 161.2 1.9
mir128	150 2	mir15a 112 10	mir187 140 3	mir21 205 22	mir-122 171.7 0.3	mir-205 183.7 0.9	mir-192 171.9 4.5
mir142	133 10	mir16 124 17	mir20 151 7	mir337 191 27	mir-124 150.0 0.2	mir-220 170.9 0.7	mir-193 185.3 5.9
mir146	148 5	mir191 113 21	mir21 169 4	mir345 172 10	mir-126 153.6 0.3	mir-290 167.2 1.4	mir-206 187.9 7.1
mir147	126 6	mir20 116 13	mir223 131 11	mir373 174 18	mir-129 145.1 0.3	mir-291 200.5 0.9	mir-215 147.5 2.7
mir195	131 2	mir224 125 6	mir26a 138 4		mir-137 165.9 0.2	mir-294 164.6 1.1	mir-220 170.1 3.9
mir201	122 6	mir26a 113 6	mir294 135 13		mir-147 150.1 0.4	mir-295 188.2 0.9	mir-329 171.5 1.2
mir297	125 8	mir290 117 8	mir373 146 4		mir-337 147.2 0.4	mir-302 214.6 1.7	mir-371 171.6 3.0
mir320	124 2	mir345 119 32				mir-372 203.3 0.8	mir-409 169.7 7.6
mir324-3p	130 4					mir-411 168.8 0.9	mir-7a 154.6 4.7
mir325	128 4					mir-7d 159.1 2.8	mir-7d 159.1 2.8
mir371	135 2					mir-7g 160.8 3.0	mir-7g 160.8 3.0
mir376b	133 2						
mir409	129 11						

FIG. 22

miRNA	sequence	A549 Proliferation (% NC)	Jurkats Proliferation (% NC)
let-7a	ugagguaguagguuguauaguu	119	21
let-7b	ugagguaguagguuguguguu	124	50
let-7c	ugagguaguagguuguauuguu	114	85
let-7d	ugagguaguagguugcauagu	113	97
let-7g	ugagguaguaguuuuagucagu	114	105

**FIG. 23**




FIG. 24



EUROPEAN SEARCH REPORT

Application Number  
EP 14 17 7498

5

10

15

20

25

30

35

40

45

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2004/076622 A2 (NAT INST OF ADVANCED IND SCIEN [JP]; TAIRA KAZUNARI [JP]; KAWASAKI HIR) 10 September 2004 (2004-09-10) * abstract * * page 72 - page 73, paragraph 1 * * page 81, line 16 - line 21 * * page 100; table 1a * * sequence 473 *	1-15	INV. C12N15/11 C12N15/113 C12Q1/68
A	WO 2004/044123 A2 (ROSETTA GENOMICS LTD [IL]; BENTWICH ITZHAK [IL]) 27 May 2004 (2004-05-27) * abstract * * page 16, last paragraph * * page 18, last paragraph * * sequence 1179 *	1-15	
A	WO 2004/066183 A (EUROP MOLECULAR BIOLOGY LAB [DE]; COHEN STEPHEN [DE]; BRENNECKE JULIUS) 5 August 2004 (2004-08-05) * the whole document *	1-15	TECHNICAL FIELDS SEARCHED (IPC)
A	CARRINGTON J C AND AMBROS V: "Role of MicroRNAs in Plant and Animal Development", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 301, 18 July 2003 (2003-07-18), pages 336-338, XP002989683, ISSN: 0036-8075 * the whole document *	1-15	C12N C12Q
A	WO 02/48168 A1 (ISIS PHARMACEUTICALS INC [US]; BAKER BRENDA F [US]; COWSERT LEX M [US]) 20 June 2002 (2002-06-20) * the whole document *	1-15	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 21 October 2014	Examiner Grötzing, Thilo
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

1

50

55

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 14 17 7498

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-10-2014

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004076622 A2	10-09-2004	AU 2004215097 A1	10-09-2004
		CA 2515586 A1	10-09-2004
		CN 1768139 A	03-05-2006
		EP 1592791 A2	09-11-2005
		JP 2006519008 A	24-08-2006
		KR 20050115231 A	07-12-2005
		US 2006247193 A1	02-11-2006
WO 2004076622 A2	10-09-2004		
WO 2004044123 A2	27-05-2004	AU 2003282352 A1	03-06-2004
		EP 1572962 A2	14-09-2005
		US 8039608 B1	18-10-2011
		US 8084598 B1	27-12-2011
		US 2006003322 A1	05-01-2006
		US 2007134655 A1	14-06-2007
WO 2004044123 A2	27-05-2004		
WO 2004066183 A	05-08-2004	NONE	
WO 0248168 A1	20-06-2002	AU 4342902 A	24-06-2002
		WO 0248168 A1	20-06-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- US 68373605 P [0001]
- US 62717104 P [0001]
- US 64963405 P [0001]
- US 575743 P [0036] [0121]
- US 649584 P [0036] [0202]
- US 141707 A [0036]
- US 5681947 A [0152] [0402]
- US 5652099 A [0152] [0402]
- US 5763167 A [0152] [0402]
- US 5614617 A [0152] [0402]
- US 5670663 A [0152] [0402]
- US 5872232 A [0152] [0402]
- US 5859221 A [0152] [0402]
- US 5446137 A [0152] [0402]
- US 5886165 A [0152] [0402]
- US 5714606 A [0152] [0402]
- US 5672697 A [0152] [0402]
- US 5466786 A [0152] [0402]
- US 5792847 A [0152] [0402]
- US 5223618 A [0152] [0402]
- US 5470967 A [0152] [0402]
- US 5378825 A [0152] [0402]
- US 5777092 A [0152] [0402]
- US 5623070 A [0152] [0402]
- US 5610289 A [0152] [0402]
- US 5602240 A [0152] [0402]
- US 5858988 A [0152] [0402]
- US 5214136 A [0152] [0402]
- US 5700922 A [0152] [0402]
- US 5708154 A [0152] [0402]
- US 5728525 A [0152] [0153] [0402]
- US 5637683 A [0153] [0402]
- US 6251666 B [0153] [0402]
- US 5480980 A [0153] [0402]
- US 4704362 A [0157] [0402]
- US 5221619 A [0157] [0402]
- US 5583013 A [0157] [0402]
- EP 266032 A [0157] [0402]
- US 5705629 A [0157] [0402]
- US 4659774 A [0157] [0159] [0402]
- US 4816571 A [0157] [0159] [0402]
- US 5141813 A [0157] [0159] [0402]
- US 5264566 A [0157] [0159] [0402]
- US 4959463 A [0157] [0159] [0402]
- US 5428148 A [0157] [0159] [0402]
- US 5554744 A [0157] [0159] [0402]
- US 5574146 A [0157] [0159] [0402]
- US 5602244 A [0157] [0159] [0402]
- US 4683202 A [0158] [0402]
- US 4682195 A [0158] [0402]
- US 5645897 A [0158] [0402]
- US 5994624 A [0185] [0195] [0402]
- US 5981274 A [0185] [0195] [0402]
- US 5945100 A [0185] [0195] [0402]
- US 5780448 A [0185] [0195] [0402]
- US 5736524 A [0185] [0195] [0402]
- US 5702932 A [0185] [0195] [0402]
- US 5656610 A [0185] [0195] [0402]
- US 5589466 A [0185] [0195] [0402]
- US 5580859 A [0185] [0195] [0402]
- US 5789215 A, Harlan and Weintraub [0185] [0195] [0402]
- US 5384253 A [0185] [0195] [0402]
- WO 9409699 A [0185] [0195] [0402]
- WO 9506128 A [0185] [0195] [0402]
- US 5610042 A [0185] [0195] [0402]
- US 5322783 A [0185] [0195] [0402]
- US 5563055 A [0185] [0195] [0402]
- US 5550318 A [0185] [0195] [0402]
- US 5538877 A [0185] [0195] [0402]
- US 5538880 A [0185] [0195] [0402]
- US 5302523 A, Kaeppler [0185] [0195] [0402]
- US 5464765 A [0185] [0195] [0402]
- US 5591616 A [0185] [0195] [0402]
- US 1993 A, Omirulleh [0185]
- US 4684611 A [0185] [0195] [0402]
- US 4952500 A [0185] [0195] [0402]
- US 6770291 B [0197]
- US 4404289 A [0203] [0402]
- US 4405711 A [0203] [0402]
- US 4337063 A [0203] [0402]
- US 5268486 A [0203] [0402]
- BR 1529202 [0203]
- US 6723509 B [0205] [0402]
- US 5143854 A [0223] [0402]
- US 5202231 A [0223] [0402]
- US 5242974 A [0223] [0402]
- US 5288644 A [0223] [0402]
- US 5324633 A [0223] [0402]
- US 5384261 A [0223] [0402]
- US 5405783 A [0223] [0402]
- US 5412087 A [0223] [0402]
- US 5424186 A [0223] [0402]
- US 5429807 A [0223] [0402]
- US 5432049 A [0223] [0402]
- US 5436327 A [0223] [0402]
- US 5445934 A [0223] [0402]
- US 5468613 A [0223] [0402]

## EP 2 808 390 A1

- US 5470710 A [0223] [0402]
- US 5472672 A [0223] [0402]
- US 5492806 A [0223] [0402]
- US 5525464 A [0223] [0402]
- US 5503980 A [0223] [0402]
- US 5510270 A [0223] [0402]
- US 5527681 A [0223] [0402]
- US 5529756 A [0223] [0402]
- US 5532128 A [0223] [0402]
- US 5545531 A [0223] [0402]
- US 5547839 A [0223] [0402]
- US 5554501 A [0223] [0402]
- US 5556752 A [0223] [0402]
- US 5561071 A [0223] [0402]
- US 5571639 A [0223] [0402]
- US 5580726 A [0223] [0402]
- US 5580732 A [0223] [0402]
- US 5593839 A [0223] [0402]
- US 5599695 A [0223] [0402]
- US 5599672 A [0223] [0402]
- US 5610287 A [0223] [0402]
- US 5624711 A [0223] [0402]
- US 5631134 A [0223] [0402]
- US 5639603 A [0223] [0402]
- US 5654413 A [0223] [0402]
- US 5658734 A [0223] [0402]
- US 5661028 A [0223] [0402]
- US 5665547 A [0223] [0402]
- US 5667972 A [0223] [0402]
- US 5695940 A [0223] [0402]
- US 5700637 A [0223] [0402]
- US 5744305 A [0223] [0402]
- US 5800992 A [0223] [0402]
- US 5807522 A [0223] [0402]
- US 5830645 A [0223] [0402]
- US 5837196 A [0223] [0402]
- US 5871928 A [0223] [0402]
- US 5847219 A [0223] [0402]
- US 5876932 A [0223] [0402]
- US 5919626 A [0223] [0402]
- US 6004755 A [0223] [0402]
- US 6087102 A [0223] [0402]
- US 6368799 A [0223]
- US 6383749 A [0223]
- US 6617112 A [0223]
- US 6638717 A [0223]
- US 6720138 A [0223]
- WO 9317126 A [0223] [0402]
- WO 9511995 A [0223] [0402]
- WO 9521265 A [0223] [0402]
- WO 9521944 A [0223] [0228] [0402]
- WO 9535505 A [0223] [0402]
- WO 9631622 A [0223] [0402]
- WO 9710365 A [0223] [0402]
- WO 9727317 A [0223] [0402]
- WO 9935505 A [0223] [0402]
- WO 09923256 A [0223] [0402]
- WO 09936760 A [0223] [0402]
- WO 0138580 A [0223] [0402]
- WO 0168255 A [0223] [0402]
- WO 03020898 A [0223] [0402]
- WO 03040410 A [0223] [0402]
- WO 03053586 A [0223] [0402]
- WO 03087297 A [0223] [0402]
- WO 03091426 A [0223] [0402]
- WO 03100012 A [0223] [0402]
- WO 04020085 A [0223] [0402]
- WO 04027093 A [0223] [0402]
- EP 373203 A [0223] [0402]
- EP 785280 A [0223] [0402]
- EP 799897 A [0223] [0402]
- GB 8803000 A [0223] [0402]
- WO 9743450 A [0226] [0402]
- WO 03023058 A [0226] [0402]
- WO 03022421 A [0226] [0402]
- WO 03029485 A [0226] [0402]
- WO 03067217 A [0226] [0402]
- WO 03066906 A [0226] [0402]
- WO 03076928 A [0226] [0402]
- WO 03093810 A [0226] [0402]
- WO 03100448 A1 [0226]
- WO 0071096 A [0250]
- US 20030203865 A [0250]
- US 20020150626 A [0250]
- US 20030032615 A [0250]
- US 20040048787 A [0250]
- US 5844107 A [0250]
- US 5877302 A [0250]
- US 6008336 A [0250]
- US 6077835 A [0250]
- US 5972901 A [0250]
- US 6200801 B [0250]
- US 5972900 A [0250]
- US 4828979 A [0402]
- US 4849513 A [0402]
- US 4910300 A [0402]
- US 5573913 A [0402]
- US 6262252 B [0402]
- US 6368799 B [0402]
- US 6376179 B [0402]
- US 6383749 B [0402]
- US 6617112 B [0402]
- US 6638717 B [0402]
- US 6720138 B [0402]
- US 60649584 B [0402]
- US 60575743 B [0402]
- GB 1529202 A [0402]
- WO 03100448A1 A [0402]

## Non-patent literature cited in the description

- **MARTIN et al.** *RNA*, 1998, vol. 4 (2), 226-30 [0210]
- Remington's Pharmaceutical Sciences. Mack Printing Company, 1990 [0254] [0256]
- Remington's Pharmaceutical Sciences. Mack Printing Company, 1990, 1289-1329 [0255]
- **FINGL et al.** *The Pharmacological Basis of Therapeutics*. 1975, 1 [0276]
- **AGRAWAL ; ZAMECNIK.** *Nucleic Acids Research*, 1990, vol. 18 (18), 5419-5423 [0402]
- **ALLEN et al.** *Biochemistry*, 1989, vol. 28, 4601-4607 [0402]
- **AMBROS.** *Cell*, 2001, vol. 107 (7), 823-826 [0402]
- **BAGLIONI ; NILSON.** *Interferon*, 1983, vol. 5, 23-42 [0402]
- **BAYER ; WILCHEK.** *Methods of Biochemical Analysis*, 1980, vol. 26, 1-45 [0402]
- **BAYER et al.** *Analytical Biochemistry*, 1985, vol. 149, 529-536 [0402]
- **BEAUCAGE ; LYER.** *Tetrahedron*, 1992, vol. 48, 2223-2311 [0402]
- **BERNSTEIN et al.** *Nature*, 2001, vol. 409, 363-366 [0402]
- **BIJSTERBOSCH et al.** *Biochem. Pharmacol.*, 2001, vol. 62 (5), 627-633 [0402]
- **BLACKIE et al.** *Bioorg. Med. Chem. Lett.*, 2002, vol. 12 (18), 2603-2606 [0402]
- **BOBO et al.** *Diagnosis of Chlamydia trachomatis Cervical Infection by Detection of Amplified DNA with an Enzyme Immunoassay*, 1990 [0402]
- **BORLAKOGLU et al.** *Biochem. Pharmacol.*, 1990, vol. 40 (2), 265-272 [0402]
- **BOSHER ; LABOUESSE.** *Nat. Cell Biol.*, 2000, vol. 2, E31-E36 [0402]
- **BRENNECKE et al.** *Cell*, 2003, vol. 113, 25-36 [0402]
- **BRUMBAUGH et al.** *Proc Natl Acad Sci USA*, 1988, vol. 85 (15), 5610-5614 [0402]
- **BRUMMELKAMP et al.** *Science*, 2002, vol. 296 (5567), 550-553 [0402]
- **CALIN et al.** *Proc. Natl. Acad. Sci. USA*, 2002, vol. 99, 15524-15529 [0402]
- **CAPLEN et al.** *Proc Natl Acad Sci USA*, 2001, vol. 98, 9742-9747 [0402]
- **CARDULLO et al.** *Proc Natl Acad Sci USA*, 1988, vol. 85 (23), 8790-8794 [0402]
- **CARRINGTON et al.** *Science*, 2003, vol. 301 (5631), 336-338 [0402]
- **CHANG et al.** *Nature*, 2004, vol. 430 (7001), 785-789 [0402]
- **CHEN ; OKAYAMA.** *Mol. Cell Biol.*, 1987, vol. 7 (8), 2745-2752 [0402]
- **CHEN et al.** *Science*, 2004, vol. 303 (5654), 83-86 [0402]
- **COGONI, C. ; MACINO.** *Science*, 1999, vol. 286, 342-344 [0402]
- **COGONI ; MACINO.** *Nature*, 1999, vol. 399, 166-169 [0402]
- **CONWAY et al.** *Nucleic Acids Res. Symposium Series*, 1989, vol. 21, 43-44 [0402]
- **CROOKE.** *Antisense Drug Technology*. Marcel Dekker and Co, 2001 [0402]
- **CUMMINS et al.** *IRT: Nucleosides and nucleosides*, La Jolla CA, 1996, vol. 72 [0402]
- **DALMAY et al.** *EMBO J*, 2001, vol. 20, 2069-2078 [0402]
- **DALMAY et al.** *Cell*, 2000, vol. 101, 543-553 [0402]
- **DENLI et al.** *Trends Biochem. Sci.*, 2003, vol. 28, 196 [0402]
- **DEWANJEE et al.** *Biotechniques*, 1994, vol. 5, 844-846 [0402]
- **DIDENKO.** *Biotechniques*, 2001, vol. 31 (5), 1106-16, 1118, , 1120-1 [0402]
- **DOENCH et al.** *Genes & Dev.*, 2003, vol. 17, 438-442 [0402]
- **DOENCH et al.** *Genes Dev.*, 2004, vol. 18 (5), 504-11 [0402]
- **DONG et al.** *Crit Rev Oncol Hematol.*, 2005, vol. 54 (2), 85-93 [0402]
- **DOSTIE et al.** *RNA*, 2003, vol. 9, 180-186 [0402]
- **DRAPER ; GOLD.** *Biochemistry*, 1980, vol. 19, 1774-1781 [0402]
- **ELBASHIR et al.** *Nature*, 2001, vol. 411, 494-498 [0402]
- **EMPTAGE et al.** *Neuron*, January 2001, vol. 29 (1), 197-208 [0402]
- **FECHHEIMER et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 8463-8467 [0402]
- **FIRE et al.** *Nature*, 1998, vol. 391, 806-811 [0402]
- **FORSTER et al.** *Nucleic Acids Res.*, 1985, vol. 13 (3), 745-761 [0402]
- **FRALEY et al.** *Proc. Natl. Acad. Sci. USA*, 1979, vol. 76, 3348-3352 [0402]
- **FROEHLER et al.** *Nucleic Acids Res.*, 1986, vol. 14 (13), 5399-5407 [0402]
- **GILLAM et al.** *J. Biol. Chem.*, 1978, vol. 253, 2532 [0402]
- **GILLAM et al.** *Nucleic Acids Res.*, 1979, vol. 6, 2973 [0402]
- **GOPAL.** *Mol. Cell Biol.*, 1985, vol. 5, 1188-1190 [0402]
- **GRAHAM ; VAN DER EB.** *Virology*, 1973, vol. 52, 456-467 [0402]
- **GRIFFEY et al.** *J Mass Spectrom*, 1997, vol. 32 (3), 305-13 [0402]
- **GRISHOK et al.** *Cell*, 2001, vol. 106, 23-34 [0402]
- **HA et al.** *Genes Dev.*, 1996, vol. 10, 3041-3050 [0402]
- **HAMILTON ; BAULCOMBE.** *Science*, 1999, vol. 286, 950-952 [0402]
- **HAMMOND et al.** *Nat. Rev. Genet.*, 2001, vol. 2 (2), 110-9 [0402]

- **HARALAMBIDIS et al.** *Nucleic Acids Res.*, 1990, vol. 18 (3), 493-9 [0402]
- **HARLAND ; WEINTRAUB.** *J. Cell Biol.*, 1985, vol. 101, 1094-1099 [0402]
- **HOLTKE ; KESSLER.** *Nucleic Acids Res.*, 1990, vol. 18 (19), 5843-51 [0402]
- **HUTVAGNER ; ZAMORE.** *Science*, 2002, vol. 297 (5589), 2056-2060 [0402]
- **HUTVAGNER et al.** *PLoS Biol.*, 2004, vol. 2 (4), E98 [0402]
- **HUTVAGNER et al.** *Science*, 2001, vol. 293, 834-838 [0402]
- **ITAKURA ; RIGGS.** *Science*, 1980, vol. 209, 1401-1405 [0402]
- **ITAKURA et al.** *J. Biol. Chem.*, 1975, vol. 250, 4592 [0402]
- **JABLONSKI et al.** *Nucleic Acids Res.*, 1986, vol. 14 (15), 6115-6128 [0402]
- **KAEPPLER et al.** *Plant Cell Reports*, 1990, vol. 9, 415-418 [0402]
- **KANEDA et al.** *Science*, 1989, vol. 243, 375-378 [0402]
- **KATO et al.** *J. Biol. Chem.*, 1991, vol. 266, 3361-3364 [0402]
- **KELLER et al.** *Analytical Biochemistry*, 1988, vol. 170, 441-450 [0402]
- **KETTING et al.** *Cell*, 1999, vol. 99, 133-141 [0402]
- **KHORANA.** *Science*, 1979, vol. 203, 614 [0402]
- **KIMURA et al.** *Cancer Research*, 1995, vol. 55, 1379-1384 [0402]
- **KIRIAKIDOU et al.** *Genes Dev.*, 2004, vol. 18 (10), 1165-78 [0402]
- **KITAGAWA et al.** *Brain Res.*, 1991, vol. 561, 203-11 [0402]
- **KLOSTERMEIER ; MILLAR.** *Biopolymers*, 2001, vol. 61 (3), 159-79 [0402]
- **KNIGHT et al.** *Science*, 2001, vol. 2, 2 [0402]
- **KORNBERG ; BAKER.** DNA Replication. Freeman, 1992 [0402]
- **KUHNAST et al.** *Bioconjug Chem*, 2000, vol. 5, 627-636 [0402]
- **LAGOS-QUINTANA et al.** *Science*, 2001, vol. 294 (5543), 853-858 [0402]
- **LANGER et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78 (11), 663-6637 [0402]
- **LAU et al.** *Science*, 2001, vol. 294 (5543), 858-862 [0402]
- **LEE ; AMBROS.** *Science*, 2001, vol. 294 (5543), 862-864 [0402]
- **LEE et al.** *Nature*, 2003, vol. 425 (6956), 415-419 [0402]
- **LEE.** *EMBO J.*, 2002, vol. 21 (17), 4663-4670 [0402]
- **LEONETTI et al.** *Bioconjugate Chem.*, 1990, vol. 1, 149-153 [0402]
- **LEWIS.** *Cell*, 2003, vol. 115 (7), 787-798 [0402]
- **LIN ; AVERY.** *Nature*, 1999, vol. 402, 128-129 [0402]
- **LIU et al.** *Anal. Biochem.*, 2001, vol. 289, 239-245 [0402]
- **LORENZ et al.** *Bioorg. Med. Chem. Lett.*, 2004, vol. 14 (19), 4975-4977 [0402]
- **MACKELLAR et al.** *Nucl. Acids Res.*, 1992, vol. 20, 3411-3417 [0402]
- **MANOHARAN.** *Antisense Nucleic Acid Drug Dev.*, 2002, vol. 12 (2), 103-128 [0402]
- **MARTIN et al.** *RNA*, 1998, vol. 4 (2), 226-20 [0402]
- **MEIJER et al.** *Progress in Cell cycle research.* vol. 5, 219-224 [0402]
- **MEISTER et al.** *RNA*, 2004, vol. 10 (3), 544-50 [0402]
- **MONTGOMERY et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 155-2, 15507 [0402]
- **MOURRAIN et al.** *Cell*, 2000, vol. 101, 533 [0402]
- **NICOLAU ; SENE.** *Biochim. Biophys. Acta*, 1982, vol. 721, 185-190 [0402]
- **NICOLAU et al.** *Methods Enzymol.*, 1987, vol. 149, 157-176 [0402]
- **NYKANEN et al.** *Cell*, 2001, vol. 107 (3), 309-321 [0402]
- **OLSEN et al.** *Dev. Biol.*, 1999, vol. 216, 671 [0402]
- **OMIRULLEH et al.** *Plant Mol. Biol.*, 1993, vol. 21 (3), 415-428 [0402]
- **ORAVCOVA et al.** *Blood Press Suppl.*, 1994, vol. 1, 61-64 [0402]
- **PASQUINELLI ; RUVKUN.** *Ann. Rev. Cell Dev. Biol.*, 2002, vol. 18, 495-513 [0402]
- **PIUTLLE et al.** *Gene*, 1992, vol. 112 (1), 101-5 [0402]
- **PLASTERK ; KETTING.** *Curr. Opin. Genet. Dev.*, 2000, vol. 10, 562-567 [0402]
- **POTRYKUS et al.** *Mol. Gen. Genet.*, 1985, vol. 199 (2), 169-77 [0402]
- **REGNIER ; PREAT.** *Pharm Res*, 1998, vol. 10, 1596-602 [0402]
- **REINHART et al.** *Nature*, 2000, vol. 403, 901-906 [0402]
- **REISFELD et al.** *Biochem Biophys Res Comm*, 1987, vol. 142 (2), 519-526 [0402]
- **RICHARDSON ; GUMPORT.** *Nucleic Acids Res*, 1983, vol. 11 (18), 6167-84 [0402]
- **RICHARDSON ; MACY.** *Biochemistry*, 1981, vol. 20 (5), 1133-9 [0402]
- **RIPPE et al.** *Mol. Cell Biol.*, 1990, vol. 10, 689-695 [0402]
- **ROYCHOUDHURY ; KOSSEL.** *Eur J Biochem*, 1971, vol. 22 (3), 310-20 [0402]
- **RUMP et al.** *Biochem Pharmacol*, 2000, vol. 59 (11), 1407-16 [0402]
- **RUSCKOWSKI et al.** *Antisense Nucleic Acid Drug Dev.*, 2000, vol. 5, 333-345 [0402]
- **RUSCONI et al.** *Nat. Biotechnol.*, 2004, vol. 22 (11), 1423-1428 [0402]
- **SAIKI et al.** *Science*, 1985, vol. 230, 1350-1354 [0402]
- **SAMBROOK et al.** DNA microarrays: a molecular cloning manual. Cold Spring Harbor Laboratory Press, 2003 [0402]

- **SAMBROOK et al.** *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory Press, 1989 [0402]
- **SAMBROOK et al.** *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory Press, 2001 [0402]
- **SCHEIT**. *Synthesis and Biological Function*. Wiley-Interscience, 1980, 171-172 [0402]
- **SCHWARZE et al.** *Trends in Cell Biol.*, 2000, vol. 10, 290-295 [0402]
- **SEDELNIKOVA et al.** *Antisense Nucleic Acid Drug Dev.*, 2000, vol. 6, 443-452 [0402]
- **SEGGERSON et al.** *Dev. Biol.*, 2002, vol. 243, 215 [0402]
- **SHARP ; ZAMORE**. *Science*, 2000, vol. 287, 2431-2433 [0402]
- **SMARDON et al.** *Curr. Biol.*, 2000, vol. 10, 169-178 [0402]
- **SODJA et al.** *Nucleic Acids Res.*, 1978, vol. 5 (2), 385-401 [0402]
- **SOUTSCHEK et al.** *Nature*, 2004, vol. 432 (7014), 173-178 [0402]
- **SPROAT et al.** *Nucleic Acids Res.*, 1989, vol. 17 (9), 3373-3386 [0402]
- **STALNACKE et al.** *Eur. J. Nucl. Med.*, 1985, vol. 5, 166-170 [0402]
- **SUI et al.** *Proc. Natl. Acad. Sci. USA*, 2002, vol. 99 (8), 5515-5520 [0402]
- **TABARA et al.** *Cell*, 1999, vol. 99, 123-132 [0402]
- **TAKEDA ; IKEDA**. *Nucl. Acids Res.*, 1984, vol. 15, 101-104 [0402]
- **TUSCHL**. *Chembiochem*, 2001, vol. 2, 239-245 [0402]
- **UHLENBECK et al.** *Nucleic Acids Res.*, 1982, vol. 10 (11), 3341-52 [0402]
- **URDEA et al.** *Clinical Chemistry*, 1989, vol. 35 (8), 1571-1575 [0402]
- **VELLA et al.** *Genes Dev.*, 2004, vol. 18 (2), 132-7 [0402]
- **VISCIDI et al.** *J. Clinical Microbiology*, 1986, vol. 23 (2), 311-317 [0402]
- **VYAS et al.** *Crit. Rev. Ther. Drug Carrier Syst.*, 2001, vol. 18, 1-76 [0402]
- **WATERHOUSE et al.** *Nature*, 2001, vol. 411, 834-842 [0402]
- **WEEKS et al.** *Clin. Chem.*, 1983, vol. 29 (8), 1474-1479 [0402]
- **WILLIAMS et al.** *Int. J. Dev. Biol.*, 1997, vol. 41 (2), 359-364 [0402]
- **WINTER ; BROWNLEE**. *Nucleic Acids Res.*, 1978, vol. 5 (9), 3129-39 [0402]
- **WONG et al.** *Gene*, 1980, vol. 10, 87-94 [0402]
- **WU et al.** *Eur. J. Pharm. Sci.*, 2000, vol. 3, 179-186 [0402]
- **WU-SCHARF et al.** *Science*, 2000, vol. 290, 1159-1162 [0402]
- **XU et al.** *Curr. Biol.*, 2003, vol. 13, 790-795 [0402]
- **YOO et al.** *Nucleic Acids Res.*, 2000, vol. 21, 4225-4231 [0402]
- **ZAMORE et al.** *Cell*, 2000, vol. 101, 25-33 [0402]
- **ZAMORE**. *Nat. Struct. Biol.*, 2001, vol. 8, 746-750 [0402]
- **ZENG et al.** *Mol Cell*, 2002, vol. 9, 1327-33 [0402]
- **ZENG et al.** *Proc. Natl. Acad. Sci.*, 2003, vol. 100, 9779-9784 [0402]
- **ZHANG et al.** *Eur. J. Nucl. Med.*, 2000, vol. 11, 1700-1707 [0402]
- **ZHANG et al.** *J. Mol. Neurosci.*, 1996, vol. 1, 13-28 [0402]
- **ZHANG et al.** *J. Nucl. Med.*, 2001, vol. 11, 1660-1669 [0402]
- **ZIAUDDIN ; SABATINI**. *Nature*, 2001, vol. 411 (6833), 107-110 [0402]

## 摘要

本发明涉及用于使用合成核酸分子将 miRNA 功能活性导入到细胞中的方法和组合物。而且，本发明涉及用于使用与治疗、诊断和预防应用有关的特异性细胞功能鉴定 miRNA 的方法和组合物，其中，合成 miRNA 和/或 miRNA 抑制剂被用于文库筛查分析中。